{"title": "PDF", "author": "PDF", "url": "https://seq.es/wp-content/uploads/2019/09/full.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "REVISTA ESPA\u00d1OLA DEREVISTA ESPA\u00d1OLA DEQuimioterapiaQuimioterapia\nISSN: 0214-3429\nVolumen 32\nN\u00famero 5\nOctubre 2019\nP\u00e1ginas: 410-484SPANISH JOURNAL\nOF CHEMOTHERAPY\nImagen portada: Mar\u00eda Teresa CorcueraPublicaci\u00f3n Oficial\nde la Sociedad Espa\u00f1ola\nde QuimioterapiaQuimioterapiaREVISTA ESPA\u00d1OLA DE\nRevista Espa\u00f1ola de \nQuimioterapia tiene un car\u00e1cter multidisciplinar y est\u00e1 dirigida a todos aquellos profesionales involucrados en la epidemiolog\u00eda, diagn\u00f3stico, cl\u00ednica y tratamiento de las enfermedades infecciosas\nFundada en 1988 por la Sociedad \nEspa\u00f1ola de Quimioterapia\nIndexada en\nScience Citation IndexExpanded (SCI),Index Medicus (MEDLINE), Excerpta Medica/EMBASE,\u00cdndice M\u00e9dico Espa\u00f1ol (IME), \u00cdndice Bibliogr\u00e1fico en Ciencias de la Salud (IBECS)\nSecretar\u00eda t\u00e9cnica \nDpto. de Microbiolog\u00edaFacultad de MedicinaAvda. Complutense, s/n28040 Madridrevista@seq.esDisponible en Internet:www.seq.esPublicidad y SuscripcionesSociedad Espa\u00f1ola de QuimioterapiaDpto. de Microbiolog\u00edaFacultad de MedicinaAvda. Complutense, s/n28040 Madrid\nAtenci\u00f3n al cliente\nTel\u00e9fono 91 394 15 12Correo electr\u00f3nicoinfo@seq.es\nConsulte nuestra p\u00e1gina web\nwww.seq.es\n\u00a9 Copyright 2019Sociedad Espa\u00f1ola deQuimioterapia\nReservados todos los derechos.\nQueda rigurosamente prohibida,sin la autorizaci\u00f3n escrita deleditor, la reproducci\u00f3n parcialo total de esta publicaci\u00f3npor cualquier medio oprocedimiento, comprendidos lareprograf\u00eda y el tratamientoinform\u00e1tico, y la distribuci\u00f3n deejemplares mediante alquiler opr\u00e9stamo p\u00fablicos, bajo lassanciones establecidas por la leySociedad Espa\u00f1ola de Quimioterapia\nPublicaci\u00f3n que cumple los requisitos de\nsoporte v\u00e1lido\nISSN\n0214-3429\ne-ISSN\n1988-9518\nDep\u00f3sito Legal\nM-32320-2012\nMaquetaci\u00f3n\nKumisai\nImpresi\u00f3n\nEspa\u00f1a\nEsta publicaci\u00f3n se imprime en papel no \u00e1cido. \nThis publication is printed in acid free paper.\nLOPD\nInformamos a los lectores que, seg\u00fan lo previsto en el Reglamento General de Protecci\u00f3n de Datos (RGPD) 2016/679 del Parlamento Europeo, sus datos personales forman parte de la base de datos de la Sociedad Espa\u00f1ola de Quimioterapia (si es usted socio)\nSi desea realizar cualquier rectificaci\u00f3n o \ncancelaci\u00f3n de los mismos, deber\u00e1 enviar una solicitud por e-mail a la Sociedad Espa\u00f1ola de Quimioterapia (info@seq.es)QuimioterapiaREVISTA ESPA\u00d1OLA DE\nDirector\nJ. Barber\u00e1n L\u00f3pez\nComit\u00e9 Editorial\nF. \u00c1lvarez Lerma (Barcelona)\nF. Baquero Mochales (Madrid)\nE. Bouza Santiago (Madrid)\nJ. A. Garc\u00eda Rodr\u00edguez (Salamanca)\nM. Gobernado Serrano (Valencia)\nConsejo Editorial\nL. Aguilar (Madrid)\nJ. I. Al\u00f3s (Madrid)\nJ. R. Azanza (Pamplona)\nJ. Arag\u00f3n (Las Palmas de Gran Canaria) \nA. Artero (Valencia)V. Asensi (Oviedo)\nG. Barbeito (Santiago de Compostela)\nJ. M. Barbero (Madrid)\nJ. Campos (Madrid)F.J. Candel (Madrid)\nE. Cant\u00f3n (Valencia)\nR. Cant\u00f3n (Madrid)\nJ. A. Capdevila Morell\n(Barcelona)\nM. Casal (C\u00f3rdoba)\nJ. Castillo (Zaragoza) \nF. Cobo (Granada)\nJ. Cobo Reinoso (Madrid)\nN. Cobos (Madrid)\nJ. L. del Pozo (Navarra)R. De la C\u00e1mara (Madrid)\nC. De la Calle (Barcelona)\nM. Dominguez-Gil (Valladolid)\nJ. Eiros (Valladolid)P. Escribano (Madrid)\nA. Estella (C\u00e1diz)\nM. C. Fari\u00f1as \u00c1lvarez (Santander)\nC. Fari\u00f1as (Santander)J. Fort\u00fan (Madrid)J. J. Gamazo (Vizcaya)\nE. Garc\u00eda S\u00e1nchez (Salamanca)\nI. Garc\u00eda Garc\u00eda (Salamanca)\nJ. E. Garc\u00eda S\u00e1nchez (Salamanca)E. Garc\u00eda V\u00e1zquez (Murcia)\nJ. G\u00f3mez G\u00f3mez (Murcia)\nM. L. G\u00f3mez-Lus (Madrid)\nJ. Gonz\u00e1lez del Castillo (Madrid)F. Gonz\u00e1lez Romo (Madrid)\nJ. J. Granizo (Madrid)\nS. Grau (Barcelona)\nJ.M. Guardiola (Barcelona)\nJ. Guinea (Madrid)\nX. Guirao (Barcelona)\nJ. Guti\u00e9rrez (Granada)\nJ. B. Guti\u00e9rrez (C\u00f3rdoba)\nB. Isidoro (Madrid)\nP. Llinares (La Coru\u00f1a)\nJ. E. Losa Garcia (Madrid)J. R. Maestre Vera (Madrid)\nL. Mart\u00ednez Mart\u00ednez (C\u00f3rdoba)\nE. Maseda (Madrid)\nR. Men\u00e9ndez (Valencia)P. Merino (Madrid))\nP. Mu\u00f1oz (Madrid)\nJ. L. Mu\u00f1oz Bellido (Salamanca)\nV. Navarro (Alicante)M. Ortega (Barcelona) \nJ. Oteo (Madrid)\nJ. A. Oteo (Logro\u00f1o)\nE. Palencia Herrej\u00f3n (Madrid) \nA. Pascual Hern\u00e1ndez (Sevilla)\nJ. Pasquau (Sevilla)J. Pem\u00e1n (Valencia)J. L P\u00e9rez-Arellano (Las Palmas)B. P\u00e9rez-Gorricho (Madrid)A. Ramos (Madrid)J. M. Ramos (Alicante)J. Reina (Palma de Mallorca)\nM. A. Ripoll (\u00c1vila)\nI. Rodriguez-Avial (Madrid)M. Ruiz (Alicante)M. Sabri\u00e1 (Barcelona)M. Salavert (Valencia)B. S\u00e1nchez Artola (Madrid)M. Segovia (Murcia)R. Serrano (Madrid)D. Sevillano (Madrid)\nA. Su\u00e1rez (Madrid)\nA. Tenorio (Huelva)A. Torres (Murcia)C. Vallejo (Oviedo)J. Vila (Barcelona)J. Yuste (Madrid)J. Mensa Pueyo (Barcelona)\nJ. J. Picazo de la Garza (Madrid)\nJ. Prieto Prieto (Madrid)\nB. Regueiro Garc\u00eda (Santiago de Compostela)\nA. Torres Mart\u00ed (Barcelona)Secretario de Redacci\u00f3n\nLuis Alou CerveraSumario\nRevisi\u00f3n de estrategias de profilaxis antif\u00fangica en ni\u00f1os inmunodeprimidos  410\nJos\u00e9 Tom\u00e1s Ramos, Concepci\u00f3n Alba Romero, Sylvia Belda, Francisco Javier Candel, Bego\u00f1a \nCarazo Gallego, Aurora Fern\u00e1ndez-Polo, Laura Ferreras Antol\u00edn, Carmen Garrido Colino, Mar\u00eda \nLuisa Navarro, Olaf Neth, Peter Olbrich, Elena Rinc\u00f3n-L\u00f3pez, Jes\u00fas Ruiz Contreras, Pere Soler-\nPalac\u00edn, On Behalf Of The Fungal Infection Study Group Of Spanish Society Of Paediatric \nInfectious Disease (SEIP); Traslational Research Network In Pediatric Infectious Diseases (RITIP)\nMicrobiota biliar en pacientes colecistectomizados: Revisi\u00f3n de la  426 \nantibioterapia emp\u00edrica\nMar\u00eda Gil Fortu\u00f1o, Laura Granel Villach, Susana Sabater Vidal, Raquel Soria Mart\u00edn, David \nMart\u00ednez Ramos, Javier Escrig Sos, Rosario Moreno Mu\u00f1oz, Rafael Igual Adell\nReacciones adversas asociadas a la vacunaci\u00f3n en pacientes inmunodeprimidos  432 \ny en situaciones especiales de una Unidad de Vacunas hospitalaria\nMar\u00eda Fern\u00e1ndez-Prada, Andrea Viejo-Gonz\u00e1lez, Alba Mart\u00ednez-Torr\u00f3n, Carmen Mart\u00ednez-Ortega, \nJes\u00fas Ruiz-Salazar, Ismael Huerta-Gonz\u00e1lez\nHepatitis C: nuevos diagn\u00f3sticos y seroconversiones en una cl\u00ednica de infecciones  440 \nde transmisi\u00f3n sexual en Madrid\nErika Esperanza Lozano Rinc\u00f3n, Carmen Rodr\u00edguez Mart\u00edn, \u00d3skar Ayerdi Aguirrebengoa, Mar Vera \nGarc\u00eda, Regino Serrano Heranz, Jorge Del Romero Guerrero\nConcordancia entre la prueba de la tuberculina y el Interferon Gamma Release  445 \nAssay-IGRA en pacientes con enfermedades inflamatorias mediadas por la inmunidad\nIgnacio P\u00e9rez Catal\u00e1n, Celia Roig Mart\u00ed, Mar\u00eda Gil Fortu\u00f1o, Patricia Torrent Ramos, Paloma Albiol \nVi\u00f1als, Mario Carballido Fern\u00e1ndez, Rosa Mar\u00eda Larrea, Carmen Ort\u00edn Mart\u00edn, Jorge Us\u00f3 Blasco, Jos\u00e9 Manuel Ramos Rinc\u00f3n\nEvoluci\u00f3n hist\u00f3rica de las enfermedades causadas por micobacterias  451 \nno pigmentadas de crecimiento r\u00e1pido en un Hospital Universitario\nMarta Garcia-Coca, Graciela Rodriguez-Sevilla, Maria Carmen Mu\u00f1oz-Egea, Concepci\u00f3n Perez-\nJorge, Nerea Carrasco-Anton, Jaime Esteban\nDeterminaci\u00f3n del valor umbral del \u00edndice de complejidad de la farmacoterapia  458 \npara predecir polifarmacia en pacientes VIH+\nRam\u00f3n Morillo-Verdugo, M\u00aa De Las Aguas Robustillo-Cort\u00e9s, Laila Abdel-Kader Mart\u00edn, Mar\u00eda \n\u00c1lvarez De Sotomayor Paz, Fernando Lozano De Le\u00f3n Naranjo, Carmen Victoria Almeida-Gonz\u00e1lez\nEstudio in vitro de la sinergia de ampicilina con ceftriaxona frente a Listeria 465\nmonocytogenes\nJos\u00e9 Antonio Lepe, \u00c1ngel Rodr\u00edguez-Villodres, Guillermo Mart\u00edn-Guti\u00e9rrez, Rafael Luque, Javier \nAznarRevisi\u00f3n\nOriginales\nOriginal BreveQuimioterapiaREVISTA ESPA\u00d1OLA DE\nVolumen 32\nN\u00famero 5Octubre 2019Sumario\nInfecciones profundas por Gardnerella  vaginalis  en el var\u00f3n. 469 \nRevisi\u00f3n de la literatura y a prop\u00f3sito de un caso\nMar\u00eda Lara Ruiz-G\u00f3mez, David Alejandro Mart\u00edn-Way, Mar\u00eda Dolores P\u00e9rez-Ram\u00edrez, Jos\u00e9 \nGuti\u00e9rrez-Fern\u00e1ndez\nFascitis necrotizante y s\u00edndrome del shock t\u00f3xico por Streptococcus  pyogenes  473 \ntras inyecci\u00f3n intramuscular\nClaudia Mendoza, Soledad Salvo, Pilar Luque, Hector Condado, Mar\u00eda Azucena Gonzalo, Sonia \nAlgarate\nInfecci\u00f3n de material prot\u00e9sico por Mycobacterium  smegmatis 475\nManuel Belda Alvarez, Mercedes Chanza Avi\u00f1o, Miguel Sanfeliu Giner, Maria Del Remedio Guna \nSerrano, Concepci\u00f3n Gimeno Cardona\nUtilidad de la PCR-m\u00faltiple (FilmArray Meningitis/Encefalitis) en el manejo 477 \nde un caso infrecuente de meningitis por Virus Herpes Simple tipo 2\nSarai Su\u00e1rez-Fern\u00e1ndez, Ana Iturzaeta, Carlos Rodr\u00edguez-Lucas\nInfecciones genitourinarias por Corynebacterium  glucuronolyticum  en el var\u00f3n. 479 \nRevisi\u00f3n de la literatura y experiencia cl\u00ednica\nMarta Ruiz-Pino, Carla Foronda-Garc\u00eda-Hidalgo, Pedro Alarc\u00f3n-Blanco, Jos\u00e9 Guti\u00e9rrez-Fern\u00e1ndezQuimioterapiaREVISTA ESPA\u00d1OLA DE\nVolumen 32\nN\u00famero 5Octubre 2019\nCartas al DirectorContents\nQuimioterapiaREVISTA ESPA\u00d1OLA DE\nVolume 32\nNumber 5\nOctober 2019\nClinical practice update of antifungal prophylaxis in immunocompromised 410 \nchildren\nJos\u00e9 Tom\u00e1s Ramos, Concepci\u00f3n Alba Romero, Sylvia Belda, Francisco Javier Candel, Bego\u00f1a \nCarazo Gallego, Aurora Fern\u00e1ndez-Polo, Laura Ferreras Antol\u00edn, Carmen Garrido Colino, Mar\u00eda \nLuisa Navarro, Olaf Nef, Peter Olbright, Elena Rinc\u00f3n-L\u00f3pez, Jes\u00fas Ruiz Contreras, Pere Soler-\nPalac\u00edn, on behalf of the Fungal Infection Study Group of Spanish Society of Paediatric Infectious \nDisease (SEIP); Traslational Research Network in Pediatric Infectious Diseases (RITIP)\nBiliary microbiote in collecistectomized patients: Review of empirical 426 \nantibiotherapy\nMar\u00eda Gil Fortu\u00f1o, Laura Granel Villach, Susana Sabater Vidal, Raquel Soria Mart\u00edn, David Mart\u00ednez \nRamos, Javier Escrig Sos, Rosario Moreno Mu\u00f1oz, Rafael Igual Adell\nVaccine-related adverse reactions in immunocompromised patients and 432 \nin special situations of a hospital Vaccine Unit\nMar\u00eda Fern\u00e1ndez-Prada, Andrea Viejo-Gonz\u00e1lez, Alba Mart\u00ednez-Torr\u00f3n, Carmen Mart\u00ednez-Ortega, \nJes\u00fas Ruiz-Salazar, Ismael Huerta-Gonz\u00e1lez\nHepatitis C: New diagnosis and seroconversions in a Madrid sexually 440 \ntransmitted diseases clinic\nErika Esperanza Lozano Rinc\u00f3n, Carmen Rodr\u00edguez Mart\u00edn, \u00d3skar Ayerdi Aguirrebengoa, Mar Vera \nGarc\u00eda, Regino Serrano Heranz, Jorge Del Romero Guerrero\nConcordance between the test of the tuberculin and Interferon 445 \nGamma Release Assay-IGRA in patients with immune-mediated inflammatory diseases \nIgnacio P\u00e9rez Catal\u00e1n, Celia Roig Mart\u00ed, Mar\u00eda Gil Fortu\u00f1o, Patricia Torrent Ramos, Paloma Albiol \nVi\u00f1als, Mario Carballido Fern\u00e1ndez, Rosa Mar\u00eda Larrea, Carmen Ort\u00edn Mart\u00edn, Jorge Us\u00f3 Blasco, \nJos\u00e9 Manuel Ramos Rinc\u00f3n\nHistorical evolution of the diseases caused by non-pigmented rapidly 451 \ngrowing mycobacteria in a University Hospital\nMarta Garcia-Coca, Graciela Rodriguez-Sevilla, Maria Carmen Mu\u00f1oz-Egea, Concepci\u00f3n Perez-\nJorge, Nerea Carrasco-Anton, Jaime Esteban\nDetermination of a cutoff value for medication regimen complexity index 458 \nto predict polypharmacy in HIV+ older patient\nRam\u00f3n Morillo-Verdugo, M\u00aa de las Aguas Robustillo-Cort\u00e9s, Laila Abdel-Kader Mart\u00edn, Mar\u00eda \n\u00c1lvarez de Sotomayor Paz, Fernando Lozano de Le\u00f3n Naranjo, Carmen Victoria Almeida-Gonz\u00e1lez\nIn vitro study of synergy of ampicillin with ceftriaxone against Listeria  465  \nmonocytogenes\nJos\u00e9 Antonio Lepe, \u00c1ngel Rodr\u00edguez-Villodres, Guillermo Mart\u00edn-Guti\u00e9rrez, Rafael Luque, Javier \nAznarReview\nOriginals\nBrief ReportContents\nQuimioterapiaREVISTA ESPA\u00d1OLA DE\nMale deep infections by Gardnerella  vaginalis . A literature review and 469 \na case report\nMar\u00eda Lara Ruiz-G\u00f3mez, David Alejandro Mart\u00edn-Way, Mar\u00eda Dolores P\u00e9rez-Ram\u00edrez, Jos\u00e9 \nGuti\u00e9rrez-Fern\u00e1ndez\nNecrotizing fasciitis and toxic shock syndrome due to Streptococcus  pyogenes  473  \nafter intramuscular injection\nClaudia Mendoza, Soledad Salvo, Pilar Luque, Hector Condado, Mar\u00eda Azucena Gonzalo, Sonia \nAlgarate\nInfection of prosthetic material due to Mycobacterium  smegmatis  475  \nManuel Belda Alvarez, Mercedes Chanza Avi\u00f1o, Miguel Sanfeliu Giner, Maria del Remedio  \nGuna Serrano, Concepci\u00f3n Gimeno Cardona\nUsefulness of FilmArray Meningitis/Encephalitis panel in the management 477 \nof an uncommon case of Herpes Simplex Virus type 2 meningitis\nSarai Su\u00e1rez-Fern\u00e1ndez, Ana Iturzaeta, Carlos Rodr\u00edguez-Lucas\nMale genitourinary infections by Corynebacterium  glucuronolyticum . 479  \nA review and clinical experience\nMarta Ruiz-Pino, Carla Foronda-Garc\u00eda-Hidalgo, Pedro Alarc\u00f3n-Blanco, Jos\u00e9 Guti\u00e9rrez-Fern\u00e1ndezVolume 32\nNumber 5\nOctober 2019\nLetters to the \neditorRev Esp Quimioter 2019;32(5): 410-425410\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).in children and to provide a comprehensive proposal for \neach type of patient.\nKey-words: antifungal prophylaxis, children, pediatric patients, HIV, \nprimary immunodeficiency, Solid organ transplantation, haematopoietic \nstem cell transplantation.\nRevisi\u00f3n de estrategias de profilaxis \nantif\u00fangica en ni\u00f1os inmunodeprimidos\nRESUMEN\nLas infecciones f\u00fangicas invasoras (IFI) constituyen un \nproblema creciente en adultos y ni\u00f1os inmunodeprimidos, \nacompa\u00f1\u00e1ndose de una elevada morbimortalidad.  El n\u00fame -\nro de ni\u00f1os inmunodeprimidos va en aumento. Los grupos de \nriesgo de IFI en pediatr\u00eda incluyen a los grandes prematuros, \nque se benefician de profilaxis con fluconazol, pacientes he -\nmato-oncol\u00f3gicos sometidos a quimioterapia o trasplante de \nprecursores hematopoy\u00e9ticos con neutropenias prolongadas, \nen quienes la profilaxis frente a hongos filamentosos suele re -\ncomendarse en situaciones de alto riesgo. En ni\u00f1os sometidos \na trasplante de \u00f3rgano s\u00f3lido, la profilaxis depende del tipo de \ntrasplante y factores de riesgo asociados. En pacientes con in -\nmunodeficiencias primarias o adquiridas como la infecci\u00f3n VIH \no tratamiento inmunosupresor prolongado, la profilaxis anti -\nf\u00fangica depender\u00e1 del tipo de inmunodeficiencia primaria y \ndel grado de inmunosupresi\u00f3n. La enfermedad granulomatosa \ncr\u00f3nica tiene riesgo particularmente elevado de IFI y requiere \nsiempre profilaxis frente a hongos filamentosos. En cambio, en \nni\u00f1os con ingresos prolongados en cuidados intensivos la pro -\nfilaxis frente a IFI habitualmente no est\u00e1 indicada. El tipo de \nprofilaxis est\u00e1 limitado por la diferente aprobaci\u00f3n de antif\u00fan -ABSTRACT\nDue to the rise in the number and types of immuno -\nsuppressed patients, invasive fungal infections (IFI) are an \nincreasing and major cause of morbidity and mortality in \nimmunocompromised adults and children. There is a broad \ngroup of pediatric patients at risk for IFI in whom prima -\nry and/or secondary antifungal prophylaxis (AFP) should \nbe considered despite scant evidence. Pediatric groups at \nrisk for IFI includes extremely premature infants in some \nsettings, while in high-risk children with cancer receiving \nchemotherapy or undergoing haematopoietic stem cell \ntransplantation (HCT), AFP against yeast and moulds is usu -\nally recommended. For solid organ transplanted, children, \nprophylaxis depends on the type of transplant and associat -\ned risk factors. In children with primary or acquired immu -\nnodeficiency such as HIV or long-term immunosuppressive \ntreatment, AFP depends on the type of immunodeficiency \nand the degree of immunosuppression. Chronic granuloma -\ntous disease is associated with a particular high-risk of IFI \nand anti-mould prophylaxis is always indicated. In contrast, \nAFP is not generally recommended in children with long \nstay in intensive care units. The choice of AFP is limited by \nthe approval of antifungal agents in different age groups \nand by their pharmacokinetics characteristics. This docu -\nment aims to review current available information on AFP Clinical practice update of antifungal prophylaxis in \nimmunocompromised children\n1Department of Public and Mother-Child Health. Hospital Cl\u00ednico San Carlos, Complutense University. Madrid. \n2Department of Salud P\u00fablica y Materno-Infantil.Complutense University. Neonatology Unit. Hospital 12 de Octubre. Madrid\n3Department of Pediatrics. Intensive Care Unit. Hospital 12 de Octubre. Madrid. Complutense University. Madrid. \n4Clinical Microbiology and Infectious Diseases Department. Transplant. Coordination Unit. IdISSC and IML Health Institutes. \nHospital Cl\u00ednico San Carlos. Madrid. Spain.\n5Department of Pediatrics. Secci\u00f3n de Enfermedades Infecciosas. Hospital Carlos Haya, M\u00e1laga.\n6Pharmacy Department. Hospital Universitari Vall d\u2019Hebron. Barcelona.\n7Department of Pediatrics. Infectious Diseases Unit. Saint George Hospital Londres. \n8Department of Pediatrics. Secci\u00f3n de Hemato-oncolog\u00eda. Hospital Gregorio Mara\u00f1\u00f3n. Madrid.\n9Department of Pediatrics. Secci\u00f3n de Enfermedades Infecciosas. Hospital Gregorio Mara\u00f1\u00f3n. Madrid.\n10Department of Pediatrics. Secci\u00f3n Infectolog\u00eda, Reumatolog\u00eda e Inmunolog\u00eda Pedi\u00e1trica. Hospital Universitario Virgen del \nRoc\u00edo, Sevilla. \n11Department of Pediatrics. Hospital 12 de Octubre. Madrid. Complutense University. Madrid. \n12Pediatric Infectious Diseases and Immunodeficiencies Unit. Hospital Universitari Vall d\u2019Hebron. Barcelona.Jos\u00e9 Tom\u00e1s Ramos1\nConcepci\u00f3n Alba Romero2\nSylvia Belda3\nFrancisco Javier Candel4\nBego\u00f1a Carazo Gallego5\nAurora Fern\u00e1ndez-Polo6\nLaura Ferreras Antol\u00edn7\nCarmen Garrido Colino8 \nMar\u00eda Luisa Navarro9\nOlaf Neth10\nPeter Olbrich10\nElena Rinc\u00f3n-L\u00f3pez9\nJes\u00fas Ruiz Contreras11\nPere Soler-Palac\u00edn12\non behalf of the Fungal \nInfection Study Group \nof Spanish Society of \nPaediatric Infectious \nDisease (SEIP); Traslational \nResearch Network in \nPediatric Infectious Diseases \n(RITIP).\nCorrespondence:\nJos\u00e9 T. Ramos Amador\nDepartmento de Salud P\u00fablica y Materno-Infantil. Complutense University. Madrid.\nHospital Cl\u00ednico San Carlos. IdISSC Health Research Institute Madrid. Spain.\nAvda Profesor Mart\u00edn Lagos s/n. 28040.\nPhone: + 34 91 330 3486\nE-mail: josetora@ucm.esReview\nArticle history\nReceived: 31 July 2019; Revision Requested: 18 August 2019; Revision Received: 30 August 2019; Accepted: 3 September 2019Clinical practice update of antifungal prophylaxis in  immunocompromised children J. T. Ramos, et al.\nRev Esp Quimioter 2019;32(5): 410-425411able in neonatal intensive care units (NICU) ranging from 3% \nto 23% in extreme premature infants, depending on the com -\nplexity of the NICU and whether surgery is involved or not. \nThis patient population has a high risk of dissemination to the \ncentral nervous system (up to 15-20% in extreme premature \nbabies), even before presenting overt clinical signs of infection, \nand high mortality rates. Despite high variations among NICU, \nCandida albicans is the most frequent isolated species, fol -\nlowed by C. parapsilosis  [3-6].\nRisk factors for IC in preterm infants include immaturi -\nty of the immune system (especially low levels of maternal \nIgG transmission and impaired functions of opsonization and \ncomplement) and epithelial barriers, frequent rupture of these \nbarriers by invasive procedures, such as catheters, intuba -\ntion or surgery, and the increase in the density of coloniza -\ntion by Candida spp. promoted mostly by the frequent use of \nbroad-spectrum antibiotics. In addition, H2-receptor blockers \nand steroids may facilitate intestinal translocation leading \nto Candida  spp. invasion and secondary systemic infection. \nTransmission through peripartum colonization and horizontal \ntransmission through health-care professionals colonized by \nCandida  spp. may also occur [3-6]. Due to its bad prognosis, \nprophylactic strategies to prevent IF are warranted [7]. \nGeneral strategies include hand hygiene; individual room \nfor families and newborns; reduction of risk factors for colo -\nnization and infection for IC, such as limitation of H2-recep -\ntor blockers, steroids and broad-spectrum antibiotics, mainly \ncarbapenems and third-generation cephalosporins; minimiz -\ning the use of invasive devices including minimal manipula -\ntion of central venous catheters, as well as early introduction \nof mother\u00b4s milk. Although some experts advocate for using \nlactoferrin alone or combined with probiotics in order to re -\nduce intestinal Candida  spp.  colonization and late onset sepsis \nin neonates weighing < 1,500 g, evidence is still scarce [7] (CII). \nThe indication of AFP, although controversial, is general -\nly recommended in preterm babies <1,000 g., in NICU with a \nprevalence of Candida spp. infection above 5-10%. Oral nys -\ntatin suspension (1ml: 100.000 U/ml) has been considered as \nan option, when fluconazole is not available or azole resist -\nance is suspected, but evidence is low [7] (CII). When indicat -\ned fluconazole is the recommended option, starting either in \nthe first 24 or 72 hours of life at a dose 3-6 mg/kg i.v. (until \ncatheter withdrawal) or orally twice weekly for 6 weeks. Mul -\ntiple clinical trials have been performed with several regimens \nof fluconazole showing the impact of fluconazole in high-risk \npreterm babies in the incidence of IC, morbidity and mortal -\nity [8-12]. Twice weekly regimens do not seem to be inferior \nto the same daily dose [10]. According to the IDSA guidelines \nprophylaxis with fluconazole is indicated in admitted neonates \nwith birth weight < 1000 gr when the prevalence of IC is high -\ner than 10% [1]. Similarly, above this threshold in Spain, differ -\nent Spanish scientific societies (Spanish Society of Infectious \nDiseases and Clinical Microbiology -SEIMC- and Spanish Socie -\nty of Paediatric Infectious Diseases-SEIP) advocate fluconazole \nprophylaxis at 3 mg/kg/day in newborns with birth weight < \n1,500 g, continuing it for all the period at risk [4,13]. The ESC -gicos a distintas edades. Este documento pretende revisar la \ninformaci\u00f3n actual disponible respecto a profilaxis antif\u00fangica \nen ni\u00f1os, con propuesta para la estrategia m\u00e1s apropiada en \ncada tipo de paciente.\nPalabras clave: profilaxis antif\u00fangica, ni\u00f1os, pacientes pedi\u00e1trico, VIH, \ninmunodeficiencia primaria, trasplante de \u00f3rgano s\u00f3lido, trasplante de \nprecursores hematopoy\u00e9ticos\nInvasive fungal infection (IFI) is considered an opportun -\nistic infection that occurs almost exclusively in immunocom -\npromised and critically ill children. The impact of an IFI can be \ndevastating and is associated with a high rate of morbimortal -\nity despite the availability of new antifungal drugs in recent \nyears.\nThe number of paediatric patients at risk for IFI is increas -\ning and include: extremely premature infants (especially those \nwith weight less than 1,500 g), children with cancer, undergo -\ning haematopoietic stem cell transplantation (HSCT) or solid \norgan transplant, neutropenic children, those with long stay \nin intensive care units (ICU) and children with primary or ac -\nquired immunodeficiency such as HIV or long-term immuno -\nsuppressive treatment [1-4]. Timely diagnosis and initiation of \nappropriate antifungal therapy is a key point to improve out -\ncomes. Thus, it is mandatory to consider antifungal prophylaxis \n(AFP) in most of these situations. Herein, a comprehensive pro -\nposals for each patient\u00b4s group based on an updated review of \nAFP strategies in children is provided.\nThe strength of recommendations and the quality of evi -\ndence are graded according to the scoring system proposed by \nthe Infectious Diseases Society of North America (IDSA) [1]. In \nthe process of providing recommendations, we have taken into \naccount the paediatric development regulations and guidelines \nfrom the European Medicines Agency (EMA). The EMA accepts \nthe requirement for extrapolation of evidence for efficacy from \nstudies in adults to paediatric patients or from older to younger \npaediatric patients when the following criteria are met: (a) un -\nderlying condition and cause of targeted disease and expected \nresponse to therapy are similar; (b) data from clinical studies on \npharmacokinetics, safety and tolerance are available for paedi -\natric patients; and (c) supportive paediatric efficacy data exists \n[2]. In this scoring system, the strength of the recommendation \nis rated as follows:  A: strongly recommended; B: moderately \nrecommended; C: weak author support; D: not recommended \nby the authors. The quality of evidence is evaluated on a 3-lev -\nel scale as follows: I: data from at least 1 well-designed and \nconducted randomized controlled trial; II: data from at least 1 \nwell-designed and conducted clinical trial, without randomiza -\ntion, cohorts or case-control analyses (preferably multicenter), \nmultiple retrospective series, or major findings of noncon -\ntrolled studies; III: expert opinions based on clinical experience, \ndescriptive case series, or expert committee reports [1].\n1.- ANTIFUNGAL PROPHYLAXIS IN NEWBORNS\nThe prevalence of invasive candidiasis (IC) is highly vari -Clinical practice update of antifungal prophylaxis in  immunocompromised children J. T. Ramos, et al.\nRev Esp Quimioter 2019;32(5): 410-425412and Candida  spp. positive urine cultures [20, 21]. However, \nthese criteria might not be fully applicable to children. \nSeveral studies have tried to identify risk factors for inva -\nsive candidemia in non-immunocompromised critically ill chil -\ndren. In one population-based, case-control study in a large \ntertiary care paediatric center, the following risk factors for \nCandida  spp. bloodstream infections were identified: presence \nof central venous catheter, underlying malignant conditions, \nand having received vancomycin  or an anti-anaerobic anti -\nbiotic for more than 3 days. The predicted risk for candidemia \nfor patients with some of these three risk factors in different \ncombinations ranged between 10% and 46%. In this study, the \nauthors concluded that these patients could be candidates for \nantifungal prophylaxis [4]. \nAnother observational study in 24 Spanish PICUs record -\ned 125 invasive Candida  spp. infections and determined that \nprevious bacterial infection, chronic metabolic disease, diges -\ntive surgery, pre-PICU stay longer than 15 days, previous col -\nonization, parenteral nutrition and invasive devices were risk \nfactors [22]. Central venous catheters, immunosuppression (in -\ncluding long-term steroids), damage of gastrointestinal tract, \nbroad-spectrum antibiotics, parenteral nutrition, renal failure \nrequiring hemodialysis, mechanical ventilation and genetic \nsusceptibility have been described in other studies as impor -\ntant risk factors [23-25]. Children younger than one year of \nage have a higher incidence of candidemia [26]. \nIn addition to risk factors, the local incidence of invasive \nCandida  spp. infections should be considered to decide wheth -\ner or not to start AFP. An incidence of 10% is considered the \nthreshold to use prophylaxis with an acceptable risk-benefit \nanalysis. Some authors suggest that in PICUs with rates of in -\nvasive candidiasis higher than 5%, AFP may be considered in \nselected patients with several risk factors (CII). \nThere are few studies about the benefits of AFP in PICU. \nReduction on invasive candidemia incidence with fluconazole \nprophylaxis has been studied in adult intensive care patients in \nfour meta-analyses, though the incidence of both candidem -\nia and mortality decreased only in two of these studies. Even \nthough evidence is scarce especially in children, prophylaxis \nmay be an option in selected critically ill children, other than \nimmunocompromised and oncological patients, considering \nthe high mortality of these infections. A personalized assess -\nment may be warranted for individual PICU patients based on \nthe presence of specific individual risk factors and local epide -\nmiology\nThe difficulty to identify risk factors for invasive Candida  \nspp. infections and the lack of evidence about the benefits of \nAFP, make early empirical treatment a preferred strategy for \nchildren with a high likelihood of fungal infection in order to \ndecrease the high mortality rates [14] and minimizing the se -\nlection of antifungal resistances. Empiric therapy for non-neu -\ntropenic patients with risk factors for fungal infections with -\nout documented invasive candidiasis is still controversial [27]. \nDecision should be based on colonization data, presence of \nrisk factors, surrogate markers of fungal infection and ongo -MID strongly recommends it in NICU with a prevalence higher \nthan 5% of IC in babies <1,000 g at birth at a dose of 3-6 \nmg/kg twice weekly i.v. or orally [14]. Also, the Latino Ameri -\ncan working group of invasive fungal infections recommends \nfluconazole prophylaxis 3 mg/kg twice a week, in newborn \nweighing < 1,000 g for 6 weeks in NICU with prevalence of \nIC > 5% [15] (AI). In NICU with a prevalence < 5% flucona -\nzole prophylaxis should be individualized and considered only \nin preterm neonates with multiple risk factors for IC (<1,000 g, \nneed for a prolonged central vascular central and broad-spec -\ntrum antibiotics (CII) [14].\nFluconazole prophylaxis is a safe strategy, and although \nisolates of Candida spp. with reduced susceptibility to azoles \nhave been described, there is no evidence of development of \nclinical emergence of resistance to azoles in newborns after \nprolonged exposure. Although there are few studies with long-\nterm follow-up, there is no evidence for any relationship with \nneurocognitive impairment, blindness, deafness or cerebral \npalsy at 24 months of life, nor impact on growth. Even though \nfluconazole may lead to increased liver enzymes, significant \nliver toxicity is uncommon with prophylaxis dosages [12].\nFilamentous fungi are infrequent in the neonatal period, \nand have only rarely been reported in preterm babies, \nincluding Aspergillus  spp. and Rhizopus  spp., albeit associated \nwith a very high mortality [16]. Micafungin is approved in \nnewborns including preterm but its activity against moulds \nis limited. Voriconazole use has been anecdotical, although \nit is not approved below 2 years of age [16, 17]. Due to its \npotential retinal toxicity in particular in the immature \npreterm retina, no clinical trials are planned in this age group \n[18]. Thus, specific AFP against moulds in this patient group is \nnot recommended [2].\n2.- ANTIFUNGAL PROPHYLAXIS IN THE \nPAEDIATRIC INTENSIVE CARE SETTING\nIndications for primary prophylaxis in non-immunocom -\npromised critically ill children are not clear. Despite a relative -\nly high incidence of IFI in patients admitted at the Pediatric \nIntensive Care Unit (PICU), evidence for primary and/or sec -\nondary AFP in non-immunocompromised critically ill children \nis lacking.\nIn the intensive care setting, by far the predominant IFI \nare due to Candida spp., being filamentous fungi anecdoti -\ncal, and therefore, AFP if considered, should be targeted only \nagainst yeasts. Some authors, based on different prediction \nscores, recommend AFP in adults for invasive candidiasis, with \nfluconazole (CII), or as an alternative an echinocandin like \ncaspofungin in non-immunocompromised high-risk patients, \nalthough the grade of recommendation is low (CIII) [19, 20].  \nRisk factors for invasive candidiasis identified in this popula -\ntion include: abdominal surgery with recurrent perforations, \nintubated patients for more than 48 h and expected to be ven -\ntilated for another 72 hours, multiple Candida  spp. coloniza -\ntion, systemic antibiotics, central venous catheters, transfusion Clinical practice update of antifungal prophylaxis in  immunocompromised children J. T. Ramos, et al.\nRev Esp Quimioter 2019;32(5): 410-425413matological and oncologic conditions (i.e. tyrosine kinase inhibi -\ntors], and it remains unclear if AFP is indicated in these cases [34]. \nTable 4 presents the different antifungal agents used for AFP. \nAzoles are the preferred drugs for prevention of IFI, considering \nanti-mould active agents in high-risk patients. Caution is advised \nfor concomitant use of triazoles with chemotherapy metabo -\nlized by cytochrome P450 isoenzymes. Options include itracona -\nzole (AII); posaconazole for patients \u226513 years of age (AII) and \nvoriconazole for patients >2 years of age (AII). Echinocandins \nand liposomal amphotericin B represent alternatives when azole-ing fever despite proper antibiotic treatment. In the absence \nof microbiological confirmation nor clinical response, therapy \nshould be maintained no more than 4 or 5 days [1].\nIn adults, daily bathing of the patients admitted in the in -\ntensive care units in chlorhexidine has been studied in one trial \nfor its role as a protective factor for Candida  spp. bloodstream \ninfections [28]. Even though significant impact on Candida  \nspp. infection is not proven, the measure is easy, inexpensive \nand may be beneficial. The impact in paediatric intensive care \nunits is still to be determined.\nIn conclusion, current recommendations about prophylax -\nis should be individualized considering the PICU epidemiology, \nas well as the individual predisposition and colonization (CII).\nThe balance between overuse of antifungal agents with \nemerging resistance and efficacy is yet to be determined and \nbetter evidence in the paediatric intensive care setting has to \nbe collected. \n3.- CANCER PATIENTS AND STEM CELL \nTRANSPLANT RECIPIENTS\n3.1 Risk factors for invasive fungal disease \nChildren receiving treatment for cancer or undergoing \nhaematopoietic stem cell transplant (HSCT) have a significant \nrisk of developing IFI, with high morbidity and mortality . Risk \nfactors for IFI in these patients are conditioned by the break -\ndown in natural barriers, defects in cell-mediated immunity \nand mainly deficient the presence of profound and persistent \nneutropenia (table 1) [29, 30]. \nPrimary AFP is generally recommended for those children \nwhose risk is greater than 10% (table 2) [29, 31, 32]. However, in \nthe choice of an appropriate AFP strategy it is important to con -\nsider some modifiers like the local epidemiology, comorbidities \nor specific treatment modalities. New therapies such as tyrosine \nkinase inhibitors and other immunomodulatory therapies (i.e. \nCAR T-cell therapy [33] broad the spectrum of patients at risk \nfor IFI [34], so the assessment of risk should be individualized.\n3.2 Primary antifungal prophylaxis\nWhereas pharmacokinetic/pharmacodynamic (PK/PD) \nand safety of the different antifungal agents are targeted in \npaediatric studies; the evidence for efficacy may need to be \nextrapolated from studies in adult population. Although there \nare only few antifungal agents currently approved for AFP in \nchildren, an increasing number of reports describe safety and \nsuggest efficacy of agents given to prevent IFI in the pediatric \npopulation. In addition, most studies do not address the op -\ntimal dosage of an antifungal agent to prevent IFI. The final \nchoice of an antifungal drug for prophylaxis should be individ -\nualized based on the patient risk, the agent activity, the toxici -\nty profile, and the PK/PD data [29, 32]. \nThe specific recommendations for AFP are summarized in \ntable 3 based on the different risk groups. There are not specific \nprophylaxis recommendations for the new drug classes for hae -Clinical factorsSevere and persistent neutropeniaa\nLymphopenia\nMucosal damage\nCentral venous catheters\nPrevious fungal colonization\nGraft versus host disease (GVHD) in HSCT\nCMV infection in HSCT\nPharmacological factorsSteroids in high-dosesb\nAnti-tumour necrosis factors agents\nAlemtuzumab\nNucleoside analogues\nCAR T-cell therapyTable 1  Risk factors for IFI\nIFI: invasive fungal infection, HSCT: haematopoietic stem cell transplant,  \nCMV: cytomegalovirus, CAR: chimeric antigen receptor\naAbsolute neutrophil count of \u2264500 cells/\u03bcL for >7-10 days\nbSteroids in pharmacological doses ( \u22650.3 mg/kg per day prednisone or equivalent)\nHigh-risk (\u2265 10%) Acute myeloid leukemia\nRecurrent or high-risk acute lymphoblastic leukemia\nAllogeneic HSCTa\nSevere aplastic anemia\nLow-risk (\u2264 5%) Standard-risk acute lymphoblastic leukemia\nAutologous HSCTb\nNon-Hodgkin\u2019s lymphoma\nSporadic Pediatric solid tumors\nBrain tumors\nHodgkin\u2019s lymphomaTable 2  Stratification of risk for IFI\nHSCT: Haematopoietic Stem Cell Transplant. GVHD: Graft versus Host Disease.\nIFI: invasive fungal infection.\naPre-engraftment phase or with associated GVHD.\nbIn the neutropenic phase it could be considered intermediate-risk.Clinical practice update of antifungal prophylaxis in  immunocompromised children J. T. Ramos, et al.\nRev Esp Quimioter 2019;32(5): 410-4254143.3 Secondary antifungal prophylaxis\nDespite the scant data in children, secondary AFP or con -\ntinued antifungal treatment after an episode of invasive mould \ninfection is recommended based on the high rate of relapse \n(30\u201350%) [31]. The drug of choice should be active against \nthe previous fungal pathogen. Secondary AFP should contin -\nue for as long as the patient is neutropenic or immunosup -\npressed (AII), e.g. allogeneic HSCT (early phase), chemotherapy \nresulting in severe neutropenia (i.e. <500/mL and at least for 7 \ndays), acute GVHD > stage II, extensive chronic GVHD, or T-cell \nsuppressing therapy, including steroids. Currently evidence is based regimes are contraindicated or not tolerated. Options in -\nclude liposomal amphotericin B (BII); micafungin (BII); and, with \nless strength of evidence, aerosolized liposomal amphotericin B \n(CII) and caspofungin (CII) [31, 34, 35]. In the absence of GvHD, \nAFP may be continued after engraftment until discontinuation of \nimmunosuppression and signs of immune recovery. In the pres -\nence of GvHD requiring augmented immunosuppression (includ -\ning steroids in therapeutic dosages or anti-inflammatory antibod -\nies), prophylaxis against IA and other relevant IFI is recommended \n(AII) [2]. Newer agents, such as isavuconazole, are under study in \nchildren, and have poor evidence to be recommended for AFP. Underlying condition Cancer Comments\nChildren undergoing allogeneic HSCT with no GVHD \nAFP is recommended during the neutropenic phase until engraftment (BII)\nAFP is recommended after engraftment until discontinuation of immune \nsuppression and immune recovery (no grading)Fluconazole (AI) \nItraconazole (BI)\nVoriconazole (BI)\nMicafungin (CI)\nLiposomal amphotericin B (CIII)\nPosaconazole (no grading)Only active against yeasts\nTDM recommended\nTDM recommended\nFor children \u226513 years\nTDM recommended\nChildren undergoing allogeneic HSCT in the presence of GVHD (acute grade II\u2013IV or chronic extensive) treated with augmented immunosuppression\nAFP against mould and yeast infections is recommended while the \nimmunosuppression is maintained (AII)Posaconazole (BI) \nVoriconazole (BI)\nItraconazole (CIII) \nLiposomal amphotericin B (no grading)\nMicafungin (no grading)For children \u226513 years\nTDM recommended\nTDM recommended\nTDM recommended\nAutologous HSCT with anticipated neutropenia >7 days\nAFP should be considered (BI) until immune recovery Fluconazole (AI) \nMicafungin (AII)\nAny mould active agent (DIII)\nPaediatric de novo or recurrent leukemia patients\nAFP should be considered in high risk patients (BII).\nNo evidence-based recommendations can be made on the\nduration in patients with persisting neutropenia in this groupItraconazole (BI)\nPosaconazole (BI) \nLiposomal amphotericin B (BII)\nFluconazole (CI) \nOther options include: Voriconazole (no grading)\nMicafungin (no grading)TDM recommended\nFor children \u226513 years \nTDM recommended\nActive only against yeastTable 3  Antifungal primary prophylaxis in children with cancer: recommendations based on risk \ngroups [31, 32, 34-39]\nAFP: Antifungal prophylaxis. TDM: Therapeutic Drug Monitoring. HSCT: Haematopoietic Stem Cell Transplant. GVHD: Graft versus Host DiseaseClinical practice update of antifungal prophylaxis in  immunocompromised children J. T. Ramos, et al.\nRev Esp Quimioter 2019;32(5): 410-425415minimize toxicity. This is important in children, because of their \npharmacokinetic variability, and especially in hematology-on -\ncology patients who have multiple conditions (associated with \ntheir underlying disease and its treatment) that affects the \nabsorption, distribution, metabolism and clearance of antifun -\ngal medications [44]. TDM is generally recommended during \nprophylaxis with itraconazole, voriconazole and posaconazole \n(AII). Recommended plasma target ranges are summarized in \ntable 5 [40, 45]. Usually, the first sample should be acquired lacking regarding the minimal duration of the therapy before \nthe continuation of anticancer treatment of the conditioning \nregime for allogeneic HSCT [31, 40]. \n3.4 Practical aspects\n3.4.1 Therapeutic drug monitoring (TDM)\nThe objective of monitoring the plasma levels of antifun -\ngals is to optimize their dose, in order to improve efficacy and Antifungal agent and dosing Dosing Spectrum Comments\nFluconazole 6\u201312 mg/kg/day QD IV/PO  (maximum \n400mg/day)Only against yeast\nItraconazole 5 mg/kg/day BD PO (>2 years of age) Both yeasts and moulds Not approved in patients <18 years. \nTDM required\nVoriconazole 2 to <12 years or 12\u201314 years and \n<50 kg:\n16 mg/kg/day BD IV/PO \n(first day: 18 mg/kg/day IV/PO BD)\n>15 years or 12\u201314 years and >50 kg:\n8 mg/kg/day BD IV/PO (first day: 12 \nmg/kg/day BD IV; 400 mg/day BD PO)Both yeasts and moulds (no against \nZygomycetes ) Not approved in patients <2 years. \nTDM required. \nIncreased risk of phototoxicity.\nPosaconazole 600 mg/day TDS PO (suspension) in \npatients >13 years [41]\n300 mg/day QD PO (3 x 100 mg \ndelayed-release tablets). First day: 600 \nmg/day BD.\n300 mg/day QD IV (first day: 300 mg/\nday BD)Both yeasts and moulds Limited PK data in patients <13 years.\nNot approved in the European Union in patients <18 \nyears. \nTDM required.\nCoverage for most fungi, including Zygomycetes .\nDelayed released tablet formulation presents better PD \ndata. \nTaken with food.\nLiposomal amphotericin B 1 mg/kg IV every other day or \n2.5 mg/kg IV twice weekly Both yeasts and moulds Still not approved for prophylaxis in children [32, 42].\nOptimal dose of alternate administration is still \nunknown. \nAlternative when azole based regime is contraindicated or \nnot tolerated.\nCaspofungin 50 mg/m2/day QD IV (first day: 70 mg/\nm2/day QD IV) (maximum 70 mg/day)Both yeasts and moulds Caspofungin does not have a label for the prophylactic\nIndication [43].\nMicafungin 1 mg/kg/day (if >50kg : 50mg) QD IV Both yeasts and moulds Approved for AFP of Candida  spp. infections in\ngranulocytopenic children. \nLess interactions than azoles with other drugs. \nConsiderably higher drug clearance in children 4 months \nto 5 years compared to older children.Table 4  Agents and antifungal dosing recommended in haemato-oncological or HSCT paediatric \npatients [31, 32, 37, 40].\nQD: once daily. BD: twice a day. TDS = three times a day. AFP: antifungal prophylaxis. For interactions, see table 6.Clinical practice update of antifungal prophylaxis in  immunocompromised children J. T. Ramos, et al.\nRev Esp Quimioter 2019;32(5): 410-425416on the type of transplanted organ and the \nreceptor risk factors to develop an IFI. There \nare no recommendations in the pediatric \nfield due to the limited published infor -\nmation, so that most of them are adapted \nfrom those published in the adult popula -\ntion. In general, patients at high risk (ex -\npected incidence higher than 10%) should \nreceive prophylaxis against filamentous \nfungi (AII). The drug of choice will depend \non the type of transplant organ and the \npopulation studied [53].\n4.1. Prophylaxis against yeasts\nLiver, pancreas and bowel recipients have the highest risk \nto develop an invasive candidiasis, thereby potentially benefit -\ning from AFP. Liver transplant recipients need to meet at least \ntwo risk factors [54, 55] (table 7). Fluconazole or echinocan -\ndins are the most recommended drugs [56], considering am -\nphotericin B when patients have risk factors for filamentous \nfungi (AIII). The most recommended duration is 4 weeks in the \nliver transplant and at least 4 weeks in the pancreas and bowel \ntransplant. In kidney recipients, invasive candidiasis is the most \nfrequent IFI, although its incidence is low, so prophylaxis is not \nrecommended (DIII) [54].\n4.2 Prophylaxis against Pneumocystis jirovecii  (PJ)\nThe incidence of PJ pneumonia in a study made in adult \npopulation in United Kingdom was 5.8% in lung or cardiopul -\nmonary transplants, 5.5% in heart, 1.2% in liver and 0.3% in \nthe kidney recipients [57]. Prophylaxis against PJ during the \nfirst months after the transplantation is recommended in \nseveral guidelines for adults and children [58]. Trimethoprim \nsulfamethoxazole (TMP-SMX) is the drug of choice [57, 59]. In \ncase of intolerance to cotrimoxazole, dapsone is the second \nline drug more used for prophylaxis, although less effectivity \nhas been observed in some pediatric studies [60]. There is little \nexperience with atovaquone and pentamidine (inhaled or in -\ntravenous).\nThe duration of PJ prophylaxis is not established, ranging \nbetween 3 and 12 months after the transplantation according \nto different scientific societies [59, 61]. Its indication should be \nprolonged after graft rejection or higher steroid needs (over \n20 mg of prednisolone or \u22650.3 mg/kg or equivalent for more \nthan 4 weeks). It has also been proposed to keep it indefinitely \nin lung or bowel transplant, in patients with chronic CMV in -\nfections and in those with a history of a previous infection by \nPJ (BII) [57].\n4.3 Prophylaxis against filamentous fungi\nInvasive aspergillosis (IA) is one of the most relevant fun -\ngal infections in SOT recipients, with an overall incidence re -\nported of 1-15%, being higher in lung transplant in surveil -\nlance studies (44%) [51], and reported mortality rates of ap -within 5-7 days of starting therapy (2-5 days for voriconazole) \nand repeated until steady-state level in the therapeutic range \nis confirmed, if there are changes in the patient\u2019s clinical con -\ndition, concomitant medications, or suspected toxicity [40]. \n3.4.2 Side effects and drug-drug interactions\nThe main side effects of the antifungals used in prophy -\nlaxis and relevant interactions for hematology-oncology pa -\ntients are summarized in table 6.\n3.4.3 Monitoring of fungal biomarkers \nSerum galactomannan (GM) screening should not be per -\nformed in neonates and children at low risk for IA (DIII). Serum \nGM should not be used as a screening test in asymptomatic \npatients undergoing AFP; several studies have shown that it \nhas a low positive predictive value in these cases (BII) [46-48]. \nTherefore, given the low pre-test risk of IA in the context of \neffective anti-mould prophylaxis, the result of the test would \nbe either negative or false positive in asymptomatic patients, \nleading to unnecessary diagnostic tests and treatments. The \ntest remains useful to assist the diagnosis of patients with a \nclinical suspicion of IFI during prophylaxis [40, 46, 47, 49, 50]. \n4.- SOLID ORGAN TRANSPLANTATION (SOT)\nPatients who received a SOT have a higher risk of IFI, being \nan important cause of morbidity and mortality. Candida  spp. are \nthe most frequent IFI, followed by filamentous fungi, especially \nAspergillus  spp. [51]. Not all recipients are at the same risk of \nIFI. The multicenter epidemiological study TRANSNET, conducted \nin adult population, shows the highest incidence of IFI in small \nbowel transplant recipients (11.6%), followed by lung (8.6%), \nliver (4.7%), heart (4%) and pancreas (3.4%) [51]. Data in chil -\ndren are still scarce, but a recent study, conducted in pediatric \npopulation revealed an IFI global incidence of 2%, cardiopulmo -\nnary and lung transplant showing the highest incidence (12.5% \nand 11.4% respectively) [52].\nAFP in SOT pediatric recipients can decrease colonization, \nand therefore, the subsequent development of IFI. Neverthe -\nless, universal AFP is not recommended, and its use will depend Antifungal Prophylaxis plasma range Treatment plasma range Quality of evidence\nItraconazole 0.5-4 mg/L 1-4 mg/L AII efficacy\nBII toxicity\nVoriconazole 1-6 mg/L (optimal 2-5 mg/L) AII efficacy\nAII toxicity\nPosaconazole >0.7 mg/L >1 mg/L BII efficacy (prophylaxis)\nAII efficacy (treatment)Table 5  Recommended plasma target ranges for antifungal drugsClinical practice update of antifungal prophylaxis in  immunocompromised children J. T. Ramos, et al.\nRev Esp Quimioter 2019;32(5): 410-425417mould activity may also be used for IA prevention. The effec -\ntiveness and safety of voriconazole prophylaxis has been stud -\nied in lung transplant recipients [2]. The IDSA guidelines rec -\nommends itraconazole or voriconazole in patients colonized \nby Aspergillus  spp., in those with a proven fungal infection in \nthe removed organ, sinusal aspergillosis or in those who have \nreceived a unipulmonary transplant [35].\nDuration of prophylaxis is unclear, but at least 3- to 4-week \ntreatment or until resolution of risk factors seems appropriate \n[2]. In lung and high-risk heart transplanted children a more \nprolonged prophylaxis (3-12 months) is warranted. The drug of \nchoice remains controversial. Lipid amphotericin B has shown proximately 22% despite novel treatment modalities. In lung \ntransplant recipients, invasive pulmonary disease has an even \nhigher mortality rate (67\u201382%) [59]. AFP against Aspergillus  \nspp. is recommended in lung transplant recipients (AIII) and in \nthose children exhibiting a high-risk profile (e.g. Model for End \nStage Liver Disease score >30, liver failure, renal failure, rein -\ntervention) (BIII) [2]. Data of IA in heart recipients are scarce. \nReduction of IFI has been observed in those patients with \nprophylaxis, but no consensus exists. Some authors recom -\nmend AFP only in patients with risk factors [2, 54]. Inhaled lipid \nformulations of amphotericin B are the most studied option, \nalthough its optimal dose, formulation and duration has not \nbeen defined in adult population. Systemic azoles with anti -Antifungal Adverse effects Interactions\nFluconazoleGastrointestinal disorders \nElevation of transaminase levelsCyclosporine, ifosfamida, irinotecan, vincristine, fentanyl, \nomeprazole, ondansetron, cotrimoxazole, prednisone, \ndexamethasone\nItraconazoleGastrointestinal disorders \nElevation of transaminase levels Periferal neuropathy \nNegative inotropic effect (less frequent)Cyclosporine, ifosfamida, irinotecan, methotrexate, \netoposide, vincristine, fentanyl, deferasirox, omeprazole, \nondansetron, ranitidine, dexamethasone, prednisone \nVoriconazoleGastrointestinal disorders \nElevation of transaminase levels \nVisual disturbances\nHallucinations\nHeadache\nRash\nLong QT-syndromeCiclosporin, etoposide, ifosfamida, irinotecan, vincristine, \nfentanyl, cotrimoxazole, ibuprofen, omeprazole, \nondansetron, dexamethasone, prednisone\nPosaconazolGastrointestinal disorders \nElevation of transaminase levels\nHeadache\nDizziness\nPeriferal neuropathy\nElectrolyte alterations \nLong QT syndrome (less frequent)Cyclosporine, etoposide, ifosfamida, irinotecan, vincristine, \nfentanyl, omeprazole, ranitidine, dexamethasone, \nprednisone\nMicafunginGastrointestinal disorders \nHeadache\nPhlebitis\nElevation of transaminase levels\nElectrolyte alterationsSirolimus, nifedipine, itraconazole\nAmphotericin BHypokalemia\nNephrotoxocity\nHeadache\nElevation of transaminase levels\nInfusion reactionsCyclophosphamide, cisplatin, cytarabine, etoposide, \nhydroxyurea, ifosfamide, irinotecan, mercaptopurine,  \nmethotrexate, temozolamide, vincristine, vinorelbine, \ndexamethasone, prednisone cyclosporine, aminoglycosides, \npentamidineTable 6  Side effects and drug interactions of antifungals used in prophylaxisClinical practice update of antifungal prophylaxis in  immunocompromised children J. T. Ramos, et al.\nRev Esp Quimioter 2019;32(5): 410-425418of underlying immune disorders and PID must always be con -\nsidered in those patients. There are several PID that may pres -\nent with both invasive and mucocutaneous fungal infections, \ncaused by moulds and/or yeasts [63, 64].\nNeutrophil defects, (severe) combined immunodeficien -\ncies and diseases caused by mutations altering relevant cy -\ntokine pathways are among the list of PID that may present \nwith severe fungal infections. Thus, primary or secondary \nAFP is recommended for most of the diseases below listed \n(table 9). However, evidence regarding the most appropri -\nate medication, duration, dosing schedule, drug monitor -\ning and dose adjustment is scarce and often extrapolated \nfrom adults and/or the onco-haematologic setting (table 4). \nChronic granulomatous disease (CGD) is the PID with the \nhighest risk for IFI, particularly IA with incidences ranging \nfrom 26% to 45%. Additionally, IA is the most common \ninfectious cause of death.  Prevention of IA plays a central \nrole in the clinical management of children with CGD and \nconsists of reducing environmental exposure to moulds and \nthe prophylactic use of antifungals. Itraconazole prophy -\nlaxis has shown to significantly reduce IFD in CGD patients \nand is recommended as prophylaxis (AII). Posaconazole is a a significant reduction of invasive fungal infections without a \nmortality reduction but is limited by its potential for nephrotox -\nicity. Echinocandins are not nephrotoxic, and promising results \nhave been published in preventive studies focusing on high-risk \nliver transplant recipients [2].\nIn paediatric kidney transplant recipients AFP to prevent \nfilamentous fungi is not recommended (DIII) [54]. In small \nbowel and pancreas recipients transplant, only patients are risk \nare candidates for prophylaxis against moulds.\nTable 8 summarized the indications about AFP in pediatric \npopulation after SOT [32].\n5.- PRIMARY IMMUNODEFICIENCIES\nPatients with primary immunodeficiencies (PID) are often \nprone to develop recurrent and/or severe infections, autoim -\nmune disorders and malignancies. Infection site, causative \npathogens, clinical course and outcome depend on a number \nof factors such as the underlying gene defect, patients\u2019 age, \nexistence of comorbidities and also environmental factors po -\ntentially related to pathogen exposure [62]. IFI are a hallmark Fungal infection Solid organ transplant Risk factors\nCandida  species Liver Retrasplant\nPost-transplant renal failure\nMore than one episode of acute rejection during the first month, requiring the use of \nsteroids or monoclonal antibodies\nColonization by Candida  spp.\nAspergillus  species Liver Retrasplant\nPost-transplant renal failure requiring dyalisis\nPretransplant fulminant liver failure\nSurgical re-intervention\nIntestine-pancreas Immunosupression\nAcute graft rejection \nHemodyalisis\nInitial graft rejection\nAnastomosis related issues\nPost-transplant need of laparotomy\nInfection by cytomegalovirus\nHeart Post-transplant hemodyalisis\nSurgical reintervention\nColonization or previous infection by Aspergillus  spp. before or after transplantation\nInfection by cytomegalovirus \nAcute graft rejectionTable 7  Risk factors to IFI in children with SOT\nSOT: Solid Organ TransplantationClinical practice update of antifungal prophylaxis in  immunocompromised children J. T. Ramos, et al.\nRev Esp Quimioter 2019;32(5): 410-4254196.- ANTIFUNGAL PROPHYLAXIS IN CHILDREN \nWITH HIV-INFECTION\n6.1 Pneumocystis jirovecii  (PJ)\nCurrently, since the advent of potent combined antiretro -favourable alternative (CIII). The use of prophylactic recom -\nbinant human interferon- \u03b3 has shown to decrease the risk \nof severe infections (including fungal infections) in CGD \nby 70%, but controversy remains about its use in routine \nprophylaxis [2, 65-68]. Solid organ transplant Predominant IFI Antifungal prophylaxis Doses Duration\nLiver Candida  spp.aFluconazole oral/ iv\nCaspofungin iv6-8 mg/kg/day \n50 mg/m2/day4 weeks\nAspergillus  spp.aIn patients with risk factors for Aspergillus :\nLiposomal amphotericin B iv1 mg/kg/day \nCaspofungin iv 50 mg/m2/day\nLung Aspergillus  spp. Liposomal amphotericin B (until extubation) 1 mg/kg/day 6-12 months\nInhaled amphotericin B (in extubated patients) 24 mg: - 1st month 3 times / week \u2013 \nlater 1 per week\nVoriconazole oral/ivbOral\n<50Kg: 18mg/kg/day divided in two doses\n>50 Kg:400 mg/day divided in two doses\nIV\n<50Kg:  16 mg/kg/day divided in two doses\n>50 Kg: 8 mg/day  divided in two doses\nItraconazole oral/ivb5 mg/kg/day divided in two doses\nHeart Aspergillus  spp. Itraconazole oral/ iv 5 mg/kg/d\u00eda divided in two doses 3-6 months\nVoriconazole oral/iv See the previous part\nCaspofungin iv 50 mg/m2/day\nMicafungin iv 1 mg/kg/day \nPancreas Candida  spp. Fluconazole oral/iv 6-8 mg/kg/day 4 weeks\nIntestine Candida  spp. Fluconazole oral/iv 6-8 mg/kg/day 4 weeks\nLiposomal amphotericin B 1 mg/kg/day\nCaspofungin iv 50 mg/m2/day\nMicafungin iv 1 mg/kg/day\nPneumocystis jirovecii  \nIndicated in all types of SOTTMP-SMX oral/iv 150 mg/m2/day divided in two doses\n3 consecutive days/ week3-12 weeks\nDapsone iv 2 mg/kg/day\nPentamidine iv 4 mg/kg/ month\nInhaled pentamidine 300 mg/ month\nAtovaquone iv 30 mg/kg/dayTable 8  Recommendations about antifungal prophylaxis in SOT\nSOT: Solid Organ Transplantation, IFI: invasive fungal infection. iv=intravenous\nThe proposed doses have been set following prophylaxis in others indications and after a consensus between the authors.\naRecommended in patients with risk factors defined in table 1.\nbTherapeutic drug monitoring is recommended. Targeted prophylaxis plasma level.  Voriconazole: \u22651 mg/l, itraconazole: \u22650,7 mg/l. Clinical practice update of antifungal prophylaxis in  immunocompromised children J. T. Ramos, et al.\nRev Esp Quimioter 2019;32(5): 410-425420viral therapy, PJ is most commonly diagnosed in non-HIV in -\nfected children [69]. PJ infection occurs in the general popula -\ntion during the first months of life. More than 80% of children \naged 2 to 4 years have antibodies against PJ. Approximately a \nthird of infected immunocompetent children will be asymp -\ntomatic or have mild respiratory symptoms. PJ pneumonia \n(PJP) occurs almost exclusively in the immunocompromised \nchild and is an AIDS-defining illness. PJ infection incidence \nis highest in the first year of life, in particular between 3 to \n6 months. The mode of PJ transmission remains to be estab -\nlished, airborne human to human transmission being the likely \ncause [70].Chemoprophylaxis is highly effective in preventing PJP \nand is recommended in all children older than 6 years with \nCD4 counts < 200 cells/mm3 or CD4 percentage <15%;  in chil -\ndren 1 to 6 years old with CD4 counts < 500 cells/mm3 or CD4 \npercentage <15%; and in infants younger than 12 months re -\ngardless of CD4 counts or CD4 percentage (AII) [70]. \nInfants with indeterminate HIV infection status should re -\nceive prophylaxis until HIV-infection has been excluded (AIII). \nPJP chemoprophylaxis is not recommended in infants found to \nbe definitely or presumed HIV-uninfected. The child should not \nhave other laboratory (e.g., no positive virologic test results) or \nclinical conditions (e.g., no AIDS-defining conditions that can -Immunodeficiency Fungi Antifungal Prophylaxis\nInvasive /systemic Mucocutaneous\nChronic granulomatous disease Frequent (>30%)\nAspergillus  spp. (pulmonary, bone \nlesions) and other moulds. \nYeasts (rare) CMC (rare) Primary prophylaxis \nItraconazole (AII)a\nPosaconazole (CIII)b\nVoriconazole not recommended (DIII)\nCongenital neutropenia Rare < 10% \nAspergillus  spp. (pulmonary infections) \nCandida  spp. (disseminated infections) The systematic prescription of antifungal prophylaxis \nis not justified (DIII). \nFor persistent profound neutropenia despite G-CSF, \nitraconazole prophylaxis can be considered (BIII). \nHyper-IgM syndrome with cellular \ndefect Pneumocystis  jirovecii  (pulmonary \ninfections) TMP-SMX\nSCID/CID P. jirovecii  (pulmonary infections) \nAspergillus  spp. (pulmonary infections) \nCandida  spp.CMC TMP-SMX (AII) \n< 1 month of age consider fluconazole\n> 1 month consider itraconazole\nSTAT3 deficiency Aspergillus  spp. CMC If CMC, consider fluconazole\nIf lung damage consider itraconazole (AIII)\nCARD9 deficiency [64]\n(Only fungi from the phylum \nAscomycota )Very common (90%)\nMostly Candida  spp. (CNS infection \n30%)\nAlso deep dermatophytosisRare (10%) \nCMC or superficial \ndermatophytosisPrimary prophylaxis: Fluconazole (AIII)\nSecondary prophylaxis:\naccording to isolated fungus /infections site \nSTAT1 gain of function Rare: mostly Candida  spp. Very common\nMostly CMCIf recurrent and/or severe CMC: Fluconazole (AIII)\nAPS-1 (APECED) Restricted to non-invasive \ncandida infections (CMC)If recurrent and/or severe CMC: Fluconazole (AIII)\nIL-12/IFN-gamma axis defect Rare: Candida  spp. CMC If recurrent and/or severe CMC: Fluconazole (AIII)\nIL-17R deficiencies, ACT1 deficiency Candida  spp. CMC If recurrent and\u00a8/or severe CMC: Fluconazole (AIII)Table 9  Indication for primary and/or secondary antifungal prophylaxis in primary immunodeficiencies \n(adapted from Aguilar C et al.) [63]\nACT1: adaptor for IL-17 receptors; APS1(APECED): autoimmune polyendocrinopathy type1; CARD9: caspase recruitment domain-containing protein 9; CID: combined \nimmunodeficiency; CMC: chronic mucocutaneous candidiasis; G-CSF: granulocyte colony stimulating factor; IFN-gamma: interferon gamma; IL17-R: interleukin-17 \nreceptor;  SCID: severe combined immunodeficiency; STAT1: signal transducer and activator of transcription 1; STAT3: signal transducer and activator of transcription 3; \nTMP-SMX: Trimethoprim-sulfamethoxazole\naItraconazole: broadest experience, dosing regimens are different in Europe and the US.\nbPosaconazole with promising but only short term results.Clinical practice update of antifungal prophylaxis in  immunocompromised children J. T. Ramos, et al.\nRev Esp Quimioter 2019;32(5): 410-425421not be explained on the basis of other causes of immunosup -\npression) or evidence of HIV infection. Presumptive exclusion \nof HIV infection in non-breastfeeding infants, can be based on \ntwo negative virologic test results, one obtained at \u22652 weeks \nand one obtained at \u22654 weeks of age; a negative test at \u22658 \nweeks of age or a negative antibody test at \u22656 months of age.\nTMP\u2013SMX is the drug of choice for prophylaxis due to its \nhigh efficacy, relative safety, low cost, and broad antimicrobial \nspectrum. It should be administrated during three consecuti -\nve or alternating days/week or on a daily base (AI). In case of \nTMP-SMX contraindication (allergy, intolerance, interactions), \nsecond choice prophylaxis includes atovaquone (AI) o dapso -\nne (BI). Aerosolized pentamidine is recommended for children \nwho cannot take TMP-SMX, atovaquone, or dapsone (BI). Intra-\nvenous pentamidine can be used in children older than age 2 \nyears when other options are unavailable (BII). \nDiscontinuation of PJP chemoprophylaxis should be con -\nsidered for HIV-infected children after having received cART for \n\u22656 months and have demonstrated for >3 consecutive months \na CD4 percentage \u226515% or CD4 count \u2265200 cells/mm3 for pa -\ntients aged \u22656 years (BII), or CD4 percentage \u226515% or CD4 count \u2265500 cells/mm3 for patients aged 1 to \n<6 years (BII) [70].\nCD4 percentage and CD4 count should \nbe re-evaluated at least every 3 months and \nprophylaxis reinstituted if the original criteria \nfor prophylaxis are reached (BIII). PJP pro -\nphylaxis should not be discontinued in HIV-\ninfected infants aged <1 year.\nAs PJ transmission occurs easily, iso -\nlation should be strongly considered and \nsharing a room with another patient with an \nundiagnosed respiratory illness that could be \nPJP should be avoided, especially during the \nfirst 2 years of life (AIII).\nAs none of the drugs used to treat and \nprevent PJP completely eliminates PJ, and \nprophylaxis is only effective while the selec -\nted drug is administered, patients who have \nexperienced an episode of PJP should remain \non a prophylactic regimen after treatment \nuntil they meet criteria for discontinuing pro -\nphylaxis (AIII). \nSecondary prophylaxis should be dis -\ncontinued applying the same criteria as \nfor discontinuing primary prophylaxis. PJP \nprophylaxis must not to be discontinued in \nHIV-infected infants aged <1 year. Once PJP \nprophylaxis has been discontinued, children \nshould be evaluated and followed-up despi -\nte normal or high CD4 counts or percentages \n(AIII). Lifelong prophylaxis should be admi -\nnistered if PJ infection reoccurs in a patient \nwith a CD4 count \u2265 200 cells/mm (CIII). Table \n10 summarizes the drugs used for PJP pro -\nphylaxis [70].\n6.2 Cryptococcosis\nAs the incidence of cryptococcosis is low in HIV infected \nchildren, neither routine testing of asymptomatic children for \nserum cryptococcal antigen (CIII), nor primary prophylaxis is \nrecommended (BIII).  Secondary prophylaxis for a duration of \nat least 12 months is indicated using fluconazole (AI) or itra -\nconazole (BI) [70].\n6.3 Hystoplasmosis\nRoutine primary prophylaxis for histoplasmosis in children \nis not recommended (BIII). Prevention of exposure is attempt -\ned by avoiding risk factors predisposing to infection such as \nexposure to contaminated areas, which can result in the inha -\nlation of histoplasma spores.\nPrevention of recurrence is attempted using induction \ntherapy (amphotericin B), followed by a consolidation thera -\npy (itraconazole) for a total of at least 12 months. In case of Antifungal Doses and route Frequency Evidence\nTMP-SMX\n1st choice150 mg TMP /m2/daily vo \nMax dose: 320 mg TMP/daily12-24h daily or \n3 consecutive days or\n3 alternating daysAI\nAtovaquone\n2nd choiceAge 1-3 and > 24 months: 30 mg/kg/day/vo\n4\u201324 months: 45 mg/kg/day/vo\n\u226513 years: 1,500mg/24h \nMax dose 1,500 mg/dailyOnce daily AI\nDapsone\n3rd choice Age >1 month\n2 mg/kg/day\n4 mg/kg/week \nMax dose 100 mg/daily\nMax dose 200mg/weekOnce daily\nOnce weeklyBI\nPentamidine 4 mg/kg/dose/iv\nAge > 5 years: \n300 mg/dosis/nebulized\nMax dose 300 mg iv2-4 weeks\nOnce monthlyBII\nBITable 10  Recommended drugs for PJP prophylaxis\nPJP: Pneumocystis jirovicii  pneumonia, Max: maximum. iv: intravenous\nIn case of TMP-SMX contraindication (allergy, intolerance, interactions) 2nd choice prophylaxis includes \natovaquone (AI) o dapsone (BI). Aerosolized pentamidine is recommended for children who cannot take \nTMP-SMX, atovaquone, or dapsone (BI). Intravenous pentamidine can be used in children older than age \n2 years when other options are unavailable (BII). Clinical practice update of antifungal prophylaxis in  immunocompromised children J. T. Ramos, et al.\nRev Esp Quimioter 2019;32(5): 410-425422sustained immunosuppression (CD4 percentage <15% at any \nage or <150 cells/mm3 in children aged \u22656 years) as well as \nin patients suffering from relapse despite appropriate thera -\npy, treatment may be prolonged (AII). Whilst experience with \nvoriconazole is limited in children, fluconazole has been shown \nto be less effective than itraconazole (CII).\nRecommendations regarding discontinuation of second -\nary prophylaxis are based on data from clinical trials in adults. \nOnce immune reconstitution (CD4 counts >150 cells/mm3 in \nchildren aged>6 years or >15% at any age) is achieved, his -\ntoplasma serum antigen is <2 ng/mL (when available) and \nitraconazole has been given for \u22651 year; treatment may be \nstopped (CIII). Histoplasma antigen is not available in most \nSpanish centers. Therapy is to be continued in case of relapse \noccurring despite appropriate treatment (BIII) [70]. \n6.4 Candidiasis\nCandidiasis due to Candida spp. is the most frequent fun -\ngal infection in HIV infected patients, being mainly localized \nand limited to the mucosa and the skin (oropharyngeal and \noesophageal candidiasis, vulvovaginitis and dermatitis). Inva -\nsive candidiasis is less frequent. \nExposure to Candida  spp. cannot be prevented as they are \ncommensals of the mucosa and the skin. However, the limi -\ntation and rational use of antibiotics is fundamental in order \nto avoid overgrowth of Candida  spp. Primary and secondary \nprevention are not indicated [70].\nREFERENCES\n1. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Os -\ntrosky-Zeichner  et al. Clinical practice guideline for the mana,ge -\nment of Candidiasis: 2016 update by the Infectious Diseases Socie -\nty of America. Clin Infect Dis.2016;62: e1\u201350.19. DOI: 10.1093/cid/\nciv1194\n2. Warris A, Lehrnbecher T, Roilides E, Castagnola E, Br\u00fcggemann RJM, \nGroll AH. ESCMID-ECMM guideline: diagnosis and management of \ninvasive aspergillosis in neonates and children. Clin Microbiol Infect. \n2019: S1198-743X(19)30282-4. DOI: 10.1016/j.cmi.2019.05.019.\n3. Benjamin DK Jr, Poole C, Steinbach WJ, Rowen JL, Walsh TJ. Ne -\nonatal candidemia and end-organ damage: a critical appraisal of \nthe literature using meta-analytic techniques.  Pediatrics  2003; \n112:634-640. \n DOI. 10.1542/peds.112.3.634\n4. Zaoutis TE, Prasad PA, Localio AR, Coffin SE, Bell LM, Walsh TJ, \nGross R. Risk factors and predictors for candidemia in pediatric in -\ntensive care unit patients: implications for prevention . Clin Infect \nDis 2010; 51:e38-e45. DOI: 10.1086/655698 \n5. Aguado JM, Ruiz I, Mu\u00f1oz P, Mensa J, Almirante B, V\u00e1zquez L, Ro -\nvira M, et al por el Grupo de Estudio de Micolog\u00eda M\u00e9dica de la \nSEIMC (GEMICOMED). Recomendaciones sobre el Tratamiento de la \nCandidiasis Invasiva y Otras Infecciones por Levaduras de la Socie -\ndad Espa\u00f1ola de Microbiolog\u00eda Cl\u00ednica y Enfermedades Infecciosas \n(SEIMC). Actualizaci\u00f3n 2010. Enferm Infecc Microbiol Clin 2011; \n29:345-61. DOI: 10.1016/j.eimc.2011.01.0086. Puig-Asensio M, Padilla B, Garnacho-Montero J, Zaragoza O, Agua -\ndo JM, Zaragoza R, et al. Epidemiology and predictive factors for \nearly and late mortality in Candida  bloodstream infections: a pop -\nulation-based surveillance in Spain. CANDIPOP Project. Clin Micro -\nbiol Infect . 2014;20:O245-54. DOI: 10.1111/1469-0691.12380\n7. Vaseleiou E, Apsemidou A, Vyzantiadis TA, Tragiannidis A. Invasive \ncandidiasis and candidemia in pediatric and neonatal patients: A \nreview of current guidelines. Curr Med Mycol . 2018; 3:28-33. DOI \n10.18502/cmm.4.3.173\n8. Healy CM, Campbell JR, Zaccaria E, Baker CJ. Fluconazole proph -\nylaxis in extremely low birthweight neonates reduces invasive \ncandidiasis mortality rates without emergence of fluconazole \nresistant Candida. Pediatrics 2008; 1 21:703-10. DOI: 10.1542/\npeds.2007-1130\n9. Kaufman DA. Challenging issues in neonatal candidiasis. Cur -\nrent Medical Research and Opinion, 2010. 26:1769-1778. DOI: \n10.1185/03007995.2010.487799\n10. Cleminson J, Austin N, McGuire W. Prophylactic systemic antifun -\ngal agents to prevent mortality and morbidity in very low birth \nweight infants.Cochrane Database of Systematic Reviews 2015, \nIssue 10. Art. No.: CD003850. DOI: 10.1002/14651858.CD003850.\npub5\n11. Ferreira da Silva J, Moreira Camargos PA, Corr\u00eaa LP, de Castro \nRomanelli RP. Fluconazole prophylaxis in preterm infants: a sys -\ntematic review. Braz J Infect Dis 2017; 21:333\u2013338. DOI: 10.1016/j.\nbjid.2017.01.008\n12. Greenberg RG, Benjamin DK Jr. Neonatal candidiasis: diagnosis, \nprevention, and treatment. J Infect. 2014;69 Suppl.1:S19\u201322. DOI: \n10.1016/j.jinf.2014.07.012\n13. Figueras C, Diaz de Heredia C, Garcia JJ, Navarro ML, Ruiz Contre -\nras J, Rossich R, et al for The Spanish Society of Paediatric Infec -\ntious Diseases (SEIP) recommendations on the diagnosis and man -\nagement of invasive candidiasis. An Pediatr (Barc) 2011;74, 337.\ne1\u2013e17. DOI: 10.1016/j.anpedi.2010.12.012\n14. Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup \nMCet al. ESCMID guideline for the diagnosis and management of \nCandida diseases 2012: prevention and management of invasive \ninfections in neonates and children caused by Candida spp. Clin \nMicrobiol Infect 2012;18 Suppl. 7:38\u201352. DOI: 10.1111/1469-\n0691.12040\n15. Santolaya ME, Alvarado Matute T, de Queiroz Telles F, Colombo AL, \nZurita J, Tiraboschi IN, et al. Recommendations for the manage -\nment of candidemia in neonates in Latin America. Grupo Proyecto \nEpico. Rev Iberoam Micol. 2013;30 Suppl. 1:158\u201370. DOI: 10.1016/j.\nriam.2013.05.011\n16. Frick MA, Boix H, Camba Longueira F, Martin-Gomez MT, Rodri -\ngo-Pend\u00e1s J\u00c1, Soler-Palacin P. Primary Cutaneous Aspergillosis in \na Preterm Infant. Pediatr Infect Dis J 2016;35:704-6. DOI:10.1097/\nINF.0000000000001136\n17. Fort\u00fan J, Carratal\u00e1 J, Gavald\u00e1 J, Lizasoa\u00edn M, Salavert M, de la C\u00e1 -\nmara R, et al por el Grupo de Estudio de Micolog\u00eda M\u00e9dica de la \nSEIMC (GEMICOMED). Recomendaciones sobre el Tratamiento de \nla Enfermedad F\u00fangica Invasiva por Aspergillus  spp y otros hongos \nfilamentosos de la Sociedad Espa\u00f1ola de Enfermedades Infecciosas \ny Microbiolog\u00eda Cl\u00ednica (SEIMC). Actualizaci\u00f3n 2010. Enfermedades \nInfecciosas y Microbiolog\u00eda Cl\u00ednica 2011 Enferm Infecc Microbiol Clinical practice update of antifungal prophylaxis in  immunocompromised children J. T. Ramos, et al.\nRev Esp Quimioter 2019;32(5): 410-425423Clin 2011; 29:435-54. DOI: 10.1016/j.eimc.2011.01.010\n18. Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am \n2005;52:895-915. DOI: 10.1016/j.pcl.2005.02.009\n19. Science M, Robinson PD, MacDonal T, Rasseckh SR, Dupuis LL, Sung \nL, Guideline for primary antifungal prophylaxis for pediatric pa -\ntients with cancer or hematopoietic stem cell transplant recipients.  \nPediatr Blood Can 2014; 612: 393-400. DOI: 10.1002/pbc.24847\n20. Corneley OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lort -\nholary O, Meesserman W, et al. ESCMID guideline for the diagnosis \nand management diseases 2012: non-neutropenic adult patients. \nClin Microbiol Infect 2012. 18 (suppl. 7): 19-37. DOI: 10.1111/1469-\n0691.12039\n21. Colombo AL, Almeida Junior JN, Slavin MA, Chen SCA, Sorrell TC. \nCandida and invasive mould diseases in non-neutropenic critically \nill patients and patients with haematological cancer. Lancet Infect \nDis 2017; e344-e356. DOI: 10.1016/S1473-3099(17)30304-3\n22. Jordan I, Balaguer M, Lopez-Castilla JD, Belda S, Shuffelman C, \nGarc\u00eda Teresa MA, et al. on behalf of the ERICAP Study Group. \nPer-Species risk factors and predictors of invasive Candida infec -\ntions in patients admitted to Pediatric Intensive Care Units: devel -\nopment of ERICAP Scoring Systems. Pediatr Infect Dis J 2014; 33: \ne187-193. DOI: 10.1097/INF.0000000000000274\n23. Blyth CC, Chen SC, Slavin MA, Nguyen Q, Marriott D, Ellis D, et \nal. Australian Candidemia Study. Not just Little adults: Candidemia \nepidemiology, molecular characterization and antifungal suscepti -\nbility in neonatal and pediatric patients, Pediatrics 2009;123:1360. \nDOI: 10.1542/peds.2008-2055.\n24. Benedict K, Roy M, Kabbani S, Anderson F,  Farley MM, Harb B, \net al. Neonatal and Pediatric candidemia: Results from Popula -\ntion-Based Active Laboratory Surveillance in Four US Location \n2009-2015. J Pediatric Infect Dis Soc 2018;7:e78. DOI: 10.1093/\njpids/piy009\n25. Kumar V, Cheng SC, Johnson MD, meekens SP, Wojtowicz A, Giam -\narellos-Bourboulis E , et al. Immunochip SNP array identifies novel \ngenetic variants conferring susceptibility to candidemia. J Infect \nDis 2012;205:934. DOI: 10.1038/ncomms5675.\n26. Pana ZD, Kotzadamis D, Roilides E. Invasive Candidiasis in Pedi -\natric Intensive Care Unit: More Challenges. Pediatr Infect Dis J \n2018;37:1309. DOI: 10.1097/INF.0000000000002186\n27. Martin-Loeches I, Antonelli M, Cuenca-Estrella M, Dimopoulos G, \nEinav S, De Waele JJ, et al. ESICM/ESCMID task force on practical \nmanagement of invasive candidiasis in critically ill patients. Inten -\nsive Care Med 2019;45;789-805. DOI.org/10.1007/s00134-019-\n05599-w .\n28. Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M, Herwaldt \nLA, Weinstein RAet al. Effect of daily chlorhexidine bathing on \nhospital-acquired infection. N Engl J Med 2013; 368:533\u201342. \nDOI:10.1056/NEJMoa1113849\n29. Dvorak CC, Fisher BT, Sung L, Steinbach WJ, Nieder M, Alexander S, \nZaoutis TE. Antifungal Prophylaxis in Pediatric Hematology/Oncol -\nogy: New Choices & New Data. Pediatr Blood Cancer. 2012;59:21\u20136. \nDOI:10.1002/pbc.23415\n30. Papachristou S, Iosifidis E, Roilides E. Invasive Aspergillosis in \nPediatric Leukemia Patients: Prevention and Treatment. J Fungi. \n2019;5:14. DOI: 10.3390/jof5010014\n31. Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, et al. Fourth European Conference on Infections in Leukaemia \n(ECIL-4): Guidelines for diagnosis, prevention, and treatment of \ninvasive fungal diseases in paediatric patients with cancer or al -\nlogeneic haemopoietic stem-cell transplantation. Lancet Oncol. \n2014;15:e327\u201340. DOI: 10.1016/S1470-2045(14)70017-8\n32. Lehrnbecher T. Antifungal prophylaxis in pediatric patients under -\ngoing therapy for cancer: Drugs and dosing. Curr Opin Infect Dis. \n2015;28:523\u201331. DOI: 10.1097/QCO.0000000000000210\n33. Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, et al. Infectious \ncomplications of CD19-targeted chimeric antigen receptor-modi -\nfied T-cell immunotherapy. Blood. 2018;131:121\u201330. DOI: 10.1182/\nblood-2017-07-793760\n34. Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christo -\npeit M, et al. Primary prophylaxis of invasive fungal infections in \npatients with haematological malignancies: 2017 update of the \nrecommendations of the Infectious Diseases Working Party (AGI -\nHO) of the German Society for Haematology and Medical Oncology \n(DGHO). Ann Hematol. 2018;97:197\u2013207. DOI: 10.1007/s00277-\n017-3196-2\n35. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, \nHerbrecht R, et al. Practice guidelines for the diagnosis and man -\nagement of aspergillosis: 2016 update by the infectious diseases \nsociety of America. Clin Infect Dis. 2016;63:e1\u201360. DOI: 10.1093/cid/\nciw326\n36. Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, et \nal. ECIL-6 guidelines for the treatment of invasive transplant pa -\ntients : Haematologica. 2017;102:433\u201344. DOI: 10.3324/haema -\ntol.2016.152900\n37. Science M, Robinson P, MacDonald T, Rassekh SR, Dupuis LL SL, \nStem. Guideline for primary antifungal prophylaxis for pediatric \npatients with cancer or hematopoietic cell transplant recipients. \nPediatr Blood Cancer. 2014;61:393\u2013400. DOI: 10.1002/pbc.24847\n38. Maertens JA, Girmenia C, Br\u00fcggemann RJ, Duarte RF, Kibbler CC, \nLjungman P, et al. European guidelines for primary antifungal \nprophylaxis in adult haematology patients: summary of the updat -\ned recommendations from the European Conference on Infections \nin Leukaemia. J Antimicrob Chemother. 2018:1\u201310. DOI: 10.1093/\njac/dky286\n39. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Langston AA, et \nal. Antimicrobial prophylaxis for adult patients with cancer-related \nimmunosuppression: ASCO and IDSA clinical practice guideline up -\ndate. J Clin Oncol. 2018;36:3043\u201354. DOI:10.1200/JCO.18.00374\n40. Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, \nLagrou K, et al. Diagnosis and management of Aspergillus diseases: \nexecutive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin \nMicrobiol Infect. 2018;24:e1\u201338. DOI: 10.1016/j.cmi.2018.01.002\n41. D\u00f6ring M, Cabanillas Stanchi KM, Queudeville M, Feucht J, Blaes -\nchke F, Schlegel P, et al. Efficacy, safety and feasibility of antifun -\ngal prophylaxis with posaconazole tablet in paediatric patients \nafter haematopoietic stem cell transplantation. J Cancer Res Clin \nOncol. 2017;143:1281\u201392. DOI: 10.1007/s00432-017-2369-7\n42. Bochennek K, Tramsen L, Schedler N, Becker M, Klingebiel T, Groll \nAH, et al. Liposomal amphotericin B twice weekly as antifungal \nprophylaxis in paediatric haematological malignancy patients. \nClin Microbiol Infect. 2011;17:1868\u201374. DOI: 10.1111/j.1469-\n0691.2011.03483.xClinical practice update of antifungal prophylaxis in  immunocompromised children J. T. Ramos, et al.\nRev Esp Quimioter 2019;32(5): 410-42542443. D\u00f6ring M, Hartmann U, Erbacher A, Lang P, Handgretinger R, \nM\u00fcller I. Caspofungin as antifungal prophylaxis in pediatric pa -\ntients undergoing allogeneic hematopoietic stem cell trans -\nplantation: A retrospective analysis. BMC Infect Dis. 2012;12. \nDOI:10.1186/1471-2334-12-151\n44. Soler-Palac\u00edn P, Frick MA, Mart\u00edn-Nalda A, Lanaspa M, Pou L, \nRosell\u00f3 E, de Heredia CD, Figueras C. Voriconazole drug monitoring \nin the management of invasive fungal infection in immunocom -\npromised children: a prospective study. J Antimicrob Chemother \n2012;67:700-6. DOI: 10.1093/jac/dkr517\n45. Lewis R, Br\u00fcggemann R, PaDOIn C, Maertens J, Marchetti O, Groll \nA, et al. Triazole Antifungal Therapeutic Drug Monitoring Final slide \nset posted on the ECIL website on ECIL 6 meeting. 2015; Availa -\nble from: https://www.ebmt.org/Contents/Resources/Library/ECIL/\nDocuments/2015 ECIL6/ECIL6-Triazole-TDM-07-12-2015-Lewis-\nR-et-al.pdf\n46. Duarte RF, S\u00e1nchez-Ortega I, Cuesta I, Arnan M, Pati\u00f1o B, Fern\u00e1n -\ndez de Sevilla A, et al. Serum galactomannan-based early detec -\ntion of invasive aspergillosis in hematology patients receiving ef -\nfective antimoulds prophylaxis. Clin Infect Dis 2014;59:1696\u2013702. \nDOI:10.1093/cid/ciu673\n47. Vena A, Bouza E, \u00c1lvarez-Ur\u00eda A, Gayoso J, Mart\u00edn-Rabad\u00e1n P, Ca -\njuste F, et al. The misleading effect of serum galactomannan test -\ning in high-risk haematology patients receiving prophylaxis with \nmicafungin. Clin Microbiol Infect  2017;23:1000.e1-1000.e4.DOI.\norg/10.1016/j.cmi.2017.05.006\n48. Lehrnbecher T, Robinson PD, Fisher BT, Castagnola E, Groll AH, \nSteinbach WJ, et al. Galactomannan, \u03b2-D-Glucan, and Polymerase \nChain Reaction-Based Assays for the Diagnosis of Invasive Fungal \nDisease in Pediatric Cancer and Hematopoietic Stem Cell Trans -\nplantation: A Systematic Review and Meta-Analysis. Clin Infect Dis. \n2016;63:1340\u20138. DOI: 10.1093/cid/ciw592\n49. Lehrnbecher T, Hassler A, Groll AH, Bochennek K. Diagnostic ap -\nproaches for invasive aspergillosis-Specific considerations in the \npediatric population. Front Microbiol. 2018;9:1\u20138. DOI: 10.3389/\nfmicb.2018.00518\n50. Tong T, shen J, Xu Y. Serum galactomannan for diagnosing inva -\nsive aspergillosis in pediatric patients: A meta-analysis. Microb \nPathog [Internet]. 2018;118:347\u201356. DOI.org/10.1016/j.mic -\npath.2018.03.059\n51. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA et \nal. Invasive fungal infections among organ transplant recipi -\nents: results of the Trasplant- Associated Infection Surveillance \nNetwork (TRANSNET). Clin Infect Dis. 2010; 50: 1101-1111. \nDOI:10.1086/651262\n52. Saxena SG, Gee J, Klieger S, Kajon A, Petersen H, Zaoutis T, Fish -\ner B. Invasive Fungal Disease in Pediatric Solid Organ Transplant \nRecipients. J Pediatr Infectious Diseases Society 201; 7, 219-225. \nDOI:10.1093/jpids/pix041\n53. Garcia-Vidal C, Alastruey-Izquierdo A, Aguilar-Guisado M, Car -\nratal\u00e0 J, Castro C, Fern\u00e1ndez-Ruiz M, et al. Executive summary of \nclinical practice guideline for the management of invasive diseases \ncaused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC/\nREIP. Enferm Infecc Microbiol Clin. 2018 Jun 27. pii: S0213-\n005X(18)30200-3. DOI: 10.1016/j.eimc.2018.03.018\n54. Brizendine KD, Vishin S, Baddley JW. Antifungal prophylaxis in sol -id organ transplant recipients. Expert Rev. Anti Infect Ther 2011; 9 \n(5): 571- 581. DOI: 10.1586/eri.11.29\n55. Zaragoza R, Aguado JM, Ferrer R, Rodr\u00edguez AH, Maseda E, Llinares \nP Antifungal prophylaxis in solid organ transplant recipients. Rev \nIberoam Micol 2016; 33: 187-195. DOI: 10.1016/j.riam.2016.02.001\n56. Fort\u00fan J, Muriel A, Mart\u00edn-D\u00e1vila P, Montejo M, Len O, Torre-Cis -\nneros J, Carratal\u00e1 J, et al. Caspofungin versus fluconazole as proph -\nylaxis of invasive fungal infection in high-risk liver transplantation \nrecipients: A propensity score analysis. Liver Transpl. 2016;22:427-\n35. DOI: 10.1002/lt.24391.\n57. Brakemeier S, Pfau A, Zukunft B, Budde K, Nickel P. Prophylaxis \nand treatment of Pneumocystis Jirovecci after solid organ trans -\nplantation. Pharmacol Res.2018; 134: 61-67. DOI: 10.1016/j.\nphrs.2018.06.010\n58. Patterson TF, Thompson GR, Denning DW, Fishman JA, HAdley S et \nal. Practice guideline for the diagnosis and management of Asper -\ngillosis: 2016 updateby the Infectious Diseases Society of America. \nClin Infect Dis. 2016;63:e1-e60. DOI: 10.1093/cid/ciw326\n59. Kabir V, Maertens J, Kuypers D. Fungal infections in solid organ \ntransplantation: an update on diagnosis and treatment. Transplat \nRV (Orlando). 2019; 33: 77-86. DOI: 10.1016/j.trre.2018.12.001\n60. Prasad P, Nania JJ, Shankar SM. Pneumocystis pneumonia in chil -\ndren receiving chemotherapy. Pediatr Blood Cancer. 2008; 50: \n896-8. DOI: 10.1002/pbc.21202\n61. Fishman JA, Gans H; AST Infectious Diseases Community of Prac -\ntice. Pneumocystis jiroveci in Solid Organ Transplantation - Guide -\nlines from the American Society of Transplantation Infectious Dis -\neases Community of Practice. Clin Transplant. 2019:e13587. DOI: \n10.1111/ctr.13587\n62. Picard C , Gaspar H , Al-Herz W , Bousfiha A , Casanova JL , Chatila T , \net al. International Union of Immunological Societies: 2017 Primary \nImmunodeficiency Diseases Committee Report on Inborn Errors of \nImmunity. J Clin Immunol.  2018;38:96-128. DOI: 10.1007/s10875-\n015-0201-1\n63. Aguilar C , Malphettes M , Donadieu J , Chandesris O , Coignard-Bie -\nhler H , Catherinot E , et al. Prevention of infections during primary \nimmunodeficiency. Clin Infect Dis.  2014;59:1462-70. DOI: 10.1093/\ncid/ciu646\n64. Corvilain E , Casanova JL , Puel A . Inherited CARD9 Deficien -\ncy: Invasive Disease Caused by Ascomycete Fungi in Previously \nHealthy Children and Adults. J Clin Immunol.  2018;38:656-693. \nDOI:10.1007/s10875-018-0539-2\n65. Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, \net al. Itraconazole to prevent fungal infections in chronic granu -\nlomatous disease.  N Engl J Med. 2003;348:2416-22. DOI: 10.1056/\nNEJMoa021931\n66. Slack Ma, Thomsen IP. Prevention of Infectious Complications in \nPatients with Chronic Granulomatous Disease. J Pediatric Infect \nDis Soc. 2018;7 (suppl_1): S25-S30. DOI: 10.1093/jpids/piy016\n67. Mouy R, Veber F, Blanche S, Donadieu J, Brauner R, Levron JC, et  \nal. Long-term itraconazole prophylaxis against Aspergillus infec -\ntions in thirty-two patients with chronic granulomatous disease. J \nPediatr 1994; 125:998\u20131003. DOI: 10.1016/s0022-3476(05)82023-\n2\n68. Welzen  ME, Br\u00fcggemann RJ , Van Den Berg JM , Gilissen JH, Pajkrt \nD, Klein N, et al. A twice daily posaconazole  dosing algorithm for Clinical practice update of antifungal prophylaxis in  immunocompromised children J. T. Ramos, et al.\nRev Esp Quimioter 2019;32(5): 410-425425children with chronic granulomatous disease. Pediatr Infect Dis J.  \n2011;30:794-7. DOI: 10.1097/INF.0b013e3182195808  \n69. Garc\u00eda-Moreno J, Melendo-P\u00e9rez S, Mart\u00edn-G\u00f3mez MT, Frick \nMA, Balcells-Ram\u00edrez J, Pujol-Jover M. Pneumocystis jirovecii \npneumonia in children. A retrospective study in a single center \nover three decades. Enferm Infecc Microbiol Clin . 2019 (in press) \nDOI:10.1016/j.eimc.2019.05.005\n70. Siberry GK, Abzug MJ , Nachman S ; Panel on Guidelines  for Pre-\nvention  and Treatment  of Opportunistic Infections  in HIV-Exposed  \nand HIV-Infected Children\u2014a working group of the Office of AIDS \nResearch (OAR) Advisory Council. J Pediatric Infect Dis Soc 2013; \n2:293-308. DOI: 10.1093/jpids/pit074Rev Esp Quimioter 2019;32(5): 426-431426\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Biliary microbiote in cholecystectomized \npatients: Review of empirical antibiotherapy\nABSTRACT\nIntroduction.  Cholecystitis is an important cause of hos -\npital admission. In moderate or severe cholecystitis, the delay \nin treatment can lead to serious complications. Our objective is \nto analyze the microorganisms isolated in bile from cholecys -\ntectomized patients and their sensitivity pattern, to evaluate \nthe empirical treatment in those cases in which the surgical \nremoval of the gallbladder should be delayed.\nPatients and methods . Prospective descriptive study of \nbiliary cultures of patients undergoing cholecystectomy from \nMay 2013 to February 2015, in the Surgery Department of the \nHospital General Universitari de Castell\u00f3.\nResults.  We studied 196 patients, 83 women (42.3%) and \n113 men (57.7%), with an average age of 61.5 years. The most \nused antibiotics as empiric treatment were piperacillin/tazobac -\ntam (77.8%) and amoxicillin/clavulanic (14.8%). In 46.4% of pa -\ntients (91/196) bile cultures were positive. 165 microorganisms \nwere isolated. The majority were Gram-negative bacilli (60.5%), \nmainly of the Enterobacterales  order (91/54.5%), with Escheri -\nchia coli  being the most frequent microorganism (24%) followed \nby Klebsiella spp. (12.5%). 3 E. coli  with extended-spectrum be -\nta-lactamase (ESBL) and 1 K. pneumoniae  with ESBL were iso -\nlated. Microorganisms producing carbapenemase and methicil -\nlin-resistant Staphylococcus aureus  were not isolated.\nConclusion.  The bile microbiota, with a predominance of \nEnterobacterales  is similar to that found in european studies.  \nKey-words: Cholecystitis, biliary microbiota, antibiotic therapy\nINTRODUCCI\u00d3N\nLa inflamaci\u00f3n de las v\u00edas biliares supone una de las prin -\ncipales causas de ingreso hospitalario. Se diferencian dos for -RESUMEN\nIntroducci\u00f3n.  La colecistitis constituye una importante \ncausa de ingreso hospitalario. En colecistitis moderada o se -\nvera, el retraso en el tratamiento puede acarrear complicacio -\nnes graves. Nuestro objetivo es analizar los microorganismos \naislados en bilis de pacientes colecistectomizados y su patr\u00f3n \nde sensibilidad para evaluar el tratamiento emp\u00edrico en aque -\nllos casos en que la extirpaci\u00f3n quir\u00fargica de la ves\u00edcula deba \ndemorarse.\nPacientes y m\u00e9todos . Estudio descriptivo prospectivo de \nlos cultivos biliares de pacientes sometidos a colecistectom\u00eda \ndesde mayo de 2013 hasta febrero de 2015, en el Servicio de \nCirug\u00eda del Hospital General Universitario de Castell\u00f3n.\nResultados.  Se estudiaron 196 pacientes, 83 mujeres \n(42,3%) y 113 hombres (57,7%), con una media de edad de 61,5 \na\u00f1os. Los antibi\u00f3ticos m\u00e1s utilizados como tratamiento emp\u00edrico \nfueron piperacilina/tazobactam (77,8%) y amoxicilina/clavul\u00e1ni -\nco (14,8%). En el 46,4% de los pacientes (91/196) los cultivos \nde bilis fueron positivos. Se aislaron un total de 165 microorga -\nnismos. La mayor\u00eda eran bacilos gramnegativos (60,5%), princi -\npalmente Enterobacterales  (91/54,5%), siendo Escherichia coli  el \nmicroorganismo m\u00e1s frecuente (24%) seguido de Klebsiella spp. \n(12,5%). Se aislaron 3 E. coli  productoras de betalactamasa de \nespectro extendido (BLEE) y 1 Klebsiella pneumoniae  BLEE. No \nse aislaron microorganismos productores de carbapenemasa ni \nStaphylococcus aureus  resistente a meticilina. \nConclusi\u00f3n.  La microbiota biliar, con predominio de Ente-\nrobacterales , es similar a la encontrada en estudios europeos. \nPalabras clave: Colecistitis, microbiota biliar, antibioterapiaMicrobiota biliar en pacientes colecistectomizados: \nRevisi\u00f3n de la antibioterapia emp\u00edrica\n1Servicio de Microbiolog\u00eda y Parasitolog\u00eda. Hospital General Universitari de Castell\u00f3.\n2Servicio de Cirug\u00eda General y Aparato Digestivo. Hospital General Universitari de Castell\u00f3. Mar\u00eda Gil Fortu\u00f1o1\nLaura Granel Villach2\nSusana Sabater Vidal1\nRaquel Soria Mart\u00edn1\nDavid Mart\u00ednez Ramos2\nJavier Escrig Sos2\nRosario Moreno Mu\u00f1oz1\nRafael Igual Adell1\nCorrespondencia:\nMar\u00eda Gil Fortu\u00f1o\nServicio de Microbiolog\u00eda y Parasitolog\u00eda. Hospital General Universitari de Castell\u00f3.\nAvenida de Benic\u00e0ssim, sn. 12004, Castell\u00f3 \nTfno: 964725102 (Ext 454507)\nE-mail: gil_marfor@gva.esOriginal\nArticle history\nReceived: 16 January 2019; Revision Requested: 28 January 2019; Revision Received: 21 May 2019; Accepted: 22 May 2019Microbiota biliar en pacientes colecistectomizados: Revisi\u00f3n de la antibioterapia emp\u00edrica M. Gil Fortu\u00f1o, et al.\nRev Esp Quimioter 2019;32(5): 426-431427nismos aislados en la bilis de pacientes colecistectomizados as\u00ed \ncomo su patr\u00f3n de sensibilidad, con el prop\u00f3sito de evaluar el \ntratamiento emp\u00edrico para aquellos casos en que no sea posi -\nble (o deba demorarse) la extirpaci\u00f3n quir\u00fargica de la ves\u00edcula \nbiliar.\nPACIENTES Y M\u00c9TODOS\nEstudio descriptivo prospectivo de los cultivos biliares de \npacientes sometidos a colecistectom\u00eda desde mayo de 2013 \nhasta febrero de 2015, en el Servicio de Cirug\u00eda del Hospital Ge -\nneral Universitario de Castell\u00f3n. Los criterios de inclusi\u00f3n fue -\nron: pacientes diagnosticados de colelitiasis sintom\u00e1tica (desde \nc\u00f3lico biliar simple hasta colecistitis aguda), con indicaci\u00f3n qui -\nr\u00fargica para colecistectom\u00eda tanto de forma programada como \nurgente, incluyendo la v\u00eda laparosc\u00f3pica y la abierta.\nSe excluyeron los pacientes diagnosticados de colangitis, \nlas colecistectom\u00edas realizadas por neoplasias pancre\u00e1ticas o \ntumores de la v\u00eda biliar, las colecistectom\u00edas por p\u00f3lipos vesicu -\nlares y las colecistostom\u00edas percut\u00e1neas.\nLas muestras se tomaron intraoperatoriamente y se remi -\ntieron, en las 2 horas siguientes, al Servicio de Microbiolog\u00eda \npara cultivo bacteriol\u00f3gico. Se procesaron seg\u00fan los protocolos \nestandarizados del laboratorio, realiz\u00e1ndose identificaci\u00f3n bac -\nteriana y estudio de sensibilidad (CMI) mediante los sistemas \nautomatizados Vitek 2 (bioM\u00e9rieux\u00ae) y/o Phoenix (Becton Dic -\nkinson\u00ae).\nSe analizaron variables epidemiol\u00f3gicas : sexo, edad, hos -\npitalizaci\u00f3n previa, comorbilidad, toma de antibi\u00f3ticos los 6 \nmeses previos, antibi\u00f3ticos al ingreso, antibi\u00f3tico profil\u00e1ctico;  \ncl\u00ednicas : diagn\u00f3stico, manipulaci\u00f3n previa de las v\u00edas biliares, \nestancia postoperatoria o exitus; y microbiol\u00f3gicas : cultivo de \nbilis, hemocultivos, microorganismos aislados y porcentaje de \nmicroorganismos multirresistentes. \nLos datos se incluyeron para su an\u00e1lisis estad\u00edstico en el \npaquete GNU GPL (General Public License) PSPP, ver si\u00f3n 1.2.0. \nLas variables cuantitativas se expresaron como media, desvia -\nci\u00f3n est\u00e1ndar (DE) y/o rango, o bien como valor absoluto y por -\ncentaje.  Para la comparaci\u00f3n de variables cualitativas o categ\u00f3 -\nricas se emple\u00f3 el test de chi-cuadrado ( \u03c72). Las diferencias se \nconsideraron estad\u00edsticamente significativas cuando p < 0,05.\nRESULTADOS\nSe estudiaron 196 pacientes, 83 mujeres (42,3%) y 113 \nhombres (57,7%), con una media de edad de 58,68 a\u00f1os (ran -\ngo:16-91). 109 (55,6%) hab\u00edan estado hospitalizados los 12 \nmeses previos y 112 (57,1%) presentaban alguna comorbilidad \n(hipertensi\u00f3n arterial, diabetes mellitus, dislipemia, cardiopat\u00eda, \nenfermedad pulmonar obstructiva cr\u00f3nica  o neoplasia). \nRespecto a la antibioterapia, 92 pacientes (47%) hab\u00edan \ntomado alg\u00fan antibi\u00f3tico en  los 6 meses previos a la cirug\u00eda. \nLos 54 pacientes (27,6%) operados de urgencia por colecistitis \naguda llevaron antibi\u00f3ticos como parte del tratamiento duran -mas cl\u00ednicas: la colecistitis, relacionada con la inflamaci\u00f3n de \nla ves\u00edcula biliar, y la colangitis, que afecta a los conductos \nbiliares. \nLa colecistitis aguda aparece, en el 90-95% de los casos, \ntras la obstrucci\u00f3n completa y prolongada del cuello de la ves\u00ed -\ncula o del conducto c\u00edstico por c\u00e1lculos ( colelitiasis ), pero tam -\nbi\u00e9n tras isquemia, trastornos de la motilidad, infecciones o \ncolagenopat\u00edas [1]. Si no se instaura tratamiento precoz puede \naparecer infecci\u00f3n secundaria a la colestasis y complicaciones \ncomo empiema vesicular, colecistitis gangrenosa, absceso ab -\ndominal o hep\u00e1tico, perforaci\u00f3n de la ves\u00edcula con peritonitis e \nincluso sepsis. Seg\u00fan las Tokio Guidelines (TG) [1] hay tres gra -\ndos en la colecistitis aguda que van desde la inflamaci\u00f3n local \nsin signos generales, Grado I, a la disfunci\u00f3n org\u00e1nica severa \no Grado III (tabla 1). El tratamiento puede ser desde conser -\nvador con antibioterapia (acompa\u00f1ada o no de drenaje biliar \npor colecistostom\u00eda en aquellos pacientes de riesgo) hasta qui -\nr\u00fargico realizando colecistectom\u00eda. El prop\u00f3sito de la antibio -\nterapia es limitar la respuesta inflamatoria local y sist\u00e9mica, y \nprevenir tanto la infecci\u00f3n postquir\u00fargica como la formaci\u00f3n \nde abscesos intrahep\u00e1ticos. En la colecistitis leve su papel es \nfundamentalmente profil\u00e1ctico, mientras que en la moderada \no severa es terap\u00e9utico mientras no pueda extirparse la ves\u00ed -\ncula. Los antibi\u00f3ticos deber\u00edan administrarse en las primeras 6 \nhoras tras la sospecha de infecci\u00f3n biliar excepto en pacientes \ns\u00e9pticos, en los que su administraci\u00f3n no deber\u00eda demorarse \nm\u00e1s de 1 hora. Para instaurar el tratamiento emp\u00edrico deben \nconsiderarse, entre otros factores, los microorganismos proba -\nbles, la sensibilidad local, los antecedentes de hospitalizaci\u00f3n o \nla toma de antibi\u00f3ticos en los 6 meses previos, por aumento en \nel riesgo de aparici\u00f3n de resistencias.\nEl porcentaje de positividad de los cultivos en colecistitis \naguda ronda el 29-54% [2]. Los microorganismos habitualmen -\nte aislados pertenecen al orden Enterobacterales  (con predo -\nminio de Escherichia coli y Klebsiella pneumoniae ). Aproxima -\ndamente el 5% de las infecciones comunitarias y el 10% de las \nnosocomiales lo son por E. coli o K. pneumoniae  productoras de \nbetalactamasa de espectro extendido (BLEE) [3]. La mayor\u00eda de \nlas gu\u00edas recomiendan emplear antibi\u00f3ticos de amplio espectro \nen pacientes con infecci\u00f3n grave, que hayan recibido antibi\u00f3ti -\ncos previamente o con comorbilidad importante [4].\nEl objetivo de nuestro estudio es analizar los microorga -\nTabla 1  Criterios de severidad para la \ninfecci\u00f3n de origen biliar\n-Grado I o leve: Inflamaci\u00f3n local sin signos generales\n-Grado II o moderada: Fiebre>38, leucocitosis>18000/mL, masa dolorosa \npalpable, evoluci\u00f3n>72h, signos inflamatorios (coleperitoneo, absceso pe -\nrivesicular o hep\u00e1tico, colecistitis gangrenosa o enfisematosa).\n-Grado III o grave: Hipotensi\u00f3n que requiere f\u00e1rmacos, alteraci\u00f3n de cons -\nciencia, disfunci\u00f3n respiratoria, renal (Creatinina >2 mg/dl), hep\u00e1tica (INR \n>1,5) o hematol\u00f3gica (plaquetas <100.000/mL)Microbiota biliar en pacientes colecistectomizados: Revisi\u00f3n de la antibioterapia emp\u00edrica M. Gil Fortu\u00f1o, et al.\nRev Esp Quimioter 2019;32(5): 426-43142834% en los que no exist\u00eda este antecedente \n(36/105), p<0,001. Aquellos pacientes a los \nque se les administr\u00f3 antibioterapia al ingre -\nso presentaron bactibilia en un 54% (32/59) \nversus el 44% (60/137) en los no tratados, no \nencontr\u00e1ndose diferencias estad\u00edsticamente \nsignificativas entre antibioterapia al ingreso \ny bactibilia, p=0,18.\nSe aislaron un total de 165 microorga -\nnismos. La mayor\u00eda eran bacilos gramnega -\ntivos (60,5%), en su mayor parte del orden \nEnterobacterales  (91/54,5%), siendo E. coli  \nel microorganismo m\u00e1s frecuente (24%) se -\nguido de Klebsiella spp. (12,5%). Otros ba -\ncilos gramnegativos fueron Pseudomonas \naeruginosa  en 3 muestras, Aeromonas spp. \n(3) o Campylobacter jejuni  (1). En cuanto a \nlos grampositivos se aisl\u00f3 Enterococcus spp. \nen 19 muestras (11,5%), destacando 3 E. fae -\ncium  y 3 E.casseliflavus/gallinarum , Strepto -\ncoccus spp. en 19 (11,4%) y Staphylococcus \nspp. en un s\u00f3lo paciente. El 10,2% de los \nmicroorganismos eran anaerobios y el 2,4% \nlevaduras (tabla 2).\n Se aislaron 4 microorganismos multirre -\nsistentes (2,4%) (3 E. coli  BLEE y 1 K. pneumo -\nniae BLEE), 3 en pacientes con hospitalizaci\u00f3n \ny antibioterapia previas (75%). No se aislaron \nmicroorganismos productores de carbapene -\nmasa ni S. aureus  resistente a meticilina. \nSe solicitaron hemocultivos en 18 oca -\nsiones (19,5%). En 6 se detect\u00f3 crecimiento \npero s\u00f3lo dos de ellos se consideraron signifi -\ncativos (2,1%), con aislamiento del mismo germen que en bilis.\nDISCUSI\u00d3N\nLas posibles causas de bactibilia podr\u00edan estar relacionadas \ncon la presencia o no de colecistitis aguda y la gravedad de la \nmisma, el uso de antibi\u00f3ticos, la manipulaci\u00f3n previa de la v\u00eda \nbiliar o la comorbilidad asociada.\nEl porcentaje de bactibilia en pacientes con manipulaci\u00f3n \nprevia de la v\u00eda biliar es dos veces mayor que cuando no existe \neste antecedente (88% vs 40,3%). Rupp  et al. [5], encuentran \nun 71,6% de bactibilia tras CPRE (con predominio de grampo -\nsitivos, a diferencia de nuestra serie). A\u00fan as\u00ed, en las TG18 no se \nrecomienda profilaxis antibi\u00f3tica ante este procedimiento [6].\nEl cultivo de bilis deber\u00eda solicitarse en los grados II y III \npuesto que en pacientes sin cl\u00ednica de infecci\u00f3n existe contro -\nversia sobre la necesidad de instaurar tratamiento antibi\u00f3tico \nante el hallazgo de bactibilia. No obstante, trabajos como el \nde Troyano-Escribano et al.  [7], sobre 368 pacientes sometidos \na colecistectom\u00eda electiva (excluyendo a aquellos con signos \nde infecci\u00f3n biliar aguda) mostraron bactibilia en el 28,7%, \n(sobre todo tras cirug\u00eda abierta) aunque este hallazgo no se te el ingreso y los 142 (72,4%) pacientes intervenidos de forma \nprogramada, profilaxis con 2 g de cefazolina 30 minutos an -\ntes de la colecistectom\u00eda. Para el tratamiento de la colecistitis \naguda los antibi\u00f3ticos m\u00e1s utilizados fueron: piperacilina/ta -\nzobactam (77,8%), amoxicilina/clavul\u00e1nico (14,8%), ertapenem \n(3,7%) y ciprofloxacino m\u00e1s metronidazol (3,7%) en al\u00e9rgicos a \nla penicilina. La duraci\u00f3n media del tratamiento antibi\u00f3tico en \nla colecistitis fue de 5 d\u00edas (DE: 2,40). En 25 casos (12,8%) se \nrealiz\u00f3 colangiopancreatograf\u00eda retr\u00f3grada endosc\u00f3pica (CPRE) \npor coledocolitiasis. La estancia media postoperatoria fue de \n4,2 d\u00edas (DE: 5,09; rango: 1-44). 4 pacientes (2%) fallecieron, 2 \nde ellos por shock s\u00e9ptico.\nEn el 46,4% de los pacientes (91/196) los cultivos de bi -\nlis fueron positivos: 52 (57,1%) con un microorganismo, 22 \n(24,2%) con dos y 17 (18,7%) con tres o m\u00e1s. Se encontr\u00f3 bac -\ntibilia en el 88% de los pacientes con CPRE previa (25) fren -\nte al 40,9% de los casos sin CPRE (171), p<0,001. En aquellos \npacientes con ingresos previos la presencia de bactibilia fue \ndel 57,8% (63/109) frente al 33,3% en los que no estuvieron \ningresados (29/87), p=0,001. En cuanto a la influencia del tra -\ntamiento antibi\u00f3tico, la bactibilia fue del 61,5% en los pacien -\ntes con antibioterapia en los  6 meses previos (56/91) frente al GRAMNEGATIVOS 100 % (60,6) GRAMPOSITIVOS 44 % (26,6)\nEnterobacterales  91 54,5 Enterococcus  spp. 19 11,5\nE. coli\nKlebsiella  spp.\nEnterobacter  spp.\nCitrobacter  spp.\nProteus  spp.\nProvidencia  rettgeri\nPantoea  agglomerans\nSerratia  spp.40\n21\n13\n7\n4\n2\n2\n224\n12,5\n7,8\n4,2\n2,4\n1,2\n1,2\n1,2E. faecalis\nE. faecium\nE. casseliflavus/gallinarum\nOtras especies9\n3\n3\n45,4\n1,8\n1,8\n2,4\nOtros BGNs 9 5,4 Streptococcus  spp. 19 11,1\nPseudomonas  aeruginosa\nAeromonas  spp.\nHaemophilus  influenzae\nCampylobacter  jejuni\nShewanella  putrefaciens3\n3\n1\n1\n11,8\n1,8\n0,6\n0,6\n0,6\nOtros grampositivos 6 3,6\nANAEROBIOS 17 % (10,2) LEVADURAS 4 % (2,4)\nClostridium  spp.\nBGN anaerobio\nBacteroides  spp.\nPrevotella  spp.8\n5\n2\n24,8\n3\n1,2\n1,2C. albicans\nC. glabrata\nC. tropicalis2\n1\n11,2\n0,6\n0,6Tabla 2  Microorganismos aislados en bilis (n=165)\nBGN: bacilos gramnegativosMicrobiota biliar en pacientes colecistectomizados: Revisi\u00f3n de la antibioterapia emp\u00edrica M. Gil Fortu\u00f1o, et al.\nRev Esp Quimioter 2019;32(5): 426-431429sistentes no supera el 10-20%, ceftazidima o cefepima con \nmetronidazol [10]. Al analizar nuestros datos encontramos un \n4,8 % de microorganismos multirresistentes.  Adem\u00e1s, ante la \npresencia de f\u00edstula o anastomosis bilio-ent\u00e9rica se recomien -\nda cubrir anaerobios con metronidazol si se est\u00e1n empleando \ncefalosporinas o aztreonam. Las fluoroquinolonas, dado el au -\nmento de resistencias, no se recomiendan como tratamiento \nemp\u00edrico; s\u00f3lo estar\u00eda indicado su empleo en al\u00e9rgicos a be -\ntalact\u00e1micos para continuar el tratamiento v\u00eda oral (si se de -\nmuestra sensibilidad en el antibiograma).\nA parte del espectro deber\u00eda tenerse en cuenta la penetra -\nci\u00f3n del antibi\u00f3tico en bilis, sobre todo ante obstrucciones. En \nla tabla 3 se citan los antibi\u00f3ticos m\u00e1s adecuados [2].\nEl antibi\u00f3tico m\u00e1s utilizado en nuestra serie fue piperacili -\nna/tazobactam, un betalact\u00e1mico con buena penetraci\u00f3n biliar \ny efecto anaerobicida, activo en medio \u00e1cido (en presencia de \nabscesos) y que no requiere ajuste de dosis ante insuficiencia \nhep\u00e1tica. Adem\u00e1s no induce la producci\u00f3n de betalactamasas \n[3]. Encontramos un porcentaje de resistencia frente a pipe -\nracilina/tazobactam del 4,8 %  (5 bacilos gramnegativos y 3 E. \nfaecium ). En segundo lugar se emple\u00f3 amoxicilina/clavul\u00e1nico, \ncon una resistencia elevada (del 24,2 %), ya que cada vez son \nm\u00e1s frecuentes las enterobacterias productoras de BLEE, AmpC \nplasm\u00eddicas o betalactamasas resistentes al inhibidor (IRT). En \ncuanto a los carbapen\u00e9micos, frente a ertapenem (el tercer \nantibi\u00f3tico m\u00e1s empleado) la resistencia fue del 15%, si tene -\nmos en cuenta la resistencia intr\u00ednseca tanto en Pseudomonas  \ncomo en Enterococcus , frente a meropenem del 11,5 % (a ex -\npensas de Enterococcus ) y frente a imipenem del 1,2% (dos E. \nfaecium ). \nPodr\u00edamos sustituir ertapenem por imipenem, con mayor \nporcentaje de sensibilidad y mejor penetraci\u00f3n biliar . La resis -\ntencia a cefepima (antibi\u00f3tico con buena penetraci\u00f3n en bilis) \nfue del 12,1 %. \nLa resistencia a ciprofloxacino fue del 9,1 % y a metroni -\ndazol del 1,2%. En cambio a amikacina fue del 1,2%, pero por \nsu escasa  penetraci\u00f3n biliar, no se indicar\u00eda como tratamiento \nemp\u00edrico.\nEn la colecistitis aguda Grado III se recomienda emplear \nantibi\u00f3ticos activos frente a  Pseudomonas aeruginosa , ya que \ncl\u00e1sicamente se ha encontrado en un 20% de los cultivos. En \nla TG18 [6] , se constata una disminuci\u00f3n hasta el 3,6% y para \nautores como Armi\u00f1anzas et al. .[11] menos de un 1%. Nosotros \nhemos encontrado un 1,8%. No obstante, la recomendaci\u00f3n de \ncubrirla se mantiene dado el exceso de mortalidad que supon -\ndr\u00eda el no hacerlo. Si la resistencia a ceftazidima supera el 20% \n(en nuestra serie no encontramos resistencias), se recomienda \nel empleo de carbapen\u00e9micos (excepto ertapenem), piperacili -\nna/tazobactam y aminogluc\u00f3sidos [6].\nCefazolina se emple\u00f3 como profilaxis en cirug\u00eda programa -\nda, por ser el antibi\u00f3tico de elecci\u00f3n, eficaz y razonablemente \nseguro, con una pauta corta de administraci\u00f3n que minimiza \ntanto las reacciones adversas como el desarrollo de resistencias \no la infecci\u00f3n por Clostridioides difficile [12]. Presenta actividad \nfrente a microoorganismos que frecuentemente colonizan el relacion\u00f3 con la aparici\u00f3n de complicaciones postquir\u00fargicas. \nLa positividad de los cultivos de bilis en la colecistitis aguda \npuede alcanzar el 54%, aunque es menor que en la colangitis \n(hasta el 93%) [8]. Una vez aislados los microorganismos cau -\nsales, deber\u00eda modificarse el antibi\u00f3tico o desescalarse seg\u00fan \nantibiograma [6]. En nuestro caso, en un 46,9% de las mues -\ntras se encontr\u00f3 bactibilia. En ninguna ocasi\u00f3n se modific\u00f3 el \nantibi\u00f3tico por el resultado del cultivo ya que muchas veces \nlos pacientes ya hab\u00edan sido dados de alta con un tratamiento \nantibi\u00f3tico secuencial.\nLas TG18 [6] revisan la duraci\u00f3n del tratamiento antibi\u00f3 -\ntico en la colecistitis aguda: entre 24 h tras la colecistectom\u00eda \nen los Grados I y II sin complicaciones, y de 4 a 7 d\u00edas en el \nGrado III una vez controlado el foco mediante colecistectom\u00eda. \nEn nuestra serie todas las colecistitis fueron tratadas una media \nde 6 d\u00edas independientemente del grado, conducta que deber\u00eda \nmodificarse ya que, tras el control del foco, la prolongaci\u00f3n del \ntratamiento antibi\u00f3tico no aporta beneficios adicionales, sino \nque favorece la selecci\u00f3n de bacterias resistentes.\nSe define el tratamiento emp\u00edrico como aquel admi -\nnistrado hasta disponer del resultado del cultivo [6] y las re -\ncomendaciones en las gu\u00edas cl\u00ednicas var\u00edan en funci\u00f3n de la \ngravedad de la infecci\u00f3n. No obstante cada vez existen m\u00e1s \nmicroorganismos multirresistentes  en la comunidad (como las \nenterobacterias portadoras de BLEE, generalmente resistentes \na betalact\u00e1micos, cefalosporinas y fluoroquinolonas) por lo que \ndeben considerarse los factores de riesgo (como el tratamiento \nantibi\u00f3tico previo o la estancia hospitalaria mayor de 15 d\u00edas) \n[4] y la flora local, que puede variar enormemente. Por ejemplo, \npara Kwon et al. [9] , en Se\u00fal, la especie m\u00e1s frecuentemente \naislada fue Enterococcus  spp. (a expensas de E. faecium, ha-\nbitual en receptores de transplante hep\u00e1tico) lo que les llev\u00f3 a \nreplantearse el tratamiento emp\u00edrico.\nLa Gu\u00eda de la Infectious Diseases Society of America (IDSA)  \nrecomienda el tratamiento con carbapen\u00e9micos, piperacilina/\ntazobactam o, si la prevalencia de microorganismos multirre -Elevada penetraci\u00f3n (ABSCR \u2265 1) Baja penetraci\u00f3n (ABSCR <1)\nPiperacilina/tazobactam (4,8) Ceftriaxona (0,75)\nTigeciclina (> 10) Cefotaxima (0,23)\nAmoxicilina/clavul\u00e1nico (1,1) Meropenem (0,38)\nCiprofloxacino (> 5) Ceftazidima (0,18)\nAmpicillina/Sulbactam (2,4) Vancomicina (0,41)\nCefepima (2,04) Amikacina (0,54)\nLevofloxacino (1,6) Gentamicina (0,30)\nPenicilina G(>5)\nImipenem (1,01)Tabla 3  Antibi\u00f3ticos empleados en infecciones \ndel tracto biliar y su capacidad de \npenetraci\u00f3n en bilis. ( Tomada de \nAnsaloni et al. [2])\n(ABSCR Antibiotics Bile/Serum Concentration Ratio). Microbiota biliar en pacientes colecistectomizados: Revisi\u00f3n de la antibioterapia emp\u00edrica M. Gil Fortu\u00f1o, et al.\nRev Esp Quimioter 2019;32(5): 426-431430vaduras en otras localizaciones. Se relacionan con antibiotera -\npia previa, inmunodepresi\u00f3n y manipulaci\u00f3n de las v\u00edas biliares. \nEn nuestro caso todos los pacientes presentaron hospitaliza -\nci\u00f3n y antibioterapia previa y se les realiz\u00f3 CPRE. La gu\u00eda IDSA \n[10] recomienda el tratamiento antif\u00fangico s\u00f3lo ante cuadros \ngraves, con fluconazol si se aisla C. albicans  o con una equi -\nnocandina si se trata de especies resistentes a azoles, como C. \nkrusei o C. glabrata.  En nuestra serie no fue necesario a\u00f1adir \ntratamiento antif\u00fangico.\nEn la TG18 [6] se recomienda la toma de hemocultivos en \ncolecistitis de Grado II y III (y no en la de Grado I de adquisi -\nci\u00f3n comunitaria). La gu\u00eda IDSA tampoco la recomienda en la \ncomunitaria ya que no var\u00eda el manejo terap\u00e9utico (de 1.062 \nhemocultivos, s\u00f3lo un 1,6% generaron un cambio) [10]. \u00danica -\nmente se extrajeron hemocultivos en caso de fiebre durante el \npostoperatorio, independientemente del grado de colecistitis, \nya que habitualmente son negativos en las colecistitis no com -\nplicadas [8]. En nuestro caso s\u00f3lo el 2,1% de los hemocultivos \nse consideraron significativos. \nA nuestro estudio cabe a\u00f1adir algunas limitaciones. La pri -\nmera es que se incluye el an\u00e1lisis microbiol\u00f3gico de ves\u00edculas \nextirpadas por diversas patolog\u00edas. Ser\u00eda interesante (con un \nmayor n\u00famero de pacientes) poder estratificar por etiolog\u00eda y \ncomparar la posible variaci\u00f3n en la microbiota encontrada. Otra \nlimitaci\u00f3n es que en cuadros como las colecistitis, que combi -\nnan el tratamiento m\u00e9dico con el quir\u00fargico, es dif\u00edcil saber \nhasta qu\u00e9 punto el papel de la antibioterapia es determinante \nen la curaci\u00f3n. Como conclusiones, la microbiota biliar de nues -\ntro estudio no difiere de otros trabajos a nivel europeo, aunque \ns\u00ed de aquellos realizados en pa\u00edses asi\u00e1ticos. El porcentaje de \nmicroorganismos multirresistentes es bajo respecto a otras se -\nries. Piperacilina/tazobactam es una buena elecci\u00f3n en nuestro \nmedio para el tratamiento de pacientes con colecistitis leve y \nmoderada, puesto que su elevada penetraci\u00f3n biliar, el efecto \nanaerobicida y, sobre todo, la baja capacidad para inducir la \nproducci\u00f3n de betalactamasas lo convierten en un antibi\u00f3tico \n\u00f3ptimo para estos cuadros. Habr\u00eda que reducir, no obstante, el \ntiempo de tratamiento en colecistitis no graves. La resistencia \nobservada ante amoxicilina/clavul\u00e1nico deber\u00eda hacernos re -\nplantear su uso como tratamiento emp\u00edrico.\nAGRADECIMIENTOS\nAl personal de Quir\u00f3fano por su colaboraci\u00f3n en la recogi -\nda de muestras y al del Servicio  de Microbiolog\u00eda por el proce -\nsamiento de las mismas.\nFINANCIACI\u00d3N\nLos autores declaran no haber recibido financiaci\u00f3n para \nla realizaci\u00f3n de este art\u00edculo\nCONFLICTOS DE INTER\u00c9S\nLos autores declaran no tener conflictos de inter\u00e9slecho quir\u00fargico. En cirug\u00eda limpia-contaminada como la ab -\ndominal es activo frente a microorganismos de la flora cut\u00e1 -\nnea ( Staphylococcus  coagulasa-negativo o S. aureus  sensible \na meticilina), Streptococcus spp  y ciertas enterobacterias. En \nnuestra serie s\u00f3lo hubo dos infecciones de la herida lo que su -\ngiere que este antibi\u00f3tico es efectivo para evitar la infeccci\u00f3n \nsecundaria al acto quir\u00fargico.\nEl hallazgo de Aeromonas caviae  en bilis es excepcional. \nSe adquiere en climas templados, tras contacto con agua dul -\nce o salobre, mordedura por animales acu\u00e1ticos o consumo de \nalimentos contaminados. Puede presentarse como colangitis \naguda en pacientes con obstrucci\u00f3n previa de la v\u00eda biliar (por \nlitiasis o estenosis) [13]. En nuestra serie se aisl\u00f3 en 3 muestras \n(3,2%), siempre en cultivo monomicrobiano. En la historia cl\u00ed -\nnica no constaban factores de riesgo destacables.\nCampylobacter spp. se aisla con muy baja frecuencia en \ncuadros de colecistitis. Necesita  condiciones especiales para su \ncrecimiento, y no se recomienda su cultivo a menos que en \nla tinci\u00f3n de Gram se visualicen bacilos gramnegativos curvos \n[14]. En nuestro caso se aisl\u00f3 C. jejuni  resistente a ciprofloxa -\ncino en una mujer de 64 a\u00f1os con colecistitis aguda liti\u00e1sica y \nantecedentes de pancreatitis aguda, sin constancia de diarrea \nprevia. La evoluci\u00f3n fue favorable con amoxicilina/clavul\u00e1nico.\nEnterococcus spp. muestra algunas dificultades en el tra -\ntamiento por presentar resistencia intr\u00ednseca a antibi\u00f3ticos \nmuy empleados como cefalosporinas y baja sensibilidad a qui -\nnolonas o cotrimoxazol. \nSu patogenicidad en la infecci\u00f3n biliar es incierta [10] aun-\nque se recomienda su tratamiento en pacientes inmunodepri -\nmidos [2]. E. faecalis  suele ser sensible a ampicilina, mientras \nque en E. faecium  (un 1,8% en nuestra serie) es frecuente la \nresistencia a betalact\u00e1micos por alteraciones en la PBP5 (in -\ncluyendo piperacilina/tazobactam, ampliamente utilizado en \ninfecciones intraabdominales), por lo que deber\u00eda emplearse \nvancomicina, linezolid o daptomicina.  El uso de carbapen\u00e9mi -\ncos deber\u00eda limitarse a imipenem para  E. faecalis , puesto que  E. \nfaecium suele ser resistente. La aparici\u00f3n de cepas con resisten -\ncia adquirida a glucop\u00e9ptidos (VanA/B) todav\u00eda es infrecuente \nen nuestro pa\u00eds [15]. En nuestra serie encontramos un 1,8% de \nespecies intr\u00ednsecamente resistentes a vancomicina como E. \ncasseliflavus, E. gallinarum o E. flavescens, todos sensibles a \nampicilina.\nRespecto a los anaerobios no se recomienda clindamici -\nna como tratamiento emp\u00edrico por la resistencia que presenta \nBacteroides spp. Cueto et al . [16], cuyo trabajo estudia la flo -\nra biliar en colecistitis aguda, no constatan ning\u00fan anaerobio, \naunque s\u00ed recomiendan su cobertura antibi\u00f3tica. En nuestro \ncaso se aislaron anaerobios en el 16,6% de los pacientes (en \ncultivo puro s\u00f3lo en uno). No encontramos relaci\u00f3n con f\u00edstulas \nbilio-ent\u00e9ricas pero destacaba el antecedente de CPRE previa \nen el 21,4% de los casos por lo que deber\u00edan cubrirse, especial -\nmente, en estos pacientes.\nSe aisl\u00f3 Candida spp. en 4 muestras (2,4%), porcentaje si -\nmilar a otros trabajos:  Cueto et al. [16] encuentran un 3,4%, \nmientras que Kwon [9] un 2,6%. En ning\u00fan caso se aislaron le -Microbiota biliar en pacientes colecistectomizados: Revisi\u00f3n de la antibioterapia emp\u00edrica M. Gil Fortu\u00f1o, et al.\nRev Esp Quimioter 2019;32(5): 426-431431BIBLIOGRAF\u00cdA\n1. Kimura Y, Takada T, Strasberg SM, Pitt HA, Gouma DJ, Garden OJ et \nal. TG13 current terminology, etiology and epidemiology of acu -\nte colangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2013; \n20:8-23. doi: 10.1007/s00534-012-0564-0\n2. Ansaloni L, Pisano M, Coccolini F, Peitzmann AB, Fingerhut A, Cate -\nna F et al. 2016 WSES guidelines on acute calculous cholecystitis. \nWorld J Emerg Surg. 2016; 11:25. doi: 10.1186/s13017-016-0082-\n5\n3. Mensa J, Gatell JM, Garc\u00eda-S\u00e1nchez JE, Letang E, L\u00f3pez-Su\u00f1\u00e9 E, \nMarco F. Gu\u00eda de Terap\u00e9utica Antimicrobiana. 2018. Ed.Antares.\n4. Guirao X, Arias J, Bad\u00eda JM, Garc\u00eda-Rodr\u00edguez JA, Mensa J, \u00c1lvarez-\nLerma F et al. Recomendaciones en el tratamiento antibi\u00f3tico em -\np\u00edrico de la infecci\u00f3n intraabdominal. Cir Esp. 2010; 87(2):63-81. \ndoi:10.1016/j.ciresp.2009.09.014\n5. Rupp C, Bode K, Weiss KH, Rudolph G, Bergemann J, Kloeters-Pla -\nchky P et al. Microbiological assesment of bile and corresponding \nantibiotic treatment: a Strobe-Compliant Observational Study of \n1401 Endoscopic Retrograde Cholangiographies. Medicine (Balti -\nmore). 2016; 95 (10): e2390 doi: 10.1097/MD.0000000000002390.\n6. Gomi H, Solomkin J, Schlossberg D, Okamoto K, Takada T, Strasberg \nM et al. Tokyo Guidelines 2018: antimicrobial theraphy for acu -\nte colangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018; \n25:3-16. doi: 10.1002/jhbp.518.\n7. Troyano Escribano D, Balibrea J, Molinos S, Ausina V, Fern\u00e1ndez \nLlamazares J, Oller B. Bactibilia and antibiotic resistance in elective \ncholecystectomy: an updated ecologic survey. Surg Infect. 2015; \nJun;16(3):287-92. doi: 10.1089/sur.2014.023\n8. Garc\u00eda-S\u00e1nchez JE, Garc\u00eda-Garc\u00eda MI, Garc\u00eda-Garrote F, S\u00e1nchez-\nRomero I. Diagn\u00f3stico microbiol\u00f3gico de las infecciones intraab -\ndominales. Enferm Infecc Microbiol Clin.2013; 31(4):230-239. doi: \n10.1016/j.eimc.2012.01.023\n9. Kwon W, Jang JY, Kim EC, Park JW, Han IW, Kang MJ et al. Chan -\nging trend in bile microbiology and antibiotic susceptibilities: over \n12 years of experience. Infection. 2013; 41:93-102. doi: 10.1007/\ns15010-012-0358-y\n10. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC, \nBaron EJ et al. Diagnosis and Management of Complicated Intra-\nabdominal Infection in Adults and Children: Guidelines by the \nSurgical Infection Society and the Infectious Diseases Society of \nAmerica. Clin Infect Dis 2010;15(2):133-64. doi: 10.1086/649554.\n11. Armi\u00f1anzas C, Tigera T, Ferrer D, Calvo J, Herrera LA, Pajar\u00f3n M et \nal. Papel de la bacteriobilia en las complicaciones postoperatorias. \nRev Esp Quimioter. 2016; 29(3): 123-129.\n12. Asensio A. Infecci\u00f3n de la localizaci\u00f3n quir\u00fargica. Profilaxis antimi -\ncrobiana en cirug\u00eda.Enferm Infecc Microbiol Clin. 2014;32(1):48\u2013\n53. doi: 10.1016/j.eimc.2013.11.003\n13. Vargas JC, Fern\u00e1ndez M, Mu\u00f1oz I, Sanza A. Pileflebitis por Aeromo -\nnas caviae  secundaria a colecistitis aguda. Enferm Infecc Microbiol \nClin. 2016; 34(1):69-77. \n14. Udayakumar D, Sanaullah M. Campylobacter cholecystitis. Int J \nMed Sci. 2009 ;6(6):374-5. PMID: 19960123.15. Cercenado E. Enterococcus : resistencias fenot\u00edpicas y genot\u00edpicas \ny epidemiolog\u00eda en Espa\u00f1a. Enferm Infecc Microbiol Clin. 2011; \n29(Supl 5):59-65. doi:10.1016/S0213-005X(11)70045-3\n16. Cueto-Ramos R, Hern\u00e1ndez-Guedea M, P\u00e9rez-Rodr\u00edguez E, Reyna-\nSep\u00falveda F, Mu\u00f1oz-Maldonado G. Identificaci\u00f3n de flora bacte -\nriana en cultivos de bilis y pared de ves\u00edcula biliar de pacientes \nsometidos a colecistectom\u00eda laparosc\u00f3pica en el Hospital Univer -\nsitario \u00abDr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u00bb. Cir Cir. 2017; 85(6):515-521. \ndoi: 10.1016/j.circir.2016.10.030Rev Esp Quimioter 2019;32(5): 432-439432\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Vaccine-related adverse reactions in \nimmunocompromised patients and in special \nsituations of a hospital Vaccine Unit\nABSTRACT\nObjectives. The aim of the study was to describe the type \nof vaccines administered in the Vaccine Unit at a reference hos -\npital. Calculate the overall and specific reporting rate of adverse \nreactions.\nMethods.  Retrospective observational study for the period \nbetween November 2014 and November 2017, on patients who \ndeveloped an adverse drug reaction (ADR) after the administration \nof a vaccine and who were notified to the Spanish Pharmacovi -\ngilance System. The variables analyzed were age, sex, risk group, \nvaccine class, co-administration and type of ADR. A univariate and \nbivariate analysis was performed. The global and vaccine specific \nrate of ADR notification was calculated. \nResults.  A total of 18,123 vaccines were administered, of \nwhich 20.7% corresponded to hepatitis B virus vaccine. Fifty-three \nRAM suspects were reported. In 64.2% of cases only one vaccine \nwas administered. Inactivated vaccines accounted for 88.7% of \nnotifications. The highest number of notifications was generated \nby the 23 serotypes pneumococcal polysaccharide vaccine. The \noverall reporting rate was 0.42%. The hexavalent vaccine had the \nhighest reporting rate (2.81%). 49.1% of the ADR were systemic.\nConclusions.  The overall reporting rate was low but higher \nthan that of other authors. Proper reporting of possible adverse \npost-vaccine reactions is essential to contribute to vaccine safety \nand to increase public confidence in vaccines.\nKeywords: vaccines, adverse effects, immunosuppression, pharmacovigilance\nINTRODUCCI\u00d3N\nLas vacunas son uno de los grandes logros para la salud \np\u00fablica mundial ya que cada a\u00f1o evitan alrededor de 2 a 3 RESUMEN\nObjetivos.  Describir el tipo de vacunas administradas en la Uni -\ndad de Vacunas de un hospital de referencia y calcular la tasa de \nnotificaci\u00f3n global y espec\u00edfica de las reacciones adversas asociadas.\nM\u00e9todos.  Estudio observacional retrospectivo, realizado \nen el periodo entre noviembre de 2014 y noviembre de 2017, \nde los pacientes que desarrollaron una reacci\u00f3n adversa a me -\ndicamento (RAM) tras la administraci\u00f3n de una vacuna y que \nfue notificada al Sistema Espa\u00f1ol de Farmacovigilancia. Las va -\nriables analizadas fueron edad, sexo, grupo de riesgo, tipo de \nvacuna, coadministraci\u00f3n y tipo de RAM. Se llev\u00f3 a cabo un \nan\u00e1lisis univariante y bivariante. Se calcul\u00f3 la tasa de notifica -\nci\u00f3n de RAM global y espec\u00edfica para cada vacuna.\nResultados. Se administraron un total de 18.123 vacunas \nde las que el 20,7% correspond\u00edan a la vacuna frente al virus de \nla hepatitis B. Se notificaron 53 sospechas de RAM. En el 64,2% \nde las ocasiones se hab\u00eda administrado solamente una vacu -\nna. El 88,7% de las notificaciones correspondieron a vacunas \ninactivadas. La vacuna frente neumococo polisac\u00e1rida de 23 \nserotipos fue la que gener\u00f3 el mayor n\u00famero de notificaciones. \nLa tasa de notificaci\u00f3n global de RAM fue de 0,42%. La vacu -\nna hexavalente fue la que registr\u00f3 la tasa de notificaci\u00f3n m\u00e1s \nelevada (2,81%). El 49,1% de las RAM fueron de tipo sist\u00e9mico.\nConclusiones. La tasa de notificaci\u00f3n global fue baja \naunque superior a la registrada por otros autores. La correcta \nnotificaci\u00f3n de posibles reacciones adversas postvacunales es \nimprescindible para contribuir a la seguridad vacunal y para \naumentar la confianza de la poblaci\u00f3n en las vacunas.\nPalabras clave: vacunas, reacci\u00f3n adversa, inmunosupresi\u00f3n, \nfarmacovigilancia.Reacciones adversas asociadas a la vacunaci\u00f3n \nen pacientes inmunodeprimidos y en situaciones \nespeciales de una Unidad de Vacunas hospitalaria\n1Servicio de Medicina Preventiva y Salud P\u00fablica. Hospital Vital \u00c1lvarez Buylla (Mieres, Asturias). \n2Facultad de Medicina y Ciencias de la Salud, Universidad de Oviedo (Oviedo, Asturias). \n3Servicio de Farmacia Hospitalaria. Hospital Universitario Marqu\u00e9s de Valdecilla (Santander, Cantabria) \n4Servicio de Medicina Preventiva y Salud P\u00fablica. Hospital Valle del Nal\u00f3n (Ria\u00f1o, Asturias). \n5Servicio de Farmacia. Direcci\u00f3n General de Pol\u00edtica y Planificaci\u00f3n Sanitarias. Consejer\u00eda de Sanidad del Principado de \nAsturias (Oviedo, Asturias). \n6Servicio de Vigilancia Epidemiol\u00f3gica. Direcci\u00f3n General de Salud P\u00fablica. Consejer\u00eda de Sanidad del Principado de \nAsturias (Oviedo, Asturias).Mar\u00eda Fern\u00e1ndez-Prada1\nAndrea Viejo-Gonz\u00e1lez2\nAlba Mart\u00ednez-Torr\u00f3n3\nCarmen Mart\u00ednez-Ortega4\nJes\u00fas Ruiz-Salazar5\nIsmael Huerta-Gonz\u00e1lez6\nCorrespondencia:\nAlba Mart\u00ednez-Torr\u00f3n. \nServicio de Farmacia Hospitalaria. Hospital Universitario Marqu\u00e9s de Valdecilla.\nAvda. Valdecilla 25, 39008. Santander, Cantabria, Espa\u00f1a.\nTfno.: (+34) 661.26.52.65\nE-mail: alba88_9@hotmail.comOriginal\nArticle history\nReceived: 11 February 2019; Revision Requested: 4 March 2019; Revision Received: 6 May 2019; Accepted: 22 May 2019Reacciones adversas asociadas a la vacunaci\u00f3n en pacientes inmunodeprimidos y en situaciones especiales \nde una Unidad de Vacunas hospitalariaM. Fern\u00e1ndez-Prada, et al.\nRev Esp Quimioter 2019;32(5): 432-439433Unidad de Vacunas de un hospital auton\u00f3mico de referencia; b) \ncalcular la tasa de notificaci\u00f3n de RAM global y para cada una \nde las vacunas al SEFV-H y c) describir las caracter\u00edsticas cl\u00edni -\ncas de los pacientes en los que se identific\u00f3 una RAM asociada \na la vacunaci\u00f3n.\nMATERIAL Y M\u00c9TODOS\nTipo y per\u00edodo de estudio. Estudio observacional retros -\npectivo correspondiente al periodo entre el 1 de noviembre de \n2014 y el 30 de noviembre de 2017.\n\u00c1mbito de estudio. El estudio ha sido realizado en la Uni -\ndad de Vacunas de un hospital auton\u00f3mico de referencia.\nPoblaci\u00f3n de estudio. Se han incluido los pacientes adul -\ntos y pedi\u00e1tricos en r\u00e9gimen de hospitalizaci\u00f3n o ambulatorio \ny en situaci\u00f3n de inmunosupresi\u00f3n secundaria a una enferme -\ndad o un tratamiento tales como: infecci\u00f3n por el virus de la \ninmunodeficiencia humana, trasplante de \u00f3rgano s\u00f3lido y de \nprogenitores hematopoy\u00e9ticos, quimioterapia, tratamiento \ninmunomodulador, asplenia anat\u00f3mica o funcional e inmu -\nnodeficiencia cong\u00e9nita o primaria. Por otro lado, tambi\u00e9n \nse han incluido otras situaciones especiales entre las que se \nencuentran las gestantes hospitalizadas en el tercer trimestre \nhospitalizadas, los prematuros hospitalizados y los familiares \no convivientes de pacientes inmunodeprimidos que acud\u00edan \ncomo acompa\u00f1antes y a los que se les indicaba vacunaci\u00f3n.\nVariables de estudio. Se han tenido en cuenta variables \nsociodemogr\u00e1ficas (edad y sexo), el grupo de riesgo o situaci\u00f3n \nespecial del paciente, la clasificaci\u00f3n de la vacuna (atenuada/\ninactivada y tipo de vacuna*) y si se coadministraron  m\u00e1s de \nuna vacuna en el mismo acto (s\u00ed/no) . Las principales varia -\nbles dependientes fueron la presencia de RAM (s\u00ed/no) y el tipo \nde reacci\u00f3n (local/sist\u00e9mica).\n* Se incluy\u00f3 el preparado de la prueba del Mantoux (tuber -\nculina) dentro de la variable \u201ctipo de vacuna administrada\u201d a \nsabiendas de que no es una vacuna ya que al inicio del estudio \neste producto era gestionado desde la Unidad de Vacunas y se \nten\u00eda en cuenta tanto en el stock como en la farmacovigilancia.\nFuentes de datos.  Para el c\u00e1lculo de la frecuencia de \nadministraci\u00f3n de cada una de las vacunas se consultaron los millones de fallecimientos [1]. Durante los dos \u00faltimos siglos \nhan permitido erradicar la viruela, reducir las tasas de morta -\nlidad infantil y evitar anomal\u00edas cong\u00e9nitas y discapacidades \npermanentes [1-3].\nLa seguridad de las vacunas es un hecho contrastado con \nuna s\u00f3lida base de evidencia cient\u00edfica. Los ensayos cl\u00ednicos \nprevios a la comercializaci\u00f3n, as\u00ed como los controles de ca -\nlidad durante la fabricaci\u00f3n, hacen que se hayan convertido \nen f\u00e1rmacos muy seguros [4-6]. Al igual que el resto de medi -\ncamentos, las vacunas pueden producir un efecto indeseable \nno intencionado y perjudicial denominado reacci\u00f3n adversa a \nmedicamento (RAM) [7]. Cuando la RAM no es de tipo local \nresulta complicado establecer causalidad. Sin embargo, se sos -\npecha que la RAM puede estar relacionada con la vacuna si \nse cumplen algunas de las siguientes condiciones: secuencia \ntemporal compatible, conocimiento previo, efecto de reexpo -\nsici\u00f3n, anafilaxia, confirmaci\u00f3n por parte de un laboratorio de \nla relaci\u00f3n de las lesiones con la vacuna o la realizaci\u00f3n de un \nestudio epidemiol\u00f3gico [4, 8, 9].\nPor otro lado, la notificaci\u00f3n a los sistemas de farmaco -\nvigilancia de cualquier sospecha de RAM es clave [10] ya que \npermite identificar efectos adversos previamente desconoci -\ndos, valorar los riesgos de los medicamentos comercializados, \nproponer medidas de salud p\u00fablica e informar a toda la po -\nblaci\u00f3n sobre la seguridad de los medicamentos. En Espa\u00f1a, el \nSistema Espa\u00f1ol de Farmacovigilancia de Medicamentos de Uso \nHumano (SEFV-H) es responsable de registrar y gestionar las \nsospechas de RAM [11]. Tanto profesionales sanitarios como \npacientes que sospechen cualquier RAM pueden notificarla a \ntrav\u00e9s de la web https://www.notificaram.es [11, 12].\nEn la sociedad actual, existen grupos poblacionales con \ndudas hacia la vacunaci\u00f3n lo que ha generado una baja tole -\nrancia ante la aparici\u00f3n de cualquier RAM tras la administra -\nci\u00f3n de una vacuna [13]. Por ello, trabajar en la seguridad de las \nvacunas es clave para mejorar la confianza de la poblaci\u00f3n en \nesta herramienta preventiva y que tanto la poblaci\u00f3n infantil \ncomo la adulta, mantenga elevadas coberturas de vacunaci\u00f3n \n[3].\nAs\u00ed pues, los objetivos de la presente investigaci\u00f3n son: \na) describir la distribuci\u00f3n de las vacunas administradas en la \nFigura 1  F\u00f3rmulas para el c\u00e1lculo de la tasa de notificaci\u00f3n global (A) y tasa de \nnotificaci\u00f3n espec\u00edfica (B) para cada una de las vacunas (\u201cX\u201d)\nReacciones adversas asociadas a la vacunaci\u00f3n en pacientes inmunodeprimidos y en situaciones especiales \nde una Unidad de Vacunas hospitalariaM. Fern\u00e1ndez-Prada, et al.\nRev Esp Quimioter 2019;32(5): 432-439434por el Comit\u00e9 de \u00c9tica de la Investigaci\u00f3n de la Comunidad Au -\nt\u00f3noma (referencia 149/18).\nAn\u00e1lisis estad\u00edstico. Se realiz\u00f3 la estad\u00edstica descriptiva \nde cada variable (an\u00e1lisis univariante), expresando las frecuen -\ncias absolutas y relativas de las variables cualitativas investiga -\ndas. Se calcul\u00f3 la media como medida de tendencia central, as\u00ed \ncomo la desviaci\u00f3n t\u00edpica y el valor m\u00ednimo y m\u00e1ximo para las registros de stock vacunales de enfermer\u00eda. En el caso del c\u00e1l -\nculo de la tasa de notificaci\u00f3n global y espec\u00edfica para cada tipo \nde vacuna se utiliz\u00f3 el registro informatizado de sospechas de \nRAM relacionadas con la vacunaci\u00f3n iniciado en el a\u00f1o 2014 \nen la propia Unidad en el que tambi\u00e9n se incluye informaci\u00f3n \ncl\u00ednica de cada RAM. \nAspectos \u00e9ticos. La presente investigaci\u00f3n fue aprobada Tipo de vacuna Nombre comercial N\u00ba de vacunas  \nadministradasPorcentaje sobre el total \nde vacunas administradasa\nHepatitis B adulto adyuvada FENDRIX\u00ae 3.768 20,79%\nGripe CHIROFLU\u00ae 2.987 16,48%\nNeumococo conjugada de 13 serotipos PREVENAR13\u00ae 2.806 15,48%\nNeumococo polisac\u00e1rida de 23 serotipos PNEUMOVAX23\u00ae 1.693 9,34%\nHepatitis A adulto VAQTA50\u00ae 1.390 7,67%\nHaemophilus influenzae  tipo b HIBERIX\u00ae 973 5,37%\nMeningococo C NEISVAC-C\u00ae 828 4,57%\nT\u00e9tanos-difteria adulto DIFTAVAX\u00ae 468 2,58%\nHepatitis B adulto ENGERIX20\u00ae 411 2,27%\nT\u00e9tanos-difteria adulto DITANRIX\u00ae 380 2,10%\nMeningococo B BEXSERO\u00ae 337 1,86%\nHexavalente (T\u00e9tanos-difteria-tos ferina- H. influenzae  b-hepatitis B-polio) INFANRIXHEXA\u00ae 314 1,73%\nVaricela VARIVAX\u00ae 307 1,69%\nTriple v\u00edrica (Sarampi\u00f3n-rubeola-parotiditis) MMRVAXPRO\u00ae 231 1,27%\nHepatitis A adulto HAVRIX1440\u00ae 227 1,25%\nHexavalente (T\u00e9tanos-difteria-tos ferina- H. influenzae  b-hepatitis B-polio) HEXYON\u00ae 178 0,98%\nPolio IMOVAX\u00ae 174 0,96%\nT\u00e9tanos-difteria adulto MASSBIOLOGICS\u00ae 137 0,76%\nHepatitis A infantil HAVRIX720\u00ae 104 0,57%\nT\u00e9tanos-difteria-tos feria de baja carga BOOSTRIX\u00ae 97 0,54%\nVirus del papiloma humano bivalente CERVARIX\u00ae 97 0,54%\nHepatitis B infantil ENGERIX10\u00ae 59 0,33%\nTuberculina 57 0,31%\nGripe CHIROMAS\u00ae 35 0,19%\nPentavalente (T\u00e9tanos-difteria-tos ferina- H. influenzae  b-polio) PENTAVAC\u00ae 18 0,10%\nTriple v\u00edrica (Sarampi\u00f3n-rubeola-parotiditis) PRIORIX\u00ae 16 0,09%\nTetrav\u00edrica  (Sarampi\u00f3n-rubeola-parotiditis-varicela) PROQUAD\u00ae 10 0,06%\nMeningoc\u00f3cica ACWY NIMENRIX\u00ae 9 0,05%\nT\u00e9tanos-difteria-tos feria de alta carga INFANRIX\u00ae 5 0,03%\nVirus del papiloma humano tetravalente GARDASIL\u00ae 4 0,02%\nRabia ANTIRR\u00c1BICA MERIEUX\u00ae 3 0,02%\nTOTAL 18.123 100%Tabla 1  Vacunas administradas durante el periodo de estudio seg\u00fan el tipo de vacuna y su nombre \ncomercial.\na(N\u00ba de vacunas administradas / Total de vacunas administradas) x100Reacciones adversas asociadas a la vacunaci\u00f3n en pacientes inmunodeprimidos y en situaciones especiales \nde una Unidad de Vacunas hospitalariaM. Fern\u00e1ndez-Prada, et al.\nRev Esp Quimioter 2019;32(5): 432-439435total de 76 vacunas dado que en algunos casos se hab\u00eda coad -\nministrado dos o m\u00e1s vacunas. De los 53 pacientes afectados, el \n35,85% (19) fueron hombres y el 64,15% (34) mujeres. La me -\ndia de edad (desviaci\u00f3n t\u00edpica) fue de 47,40 (\u00b1 19,95) a\u00f1os, con \nun rango de edad entre 3 y 87 a\u00f1os. De ellos, 21 padec\u00edan una \nenfermedad autoinmune, pero solo 10 ten\u00edan un tratamien -\nto inmunosupresor en el momento en el que se les administr\u00f3 \nla vacuna. De las reacciones adversas notificadas, en el 64,2% \nde las ocasiones se hab\u00eda administrado solamente una vacuna, \nmientras que en el 35,9% se administraron 2 o m\u00e1s vacunas en \nel mismo acto vacunal. Por otro lado, el 88,7% de las notifica -\nciones fue debido a una vacuna inactivada y, en el 11,4% de \nlas notificaciones, se hab\u00eda administrado o coadministrado una \nvacuna atenuada.\nLa tasa de notificaci\u00f3n global fue del 0,42%. La tabla 2 \nincluye la descripci\u00f3n de las vacunas que fueron consideradas \nsospechosas de RAM y que fueron incluidas en las notificacio -\nnes a farmacovigilancia, as\u00ed como el porcentaje y tasa de no -\ntificaci\u00f3n seg\u00fan el tipo de vacuna. En este sentido, se observa \nc\u00f3mo la vacuna que m\u00e1s n\u00famero de veces gener\u00f3 una notifi -\ncaci\u00f3n fue la VNP23, en 23 ocasiones (30,26%), mientras que la \nvacuna que present\u00f3 mayor tasa de notificaci\u00f3n espec\u00edfica fue \nla hexavalente (2,81%).\nEn el an\u00e1lisis bivariante no se encontr\u00f3 asociaci\u00f3n esta -variables cuantitativas. Se llev\u00f3 a cabo un an\u00e1lisis bivariante \npara conocer si las variables de estudio seleccionadas ten\u00edan \no no asociaci\u00f3n. Para las variables cualitativas dicot\u00f3micas se \naplic\u00f3 el test exacto de Fisher dado que el tama\u00f1o muestral \nera peque\u00f1o. Se calcul\u00f3 la tasa de notificaci\u00f3n global y la es -\npec\u00edfica para cada una de las vacunas (\u201cX\u201d) en el periodo de \nestudio mediante las f\u00f3rmulas A y B de la figura 1. Se consider\u00f3 \nestad\u00edsticamente significativo si p<0,05. Se utiliz\u00f3 el programa \nPredictive Analytics SoftWare versi\u00f3n 18.0.\nRESULTADOS\nDurante el periodo de estudio se administraron un total \nde 18.123 vacunas. De ellas, el 20,79% fueron frente a la hepa -\ntitis B (con vacuna adyuvada con AS04C), cerca de un 16,48% \ncorrespond\u00edan a la vacunaci\u00f3n antigripal estacional y alrede -\ndor del 25% frente a neumococo [15,48% correspondi\u00f3 a la \nvacuna conjugada de 13 serotipos (VNC13) y casi un 9,34% a \nla polisac\u00e1rida de 23 serotipos (VNP23)]. Del total de las vacu -\nnas administradas, 17.559 (96,89%) fueron inactivadas y 564 \n(3,11%) fueron vacunas vivas-atenuadas. La tabla 1  describe las \nvacunas administradas seg\u00fan la clasificaci\u00f3n.\nDurante los tres a\u00f1os se realizaron 53 notificaciones de \nsospechas de RAM asociadas a la vacunaci\u00f3n que incluyeron un Tipo de vacuna Marca de la vacunaFrecuencia  \nde notificacionesPorcentaje  \nde notificacionesaTasa de notificaci\u00f3n  \nespec\u00edfica (figura 1)\nHexavalente (T\u00e9tanos-difteria-tos ferina- H. influenzae  b-hepatitis B-polio) HEXYON\u00ae 5 6,58% 2,81%\nNeumococo polisac\u00e1rida de 23 serotipos PNEUMOVAX23\u00ae 23 30,26% 1,36%\nTriple v\u00edrica (Sarampi\u00f3n-rubeola-parotiditis) MMRVAXPRO\u00ae 3 3,95% 1,30%\nT\u00e9tanos-difteria-tos feria de baja carga BOOSTRIX\u00ae 1 1,32% 1,03%\nVaricela VARIVAX\u00ae 3 3,95% 0,98%\nHexavalente (T\u00e9tanos-difteria-tos ferina- H. influenzae  b-hepatitis B-polio) INFANRIXHEXA\u00ae 3 3,95% 0,96%\nPolio IMOVAX\u00ae 1 1,32% 0,57%\nHepatitis A adulto HAVRIX1440\u00ae 1 1,32% 0,44%\nT\u00e9tanos-difteria adulto DIFTAVAX\u00ae 2 2,63% 0,43%\nNeumococo conjugada de 13 serotipos PREVENAR13\u00ae 10 13,16% 0,36%\nHepatitis B adulto adyuvada FENDRIX\u00ae 13 17,11% 0,35%\nMeningococo B BEXSERO\u00ae 1 1,32% 0,30%\nMeningococo C NEISVAC-C\u00ae 2 2,63% 0,24%\nHepatitis B adulto ENGERIX20\u00ae 1 1,32% 0,24%\nHepatitis A adulto VAQTA50\u00ae 2 2,63% 0,14%\nGripe CHIROFLU\u00ae 4 5,27% 0,13%\nH. influenzae  tipo b HIBERIX\u00ae 1 1,32% 0,10%\nTOTAL 76 100%Tabla 2  RAM sospechosas notificadas a farmacovigilancia durante el periodo de estudio seg\u00fan el tipo de \nvacuna y su nombre comercial.\na(Frecuencia de notificaciones / N\u00ba total notificaciones) x100Reacciones adversas asociadas a la vacunaci\u00f3n en pacientes inmunodeprimidos y en situaciones especiales \nde una Unidad de Vacunas hospitalariaM. Fern\u00e1ndez-Prada, et al.\nRev Esp Quimioter 2019;32(5): 432-439436En primer lugar, destacar que la mayor\u00eda de las vacunas \nque fueron administradas en el per\u00edodo de estudio fueron in -\nactivadas. Esto se debe a que los pacientes que acuden a la \nUnidad de Vacunas est\u00e1n inmunodeprimidos y, por tanto, las \nvacunas atenuadas est\u00e1n contraindicadas o se administran en \nsituaciones muy concretas  [14]. Adem\u00e1s, la mayor\u00eda de los pa -\ncientes eran adultos por lo que muchos de ellos hab\u00edan sido \ninmunizados de manera natural o artificial en la infancia [15]. \nLa vacuna m\u00e1s frecuentemente administrada fue la del VHB \ndebido a la necesidad de vacunar con cuatro dosis a la mayo -\nr\u00eda de los adultos inmunodeprimidos  [16, 17] que no fueron \ninmunizados en la infancia puesto que la introducci\u00f3n de esta \nvacuna en el calendario vacunal se aprob\u00f3 en el a\u00f1o 1982 [15]. \nAl mismo tiempo, la vacuna antigripal se encuentra entre las \nm\u00e1s administradas ya que la indicaci\u00f3n es generalizada para \nestos pacientes en cada campa\u00f1a estacional [18]. Por \u00faltimo, la \nVNC13 fue la tercera por orden de frecuencia; esta es de espe -\ncial inter\u00e9s por un mayor riesgo de neumon\u00eda neumoc\u00f3cica y \nenfermedad neumoc\u00f3cica invasora en este grupo [19].\nEn general, puede considerarse que la tasa de notificaci\u00f3n \nglobal observada en el presente estudio es baja (0,42%), sobre todo \nsi se compara con las RAM descritas para otros f\u00e1rmacos como, \npor ejemplo, el acenocumarol (2,25%)  [20] o la carbamacepina (2-\n4%) [21]. No obstante, lo descrito en esta investigaci\u00f3n es supe -\nrior a lo observado por autores como Batalla et al, donde la tasa \nde notificaci\u00f3n fue 0,01%  [22] y 7,2 por cada 100.000 vacunas \nadministradas [23]. La elevada tasa de notificaci\u00f3n de la vacuna \nhexavalente se explica por tener mayor carga antig\u00e9nica frente a \ndifteria y tos ferina (presentaci\u00f3n infantil) y estar siendo aplicada \nen poblaci\u00f3n adulta  [24]. En cuanto a la tasa de notificaci\u00f3n de la \nVNP23, est\u00e1 descrito en la literatura cient\u00edfica que se trata de una \nvacuna con mayor reactogenicidad, sobre todo local  [25, 26].\nMerece la pena destacar que en 1977, Rawlins y Thomp -\nson, establecieron una clasificaci\u00f3n para los efectos adversos que \nengloba varios mecanismos part\u00edcipes en su aparici\u00f3n, dividi\u00e9n -\ndolos en reacciones tipo A y tipo B [27]. Las reacciones tipo A \nson las m\u00e1s frecuentes, aparecen con dosis normales y son dosis-\ndependiente, provocadas por un efecto predecible y exagerado, \nson leves y definidas, frecuentemente locales y desaparecen en \nun corto espacio de tiempo, se corresponden con el 80-90% de \nlas RAM  [3, 27]. Por el contrario, las reacciones tipo B son in -\nusuales e impredecibles, su mecanismo de aparici\u00f3n no guarda \nrelaci\u00f3n con la farmacocin\u00e9tica a dosis normales del f\u00e1rmaco y \nrepresentan el 10-20% de los efectos adversos  [27]. Atendiendo d\u00edsticamente significativa entre la variable sexo y el tipo de \nreacci\u00f3n adversa (p=0,888) ni el tipo de vacuna administrada \n(p=0,405) (tabla 3). Tampoco la hubo entre las variables tipo de \nvacuna y tipo de reacci\u00f3n (p=0,135). Por \u00faltimo, no se encontr\u00f3 \ncorrelaci\u00f3n entre el n\u00famero de vacunas administradas y el tipo \nde reacci\u00f3n adversa registrada posteriormente (p=0,219).\nEn relaci\u00f3n con la cl\u00ednica de RAM observadas, 19 fueron de \ntipo local (35,8%), 26 de tipo sist\u00e9mico (49,1%) y, en 8 (15,1%), \nse observaron s\u00edntomas locales y sist\u00e9micos al mismo tiempo. \nA pesar de que 15 pacientes precisaron asistencia inmediata \no ambulatoria, solo en un caso se precis\u00f3 hospitalizaci\u00f3n y el \ndesenlace de todas las reacciones fue favorable, desaparecien -\ndo los s\u00edntomas a las pocas horas o d\u00edas y sin dejar secuelas ni \ndiscapacidades. La reacci\u00f3n m\u00e1s frecuentemente observada fue \ninflamaci\u00f3n en 16 del total de notificaciones (30,19%), relacio -\nnada con otros s\u00edntomas como impotencia funcional, prurito, \nmalestar general, dolor o tumefacci\u00f3n, seguida del eritema que \napareci\u00f3 en 9 pacientes (16,98%) y la fiebre en 8 (15,09%). Den -\ntro de las reacciones locales se identificaron 3 posibles casos \nde hipersensibilidad al aluminio contenido en la vacuna como \nadyuvante. De las reacciones sist\u00e9micas, 9 pacientes padecieron \nflushing , dificultad respiratoria y taquicardia. Estas reacciones \nadversas estaban posiblemente relacionadas con la VNP23. Por \notro lado, en 5 casos se observ\u00f3 reactivaci\u00f3n de la patolog\u00eda de \nbase (ptosis palpebral en paciente con miastenia gravis  tras la \nadministraci\u00f3n de VNC13, diarrea en paciente con enfermedad \nde Crohn tras vacuna frente a la VNC13 y parestesia y dificultad \npara la deambulaci\u00f3n en una paciente con esclerosis m\u00faltiple \ntras la administraci\u00f3n de vacuna de varicela, etc).\nLas figuras 2, 3 y 4  muestran algunas de las reacciones \nlocales que fueron notificadas a farmacovigilancia.\nDISCUSI\u00d3N\nCon los resultados obtenidos a trav\u00e9s de la metodolog\u00eda \nexpuesta se considera que se ha dado cumplida respuesta al \nobjetivo de la investigaci\u00f3n. Por un lado, se ha descrito la distri -\nbuci\u00f3n de las vacunas administradas en una Unidad de Vacunas \nde un hospital auton\u00f3mico de referencia en el contexto de la \nasistencia a pacientes inmunodeprimidos y/o en situaciones es -\npeciales. Por otro, se ha calculado la tasa de notificaci\u00f3n a far -\nmacovigilancia global y espec\u00edfica para cada una de las vacu -\nnas administradas en el per\u00edodo de estudio. Igualmente, se han \ndetallado las caracter\u00edsticas cl\u00ednicas de las RAM identificadas.SexoTipo de vacuna Tipo de reacci\u00f3n adversa\nInactivada Viva Viva + inactivada Total p Local Sist\u00e9mica Local + sist\u00e9mica Total p\nHombre 18 0 1 19\n0,4056 10 3 19\n0,888 Mujer 29 3 2 34 13 16 5 34\nTotal 47 3 3 53 19 26 8 53Tabla 3  An\u00e1lisis bivariante.Reacciones adversas asociadas a la vacunaci\u00f3n en pacientes inmunodeprimidos y en situaciones especiales \nde una Unidad de Vacunas hospitalariaM. Fern\u00e1ndez-Prada, et al.\nRev Esp Quimioter 2019;32(5): 432-439437Por \u00faltimo, el presente trabajo no se encuentra exento \nde limitaciones. Se trata de un estudio realizado en una \u00fanica \nUnidad de Vacunas que, a\u00fan siento el punto de vacunaci\u00f3n de \nreferencia en la comunidad aut\u00f3noma, no permite generalizar \nlos resultados. Adem\u00e1s, el per\u00edodo de estudio solamente abarca \ntres a\u00f1os lo cual quiere decir que la baja frecuencia de admi -\nnistraci\u00f3n de algunas vacunas como la tetrav\u00edrica o la vacuna \nfrente al VPH tetravalente, por ejemplo, puede no ser suficiente \ncomo para detectar RAM postvacunales diferentes a lo espe -\nrado.\nComo propuestas de futuro parece interesante destacar \nque, en base a la importancia y la necesidad tanto \u00e9tica como \nlegal de la farmacovigilancia, deber\u00eda reforzarse la formaci\u00f3n \nen la identificaci\u00f3n, notificaci\u00f3n y manejo de las RAM rela -\ncionadas con los medicamentos en general y las vacunas en \nparticular, de todos los profesionales sanitarios (enfermer\u00eda, \nmedicina, farmacia y odontolog\u00eda, sobre todo). Igualmente, la \nformaci\u00f3n espec\u00edfica y acreditada a lo largo de la carrera profe -\nsional contribuir\u00eda al incremento del n\u00famero de notificaciones. \nAdem\u00e1s, el feedback  peri\u00f3dico por parte de los responsables del \nCentro de Farmacovigilancia de la Consejer\u00eda de Sanidad hacia \nlos profesionales sobre los casos notificados a nivel auton\u00f3mico \no las actuaciones llevadas a cabo por su parte podr\u00eda reforzar \ndicha conducta.\nEn conclusi\u00f3n, la vacuna frente al VHB registr\u00f3 la mayor fre -\ncuencia absoluta de administraci\u00f3n. La vacuna hexavalente y la \nVNP23 fueron las que obtuvieron una mayor tasa de notificaci\u00f3n \nespec\u00edfica. La correcta notificaci\u00f3n de posibles RAM postvacu -\nnales es imprescindible para contribuir a la seguridad vacunal y \npara aumentar la confianza de la poblaci\u00f3n en las vacunas.a esta clasificaci\u00f3n las reacciones adversas notificadas en la pre -\nsente investigaci\u00f3n podr\u00edan corresponder con las de tipo B dado \nque estas se consideran aberrantes con respecto a lo esperado y \nla frecuencia de aparici\u00f3n es inferior al 20%.\nLa aparici\u00f3n de una reacci\u00f3n adversa postvacunal se cree \nque es multifactorial y no se conocen con exactitud con me -\ncanismos de respuesta. Por lo que respecta a los resultados \nrelacionados con la variable sexo, existe concordancia con lo \ndescrito en la literatura cient\u00edfica. Esto es, al igual que refieren \nHarrisa et al [28], en la presente investigaci\u00f3n se observa que el \nsexo femenino registra mayor frecuencia de RAM asociadas a \nla vacunaci\u00f3n, aunque las diferencias no resultan estad\u00edstica -\nmente significativas. Quiz\u00e1s factores gen\u00e9ticos, inmunol\u00f3gicos \nu hormonales puedan explicar estos resultados  [28]. Aparte de \nlo anterior, parece l\u00f3gico pensar que no exista relaci\u00f3n entre el \nsexo y el tipo de reacci\u00f3n ni el tipo de vacuna.\nEn lo concerniente a la coadministraci\u00f3n de vacunas en un \nmismo acto, se sabe que esta pr\u00e1ctica es segura y efectiva por \nlo que no est\u00e1 relacionada con la mayor aparici\u00f3n ni intensidad \nde las RAM, siempre que las vacunas se administren en dife -\nrentes zonas anat\u00f3micas, no se trate de vacunas conjugadas \ny polisac\u00e1ridas frente a la misma enfermedad y se realice con \ndistintas jeringas [29].\nA pesar de que las RAM observadas se resolvieron sin se -\ncuelas ni discapacidades, desde el punto de vista de la seguri -\ndad vacunal resulta de gran inter\u00e9s el control y seguimiento \nde las mismas con el fin de detectar posibles se\u00f1ales o alertas \nrelacionadas con estos f\u00e1rmacos  [3, 30]. Todos los datos refe -\nrentes a esta investigaci\u00f3n han sido contrastados con el Centro \nAuton\u00f3mico de Farmacovigilancia.Figura 2  Hematomas en ambos miembros \nsuperiores relacionados con la \nadministraci\u00f3n de las vacunas VHB y \nVNP23.Figura 3  Reacci\u00f3n adversa local relacionada con la \nadministraci\u00f3n de VNP23 y B) resoluci\u00f3n \nde la reacci\u00f3n adversa a los 30 d\u00edas\nReacciones adversas asociadas a la vacunaci\u00f3n en pacientes inmunodeprimidos y en situaciones especiales \nde una Unidad de Vacunas hospitalariaM. Fern\u00e1ndez-Prada, et al.\nRev Esp Quimioter 2019;32(5): 432-439438FINANCIACI\u00d3N\nNo existen relaciones financieras, laborales o de otra \u00edn -\ndole. Es decir, no hemos recibido \u201cbeneficios en dinero, bienes, \nhospitalidad o subsidios\u201d de fuente alguna que tenga un inter\u00e9s \nparticular en los resultados de la investigaci\u00f3n.\nCONFLICTOS DE INTERESES\nLos autores declaran que no tienen Conflictos de intereses\nBIBLIOGRAF\u00cdA\n1. Centers for Disease Control and Prevention . Atlanta: MMWR. \nUpdate: Vaccine side effects, adverse reactions, contraindications \nand precaution. Recommendations of the Advisory Committee on \nImmunization Practices (ACIP). [acceso 13 de febrero de 2018]. \nDisponible en: http://www.cdc.gov/mmwr/preview/mmwrht -\nml/00046738.htm\n1. Galindo Santana BM, Arroyo Rojas L, Concepci\u00f3n D\u00edaz D. Seguridad \nde las vacunas y su repercusi\u00f3n en la poblaci\u00f3n. Rev Cubana Salud \nP\u00fablica. 2011;37:149-58.\n2. Centers for Disease Control and Prevention. Epidemiology and Pre -\nvention of Vaccine-Preventable Diseases. Hamborsky J, Kroger A, \nWolfe S, eds. 13th ed., Supplement. Washington D.C. Public Health \nFoundation, 2017.\n3. Centers for Disease Control and Prevention. Atlanta. Cap\u00edtulo 4: Va -\nccination safety. Epidemiology and Prevention of Vaccine-Preven -\ntable Diseases. The Pink Book: Course Textbook. 2015. [Acceso 11 \nde marzo de 2019]. Disponible en: https://www.cdc.gov/vaccines/\npubs/pinkbook/safety.html\n4. Cunningham AL, Gar\u00e7on N, Leo O, Friedland LR, Strugnell R, Lau -\np\u00e8ze B, et al. Vaccine development: from concept to early testing. Vaccine2016; 34(52):6655-64. doi: 10.1016/j.vaccine.2016.10.016.\n5. Plotkin S, Robinson JM, Cunningham G, Igbal R, Larsen S. The com -\nplexity and cost of vaccine manufacturing \u2013 an overview. Vaccine \n2017; 35(33):4064-71. doi: 10.1016/j.vaccine.2017.06.003\n6. Comit\u00e9 Asesor de Vacunas (CAV-AEP) [Internet]. Madrid: Manuel \nMerino Mo\u00edna; [acceso 23 de febrero de 2018]. Manual de Vacunas \nen l\u00ednea de la AEP; Cap\u00edtulo 3. Seguridad de las vacunas. Contra -\nindicaciones y precauciones. Disponible en: http://vacunasaep.org/\ndocumentos/manual/cap-3\n7. Escudero C, Garc\u00eda-Fern\u00e1ndez C, Ib\u00e1\u00f1ez MD. Reacciones al\u00e9rgicas a \nlas vacunas. Vacunas. 2008; 9:156-60.\n8. Eseverri JL, Ranea S, Marin, A. Reacciones adversas a vacunas. Aller -\ngol Immunopathol. 2003; 31:125-38. PMID: 12783762\n9. Virga C, Aguzzi A. FARMACOVIGILANCIA: estudio de las reacciones \nadversas a medicamentos (RAM). Archivos venezolanos de farma -\ncolog\u00eda y terap\u00e9utica. 2011;30:61-3.\n10. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Ma -\ndrid: Ministerio de Sanidad Servicio Sociales e Igualdad; [acceso el \n03 de octubre de 2018]. Notificaci\u00f3n de sospechas de reacciones \nadversas a medicamentos. Disponible en: www.notificaram.es\n11. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios [Inter -\nnet]. Madrid: Ministerio de Sanidad Servicio Sociales e Igualdad; \n[acceso el 26 de febrero de 2018]. Informaci\u00f3n para las notificacio -\nnes de sospechas de reacciones adversas a medicamentos por par -\nte de profesionales sanitarios. Disponible en: https://www.aemps.\ngob.es/vigilancia/medicamentosUsoHumano/SEFV-H/NRA-SEFV-H/\nnotificaSospechas-RAM-profSanitarios.htm\n12. Mart\u00ednez-Diz S, Mart\u00ednez Romero M, Fern\u00e1ndez-Prada M, Cruz \nPiqueras M, Molina Ruano R, Fern\u00e1ndez Sierra MA. Demandas y \nexpectativas de padres y madres que rechazan la vacunaci\u00f3n y \nperspectiva de los profesionales sanitarios sobre la negativa a \nvacunar. An Pediatr (Barc). 2014;80:370-8. doi: 10.1016/j.anpe -\ndi.2013.08.009Figura 4  Reacci\u00f3n local a las 24 horas de la vacunaci\u00f3n con VNC13, B) Evoluci\u00f3n de \nla reacci\u00f3n a las 48 horas y C) Remisi\u00f3n de la lesi\u00f3n a las 72 horas\nReacciones adversas asociadas a la vacunaci\u00f3n en pacientes inmunodeprimidos y en situaciones especiales \nde una Unidad de Vacunas hospitalariaM. Fern\u00e1ndez-Prada, et al.\nRev Esp Quimioter 2019;32(5): 432-43943913. Comit\u00e9 Asesor de Vacunas (CAV-AEP). Madrid: Manuel Merino Mo\u00ed -\nna; [acceso 2 de mayo de 2018]. Manual de Vacunas en l\u00ednea de la \nAEP; Cap\u00edtulo 14. Vacunaci\u00f3n en ni\u00f1os inmunodeprimidos o con \ntratamiento inmunosupresor. Disponible en: https://vacunasaep.\norg/documentos/manual/cap-14\n14. Comit\u00e9 Asesor de Vacunas (CAV-AEP). Madrid: Manuel Merino Mo\u00ed -\nna; [acceso 10 de febrero de 2018]. Manual de Vacunas en l\u00ednea de \nla AEP; Cap\u00edtulo 7. Calendarios de vacunaci\u00f3n en Espa\u00f1a. Disponi -\nble en: https://vacunasaep.org/documentos/manual/cap-7\n15. Shouval D. Prevention of hepatitis B reactivation in immunosup -\npressed patients with cancer. Medwave. 2007;7:e3326.\n16. Idrovo V, Yanette C, Su\u00e1rez Q. Epidemiolog\u00eda e historia natural de la \nhepatitis B. Rev Col Gastroenterol. 2009;24:4-11.\n17. Ministerio de Sanidad Servicios Sociales e Igualdad. Recomendacio -\nnes de vacunaci\u00f3n frente a la gripe. Temporada 2017-18. Madrid: \nMSSSI;2017 [acceso 18 de mayo de 2018]. Disponible en: https://\nwww.mscbs.gob.es/profesionales/saludPublica/prevPromocion/va -\ncunaciones/docs/Recomendaciones_vacunacion_gripe.pdf\n18. Picazo J, Gonz\u00e1lez-Romo F, Garc\u00eda Rojas A. Consenso sobre la vacu -\nnaci\u00f3n anti-neumoc\u00f3cica en el adulto con patolog\u00eda de base. Rev \nEsp Quimioter. 2013;26:232-52. PMID: 24080892\n19. Castro C, Bustos L, Ocampo R, Molina E, Cabrero P, Vergara R, et \nal. Effectiveness and safety of oral anticoagulation treatment with \nacenocoumarol in non-valvular atrial fibrillation. Rev Med Chil. \n2017;145:1243-51. doi: 10.4067/S0034-98872017001001243.\n20. Morales Acedo MJ, Mora Garc\u00eda E, Mart\u00ednez Blanco J. Reacciones \nadversas de la carbamacepina. A prop\u00f3sito de un caso. Semergen. \n2000; 26:325-7. \n21. Batalla J, Parr\u00f3n I, Bold\u00fa M. Programa de sospecha de reacciones \nadversas a vacunas de Catalu\u00f1a. Resultados del primer a\u00f1o. Vacu -\nnas. 2000; 1:119-25.\n22. Batalla J, Urbiztondo L, Mart\u00ednez M. Incidencia de los efectos ad -\nversos asociados con la vacunaci\u00f3n sistem\u00e1tica y los programas de \nvacunaci\u00f3n en Catalu\u00f1a. Vacunas. 2004; 4:127-31.\n23. Huerta I. Calendario de vacunaciones del adulto y vacunaci\u00f3n en \nsituaciones especiales. Oviedo: Servicio de Vigilancia Epidemiol\u00f3gi -\nca. Principado de Asturias. Direcci\u00f3n General de Salud P\u00fablica;2014 \n[acceso 18 de mayo de 2018] Disponible en: https://www.asturias.\nes/Astursalud/Ficheros/AS_Salud%20Publica/AS_Prevencion/Va -\ncunas%202014/Guia_indicaciones_Calendario_Adultos_2014.pdf\n24. WHO. Twenty-three-valent pneumococcal polysaccharide vacci -\nne. WHO position paper. WklyEpidemiol Rec. 2008; 83(42):373-84. \nPMID: 18927997\n25. Li G, Liang Q, Shi J. Safety and immunogenicity of 23-va -\nlent pneumococcal polysaccharide vaccine in 2 to 70 year old \nhealthy people in China: A phase III double blind, randomized \nclinical trial. Hum Vaccin Immunother. 2015; 11:699-703. doi: \n10.1080/21645515.2015.1011015\n26. Rawlins MD, Thompson JW. Mechanism of adverse drug reactions. \nEn: Davies DM, ed. Textbook of adverse drug reactions, 4 ed. Oxford: \nOxford University Press, 1991:18-45.\n27. Harrisa T, Nair J, Fediureka J. Assessment of sex-specific differen -\nces in adverse events following immunization reporting in Onta -rio, 2012\u201315. Vaccine. 2017; 35(19):2600-4. doi: 10.1016/j.vacci -\nne.2017.03.035\n28. Comit\u00e9 Asesor de Vacunas (CAV-AEP) [Internet]. Madrid: Manuel \nMerino Mo\u00edna; [acceso 17 de mayo de 2018]. Manual de Vacunas \nen l\u00ednea de la AEP; Cap\u00edtulo 2. Coadministraci\u00f3n de las vacunas \nentre s\u00ed y con otros productos biol\u00f3gicos. Disponible en: https://\nvacunasaep.org/documentos/manual/cap-2\n29. Plotkin S, Robinson JM, Cunningham G, Iqbal R, Larsen S. The com -\nplexity and cost of vaccine manufacturing \u2013 An overview. Vaccine. \n2017; 35(33):4064-71. doi: 10.1016/j.vaccine.2017.06.003Rev Esp Quimioter 2019;32(5): 440-444440\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Hepatitis C: New diagnosis and \nseroconversions in a Madrid sexually \ntransmitted diseases clinic\nABSTRACT\nIndroduction.  The aim of this study was to evaluate the \nincidence of new hepatitis C virus (HCV) infections, based on \ntheir sexual orientation, human immunodeficiency virus (HIV) \nstatus, geographical regions and coinfection with other sexu -\nally transmitted diseases (STDs).\nMaterial and methods.  This study was carried out \nat the Sandoval Health Center, reference clinic of Sexually \nTransmitted Diseases (STDs) in Madrid. All HCV seronegative \nindividuals who were reanalyzed for this virus were included, \nbetween January 2010 and December 2016.\nResults . A total of 59 new diagnoses of HCV were diag -\nnosed. The proportion of men who have sex with men (MSM) \ndiagnosed with HCV was 37% in 2010 and 75% in 2016 and \nwas even higher in the group of coinfected with HIV/HCV \n(94%). A total of 67 seroconverters for HCV were detected \n(1.2%) of which 100% were MSM. The proportion of HCV sero -\nconverters with HIV was 89%. \nConclusions . HCV infection continues to be a current \nhealth problem, especially in HIV-positive MSM.\nKey-words: HCV; new diagnostics; seroconverters; HIV; MSM\nINTRODUCCI\u00d3N\nLa infecci\u00f3n por el virus de la hepatitis C (VHC) constitu -\nye un problema de salud que afecta aproximadamente a 185 \nmillones de personas en todo el mundo, de las que cada a\u00f1o \nfallecen 350.000 [1]. Hasta un 75-80% de las personas que en -\ntran en contacto con el VHC desarrollar\u00e1n una infecci\u00f3n cr\u00f3 -\nnica, con un espectro de afectaci\u00f3n hep\u00e1tica que var\u00eda desde \nm\u00ednimos cambios histol\u00f3gicos, hasta extensa fibrosis con cirro -RESUMEN\nObjetivo.  El objetivo es evaluar las nuevas infecciones por \nel virus de la hepatitis C ( VHC) en funci\u00f3n de su orientaci\u00f3n \nsexual, situaci\u00f3n serol\u00f3gica respecto al v irus de la inmunodefi -\nciencia humana  (VIH), regi\u00f3n geogr\u00e1fica de origen y la coinfec -\nci\u00f3n con otras infecciones de transmisi\u00f3n sexual (ITS). \nMaterial y m\u00e9todos.  Estudio realizado en el Centro \nSanitario Sandoval, cl\u00ednica de referencia de ITS en Madrid. Se \nincluyeron todas las personas seronegativas al VHC que fueron \nreanalizadas para este virus, entre enero de 2010 y diciembre \nde 2016.\nResultados.  Se diagnosticaron 59 nuevos diagn\u00f3sticos de \ninfecci\u00f3n por el VHC. La proporci\u00f3n de hombres que tienen se -\nxo con hombres ( HSH) dentro de los nuevos diagn\u00f3sticos fue \ndel 37% en 2010 y del 75% en 2016 y, fue a\u00fan mayor en el \ngrupo de coinfectados por el VIH/VHC (94%). Se detectaron 67 \nseroconvertores al VHC (1,2%). El 100% eran HSH. El 89% de \nlos seroconvertores al VHC eran seropositivos para el VIH. \nConclusiones . La infecci\u00f3n por el VHC sigue siendo un \nproblema de salud vigente, especialmente en colectivos de \nriesgo, como los HSH seropositivos para el VIH. \nPalabras clave: VHC; nuevos diagn\u00f3sticos; seroconvertores; VIH; HSHHepatitis C: nuevos diagn\u00f3sticos y seroconversiones \nen una cl\u00ednica de infecciones de transmisi\u00f3n sexual \nen Madrid\n1Servicio de Medicina Interna. Hospital Universitario del Henares. Coslada. Madrid. Espa\u00f1a.\n2Laboratorio de an\u00e1lisis cl\u00ednicos del Centro Sanitario Sandoval. Madrid. Espa\u00f1a.\n3Departamento de VIH e infecciones de transmisi\u00f3n sexual del Centro Sanitario Sandoval. Madrid. Espa\u00f1a.\n4Centro Sanitario Sandoval. Madrid. Espa\u00f1a.Erika Esperanza Lozano \nRinc\u00f3n1\nCarmen Rodr\u00edguez Mart\u00edn2\n\u00d3skar Ayerdi \nAguirrebengoa3\nMar Vera Garc\u00eda3\nRegino Serrano Heranz1\nJorge Del Romero Guerrero4\nCorrespondencia:\nErika Esperanza Lozano Rinc\u00f3n. \nServicio de Medicina Interna. Hospital Universitario del Henares\nMarie Curie s/n. Coslada. Madrid. Espa\u00f1a. \nTfno: +34 666053716.\nE-mail: erika.lozano.rincon@gmail.comOriginal\nArticle history\nReceived: 18 February 2019; Revision Requested: 21 March 2019; Revision Received: 27 May 2019; Accepted: 28 May 2019Hepatitis C: nuevos diagn\u00f3sticos y seroconversiones en una cl\u00ednica de infecciones de transmisi\u00f3n sexual en \nMadridE. E. Lozano Rinc\u00f3n, et al.\nRev Esp Quimioter 2019;32(5): 440-444441que fueron nuevamente analizadas para este virus y todas las \npersonas con diagn\u00f3stico de VHC sin serolog\u00eda previa conocida \n(nuevos diagn\u00f3sticos), entre el 01 de enero de 2010 y el 31 de \ndiciembre de 2016. \nA todos los pacientes seronegativos para el VHC se les rea -\nliz\u00f3 anualmente una nueva serolog\u00eda y todos ellos respondie -\nron a un cuestionario epidemiol\u00f3gico estructurado, con objeto \nde conocer variables sociodemogr\u00e1ficas y conductuales. \nLa determinaci\u00f3n del anticuerpo para el VHC (Anti-VHC) \nse llev\u00f3 a cabo mediante un inmunoensayo de micropart\u00edculas \npor quimioluminiscencia (CMIA), Abbott diagnostics division \u00ae. \nLa carga viral se determin\u00f3 mediante Versant \u00ae HCV RNA 1(kP -\nCR), Siemens.\nRESULTADOS\nDel total de 26.805 consultas atendidas en el a\u00f1o 2016, se \ndiagnosticaron microbiol\u00f3gicamente 3.362 episodios de ITS, de \nlos cuales 287 correspond\u00edan a nuevos diagn\u00f3sticos de infec -\nci\u00f3n por el VIH y 59 a nuevos diagn\u00f3sticos de infecci\u00f3n por el \nVHC (lo que representaba un 2% del total de las ITS diagnos -\nticadas). \nDesde el a\u00f1o 2010 y hasta el a\u00f1o 2016 se reanalizaron un \ntotal de 4.740 muestras para detectar la presencia de anticuer -\npos para el VHC, pertenecientes a 4.271 hombres, 414 mujeres \ny 55 transexuales (TSX). La edad media de los mismos fue de 36 \na\u00f1os (desviaci\u00f3n est\u00e1ndar: 7,18).\nDe todas las muestras reanalizadas (4.740) se detectaron \n67 seroconvertores para el  VHC (1,4%). El 100% fueron  hom-sis (entre un 5-25% evolucionar\u00e1n a cirrosis en d\u00e9cadas) con \no sin desarrollo de carcinoma hepatocelular (CHC). Adem\u00e1s, \nla infecci\u00f3n por VHC es una de las principales indicaciones de \ntrasplante hep\u00e1tico (TH) en nuestro medio.\nPese a la alta prevalencia de la infecci\u00f3n, la mayor\u00eda de los \nindividuos afectados no conocen que est\u00e1n infectados [2]. \nLos reg\u00edmenes de tratamiento de la infecci\u00f3n por el VHC, \nbasados en la combinaci\u00f3n de agentes antivirales de acci\u00f3n \ndirecta (AAD), consiguen unas tasas de respuesta virol\u00f3gica \nsostenida por encima del 90%, incluso en pacientes que fra -\ncasaron previamente a las terapias basadas en interfer\u00f3n [3]. \nSin embargo, a pesar de estos avances en la eficacia del \ntratamiento, se siguen observando nuevas infecciones, sobre \ntodo en personas seropositivas para el virus de la inmunodefi -\nciencia humana (VIH). En los pa\u00edses con terapia antirretroviral \ndisponible para el VIH, la mortalidad por el VHC supera a la \nproducida por el VIH y por el virus de la hepatitis B (VHB). \nEl objetivo del presente trabajo es evaluar la incidencia \nde nuevas infecciones por el VHC en personas inicialmente \nseronegativas, en funci\u00f3n de su orientaci\u00f3n sexual, situaci\u00f3n \nserol\u00f3gica respecto al VIH, regi\u00f3n geogr\u00e1fica de origen y la \ncoinfecci\u00f3n con otras infecciones de transmisi\u00f3n sexual (ITS), \nespecialmente el linfogranuloma ven\u00e9reo  (LGV). \nMATERIAL Y M\u00c9TODOS \nEstudio retrospectivo realizado en el Centro Sanitario \nSandoval (CSS), cl\u00ednica de referencia de ITS en la Comunidad de \nMadrid. Se incluyeron todas las personas seronegativas al VHC \nFigura 1  N\u00famero de seroconvertores por a\u00f1o y proporci\u00f3n de coinfectados \npor el VIH, en el Centro Sanitario Sandoval (CSS) (2010-2016)\nHepatitis C: nuevos diagn\u00f3sticos y seroconversiones en una cl\u00ednica de infecciones de transmisi\u00f3n sexual en \nMadridE. E. Lozano Rinc\u00f3n, et al.\nRev Esp Quimioter 2019;32(5): 440-444442fue a\u00fan mayor cuando se analiz\u00f3 en el grupo de coinfectados \npor el VIH/VHC (94%). \nDISCUSI\u00d3N\nLa principal v\u00eda de transmisi\u00f3n del VHC es la sangre. No \nobstante, en los \u00faltimos a\u00f1os estamos asistiendo a un aumen -\nto de la transmisi\u00f3n sexual del VHC [4]. \nLa transmisi\u00f3n del VHC entre parejas heterosexuales (HTX) \ncon relaci\u00f3n mon\u00f3gama es muy rara, con una prevalencia que \noscila entre el 0 y el 27% [5]. \nSeg\u00fan algunos estudios [6], cuando se excluye a las pare -\njas con exposici\u00f3n parenteral conocida, la prevalencia es < 5%. \nSin embargo, esta prevalencia aumenta en HSH especialmente \nen aquellos coinfectados por el VIH donde puede estar en tor -\nno al 3-39%, frente al 0-19% de los no coinfectados por el \nVIH [7]. De acuerdo con nuestros resultados, la prevalencia de \ninfecci\u00f3n por el VIH en los seroconvertores al VHC fue del 89% \ny el 100% de los seroconvertores eran HSH.\nEn esta l\u00ednea de investigaci\u00f3n, se ha planteado que el con -\ntacto con parejas infectadas por el VIH podr\u00eda facilitar la trans -\nmisi\u00f3n del VHC, dado que algunos trabajos han demostrado \nque los pacientes coinfectados tienen cargas virales mayores \nque los monoinfectados [8]. \nSe han descrito factores biol\u00f3gicos, sociales y conductua -\nles relacionados con el incremento en la transmisi\u00f3n sexual de \nla infecci\u00f3n por el VHC en HSH, especialmente en coinfectados \npor el VIH. bres que tienen sexo con hombres (HSH) frente al 0% de hete -\nrosexuales (HTX). \nEn relaci\u00f3n a la regi\u00f3n geogr\u00e1fica de procedencia de los \nseroconvertores, un 68% (46/67) eran espa\u00f1oles y un 34% \n(23/67) no espa\u00f1oles, de los cuales un 69% (16/23) proced\u00edan \nde Latinoam\u00e9rica. \nEn cuanto  a la coinfecci\u00f3n con otras ITS, se analiz\u00f3 prin -\ncipalmente la relaci\u00f3n con el LGV ( Chlamydia trachomatis  se-\nrovares L1-L3). Del total de los 67 seroconvertores para el  VHC, \n13 (19%) estaban coinfectados por LGV.\nEn el total de los 67 seroconvertores se cuantific\u00f3 el ARN-\nVHC. En 21 personas la carga viral fue indetectable y detecta -\nble en los 46 restantes (rango: 111 UI - >40.000.000 UI).\nSeg\u00fan la situaci\u00f3n respecto al VIH, el 89% (60/67) de los \nseroconvertores al VHC fueron seropositivos para el VIH (figura \n1).\nDurante el periodo de estudio, se increment\u00f3 el diagn\u00f3sti -\nco de nuevos casos de infecci\u00f3n por el VHC en un 13,5%. \nEntre los nuevos diagn\u00f3sticos de infecci\u00f3n por el VHC, la \nproporci\u00f3n de HSH aument\u00f3 progresivamente, desde el a\u00f1o \n2010 hasta el 2016, siendo m\u00e1s marcada en la segunda mitad \ndel periodo analizado (de 2013 a 2016). \nAs\u00ed, la proporci\u00f3n de HSH dentro de los nuevos diagn\u00f3s -\nticos de infecci\u00f3n por el VHC fue del 37% en el a\u00f1o 2010, del \n53% en el a\u00f1o 2013 y ascendi\u00f3 hasta el 75% en el a\u00f1o 2016. \nEstos datos traducen un incremento, estad\u00edsticamente signifi -\ncativo (p < 0,025), del  131% (figura 2). La proporci\u00f3n de HSH Figura 2  Nuevos diagn\u00f3sticos de infecci\u00f3n por el VHC y proporci\u00f3n de \nHSH, en el Centro Sanitario Sandoval (CSS) (2010-2016).\nHepatitis C: nuevos diagn\u00f3sticos y seroconversiones en una cl\u00ednica de infecciones de transmisi\u00f3n sexual en \nMadridE. E. Lozano Rinc\u00f3n, et al.\nRev Esp Quimioter 2019;32(5): 440-444443infecci\u00f3n por el VHC y por el VIH.\nFINANCIACI\u00d3N\nLos autores declaran que no han recibido financiaci\u00f3n pa -\nra la realizaci\u00f3n de este trabajo.\nCONFLICTO DE INTERESES\nLos autores declaran que no presentan  conflictos de in -\ntereses.\nREFERENCIAS\n1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global Epide -\nmiology of Hepatitis C Virus Infection: new estimates of age-speci -\nfic antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333-\n42. DOI: 10.1002/hep.26141\n2. Albillos Mart\u00ednez A, Ca\u00f1ada Merino JL, Molero Garc\u00eda JM, P\u00e9rez Ca -\nchafeiro S, P\u00e9rez Escanilla F, Sim\u00f3n Marco MA, Turnes V\u00e1zquez J; \nAEEH, SEMERGEN, semFYC, SEMG. Consenso de recomendaciones \npara el diagn\u00f3stico precoz, la prevenci\u00f3n y la atenci\u00f3n cl\u00ednica de la \nhepatitis C en Atenci\u00f3n Primaria. Madrid: Luz\u00e1n 5; 2017.\n3. Gutierrez JA, Lawitz EJ, Poordad F. Interferon-free, direct-\nacting antiviral therapy for chronic hepatitis C. J Viral He -\npat. 2015;22(11):861-70. DOI: 10.1111/jvh.12422\n4. Midgard H, Weir A, Palmateer N, Lo Re III V, Pineda JA, Mac\u00edas J, \net al. HCV epidemiology in high-risk groups and the risk of re -\ninfection. J Hepatol.2016;65(1 Suppl):S33-S45. DOI:10.1016/j.\njhep.2016.07.012\n5. Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, Gish \nRG, Busch MP, Reingold AL, Alter MJ. Sexual transmission of he -\npatitis C virus among monogamous heterosexual couples: the \nHCV partners study. Hepatology. 2013;57(3):881-9. DOI: 10.1002/\nhep.26164\n6. Chan DP, Sun HY, Wong HT, Lee SS, Hung CC. Sexually acquired \nhepatitis C virus infection: a review. Int J Infect Dis. 2016;49:47-58. \nDOI: 10.1016/j.ijid.2016.05.030\n7. Chen YC, Wiberg KJ, Hsieh YH, Bansal A, Bolzan P, Guy JA, et al. \nFavorable socioeconomic status and recreational polydrug use \nare linked with sexual Hepatitis C Virus transmission among Hu -\nman Immunodeficiency Virus-infected men who have sex with \nmen. Open Forum Infect Dis. 2016;3(3):ofw137. DOI:10.1093/ofid/\nofw137\n8. Neukam K, Garc\u00eda-Rey S, Cifuentes C, Mac\u00edas J, Mira JA, V\u00e1zquez \nMJ, et al. HIV-coinfection leads to a modest increase in plasma \nHCV-RNA load in patients with chronic HCV infection. Antiviral \nRes. 2012;95(3):212-5. DOI: 10.1016/j.antiviral.2012.06.009\n9. European AIDS Treatment Network (NEAT) Acute Hepatitis C In -\nfection Consensus Panel. Acute hepatitis C in HIV-infected indi -\nviduals: recommendations from the European AIDS Treatment \nNetwork (NEAT) Acute Hepatitis C Infection Consensus Conference. \nAIDS. 2011;25(4):399-409. DOI: 10.1097/QAD.0b013e328343443bEn relaci\u00f3n a los factores biol\u00f3gicos, no hay evidencias \nclaras de que los pacientes VIH seropositivos sean m\u00e1s sus -\nceptibles a la infecci\u00f3n por el VHC como consecuencia de la \ndeficiencia del sistema inmune [9]. En algunos estudios se ha \npostulado que, pacientes HSH-VIH positivos podr\u00edan tener ma -\nyor carga viral de VHC en semen que aquellos pacientes HSH-\nVIH negativos, independientemente de la carga viral del VHC \nen plasma [10]. Otro factor biol\u00f3gico implicado estar\u00eda rela -\ncionado con la inflamaci\u00f3n gastrointestinal cr\u00f3nica asociada a \npacientes VIH seropositivos, ya que podr\u00eda debilitar la mucosa \na ese nivel y favorecer la transmisi\u00f3n del VHC [11]. \nEntre los factores conductuales y de comportamiento, el \naumento del consumo de drogas recreativas (intravenosas o \nno) para mantener relaciones sexuales, t\u00e9rmino que se define \ncomo \u201cCHEMSEX\u201d, est\u00e1 contribuyendo al aumento de la trans -\nmisi\u00f3n sexual del VHC. \nOtro factor conductual favorecedor de la transmisibilidad \ndel VHC ser\u00edan las pr\u00e1cticas sexuales de riesgo, mucho m\u00e1s \ntraum\u00e1ticas entre los HSH, as\u00ed como las relaciones sexuales \ndesprotegidas, con m\u00faltiples parejas, el empleo de juguetes se -\nxuales que pueden provocar laceraci\u00f3n o lesi\u00f3n de la mucosa \nrectal y la presencia de otras infecciones de transmisi\u00f3n sexual, \nespecialmente a nivel ano-genital. \nEn relaci\u00f3n con estos factores analizados, y con el objetivo \nde reducir la tasa de infecci\u00f3n por el VIH en aquellos paciente \ncon riesgo \u201csustancial\u201d, el estudio llevado a cabo por Ayerdi-\nAguirrebengoa et al.  [12], argumenta que los HSH y HTX sero -\nnegativos, con pareja positiva para el VIH, ITS bacteriana en los \n\u00faltimos 6 meses, m\u00faltiples parejas sexuales, no uso sistem\u00e1tico \ndel preservativo y trabajadores del sexo, ser\u00edan candidatos a \nprofilaxis preexposici\u00f3n (PrEP) para el VIH, y as\u00ed disminuir, en la \nmedida de lo posible, la probabilidad de seroconversi\u00f3n al VIH. \nEsta medida, tambi\u00e9n estar\u00eda indicada en los usuarios de dro -\ngas inyectables y en los transexuales con pr\u00e1cticas de riesgo. \nLa globalizaci\u00f3n y el uso de aplicaciones m\u00f3viles para la \nb\u00fasqueda de contactos sexuales, son algunos de los factores \nsociales m\u00e1s importantes implicados en el incremento de la \ntransmisi\u00f3n sexual del VHC. En nuestro estudio, la prevalen -\ncia de seroconvertores al VHC, seg\u00fan su regi\u00f3n geogr\u00e1fica de \nprocedencia, fue del 68% en espa\u00f1oles y del 34% en inmigran -\ntes, la mayor parte de los cuales (hasta un 69%) proced\u00edan de \nLatinoam\u00e9rica. \nEn relaci\u00f3n con lo expuesto previamente, en Espa\u00f1a, \nBerenguer et al. [13] han analizado los cambios en la prevalen -\ncia y las caracter\u00edsticas epidemiol\u00f3gicas de los pacientes coin -\nfectados en los \u00faltimos a\u00f1os. Entre los factores relacionados \nse incluyen el aumento del uso de drogas intravenosas como \nmecanismo de transmisi\u00f3n del VIH, la emergencia de nuevos \ncasos de infecci\u00f3n por el VHC en HSH con pr\u00e1cticas sexuales \nde riesgo y la aparici\u00f3n de nuevos tratamientos m\u00e1s efectivos \npara tratar la infecci\u00f3n por el VHC. \nConsiderando lo expuesto previamente, ser\u00eda necesario \nimplementar intervenciones espec\u00edficas dirigidas a prevenir \nla transmisi\u00f3n del VHC, as\u00ed como otras ITS, en especial en los \nHSH-VIH positivos que presenten pr\u00e1cticas de riesgo para la Hepatitis C: nuevos diagn\u00f3sticos y seroconversiones en una cl\u00ednica de infecciones de transmisi\u00f3n sexual en \nMadridE. E. Lozano Rinc\u00f3n, et al.\nRev Esp Quimioter 2019;32(5): 440-44444410. Samuel S. Turner, Sara Gianella, Marcus J-S. Yip, Wouter O. van Se -\nggelen, Robert D. Gillies, Andrew L. Foster, Zachary R. Barbati, Da -\nvey M. Smith, and Daniel S. Fierer. Shedding of Hepatitis C Virus \nin Semen of Human Immunodeficiency Virus-Infected Men. Open \nForum Infect Dis. 2016;3(2):ofw057. DOI: 10.1093/ofid/ofw057\n11. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C vi -\nrus: evolving epidemiology and treatment paradigms. Clin Infect \nDis. 2012;55 Suppl 1:S33-42. DOI: 10.1093/cid/cis367\n12. Oskar Ayerdi-Aguirrebengoa, Mar Vera-Garc\u00eda, Teresa Puerta-L\u00f3 -\npez, Montserrat Raposo-Utrilla, Camen Rodr\u00edguez-Mart\u00edn y Jorge \nDel Romero-Guerrero. \u00bfA qui\u00e9n proponer la profilaxis preexposi -\nci\u00f3n al virus de la inmunodeficiencia humana? Enferm Infecc Mi -\ncrobiol Clin. 2017;35(5):299\u2013302. DOI: 10.1016/j.eimc.2016.06.006\n13. Berenguer J, Rivero A, Jarr\u00edn I, N\u00fa\u00f1ez MJ, Vivancos MJ, Crespo M, \net al. Human Immunodeficiency Virus/Hepatitis C Virus coinfection \nin Spain: prevalence and patient characteristics. Open Forum Infect \nDis. 2016;3(2):ofw059. DOI: 10.1093/ofid/ofw059Rev Esp Quimioter 2019;32(5): 445-450445\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Concordance between the test of the tuberculin \nand Interferon Gamma Release Assay-IGRA in \npatients with immune-mediated inflammatory \ndiseases \nABSTRACT\nIntroduction.  The immunosuppressive therapies in \nthe treatment of the immune-mediated inflammatory \ndiseases (EIMI) predispose individuals to the tuberculosis, \nso the screening of latent tuberculosis infection (ITL) and \nthe treatment reduces the likelihood of a progression to an \nactive tuberculosis. The aim of the study was to analyze the \nconcordance between the test of the tuberculin (PT) and \n\u201cInterferon Gamma Release Assay-IGRA\u201d in relation to the type \nof EIMI and the immunosuppressive treatment (IS).\nMaterial and methods.  Transversal study of patients with \nEIMI candidates or in treatment IS forwarded to the ITL screening, \nfrom April 2017 until May 2018. The outcome variables were PT \nand IGRA. The explicative variables were: EIMI, IS, age, gender, \nprior BCG vaccination and tuberculosis risk factors.\nResults.  A total of 146 patients were analyzed (33[22.6%] \nvaccinated with BCG, 1 [0.7%] with a pre-diagnosis of \ntuberculosis, and 22 [15.1%] from an endemic country). Kappa \nindex (k) was 0,338 between PT and IGRA for the whole sample. \nA lower concordance was found in patients with the Crohn\u2019s \ndisease (k=0.125), in the ones treated with corticosteroids \n(k=0.222), vaccinated with BCG (k=0.122) and in patients from \ntuberculosis endemic countries (k=0.128).\nConclusion.  The concordance between PT and IGRA \nis affected in patients with EIMI, and to a greater extent to \npatients with the inflammatory bowel disease, with the \ncorticotherapy, with the BCG vaccination, or in the ones from \nendemic countries.\nKeywords: tuberculosis, interferon gamma Release Assays, Tuberculin test, \nLatent Tuberculosis Infection, Autoimmune Diseases, Immunosuppressive \nAgents.RESUMEN\nIntroducci\u00f3n. Las terapias inmunosupresoras en el \ntratamiento de las enfermedades inflamatorias mediadas por \nla inmunidad (EIMI) predisponen a la tuberculosis, por lo que el \ncribado de infecci\u00f3n tuberculosa latente (ITL) y su tratamiento \nreduce la probabilidad de progresi\u00f3n a tuberculosis activa. \nEl objetivo del estudio fue analizar la concordancia entre la \nprueba de la tuberculina (PT) e \u201cInterferon Gamma Release \nAssay-IGRA\u201d en relaci\u00f3n con el tipo de EIMI y tratamiento \ninmunosupresor (IS).\nMaterial y m\u00e9todos. Estudio transversal en pacientes con \nEIMI candidatos o en tratamiento IS remitidos para cribado de \nITL, de Abril del 2017 hasta Mayo del 2018. Variables resultado \nfueron PT e IGRA. Variables explicativas: EIMI, IS, edad, sexo, \nvacunaci\u00f3n BCG previa y factores de riesgo de tuberculosis.\nResultados. Se estudiaron  146 pacientes (33 [22,6%] \nvacunados con BCG, 1 [0,7%] con diagn\u00f3stico previo de \ntuberculosis y 22 [15,1%] originarios de pa\u00eds end\u00e9mico). \u00cdndice \nde Kappa (k) fue de 0,338 entre PT e IGRA para la totalidad de \nla muestra. Menor concordancia en pacientes con enfermedad \nde Crohn (k=0,125), en los tratados con corticoides (k=0,222), \nvacunados con BCG (k=0,122) y en pacientes procedentes de \npa\u00edses end\u00e9micos de tuberculosis (k=0,128).\nConclusiones. La concordancia entre la PT y el IGRA se \nve afectada en pacientes con EIMI y en mayor medida en la \nenfermedad inflamatoria intestinal, con la corticoterapia, con la \nvacunaci\u00f3n con BCG o en los procedentes de pa\u00edses end\u00e9micos.\nPalabras clave: tuberculosis, interferon gamma Release Assays, Tuberculin \ntest, Latent Tuberculosis Infection, Autoimmune Diseases, Immunosup -\npressive Agents.Concordancia entre la prueba de la tuberculina y el \nInterferon Gamma Release Assay-IGRA en pacientes con \nenfermedades inflamatorias mediadas por la inmunidad\n1Medicina Interna, Hospital General Universitario de Castell\u00f3n.\n2Microbiolog\u00eda, Hospital General Universitario de Castell\u00f3n.\n3Medicina Preventiva, Hospital General Universitario de Castell\u00f3n.\n4Medicina Interna, Hospital Cl\u00ednico Universitario de Valencia.\n5Unidad de Enfermedades Infecciosas, Hospital General Universitario de Castell\u00f3n.\n6Medicina Interna, Hospital General Universitario de Alicante.Ignacio P\u00e9rez Catal\u00e1n1\nCelia Roig Mart\u00ed1\nMar\u00eda Gil Fortu\u00f1o2\nPatricia Torrent Ramos3\nPaloma Albiol Vi\u00f1als4\nMario Carballido Fern\u00e1ndez3\nRosa Mar\u00eda Larrea3\nCarmen Ort\u00edn Mart\u00edn3\nJorge Us\u00f3 Blasco5\nJos\u00e9 Manuel Ramos Rinc\u00f3n6\nCorrespondencia:\nIgnacio P\u00e9rez Catal\u00e1n\nMedicina Interna, Hospital General Universitario de Castell\u00f3n. \nAvda. Benicassim s/n, Castell\u00f3n, Espa\u00f1a.\nE-mail: nachocs13@gmail.comOriginal\nArticle history\nReceived: 26 February 2019; Revision Requested: 13 April 2019; Revision Received: 28 May 2019; Accepted: 4 June 2019Concordancia entre la prueba de la tuberculina y el Interferon Gamma Release Assay-IGRA en pacientes con \nenfermedades inflamatorias mediadas por la inmunidadI. P\u00e9rez Catal\u00e1n, et al.\nRev Esp Quimioter 2019;32(5): 445-450446Las variables resultados fueron: PT en mil\u00edmetros y la \nprueba IGRA en UI/ml. Como variables modificadoras de la \nconcordancia: EIMI, tratamiento IS, edad, sexo, vacunaci\u00f3n con \nBCG previa, originario de \u00e1rea end\u00e9mica de TB, diagn\u00f3stico/\ntratamiento previo de TB, infecci\u00f3n por VIH y diabetes mellitus.\nEn cada paciente se realizaron extracciones sangu\u00edneas \npara realizar el test de IGRA QuantiFERON\u00ae-TB Gold Plus \n(QIAGEN, 40724 Hilden, Alemania) y se realiz\u00f3 simult\u00e1neamente \nla PT. Para ello, se inyect\u00f3 en los pacientes 0,1 ml de tuberculina \n(2 unidades de tuberculina PPD) (Tuberculina PPD; Evans 2 UT, \nKREIDYPHARMA, S.L. Madrid, Spain), de acuerdo con las gu\u00edas \nde la American Thoracic Society [21]. En cuanto al test de IGRA, \nse extrajo de cada paciente sangre en 4 tubos y se incubaron \nentre 16 y 24 horas a 37\u00baC. Posteriormente se centrifugaron \ny se separ\u00f3 el plasma para determinar si se hab\u00eda producido \nIFN\u03b3 (mediante enzimoinmunoensayo) como reacci\u00f3n a los \nant\u00edgenos pept\u00eddicos.\nHay que recordar que ambas pruebas inmunol\u00f3gicas son \nmediciones cuantitativas y que su clasificaci\u00f3n en resultados \npositivos o negativos se define a priori para distintos puntos \nde corte. En inmunodeprimidos la PT se define como positiva si \nel halo de la induraci\u00f3n tras la intradermorreacci\u00f3n es \u2265 5 mm \ny para el IGRA se considera un resultado positivo si en el tubo \nTB1 o TB2 se produce una cantidad de IFN \u03b3 \u2265 0,35 UI/l, aunque \nse han considerado otros puntos de corte como 0,10 o 0,70, \npara los cuales variar\u00eda la sensibilidad de la prueba [6, 7].\nSe realiza an\u00e1lisis descriptivo de frecuencias con \nestimaci\u00f3n de prevalencias de las distintas variables y se \nrealiza test de Chi-cuadrado para comparar las variables con \nla positividad de ambas pruebas diagn\u00f3sticas. Se estima la \nconcordancia entre PT e IGRA como variables categ\u00f3ricas \nmediante el test Kappa de Cohen. Para ello, estratificamos \nseg\u00fan: EIMI, tratamiento IS o no y cu\u00e1l, antecedente de \nvacunaci\u00f3n con BCG previa, seg\u00fan sea originario o no de \npa\u00eds end\u00e9mico de TB y por grupos de edad. Tambi\u00e9n se eval\u00faa \nla concordancia de ambas pruebas seg\u00fan otros puntos de \ncorte del IGRA (0,10 y 0,70 UI/ml). A tener en cuenta que la \nconcordancia entre pruebas la estimaremos mediante el \u00edndice \nde Kappa (k), consider\u00e1ndose \u201cpobre\u201c si \u00e9ste es \u2264 0,20; \u201cbaja\u201d si \n0,20 < k \u2264 0,40, \u201cmoderada\u201d si 0,40 < k \u2264 0,60, \u201csustancial\u201d si \n0,60 < k \u2264 0,80 y \u201c\u00f3ptima\u201d si k > 0,80.\nEl estudio fue aprobado por el Comit\u00e9 de \u00c9tica e \nInvestigaci\u00f3n Cl\u00ednica de nuestro centro. Se mantuvo la \nconfidencialidad de los datos obtenidos, se siguieron los \nprincipios de la declaraci\u00f3n de Helsinki (2013), las reglas de \nbuenas pr\u00e1cticas cl\u00ednicas y las leyes espa\u00f1olas aplicables a este \ntipo de estudios.\nRESULTADOS\nEstudio descriptivo.  Se incluyeron en el estudio 146 \npacientes, con una edad media de 45 a\u00f1os y 39 eran menores \nde 35 a\u00f1os (25%). De ellos, 64 (43,9%) eran varones, 33 \n(22,7%) contaban con el antecedente de vacunaci\u00f3n por BCG, \n22 (15%) eran originarios de pa\u00edses end\u00e9micos de TB, 9 (6,2%) INTRODUCCI\u00d3N\nEl auge de las terapias biol\u00f3gicas en los \u00faltimos a\u00f1os \nha supuesto una revoluci\u00f3n en el tratamiento de las \nenfermedades inflamatorias mediadas por la inmunidad (EIMI). \nLa farmacovigilancia ha evidenciado un aumento de los casos \nde tuberculosis (TB) asociada en este grupo de pacientes, \nespecialmente aquellos que se encuentran en tratamiento con \nf\u00e1rmacos anti-factor de necrosis tumoral (TNF) [1, 2]. Por este \nmotivo resulta de vital importancia el diagn\u00f3stico precoz de \ninfecci\u00f3n tuberculosa latente (ITL) y su tratamiento preventivo \ncon el fin de reducir la posibilidad de progresi\u00f3n a TB activa.\nEn la actualidad, tal como se propon\u00eda en diferentes \ntrabajos [3, 4], y tal c\u00f3mo se recoge en el \u201cDocumento de \nconsenso sobre la prevenci\u00f3n y el tratamiento de la Tuberculosis \nen pacientes candidatos a tratamiento biol\u00f3gico\u201d [5], la \npr\u00e1ctica habitual en cuanto a cribado de ITL en estos pacientes \nconsiste en la realizaci\u00f3n de las dos pruebas: la prueba de la \ntuberculina (PT) y las t\u00e9cnicas diagn\u00f3sticas basadas en la \nliberaci\u00f3n de interfer\u00f3n gamma (\u201c Interferon Gamma Release \nAssay \u201d [IGRA]), en serie o en paralelo. Cabe recordar que ambas \npruebas son mediciones cuantitativas y que su clasificaci\u00f3n en \nresultados positivos o negativos se define a priori para distintos \npuntos de corte. Se considera una PT positiva si \u2265 5 mm en \npacientes inmunodeprimidos y una prueba IGRA se considera \npositiva si \u2265 0,35 UI/ml (QuantiFERON\u00ae-TB Gold Plus), aunque \nse han considerado otros puntos de corte como 0,10 o 0,70 UI/\nml, para los cuales variar\u00eda la sensibilidad de la prueba [6, 7]).\nExiste un n\u00famero muy limitado de estudios que analicen \nel rendimiento conjunto de ambas pruebas en pacientes con \nEIMI candidatos a tratamiento IS y que analicen el efecto \nque pueden tener, tanto la EIMI como el tratamiento IS en \nel momento del cribado de ITL [6-19]. Existen resultados \ncontradictorios aunque parece que la utilidad diagn\u00f3stica de \nambas se ve disminuida en este grupo de pacientes comparado \ncon la poblaci\u00f3n sin EIMI [8, 9]. La concordancia de las pruebas \nes variable y puede verse afectada por la EIMI y el tratamiento \nIS, as\u00ed como en determinadas poblaciones (edades extremas, \npersonas vacunadas previamente con BCG) [20].\nPor ello, nos proponemos como objetivo principal \nevaluar la concordancia del IGRA y PT en funci\u00f3n de la EIMI \ny del tratamiento IS recibido. Como objetivos secundarios \nestudiaremos como var\u00eda la concordancia seg\u00fan diferentes \npuntos de corte de IGRA, seg\u00fan exista o no antecedente de \nvacunaci\u00f3n con BCG, seg\u00fan el paciente sea o no originario de \npa\u00eds end\u00e9mico de TB y en funci\u00f3n de la edad.\nMATERIAL Y M\u00c9TODOS\nEstudio transversal sobre los pacientes con EIMI remitidos \na la consulta del Servicio de Medicina Preventiva, de Abril \ndel 2017 a Mayo de 2018 para cribado de ITL, candidatos o \nen tratamiento con IS. Se excluyen aquellos pacientes que \nest\u00e9n en tratamiento con f\u00e1rmacos inmunosupresores en el \nmomento de la valoraci\u00f3n y que sean mal cumplimentadores.Concordancia entre la prueba de la tuberculina y el Interferon Gamma Release Assay-IGRA en pacientes con \nenfermedades inflamatorias mediadas por la inmunidadI. P\u00e9rez Catal\u00e1n, et al.\nRev Esp Quimioter 2019;32(5): 445-450447concordancia moderada en pacientes con psoriasis (k=0,473), \nbaja en pacientes con artritis reumatoide (k=0,378) y colitis \nulcerosa (k=0,308), y pobre en los que sufr\u00edan espondilitis \nanquilopoy\u00e9tica (k=0,186) y enfermedad de Crohn (k=0,125).\nEn funci\u00f3n del tratamiento IS, la concordancia fue \nmoderada en los pacientes que recib\u00edan tratamiento con \nmetotrexato (k=0,588) y \u00e9sta era baja en aquellos pacientes \ntratados con corticoides en monoterapia (k=0,222). A destacar \nque los pacientes que en el momento del cribado de ITL no \nrecib\u00edan ning\u00fan tratamiento IS, presentaron una concordancia \nbaja (k=0,362) entre ambas pruebas diagn\u00f3sticas. Para el resto \nde EIMI y tratamientos IS no se pudo estimar el \u00edndice k debido \nal peque\u00f1o tama\u00f1o muestral. El an\u00e1lisis de la concordancia \ndetallado queda resumido en la tabla 3.\nAdem\u00e1s se analiz\u00f3 la concordancia entre ambas pruebas \nen funci\u00f3n de diferentes variables: seg\u00fan si el paciente hab\u00eda \nrecibido o no con anterioridad vacunaci\u00f3n con BCG, siendo \nmayor en los que no (k=0,122 y k=0,483 respectivamente); \nseg\u00fan el origen del paciente, siendo menor en los que \nproced\u00edan de pa\u00edses end\u00e9micos de TB (k=0,128 y k=0,297 \nrespectivamente); seg\u00fan la edad, siendo mayor en los pacientes \nmenores de 35 a\u00f1os (k=0,393 frente a k=0,314 en los mayores \nde 35 a\u00f1os).eran diab\u00e9ticos y 74 (50,8%) estaban en tratamiento IS. La \nEIMI m\u00e1s frecuente fue la psoriasis (51), seguida de la artritis \nreumatoide (23) y la enfermedad de Crohn (21). En cuanto al \ntratamiento IS empleado, el m\u00e1s empleado fue la monoterapia \ncorticoidea (30) seguido del metotrexato (21) y la asociaci\u00f3n \ncorticoides y metotrexato (5). \nDe los 146 pacientes, 43 presentaron una PT positiva \n(29,5%), frente a 17 casos de IGRA-positivo ( \u22650,35 UI/ml) \n(11,6%). En cambio, si establecemos el punto de corte para \nconsiderar una prueba IGRA-positivo en \u22650,10 UI/ml 32 fueron \npositivos (21,9%) y una prueba IGRA-positiva \u22650,70 UI/ml, 11 \nfueron positivos (7,5%) (tabla 1).\nTanto el sexo masculino, el ser diab\u00e9tico, tener 35 o \nm\u00e1s a\u00f1os de edad, contar con el antecedente de vacunaci\u00f3n \nprevia con BCG y el ser originario de pa\u00eds end\u00e9mico se \nasocian estad\u00edsticamente en la muestra con la positividad \nde la PT. En cuanto a la positividad del IGRA, solo se observ\u00f3 \nasociaci\u00f3n estad\u00edsticamente significativa el ser originario de \npa\u00eds end\u00e9mico para punto de corte de 0,35 UI/ml y el sexo \nmasculino para punto de corte de 0,10 UI/ml (tabla 2).\nAn\u00e1lisis de la concordancia.  En la totalidad de la \nmuestra se obtuvo una concordancia baja entre la PT e IGRA, \ncon un \u00edndice de Kappa (k) de 0,338. Seg\u00fan EIMI, se obtuvo \nTest\n PT IGRA\n\u2265 0,35UI/mlIGRA\n\u2265 0,70 UI/mlIGRA\n\u2265 0,10 UI/ml\nTotal positivos, N 43 17 11 32\nEIMI, N (%)\nPsoriasis 16 (31,4) 8 (15,7) 5 (9,8) 13 (25,5)\nEnfermedad de Crohn 6 (28,6) 2 (9,5) 2 (9,5) 3 (12,3)\nArtritis reumatoide 9 (39,2) 3 (13,0) 1 (4,3) 5 (21,7)\nColitis ulcerosa 2 (13,3) 2 (13,3) 2 (13,3) 4 (26,6)\nEspondilitis anquilopoy\u00e9tica 6 (42,9) 1 (7,1) 1 (7,1) 3 (21,4)\nLupus eritematoso sist\u00e9mico 0 (0) 0 (0) 0 (0) 1 (25%)\nHidrosadenitis 2 (33,3) 0 (0) 0 (0) 1 (16,7)\nEritema nodoso 1 (50,0) 1 (50) 0 (0) 1 (50)\nEnfermedad de Beh\u00e7et 0 (0) 0 (0) 0 (0) 1 (100)\nPaniculitis 1 (50,0) 0 (0) 0 (0) 0 (0)\nTratamiento inmunosupresor, N (%)\nSin tratamiento 26 (36,1) 9 (12,5) 7 (9,7) 16 (22,2)\nCorticoides 6 (20,0) 5 (16,7) 3 (10,0) 9 (30,0)\nMetotrexato 6 (28,6) 3 (14,3) 1 (4,8) 5 (23,8)\nCorticoides y metotrexato 2 (40,0) 0 (0) 0 (0) 2 (40,0)\nUstekinumab 3 (75,0) 0 (0) 0 (0) 0 (0)Tabla 1  Resultados de la prueba tuberculina (PT) y del Interferon \nGamma Release Assay (IGRA)\nEIMI: Enfermedad Inflamatoria Mediada por Inmunidad.Concordancia entre la prueba de la tuberculina y el Interferon Gamma Release Assay-IGRA en pacientes con \nenfermedades inflamatorias mediadas por la inmunidadI. P\u00e9rez Catal\u00e1n, et al.\nRev Esp Quimioter 2019;32(5): 445-450448EIMI (siendo mucho menor en las enfermedades inflamatorias \nintestinales) [22], el tratamiento IS empleado (menor con los \ncorticoides), la vacunaci\u00f3n previa con BCG [8, 20] y el origen \ndel paciente (menor en originarios de pa\u00edses end\u00e9micos de TB).\nSeg\u00fan esto, la concordancia entre ambas pruebas \ndiagn\u00f3sticas parece alterarse por la EIMI y por el r\u00e9gimen \nterap\u00e9utico inmunosupresor que cumple. En este aspecto ser\u00eda \ninteresante conocer con m\u00e1s exactitud como se comporta \u00e9sta \nseg\u00fan que EIMI sufra o que tratamiento tome el paciente, \nhaciendo necesarios futuros estudios con mayor tama\u00f1o \nmuestral.\nComo intento de superar este defecto de concordancia, en \notros estudios se ha propuesto modificar el punto de corte del \nIGRA hasta 0,70 o 0,10 UI/ml. Seg\u00fan nuestros resultados, esto \nempeorar\u00eda la concordancia entre ambas pruebas por lo que \nno parece ser una soluci\u00f3n adecuada.\nEl estudio cuenta con varias limitaciones importantes. \nEn primer lugar, el peque\u00f1o tama\u00f1o muestral impide analizar \nla concordancia para cada EIMI y cada tratamiento IS. Ser\u00eda \ninteresante conocer c\u00f3mo se comporta la concordancia \nentre los tests para cada uno de ellos. Por otra parte, este \ntrabajo presenta las propias limitaciones del resto de estudios \nrealizados sobre esta cuesti\u00f3n y que son secundarias al hecho \nde no existir una prueba de referencia en el diagn\u00f3stico de \nITL. Por \u00faltimo, el efecto negativo de la vacunaci\u00f3n con BCG \nen la concordancia de ambas pruebas podr\u00eda ser un factor de \nconfusi\u00f3n, dado que aumenta el n\u00famero de falsos positivos de \nla PT [18, 20]. Por ello decidimos adem\u00e1s realizar un segundo \nan\u00e1lisis de la concordancia excluyendo a los pacientes que \ncontaran con dicho antecedente (tabla 3). Aunque en l\u00edneas \ngenerales mejora la concordancia (de hecho se alcanza el \nnivel de \u201cmoderada\u201d para los 113 pacientes no vacunados), en \nnuestra opini\u00f3n sigue sin ser \u00f3ptima y queda a\u00fan por descubrir \nque otros factores pueden estar influyendo en ello.\nComo conclusi\u00f3n, los resultados de este trabajo sugieren Por otra parte, si estableci\u00e9ramos en la totalidad de la \nmuestra el punto de corte para considerar positivo el IGRA en \n0,70 y 0,10 UI/ml, obtendr\u00edamos un concordancia inferior en \nambos casos (k=0,237 y 0,281 respectivamente).\nPor \u00faltimo, realizamos un an\u00e1lisis de la concordancia \nexcluyendo a los pacientes vacunados con BCG. A destacar \nque la concordancia entre la PT y el IGRA aumenta en los 113 \npacientes que no hab\u00edan sido vacunados con la BCG, siendo \n\u00e9sta moderada (k=0,483). En todas la situaciones analizadas \nen este apartado el \u00edndice kappa aumenta en relaci\u00f3n a \nla totalidad de la muestra, excepto en los pacientes con \nenfermedad de Crohn, en los menores de 35 a\u00f1os y en los que \ntomaban corticoides (tabla 3).\nDISCUSI\u00d3N\nSiguiendo las recomendaciones actuales propuestas en el \na\u00f1o 2016 en el \u201cDocumento de consenso sobre la prevenci\u00f3n \ny el tratamiento de la Tuberculosis en pacientes candidatos \na tratamiento biol\u00f3gico\u201d [5], en nuestro centro se realiza \ntanto la PT como el IGRA en paralelo en el cribado de ITL en \nel paciente con EIMI candidato a tratamiento biol\u00f3gico o ya \nen tratamiento. Estas directrices surgen con el prop\u00f3sito de \naumentar la sensibilidad del cribado de ITL.\nCentr\u00e1ndonos en nuestro objetivo principal y a pesar \nde no poderse estudiar la concordancia para algunas EIMI y \ntratamientos IS concretos dado el peque\u00f1o tama\u00f1o muestral, \ns\u00ed que podemos destacar varios resultados interesantes. \nPor una parte, en la totalidad de la muestra obtenemos una \nconcordancia \u201cbaja\u201d entre ambas pruebas, ya observada en \nanteriores publicaciones [14, 16, 18], y \u00e9sta persiste siendo \n\u201cbaja\u201d a\u00fan excluyendo a aquellos pacientes que ya han iniciado \ntratamiento IS, en contra de lo observado en otros trabajos [8]. \nAdem\u00e1s como ya se hab\u00eda comentado en estudios previos, esta \nconcordancia difiere seg\u00fan una serie de variables como son: la Test PT IGRA \u2265 0,35 UI/ml IGRA \u2265 0,70 UI/ml IGRA \u2265 0,10 UI/ml\n Positivo, \nN (%)Negativo, \nN (%)P valorPositivo, \nN (%)Negativo, \nN (%)P valorPositivo, \nN (%)Negativo, \nN (%)P valorPositivo, \nN (%)Negativo, \nN (%)P valor\nSexo masculino 26 (40,6) 38 (59,4) 0,009 9 (14,1) 55 (85,9) 0,342 7 (10,9) 57 (89,1) 0,193 20 (30,3) 40 (66,7) 0,031\nEdad \u2265 35 a\u00f1os 37 (34,6) 103 (70,5) 0,024 15 (14) 91 (85) 0,263 10 (9,4) 95 (89,6) 0,309 28 (27,2) 74 (71,8) 0,158\nEIMI 0,687 0,359 0,562 0,321\nTratamiento inmunosupresor 0,373 1 1 0,995\nAntecedente de vacunaci\u00f3n BCG 20 (60,6) 13 (39,4) 0,000 3 (9,1) 30 (90,9) 0,638 3 (9,1) 30 (90,9) 0,700 7 (21,9) 25 (78,1) 0,698\nTto. o diagn\u00f3stico previo de TB 0 (0) 1 (100) 0,517 0 (0) 1 (100) 0,927 0 (0) 1 (100) 0,951 1 (100) 0 (0) 0,195\nDiabetes mellitus 6 (66,7) 3 (33,3) 0,011 1 (91,1) 8 (88,9) 0,933 1 (11,1) 8 (88,9) 0,865 2 (25) 6 (75) 0,936\nOriginario pa\u00eds end\u00e9mico 15(68,2) 7 (31,8) 0,000 6 (27,3) 16 (72,7) 0,041 4 (19) 17 (81) 0,091 9 (40,9) 13 (59,1) 0,098Tabla 2  Asociaci\u00f3n de las distintas variables con la positividad de prueba tuberculina (PT) y del Interferon \nGamma Release Assay (IGRA)\nEIMI: Enfermedad Inflamatoria, BCG: Bacilo Calmette-G\u00e9rin, TB: tuberculosisConcordancia entre la prueba de la tuberculina y el Interferon Gamma Release Assay-IGRA en pacientes con \nenfermedades inflamatorias mediadas por la inmunidadI. P\u00e9rez Catal\u00e1n, et al.\nRev Esp Quimioter 2019;32(5): 445-450449Enfermedades Infecciosas del Hospital General Universitario \nde Castell\u00f3n por su inestimable ayuda durante el desarrollo de \neste estudio, sin los cuales no hubiera sido posible.\nCONFLICTO DE INTERESES\nLos autores declaran no tener ning\u00fan conflicto de \nintereses.\nFINANCIACI\u00d3N\nLos autores declaran no haber recibido financiaci\u00f3n para \nla realizaci\u00f3n de este estudio.que la concordancia entre la PT y el IGRA en el diagn\u00f3stico de \nITL se ve afectada en pacientes con EIMI y en mayor medida \nen aquellos sometidos a corticoterapia, padecen alguna \nenfermedad inflamatoria intestinal, cuentan con antecedente \nde vacunaci\u00f3n con BCG o provienen de \u00e1reas end\u00e9micas de \nTB. Dicha concordancia empeorar\u00eda al modificar el punto de \ncorte del IGRA de 0,35 a 0,70 o 0,10 UI/ml y mejorar\u00eda (aunque \nno hasta valores \u00f3ptimos) al excluir a los pacientes vacunados \ncon BCG.\nAGRADECIMIENTOS\nNuestro agradecimiento a todo el Servicio de Medicina \nPreventiva, al de Microbiolog\u00eda Cl\u00ednica y a la Unidad de  \n Concordancia Concordancia excluyendo pacientes \nvacunados BCG\nN k N k\nTotalidad de la muestra 146 0,338 113 0,483\nSeg\u00fan EIMI\nPsoriasis 51 0,473 42 0,634\nArtritis reumatoide 23 0,378 15 0,762\nEnfermedad de Crohn 21 0,125 17 - 0,970\nColitis ulcerosa 15 0,308 14 0,451\nEspondilitis anquilopoy\u00e9tica 14 0,186 10 0,412\nEritema nodoso 2 1 - -\nSeg\u00fan tratamiento IS\nSin tratamiento IS 72 0,362 55 0,524\nCorticoides 30 0,222 26 0,114\nMetotrexato 21 0,588 14 1\nSeg\u00fan origen\nPa\u00eds no end\u00e9mico 124 0,297 101 0,371\nPa\u00eds end\u00e9mico 22 0,128 12 0,676\nSeg\u00fan edad\n<35 a\u00f1os 39 0,393 34 0,292\n\u226535 a\u00f1os 107 0,314 79 0,510\nSeg\u00fan punto de corte de IGRA\n\u22650,70 UI/ml 146 0,237 113 0,311\n\u22650,10 UI/ml 146 0,281 113 0,395\nSeg\u00fan antecedente de BCG\nNo 113 0,483 - -\nS\u00ed 33 0,122 - -Tabla 3  Concordancia entre la prueba tuberculina(PT) e Interferon \nGamma Release Assay (IGRA)\nEIMI: Enfermedad Inflamatoria Mediada por inmunidad, IS: inmunosupresor,  \nBCG: Bacilo Calmette-G\u00e9rin, k: \u00edndice KappaConcordancia entre la prueba de la tuberculina y el Interferon Gamma Release Assay-IGRA en pacientes con \nenfermedades inflamatorias mediadas por la inmunidadI. P\u00e9rez Catal\u00e1n, et al.\nRev Esp Quimioter 2019;32(5): 445-450450BIBLIOGRAF\u00cdA\n1. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica \nJ,Schwieterman WD, et al. Tuberculosis associated with infliximab, \na tumor necrosis factor alpha-neutralizing agent. N Engl J Med \n2001; 345:1098\u20131104. DOI:10.1056/NEJMoa011110.\n2. Gomez-Reino JJ, Carmona L,Valverde VR, Martin Mola E, Montero \nMD. Treatment of rheumatoid arthritis with tumor necrosis factor \ninhibitors may predispose to significant increase in tuberculosis \nrisk. Arthritis Rheum 2003; 48:2122\u20132127. DOI:10.1002/art.11137\n3. Mu\u00f1oz L, Casas S, Juanola X, Bordas X, Martinez C, Santin M, et al. \nPrevention of anti\u2013tumor necrosis factor\u2013associated tuberculosis: \na 10-year longitudinal cohort study. Clin Infect Dis 2015; 60: 349-\n356. DOI: 10.1093/cid/ciu796\n4. Santin M, Garc\u00eda-Garc\u00eda JM, Rigau D, Altet N, Anibarro L, Casas I, et \nal. Sumario ejecutivo de la gu\u00eda de pr\u00e1ctica cl\u00ednica sobre el uso de \nlas pruebas de liberaci\u00f3n de interfer\u00f3n-gamma para el diagn\u00f3stico \nde infecci\u00f3n tuberculosa. Arch Bronconeumol 2016; 9: 477-481. \nDOI: 10.1016/j.arbres.2016.02.020\n5. Mir Viladrich I, Daud\u00e9n Tello E, Solano-L\u00f3pez G, L\u00f3pez Longo \nFJ, Taxonera Samso C, S\u00e1nchez Mart\u00ednez P, et al. Documento de \nconsenso sobre la prevenci\u00f3n y el tratamiento de la tuberculosis en \npacientes candidatos a tratamiento biol\u00f3gico. Arch Bronconeumol \n2016; 52: 36-45. DOI: 10.1016/j.arbres.2015.04.016.\n6. Maeda T, Banno S, Maeda S, Naniwa T, Hayami Y, Watanabe M, \net al. Usefulness and limitations of QuantiFERON-TB Gold in \nJapanese rheumatoid arthritis patients: proposal to decrease the \nlower cutoff level for assessing latent tuberculosis infection. Mod \nRheumatol 2010; 20:18\u201323. DOI: 10.1007/s10165-009-0226-5 \n7. Maeda T, Banno S, Maeda S, Naniwa T, Hayami Y, Watanabe M et \nal. Comparison of QuantiFERON-TB Gold and the tuberculin skin \ntest for detecting previous tuberculosis infection evaluated by \nchest CT findings in Japanese rheumatoid arthritis patients. J Infect \nChemother 2011; 17:842-848. DOI:10.1007/s10156-011-0250-1\n8. Ramos JM, Masi\u00e1 M, Rodr\u00edguez JC, L\u00f3pez C, Padilla S, Robledano \nC et al. Negative effect of immunosuppressive therapy in the \nperformance of the QuantiFERON Gold In-Tube test in patients \nwith immune-mediated inflammatory diseases. Clin Exp Med. \n2013;13:177\u2013186. DOI:10.1007/s10238-012-0192-7\n9. Sunny H Wong, Quinyan Gao, Kelvin K F Tsoi, William K K Wu, \nLai-shan Tam , Nelson Lee et al. Effect of immunosuppressive \ntherapy on interferon \u03b3 release assay for latent tuberculosis \nscreening in patients with autoimmune diseases: a systematic \nreview and meta-analysis. Thorax 2015;71:64-72. DOI:10.1136/\nthoraxjnl-2015-207811.\n10. Sellam J, Hamdi H, Roy C, Baron G, Lemann M, Pue \u0301chal X et al. \nComparison of in vitro-specific blood tests with tuberculin skin test \nfor diagnosis of latent tuberculosis before anti-TNF therapy. Ann \nRheum Dis 2007;66:1610\u20131615. DOI: 10.1136/ard.2007.069799.\n11. Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato \nN et al. Performance of two commercial blood IFN- gamma release \nassays for the detection of Mycobacterium tuberculosis infection in \npatient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol \nInfect Dis 2008;27:907\u2013913. DOI:10.1007/s10096-008-0519-1.12. Schoepfer AM, Flogerzi B, Fallegger S, Schaffer T, Mueller S, Nicod \nL et al. Comparison of interferon-gamma release assay versus \ntuberculin skin test for tuberculosis screening in inflammatory \nbowel disease. Am J Gastroenterol 2008;103: 2799\u20132806. \nDOI:10.1111/j.1572-0241.2008.02050.x\n13. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, \nCucho M et al. Comparison of an interferon-gamma assay with \ntuberculin skin testing for detection of tuberculosis (TB) infection \nin patients with rheumatoid arthritis in a TB-endemic population. J \nRheumatol 2008;35:776\u2013781. PMID:18398944.\n14. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL.Effectiveness of the \ncombination of a whole-blood interferon-gamma assay and the \ntuberculin skin test in detecting latent tuberculosis infection in \nrheumatoid arthritis patients receiving adalimumab therapy. Arthr \nRheum 2008;59:800\u2013806. DOI:10.1002/art.23705.\n15. Martin J, Walsh C, Gibbs A, McDonnell T, Fearon U, Keane J et al. \nComparison of interferon gamma release assays and conventional \nscreening tests before tumour necrosis factor alpha blockade in \npatients with inflammatory arthritis. Ann Rheum Dis 2010;69:181\u2013\n185. DOI:10.1136/ard.2008.101857.\n16. Inanc N, Aydin SZ, Karakurt S, Atagunduz P, Yavuz S, Direskeneli H \net al. Agreement between Quantiferon-TB gold test and tuberculin \nskin test in the identification of latent tuberculosis infection in \npatients with rheumatoid arthritis and ankylosing spondylitis. J \nRheumatol 2009;36:2675\u20132681. DOI:10.3899/jrheum.090268.\n17. Chiu HY, Hsueh PR, Tsai TF. Clinical experience of QuantiFERON\u00ae \n-TB Gold testing in patients with psoriasis treated with tumour \nnecrosis factor blockers in Taiwan. Br J Dermatol 2011;164:553\u2013\n559. DOI:10.1111/j.1365-2133.2010.10137.x.\n18. B\u00e9lard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen \nFK et al. Prednisolone treatment affects the performance of \nthe QuantiFERON gold in-tube test and the tuberculin skin \ntest in patients with autoimmune disorders screened for latent \ntuberculosis infection. Inflamm Bowel Dis 2011; 17:2340-2349. \nDOI:10.1002/ibd.21605.\n19. Qumseya BJ, Ananthakrishnan AN, Skaros S, Bonner M, Issa M, \nZadvornova Y et al. QuantiFERON TB gold testing for tuberculosis \nscreening in an inflammatory bowel disease cohort in the United \nStates. Inflamm Bowel Dis 2011;7:77\u201383. DOI:10.1002/ibd.21329.\n20. Bellido-Blasco JB, Pardo-Serrano F , Romeu-Garc\u00eda MA , Moreno-\nMu\u00f1oz MR, Meseguer-Ferrer N, Vizca\u00edno-Batll\u00e9s et al. Tuberculina \ny QuantiFERON\u00a9-TB: concordancia, correlaci\u00f3n cuantitativa y \nriesgo de exposici\u00f3n en estudio de contactos de tuberculosis. \nEnferm Emerg 2017;16:11-22.\n21. American Thoracic Society: Centers for Disease Control and \nPrevention (2000) Diagnostic standards and classification of \ntuberculosis in adults and children. Am J Respir Crit Car Med \n161:1376\u20131395. DOI:10.1164/ajrccm.161.4.16141.\n22. Abreu C, Afonso J, Dias CC, Ruas R, Sarmento A, et al.. Serial \nTuberculosis screening in inflamatory bowel disease patients \nreceiving anti-TNF-a therapy. J Crohns Colitis 2017;11:1223-1229. \nDOI:10.1093/ecco-jcc/jjx080.Rev Esp Quimioter 2019;32(5): 451-457451\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Evoluci\u00f3n hist\u00f3rica de las enfermedades \ncausadas por micobacterias no pigmentadas \nde crecimiento r\u00e1pido en un Hospital \nUniversitario\nRESUMEN \nIntroducci\u00f3n.  Las micobacterias no pigmentadas de \ncrecimiento r\u00e1pido (MNPCR) son un grupo de organismos \nde inter\u00e9s creciente debido al n\u00famero cada vez mayor de \npacientes potenciales y a las dificultades en el tratamiento. \nSin embargo, el n\u00famero de estudios que analizan la evoluci\u00f3n \nde estos casos a lo largo de un periodo de tiempo largo es \nescaso. \nMaterial and m\u00e9todos.  Se realiz\u00f3 un estudio \nretrospectivo entre el 1 de enero de 2004 y el 31 de diciembre \nde 2017 para evaluar el significado cl\u00ednico y los tipos de \nenfermedades causados por MNPCR. Se seleccionaron para ello \naquellos pacientes con aislamientos de MNPCR, y se revisaron \nlas historias cl\u00ednicas mediante un protocolo predefinido.\nResultados.  Se identificaron 59 pacientes (76 muestras) \ncon aislamientos de MNPCR, de los cuales 12 presentaron \nenfermedad y uno tuvo un significado dudoso (incluyendo 6 \ninfecciones respiratorias, 2 infecciones asociadas a cat\u00e9ter, \n1 infecci\u00f3n de piel y partes blandas, 1 infecci\u00f3n diseminada, \n1 conjuntivitis, 1 infecci\u00f3n de pr\u00f3tesis osteoarticular y 1 \nmastitis). El 50 % de los aislamientos de Mycobacterium \nchelonae , el 37,5 % de Mycobacterium abscessus  y el \n23,33 % de Mycobacterium fortuitum  fueron cl\u00ednicamente \nsignificativos. Ninguno de los aislamientos de otras especies \nfue significativo. \nConclusiones.  La mayor\u00eda de los aislamientos de \nmuestras respiratorias resultaron ser contaminantes/\ncolonizaciones. M. abscessus  fue el principal agente etiol\u00f3gico \nen las infecciones respiratorias, mientras que M. chelonae  y \nM. fortuitum  fueron asociados con mayor frecuencia a otras ABSTRACT \nIntroduction.  Non-pigmented rapidly growing \nmycobacteria (NPRGM) are a group of organisms of increasing \ninterest due to the growing number of potential patients \nand the difficulties for a proper treatment in many of them. \nHowever, the evolution of these diseases in a long period of \ntime and its evolutionary changes has been described only in a \nscanty number of reports.\nMaterial and methods.  We performed a retrospective \nstudy between January 1st 2004 and December 31st 2017 in \norder to evaluate the clinical significance and types of diseases \ncaused by NPRGM. Patients with isolates of NPRGM during \nthis period were selected for the study, and clinical charts were \nreviewed using a predefined protocol.\nResults.  During this period we identified 59 patients \n(76 clinical samples) with isolates of NPRGM, with 12 cases \nof clinical disease and one patient with doubtful significance \n(including 6 respiratory tract infections, 2 catheter infections, \n1 skin and soft tissue infection, 1 disseminated infection, 1 \nconjunctivitis, 1 prosthetic joint infection and 1 mastitis). Fifty \npercent of M. chelonae  isolates, 37.5% of M. abscessus  isolates \nand 23.33% of M. fortuitum  isolates were clinically significant. \nNone of the isolates of other species were significant. \nConclusions.  Most isolates in respiratory samples were \ncontaminants/colonizations. M. abscessus  was the main \netiological agent in respiratory syndromes, whereas M. \nchelonae  and M. fortuitum  were more frequently associated \nwith other infections, especially clinical devices and skin and \nsoft tissue infections. \nKeywords: Non-pigmented rapidly growing mycobacteria; Mycobacterium  \nabscessus ; Mycobacterium  chelonae ; Mycobacterium fortuitum ; clinical \nsignificance; historical evolution; epidemiology.Historical evolution of the diseases caused by \nnon-pigmented rapidly growing mycobacteria in a \nUniversity Hospital\n1Departments of Clinical Microbiology, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, UAM. Madrid, Spain\n2Internal Medicine, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz, UAM. Madrid, Spain.Marta Garcia-Coca1\nGraciela Rodriguez-Sevilla1 \nMaria Carmen Mu\u00f1oz-Egea1 \nConcepci\u00f3n Perez-Jorge1 \nNerea Carrasco-Anton2 \nJaime Esteban1\nCorrespondencia:\nJaime Esteban\nDept. Of Clinical Microbiology. IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz. Av. Reyes Cat\u00f3licos 2. \n28040-Madrid (Spain). \nPhone: +34915504900. \nE-mail: jestebanmoreno@fjd.es; jesteban@fjd.esOriginal\nArticle history\nReceived: 22 March 2019; Revision Requested: 14 May 2019; Revision Received: 20 May 2019; Accepted: 22 May 2019Historical evolution of the diseases caused by non-pigmented rapidly growing mycobacteria in a University \nHospitalM. Garcia-Coca, et al.\nRev Esp Quimioter 2019;32(5): 451-457452planktonic type of growth, as resistance to environmental \naggressions and an increased resistance against disinfectants \nand antibiotics [10].\nM. abscessus is one of the most frequently causative \nagents of nontuberculous mycobacterial pulmonary disease, \noften isolated in patients with underlying chronic lung \ndiseases, like old tuberculosis scars, silicosis, bullae and other \nlung cavities where NTM can develop a biofilm. In recent times, \npatients with chronic bronchiectasis and cystic fibrosis have \nbeen found to be a target for NPRGM infections [11-13].\nM. chelonae  and M. fortuitum  are frequently isolated \nin skin and soft tissue infections [14-15]. However, all these \norganisms can be isolated in other different clinical samples as \na cause of many types of infection. \nHere we report our experience with the diseases caused \nby these organisms isolated in our hospital during a 13-year \nperiod in order to compare these results with previous studies \nregarding these organisms.\nMATERIAL AND METHODS\nA retrospective study was performed to evaluate the clinical \nsignificance of the NPRGM. For this purpose, records dating from \nJanuary 1st 2004 to December 31st 2017 from the mycobacteriology \nlaboratory of the clinical microbiology department were reviewed. \nPatients with at least one isolate of NPRGM from clinical samples  \nwere selected for clinical charts review.\nSample processing and identification of bacterial isolates \nwas performed following the internationally accepted \nprotocols. The decontamination technique for all samples was infecciones, especialmente infecciones de piel y partes blandas \ne infecciones asociadas a dispositivos biom\u00e9dicos.\nPalabras clave: micobacterias no pigmentadas de crecimiento r\u00e1pido; \nMycobacterium  abscessus ; Mycobacterium chelonae ; Mycobacterium  \nfortuitum ; significado cl\u00ednico; evoluci\u00f3n hist\u00f3rica ; epidemiolog\u00eda.\nINTRODUCTION\nNon-tuberculous mycobacteria (NTM) are a group \nof opportunistic pathogens which are being increasingly \nrecognized as a cause of infection [1]. They are also \nenvironmental organisms that can be found in many different \necosystems without public health implications [2].\nNTM infections are an emerging phenomenon, mainly \nin the last decade [3]. It has been observed an increasing \nimportance of infections caused by these organisms, both \nlocalized and disseminated, including also outbreaks and \npseudo-outbreaks [4-5]. Among these, non-pigmented rapidly \ngrowing mycobacteria (NPRGM) are ubiquitous in nature and \nwidely distributed in water, soil and animals [2, 6].\nThe three most important species of this group, regarding \ntheir clinical relevance, are Mycobacterium fortuitum , \nMycobacterium chelonae  and Mycobacterium abscessus [7]. \nHowever, there are many other species capable of causing \nhuman diseases such as Mycobacterium mucogenicum , \nMycobacterium immunogenum , Mycobacterium goodii , \nMycobacterium peregrinum , Mycobacterium phocaium , \nMycobacterium porcinum , Mycobacterium smegmatis or \nMycobacterium wolinskyi [7-9] . \nThese microorganisms have the ability to form biofilms \nand this gives these organisms many advantages over the \nFigure 1 Number of patients with NPRGM\nNPRGM: non-pigmented rapidly growing mycobacteriaHistorical evolution of the diseases caused by non-pigmented rapidly growing mycobacteria in a University \nHospitalM. Garcia-Coca, et al.\nRev Esp Quimioter 2019;32(5): 451-457453Isolated mycobacteria were Mycobacterium fortuitum  \n(30 patients), Mycobacterium abscessus  (8 patients), \nMycobacterium mucogenicum  (9 patients), Mycobacterium \nchelonae  (6 patients), Mycobacterium peregrinum  (4 patients), \nMycobacterium porcinum  (1 patient), Mycobacterium \nsmegmatis  (1 patient) and Mycobacterium arupense  (1 \npatient) (figure 1). One patient had two different NPRGM in \ntwo different samples. M. fortuitum  was the most frequent \nisolated mycobacterium, with a sharply increase in 2005, 2007 \nand 2011. M. abscessus  had a significant increase in 2012. M. \nchelonae  was the less isolated mycobacterium with only 0 or \n1 isolates per year, except in 2016 when it was isolated three \ntimes (figure 2).\nMost of the samples were sputum and other respiratory \nsamples (58 samples) followed by wound exudates and skin \nbiopsies (5 samples), urine (3 samples), blood cultures (2 \nsamples) and several other samples (8 samples).\nClinically significant cases appeared in 12 patients (20.3 \n%). One patient was classified as doubtful, and the rest \nof them were non-clinically significant cases. Syndromes \nand treatment of the patients with true or doubtful clinical \nsignificance are shown in table 1.\nThe clinical syndromes related to NPRGM include \nrespiratory tract infections (6 cases), catheter infections (2 \ncases), skin and soft tissue infection (1 case), disseminated \ninfection (1 case), conjunctivitis (1 case), prosthetic joint \ninfection (1 case) and mastitis (1 case). \nRegarding the clinical relevance of each species, 50% of \nthe isolates of M. chelonae , 37.5% of M. abscessus  and 23.33% \nof M. fortuitum  were clinically significant. None of the isolates \nof other species  were significant. the N-acetyl-cysteine-NaOH protocol throughout all these \nyears. After decontamination, all samples were inoculated onto \nLowenstein-Jensen and Coletsos solid slants and were inoculated \nalso in a liquid medium (MGIT 960 from 2004 to 2009, from BD, \nUSA, VERSATREK (Biom\u00e9rieux, France) from 2009 to 2016 and \nBacT/ALERT 3D (Biom\u00e9rieux, France) from 2016 to date.\nMycobacterial isolates were identified using a commercial \nPCR identification test (GenoType CM/AS, Hain, Germany), and \nthose isolates that could not be identified with this technique \nwere sent to the Mycobacteria reference laboratory (Centro \nNacional de Microbiolog\u00eda, Majadahonda, Spain). Antimicrobial \nsusceptibility test was performed for all mycobacterial isolates \nwith the broth microdilution reference technique [16]. \nOn one hand, clinical charts were evaluated according \nto a predefined protocol that includes demographics, \nevaluation of risk factors (respiratory syndromes, HIV \ninfection, immunosuppressive drug treatment and presence \nof biomaterials), clinical syndrome, treatment and outcome. \nCriteria from the ATS [17] for interpretation of an isolate \nwere followed to determine the clinical significance of each \ncase. On the other hand, we considered a case of doubtful \nclinical significance when it presented with clinical signs of \ninfection in the absence of other possible causes, and showed \nimprovement after treatment with antimicrobial therapy, \nbut did not fulfill the microbiological criteria. The Clinical \nResearch Ethics Committee of our hospital approved the study \n(registration number EO137-18_FJD)\nRESULTS\nGrowing of NPRGM was observed in 76 clinical samples of \n59 patients from January 1st 2004 to December 31st 2017.Figure 2  Evolution of cases of infection caused by NPRGM (patients/year)\nNPRGM: non-pigmented rapidly growing mycobacteriaHistorical evolution of the diseases caused by non-pigmented rapidly growing mycobacteria in a University \nHospitalM. Garcia-Coca, et al.\nRev Esp Quimioter 2019;32(5): 451-457454Case Year Sex Age Underlying diseases Syndrome Positive samples Acid-fast stain Therapy Species\n1 2004 F 36 Chronic bronchopaty Dysphonia Laryngeal biopsy Positive IS+RI M. chelonae\n2 2005 F 45 NO Mastitis Skin exudate Negative CI M. fortuitum\n3 2005 M 55 Multiple myeloma Catheter infection Catheter exudate Positive AM+CI+CL M. chelonae\n4 2006 F 30 Depressive syndrome Skin and soft tissue \ninfectionSkin biopsy Negative CI M. fortuitum\n5 2007 F 51 HIV, Burkitt lymphoma Disseminated infection Blood cultures Negative CL+CO M. fortuitum\n6 2007 M 48 Multiple myeloma Catheter infection Catheter exudate Negative CO M. fortuitum\n7 2008-2013 M 45 HIV, Chronic respiratory insufficiency Bronchiectasias Sputum Negative CL M. abscessus\n8 2011 F 86 Lower eyelid myofibroblastic tumor Conjunctivitis Conjunctival exudate Not performed CL M. chelonae\n9 2012-2014 F 56 Chronic obstructive pulmonary disease Bronchiectasias Bronchial lavage Negative LE M. abscessus\n10 2012 F 80 NO Arthritis Bone prosthesis Negative CI+RI M. fortuitum\n11 2012 F 62 Alpha1-antitrypsin deficiency Bronchiectasias Sputum Positive NO M. abscessus\n12 2015 M 71 Chronic obstructive pulmonary disease Bronchiectasias Sputum Negative CI M. fortuitum\n13 2015 F 49 Asthma Bronchiectasias Bronchial lavage Negative CI+CO M. fortuitum\ncompared to 30.8 % in a previous study [18]. This fact could \nbe related to the increased number of respiratory tract isolates, \nprobably due to the environmental nature of these bacteria. \nM. abscessus , M. chelonae  and M. fortuitum  have been usually \nassociated with human diseases, while other members of the \ngroup are environmental isolates that cause human infections \nin rare cases [18-20].  M. porcinum  has emerged in the last years \nas a species clearly related to human diseases, being involved \nin respiratory infections [21], but our only isolate has no role in \nthe disease of this patient. Among other species, most clinically \nsignificant cases of M. mucogenicum  isolates are involved in \ncatheter-related infections [22]. M. peregrinum  is a species \nincluded in the Mycobacterium fortuitum complex , but only a \nfew cases of true infections have been reported, mainly related \nto surgical site infections and catheter-related infections [23]. \nM. arupense  isolates have been related to pulmonary disease \nand osteoarticular infection [24-25]. In our series, all these \nspecies appeared to be colonizing organisms or contaminants, \nwhile the clinically relevant isolates belonged to the most \ncommon pathogens of this group: M. fortuitum , M. abscessus  \nand M. chelonae.\nAccording to the literature, the isolation of NPRGM has \nnot a clear role in respiratory infection diseases such as chronic \nobstructive pulmonary disease (COPD) and bronchiectasis \n[19]. In these patients, the distinction between colonization \nand infection is a difficult clinical decision in most cases. M. \nabscessus  is known to be a pathogen implicated in respiratory \nsyndromes. It account for the majority of pulmonary infection \ncases in patients with underlying diseases like bronchiectasis, When we focus on the underlying diseases in the clinically \nsignificant group chronic respiratory disease (6 cases), presence \nof malignancy (2 cases) and human immunodeficiency virus \n(HIV) disease (2 cases) were detected. There was 1 case of \nsurgical infection related to shoulder prosthesis. \nAcid-fast bacilli were detected in stains from samples in \n4 of the significant and doubtful cases (33.33%). There was a \nclinically significant case (conjunctival exudate) in which the \nacid-fast stain was not performed. Interestingly, 2 samples of \nthe non-significant group were also acid-fast stain positive.\nRegarding the therapeutic actions in the clinically \nsignificant group, all the patients were treated with \nantimicrobial therapy except the doubtful case. There were \n8 cases treated with monotherapy regimen (3 cases with \nciprofloxacin, 2 cases with clarithromycin, 1 case with \nlevofloxacin and 1 case with cotrimoxazol). Ciprofloxacin \nand clarithromycin were the mainly used antibiotics, either \nas monotherapy or in a combination antimicrobial regimen. \nIn the implant-related infection it was necessary to remove \nthe prosthesis in order to cure the infection. All the patients \nwere cured, except 2 cases which are currently being under \nfollow-up/control. One patient died due to other pathology. \nNo resistances during therapy were detected.\nDISCUSSION\nNPRGM are usually considered environmental \nopportunistic pathogens. In our series we documented \nthat only 20.34% of the isolates were clinically significant, Table 1 Characteristics of the cases of infection caused by NPRGM and the case with doubtful significance.\nNPRGM: non-pigmented rapidly growing mycobacteria; M: Male; F: Female; NO: No disease/Not received; AM: Amikacin; CI: Ciprofloxacin; CL: Clarithromycin; CO: Cotrimoxazole; \nIS: Isoniazid; LE: Levofloxacin; RI: Rifampicin.Historical evolution of the diseases caused by non-pigmented rapidly growing mycobacteria in a University \nHospitalM. Garcia-Coca, et al.\nRev Esp Quimioter 2019;32(5): 451-457455biomaterials) is almost always related to the clinical syndrome. \nIn order to avoid the failure of the treatment, an adequate \nmicrobiological identification and susceptibility test is needed, \nwhich would allow to choose a correct antimicrobial therapy \nand management of patients.\nFUNDING\nNone to declare\nCONFLICT OF INTEREST\nThe author(s) declare(s) that they have no conflicts of \ninterest\nJE received conference payments from Heraeus and \nSysmex, and travel grants from Pfizer and bioM\u00e9rieux. No \nconflicts of interest for all other authors.\nREFERENCES\n1. Ahmed I, Jabeen K, Hasan R. Identification of non-tuberculous \nmycobacteria isolated from clinical specimens at a tertiary care \nhospital: a cross-sectional study. BMC Infect Dis. 2013;13:493. \nDOI: 10.1186/1471-2334-13-493 \n2. Falkinham JO, 3rd. Nontuberculous mycobacteria in the \nenvironment. Clin Chest Med. 2002;23(3):529-51. PMID 12370991\n3. McGrath EE, Blades Z, McCabe J, Jarry H, Anderson PB. \nNontuberculous mycobacteria and the lung: from suspicion to \ntreatment. Lung. 2010;188(4):269-82. DOI: 10.1007/s00408-010-\n9240-9\n4. Kressel AB, Kidd F. Pseudo-outbreak of Mycobacterium chelonae  \nand Methylobacterium mesophilicum  caused by contamination of \nan automated endoscopy washer. Infect Control Hosp Epidemiol. \n2001;22(7):414-8. DOI: 10.1086/501926\n5. Kohler P, Kuster SP, Bloemberg G, Schulthess B, Frank M, Tanner FC, \net al. Healthcare-associated prosthetic heart valve, aortic vascular \ngraft, and disseminated Mycobacterium chimaera  infections \nsubsequent to open heart surgery. Eur Heart J. 2015;36(40):2745-\n53. DOI: 10.1093/eurheartj/ehv342\n6. Russell CD, Claxton P, Doig C, Seagar AL, Rayner A, Laurenson IF. \nNon-tuberculous mycobacteria: a retrospective review of Scottish \nisolates from 2000 to 2010. Thorax. 2014;69(6):593-5. DOI: \n10.1136/thoraxjnl-2013-204260\n7. Brown-Elliott BA, Wallace RJ, Jr. Clinical and taxonomic status of \npathogenic nonpigmented or late-pigmenting rapidly growing \nmycobacteria. Clin Microbiol Rev. 2002;15(4):716-46. DOI: \n10.1128/crm.15.4.716-746.2002\n8. Chen YC, Jou R, Huang WL, Huang ST, Liu KC, Lay CJ, et al. \nBacteremia caused by Mycobacterium wolinskyi . Emerg Infect Dis. \n2008;14(11):1818-9. DOI: 10.3201/eid1411.080003\n9. Ashraf MS, Swinker M, Augustino KL, Nobles D, Knupp C, Liles D, \net al. Outbreak of Mycobacterium mucogenicum  bloodstream \ninfections among patients with sickle cell disease in an outpatient cystic fibrosis or granulomatous diseases like sarcoidosis \n[12, 26-28]. Twenty eight percent of cystic fibrosis patients \nare affected by this species, being associated with increased \nmorbidity and mortality, as well as with a rapid decline in lung \nfunction. Although it is not an absolute contraindication for \nlung transplantation, the pulmonary infection is associated \nwith poor prognosis following this procedure [13, 27, 29]. \nIn our series, most of NPRGM isolations from respiratory \nsamples are not considered to be the major cause implicated \nin the pathology, but in patients with bronchiectasis, M. \nabscessus  was the main isolated pathogen and all cases \nwere treated with monotherapy, except one case that was \nconsidered of doubtful significance. This last case had a special \nclinical situation due to an alpha 1-antitrypsine deficiency, and \nthe isolate was considered colonization because of the lack of \nsymptoms, despite the fact that the organism was isolated \nfrom several different samples during a long time period.\nThe second species more frequently isolated in our series \nin respiratory samples was M. fortuitum . The respiratory \ninfection caused by these mycobacteria is less common than \nM. abscessus  disease, but there are cases reported in literature \n[30-31]. \nAll of the biomaterial-related infections in our series \nrequired a combined medical and surgical therapeutic \napproach. Surgical procedures consisted of implant removal \n(meshes, catheter, and other prosthesis). M. fortuitum  was the \nmost frequently isolated mycobacteria from these infections. \nThe ability of rapidly growing mycobacteria to develop biofilms \nin different surfaces is well known [32-34]. This virulence factor \nmakes almost impossible the eradication of this bacteria using \nonly antimicrobial therapy because of the in vivo  resistance of \nsessile organisms against the different antimicrobials [35], so \nbiofilm removal is mandatory in these cases. \nIn skin and soft tissue infections M. fortuitum was the \nmain etiologic agent in our series . Acupuncture, infected \nsurgical equipment or tattoos have been established as risk \nfactors to develop a NPRGM skin infection [36-37]. The water \nused in the sterilising processes seems to be the main source of \ncontamination in many cases . Monotherapy regimen was the \nselected treatment in all cases for these infections. \nDue to the fact that NPRGM are resistant to conventional \nantituberculous drugs, the treatment has to be directed \nthrough in vitro  susceptibility testing [16], being clarithromycin \nand ciprofloxacin the most frequently selected antibiotics [38]. \nDespite the previously described development of resistance \nduring monotherapy [39], we have not detected any case of \nsuch problem, probably due to the low bacterial load presented \nin most of the cases, which minimises the probability of \nselection of resistant mutants.\nIn conclusion, the major difficulty to evaluate the \nclinical significance of NPGRM resides in the fact that most \nof these isolates are regarded as a contamination. However, \nwe observed in our series that the isolation of a specific \nNPGRM ( M. abscessus, M. fortuitum  and M. chelonae) , or in \nspecific samples (respiratory samples, skin, soft tissue, and Historical evolution of the diseases caused by non-pigmented rapidly growing mycobacteria in a University \nHospitalM. Garcia-Coca, et al.\nRev Esp Quimioter 2019;32(5): 451-457456setting. Infect Control Hosp Epidemiol. 2012;33(11):1132-6. DOI: \n10.1086/668021\n10. Esteban J, Garcia-Coca M. Mycobacterium  Biofilms. Front \nMicrobiol. 2017;8:2651. DOI: 10.3389/fmicb.2017.02651\n11. Benwill JL, Wallace RJ, Jr. Mycobacterium abscessus : challenges in \ndiagnosis and treatment. Curr Opin Infect Dis. 2014;27(6):506-10. \nDOI: 10.1097/QCO.0000000000000104\n12. Qvist T, Pressler T, Hoiby N, Katzenstein TL. Shifting paradigms \nof nontuberculous mycobacteria in cystic fibrosis. Respir Res. \n2014;15:41. DOI: 10.1186/1465-9921-15-41\n13. Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, \net al. US Cystic Fibrosis Foundation and European Cystic Fibrosis \nSociety consensus recommendations for the management of \nnon-tuberculous mycobacteria in individuals with cystic fibrosis: \nexecutive summary. Thorax. 2016;71(1):88-90. DOI: 10.1136/\nthoraxjnl-2015-207983\n14. Cho SY, Peck KR, Kim J, Ha YE, Kang CI, Chung DR, et al.  Mycobacterium \nchelonae infections associated with bee venom acupuncture. Clin \nInfect Dis. 2014;58(5):e110-3. DOI: 10.1093/cid/cit753\n15. Yu JR, Heo ST, Lee KH, Kim J, Sung JK, Kim YR, et al. Skin and Soft \nTissue Infection due to Rapidly Growing Mycobacteria: Case Series \nand Literature Review. Infect Chemother. 2013;45(1):85-93. DOI: \n10.3947/ic.2013.45.1.85\n16. CLSI. Susceptibility testing of Mycobacteria; Nocardiae and other \nAerobic Actinomycetes; Approved Standard. Second ed.; 2011. \nSecond edition. 2011. DOI: 10.1128/9781555816728 \n17. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley \nC, Gordin F, et al. An official ATS/IDSA statement: diagnosis, \ntreatment, and prevention of nontuberculous mycobacterial \ndiseases. Am J Respir Crit Care Med. 2007;175(4):367-416. DOI: \n10.1164/rccm.200604-571ST\n18. Esteban J, Fernandez Roblas R, Garcia Cia JI, Zamora N, Ortiz \nA. Clinical significance and epidemiology of non-pigmented \nrapidly growing mycobacteria in a university hospital. J Infect. \n2007;54(2):135-45. DOI: 10.1016/j.jinf.2006.02.017\n19. Esteban J, Garcia-Pedrazuela M, Munoz-Egea MC, Alcaide F. \nCurrent treatment of nontuberculous mycobacteriosis: an \nupdate. Expert Opin Pharmacother. 2012;13(7):967-86. DOI: \n10.1517/14656566.2012.677824\n20. Vaerewijck MJ, Huys G, Palomino JC, Swings J, Portaels F. \nMycobacteria in drinking water distribution systems: ecology \nand significance for human health. FEMS Microbiol Rev. \n2005;29(5):911-34. DOI:10.1016/j.femsre.2005.02.001\n21. Brown-Elliott BA, Wallace RJ, Jr., Tichindelean C, Sarria JC, McNulty \nS, Vasireddy R, et al. Five-year outbreak of community- and \nhospital-acquired Mycobacterium porcinum  infections related to \npublic water supplies. J Clin Microbiol. 2011;49(12):4231-8. DOI: \n10.1128/JCM.05122-11\n22. Adekambi T. Mycobacterium mucogenicum  group infections: \na review. Clin Microbiol Infect. 2009;15(10):911-8. DOI: \n10.1111/j.1469-0691.2009.03028.x\n23. Nagao M, Sonobe M, Bando T, Saito T, Shirano M, Matsushima A, \net al. Surgical site infection due to Mycobacterium peregrinum : a case report and literature review. Int J Infect Dis. 2009;13(2):209-\n11. DOI: 10.1016/j.ijid.2008.06.018\n24. Neonakis IK, Gitti Z, Kontos F, Baritaki S, Petinaki E, Baritaki M, \net al. Mycobacterium arupense  pulmonary infection: antibiotic \nresistance and restriction fragment length polymorphism analysis. \nIndian J Med Microbiol. 2010;28(2):173-6. DOI: 10.4103/0255-\n0857.62502\n25. Seidl A, Lindeque B. Large joint osteoarticular infection caused by \nMycobacterium arupense . Orthopedics. 2014;37(9):e848-50. DOI: \n10.3928/01477447-20140825-93\n26. Do PC, Nussbaum E, Moua J, Chin T, Randhawa I. Clinical \nsignificance of respiratory isolates for Mycobacterium \nabscessus complex  from pediatric patients. Pediatr Pulmonol. \n2013;48(5):470-80. DOI: 10.1002/ppul.22638\n27. Esther CR, Jr., Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic \nMycobacterium abscessus  infection and lung function decline \nin cystic fibrosis. J Cyst Fibros. 2010;9(2):117-23. DOI: 10.1016/j.\njcf.2009.12.001\n28. Qvist T, Eickhardt S, Kragh KN, Andersen CB, Iversen M, Hoiby N, \net al. Chronic pulmonary disease with Mycobacterium abscessus \ncomplex  is a biofilm infection. Eur Respir J. 2015;46(6):1823-6. \nDOI: 10.1183/13993003.01102-2015\n29. Lobo LJ, Chang LC, Esther CR, Jr., Gilligan PH, Tulu Z, Noone PG. \nLung transplant outcomes in cystic fibrosis patients with pre-\noperative Mycobacterium abscessus  respiratory infections. Clin \nTransplant. 2013;27(4):523-9. DOI: 10.1111/ctr.12140\n30. Cong J, Wang C, Ma L, Zhang S, Wang J. Septicemia and \npneumonia due to Mycobacterium fortuitum  infection in a \npatient with extronodal NK/T-cell lymphoma, nasal type: A case \nreport. Medicine (Baltimore). 2017;96(18):e6800. DOI: 10.1097/\nMD.0000000000006800\n31. Okamori S, Asakura T, Nishimura T, Tamizu E, Ishii M, Yoshida M, \net al. Natural history of Mycobacterium fortuitum  pulmonary \ninfection presenting with migratory infiltrates: a case report \nwith microbiological analysis. BMC Infect Dis. 2018;18(1):1. DOI: \n10.1186/s12879-017-2892-9\n32. El Helou G, Hachem R, Viola GM, El Zakhem A, Chaftari AM, Jiang \nY, et al. Management of rapidly growing mycobacterial bacteremia \nin cancer patients. Clin Infect Dis. 2013;56(6):843-6. DOI: 10.1093/\ncid/cis1032\n33. Eid AJ, Berbari EF, Sia IG, Wengenack NL, Osmon DR, Razonable \nRR. Prosthetic joint infection due to rapidly growing mycobacteria: \nreport of 8 cases and review of the literature. Clin Infect Dis. \n2007;45(6):687-94. DOI:10.1086/520982\n34. Celdran A, Esteban J, Manas J, Granizo JJ. Wound infections due \nto Mycobacterium fortuitum  after polypropylene mesh inguinal \nhernia repair. J Hosp Infect. 2007;66(4):374-7. DOI: 10.1016/j.\njhin.2007.05.006\n35. Samimi DB, Bielory BP, Miller D, Johnson TE. Microbiologic trends \nand biofilm growth on explanted periorbital biomaterials: a \n30-year review. Ophthal Plast Reconstr Surg. 2013;29(5):376-81. \nDOI: 10.1097/IOP.0b013e31829a7313\n36. Gracia-Cazana T, Milagro A, Queipo F, Gilaberte Y. Mycobacterium Historical evolution of the diseases caused by non-pigmented rapidly growing mycobacteria in a University \nHospitalM. Garcia-Coca, et al.\nRev Esp Quimioter 2019;32(5): 451-457457fortuitum infection after acupuncture treatment. Dermatol Online \nJ. 2017;23(9). PMID: 29469732\n37. Uzoigwe OF. Contaminated ink might be responsible for \nMycobacterium chelonae  infection after tattooing. BMJ. \n2013;346:f122. DOI: 10.1136/bmj.f122 \n38. Ortiz-Perez A, Martin-de-Hijas N, Alonso-Rodriguez N, Molina-\nManso D, Fernandez-Roblas R, Esteban J. Importance of antibiotic \npenetration in the antimicrobial resistance of biofilm formed by \nnon-pigmented rapidly growing mycobacteria against amikacin, \nciprofloxacin and clarithromycin. Enferm Infecc Microbiol Clin. \n2011;29(2):79-84. DOI: 10.1016/j.eimc.2010.08.016\n39. Wallace RJ, Jr., Meier A, Brown BA, Zhang Y, Sander P, Onyi GO, \net al. Genetic basis for clarithromycin resistance among isolates \nof Mycobacterium chelonae  and Mycobacterium abscessus . \nAntimicrob Agents Chemother. 1996;40(7):1676-81. PMID: \n8807061Rev Esp Quimioter 2019;32(5): 458-464458\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).polypharmacy. In conclusion, the concept of polypharmacy \nshould include not only the number of prescribed drugs but \nalso the complexity of them.\nKeywords: HIV, polypharmacy, pharmacotherapy complexity, aging\nDeterminaci\u00f3n del valor umbral del \u00edndice de \ncomplejidad de la farmacoterapia para predecir \npolifarmacia en pacientes VIH+ \nRESUMEN\nIntroducci\u00f3n . La esperanza de vida de los pacientes \nVIH+ se ha incrementado. De forma paralela han aumentado \nlas comorbilidades asociadas a la edad y la complejidad \nfarmacoterap\u00e9utica. El objetivo del estudio es estimar el valor \numbral del \u00edndice de complejidad de la farmacoterapia (MRCI) \npara la determinaci\u00f3n del criterio de polifarmacia en pacientes \nVIH+ mayores de 50 a\u00f1os. \nM\u00e9todos.  Estudio observacional, trasversal, unic\u00e9ntrico. \nSe incluyeron todos los pacientes VIH+ mayores de 50 a\u00f1os, \nen tratamiento antirretroviral activo entre el 1 enero y 31 \ndiciembre-2015. Se determin\u00f3 la presencia de polifarmacia \ny los patrones asociados. La complejidad del tratamiento se \ncalcul\u00f3 con la herramienta MRCI (Universidad de Colorado).  \nSe analiz\u00f3 el \u00edndice de complejidad total como marcador \ncuantitativo de polifarmacia mediante la realizaci\u00f3n de una \ncurva ROC y el c\u00e1lculo de su \u00e1rea bajo la curva. Se calcul\u00f3 la \nsensibilidad y la especificidad de la misma.\nResultados.  Se incluyeron 223 pacientes. El 56,1% \npresent\u00f3 polifarmacia, siendo extrema en el 9,4% de los \ncasos. En relaci\u00f3n con el patr\u00f3n de polifarmacia, el 78,0% \npresentaron un patr\u00f3n cardio-metab\u00f3lico, el 12,0% psico \ngeri\u00e1trico-depresivo, el 8,0% mixto y el 2,0% mec\u00e1nico tiroideo \n.Se determin\u00f3 un valor de \u00e1rea bajo la curva ROC de 0,931 con \nl\u00edmites entre (0,901-0,962) y p< 0,001. El valor 11,25 de \u00edndice ABSTRACT\nIntroduction . HIV+ patients have increased their life \nexpectancy with a parallel increase in age-associated co-\nmorbidities and pharmacotherapeutic complexity. The aim \nof this study was to determine an optimal cutoff value for \nMedication regimen complexity index (MRCI) to predict \npolypharmacy in HIV+ older patients \nPatients and methods.  A transversal observational single \ncohort study was conducted at a tertiary Hospital in Spain, \nbetween January 1st up to December 31st, 2014. Patients \nincluded were HIV patients over 50 years of age on active \nantiretroviral treatment. Prevalence of polypharmacy and \nit pattern were analyzed. The pharmacotherapy complexity \nvalue was calculated through the MRCI. Receiver operating \ncharacteristic curve analyses were used to calculate the \narea under the curve (AUC) for the MRCI value medications \nto determine the best cutoff value for identifying outcomes \nincluding polypharmacy. Sensitivity and specificity were also \ncalculated.\nResults.  A total of 223 patients were included. A 56.1% \nof patients had polypharmacy, being extreme polypharmacy \nin 9.4% of cases. Regarding the pattern of polypharmacy, \n78.0% had a cardio-metabolic pattern, 12.0% depressive-\npsychogeriatric, 8.0% mixed and 2.0% mechanical-thyroidal. \nThe ROC curve demonstrated that a value of medication \ncomplexity index of 11.25 point was the best cutoff for predict \npolypharmacy (AUC=0.931; sensitivity= 77.6%; specificity= \n91.8%).\nConclusions.  A cut-off value of 11.25 for MRCI is \nproposed to determine if a patient reaches the criterion of Determination of a cutoff value for medication \nregimen complexity index to predict polypharmacy \nin HIV+ older patient\n1Valme Hospital (Pharmacy Department). Seville, Spain.\n2Virgen del Roc\u00edo Hospital (Pharmacy Department), Seville, Spain. \n3Pharmacy Faculty. University of Seville, Spain\n4Infectious Diseases and Microbiology Unit, Valme Hospital, Seville, Spain.\n5Biostatistics, University of Seville, SpainRam\u00f3n Morillo-Verdugo1\nM\u00aa de las Aguas \nRobustillo-Cort\u00e9s1\nLaila Abdel-Kader Mart\u00edn2\nMar\u00eda \u00c1lvarez de \nSotomayor Paz3\nFernando Lozano de Le\u00f3n \nNaranjo4\nCarmen Victoria Almeida-\nGonz\u00e1lez5\nCorrespondence:\nMaria de las Aguas Robustillo-Cort\u00e9s.\nPharmacy Department, Valme Hospital, \nAv Bellavista s/n 41014, Seville, Spain. \nPhone: +34955015467 \nFAX: 34955015461\nE-mail: aguasrobustillo@gmail.comOriginal\nArticle history\nReceived: 26 March 2019; Revision Requested: 7 May 2019; Revision Received: 23 May 2019; Accepted: 28 May 2019Determination of a cutoff value for medication regimen complexity index to predict polypharmacy in HIV+ \nolder patientR. Morillo-Verdugo, et al.\nRev Esp Quimioter 2019;32(5): 458-464459to decrease polypharmacy in complex patients with multiple \ncomorbidities should prioritize decreasing the daily pill burden, \nthe risk of toxicity and the drug-drug interactions [15]. New \nstrategies have been developed alongside conventional triple \ncombination ART administered as multi-tablet regimens. \nThey include use of co-formulated, fixed-dose single-tablet \nregimens (STR) administered once daily, as well as non-\npreferential less-drug regimens, which reduce the number \nof compounds administered to either monotherapy or dual \ncombination therapy.\nAnother critical but less known factor is pharmacotherapy \ncomplexity (PC). Martin et al. developed a method for quanti -\nfying antiretroviral regimen complexity for HIV patients [16]. \nThis method was the first step toward obtaining a better un -\nderstanding of the impact of complex ART regimens on adher -\nence and clinical outcomes. Previously, George et al. developed \na medication regimen complexity index (MRCI) to estimate \ncomplexity of all drugs taken by a patient [17]. This tool has \nbeen used in many chronic diseases and most studies showed \nthat an increased regimen complexity is associated with poor \nclinical outcomes and reduces medication in the general pop -\nulation [18, 19].\nThere are not published studies addressing the relationship \nbetween medication regimen complexity index and polyphar -\nmacy.\nThe aim of this study was to determine an optimal cutoff \nvalue for MRCI to predict polypharmacy and to redefine the \nconcept of polypharmacy in older PLWH.\nPATIENTS AND METHODS\nA cross-sectional, observational single cohort study was \nconducted at a tertiary Hospital in Spain, from 1 January \n2014 to 31 December 2014. Patients enrolled in the study met \nthe following inclusion criteria: HIV patients over 50 years \nof age on active ART drugs. Participants were given written \ninformation about the study and its objectives, and those who \nagreed to participate provided their written informed consent.  \nPatients participating in another clinical trial or who did not \nsign the informed consent were excluded.\nData collected from the electronic medical record \nincluded demographic data (sex and age) and HIV transmission \nmode; clinical endpoints: plasma viral load (copies/milliliter \n[mL]) and CD4+ T-cell count (cells/microliter) and comorbidity \nrelated variables (number and type of comorbidities). \nPharmacotherapy variables included ART regimen, single \ntreatment regimen (STR) and concomitant medications. ART \nadherence was measured using the SMAQ questionnaire [20] \nand hospital dispensing records. A PLWH was considered \nadherent to antiretroviral treatment if according to hospital \npharmacy records adherence was >95% and was not positive \nin the SMAQ, where positive means that there was a positive \nresponse to any of the qualitative questions of the SMAQ, \nmore than two doses missed over the past week, or over 2 days \nof total non-medication during the past 6 months.de complejidad total de la farmacoterapia proporcion\u00f3 un \nvalor de especificidad del 92% y una sensibilidad del 78%.\nConclusi\u00f3n.  El valor de 11,25 de \u00edndice de complejidad es \nun buen indicador para conocer los pacientes con polifarmacia. \nEl concepto de polifarmacia no solo debe incluir el n\u00famero \nde f\u00e1rmacos que toma el paciente sino incluir tambi\u00e9n la \ncomplejidad del tratamiento.\nPalabra clave: VIH, polifarmacia, complejidad farmacoterap\u00e9utica,  \nenvejecimiento\nINTRODUCTION\nDue to the introduction of high activity antiretroviral ther -\napy, nowadays HIV-infected individuals live longer. It is esti -\nmated that by 2030 nearly three-quarters of people living with \nHIV will be 50 years or older [1]. Age-related conditions such as \ncardiovascular disease, kidney disease, and non-AIDS-defining \ncancers are likely to continue to increase among HIV-infected \npatients as their median age also increases [2]. As a result, up \nto two-thirds of these patients take concomitant medication \nto mitigate antiretroviral treatment (ART) side effects and/or to \ntreat comorbid conditions [3\u20136]. People living with HIV (PLWH) \noften exhibits a higher number of concomitant medication \nthan in the general population. This increase in drugs num -\nber has been associated with older age, female gender, obesity, \nand hepatitis B/C co-infection [4\u20136]. In addition, HIV-infected \nindividuals may be more vulnerable to age-related conditions \n[7]. This high prevalence of comorbidities has only exacerbated \nthe polypharmacy problem, which has recently become a clin -\nical concern among providers caring for HIV-infected patients \n[3\u20135]. \nThere are different definitions of polypharmacy. In nu -\nmerical terms, it is most commonly defined as at least five \nor more prescription drugs, which is also associated to worse \nhealth outcomes in older patients such as increased risk for \nmorbidity, non-adherence, drug interactions, and side effects. \nAll these disadvantages have been shown to be more prevalent \nin PLWH than in the rest of the population [4, 6, 8\u201311]. In ad -\ndition, Smit et al. observed an increasing burden of polyphar -\nmacy and age-related non-communicable diseases that could \ncause an increase in complications with first-line antiretroviral \ntreatment [12].\nAccording to the most recent recommendations in our \ncontext, the most appropriate number to define polypharmacy \nis six drugs [13]. However, no definition has included the impact \nof number of drugs, pill burden, complexity in taking drugs or \nother important factors including in the MRCI, in elderly pa -\ntients, both HIV and non-HIV. Moreover, evidence shows that \npolypharmacy increases with age but is likely under-estimated \ngiven that most studies in HIV-infected adults only account for \nprescribed medicines [4, 10, 12]. Polypharmacy in HIV-infected \nhas a major impact on ART adherence and adverse drug reac -\ntions leading to hospitalization [9, 14].\nPolypharmacy should be considered the next challenge in \nclinical follow-up of HIV-infected patients [4, 12].  Strategies Determination of a cutoff value for medication regimen complexity index to predict polypharmacy in HIV+ \nolder patientR. Morillo-Verdugo, et al.\nRev Esp Quimioter 2019;32(5): 458-464460Receiver operating characteristic (ROC) curve analyses \nwere used to calculate the area under the curve (AUC) for the \nMRCI value medications to determine the best cutoff value \nfor identifying outcomes including polypharmacy. The AUC \ndescribes the test\u2019s overall performance and it can be used \nto compare different tests. An AUC of 1 indicates perfect \ndiscrimination, whereas an AUC of 0.5 indicates discrimination \nno better than chance. Sensitivity and specificity were \ncalculated. The optimal cutoff point was obtained by using the \nYouden Index (i.e., sensitivity \u00fe specificity-1), without adjusting \nfor covariates. The Youden Index, a common summary \nmeasure of the ROC curve, represents the maximum potential \neffectiveness of a marker [25]. Logistic regression analysis was \nperformed, and area under ROC curve was calculated for the \nassociation of the number of concomitant medications with \neach of the outcomes. Data are presented as odds ratios \nwith 95% confidence intervals. All models were adjusted for \npotential covariates including age and medical conditions.\nStatistical significance was set at less than 0.05.  Data were \nanalyzed using IBM SPSS Statistics version 22.0 software.\nEthics approval. The study was approved by the institu -\ntional ethics committee of the South Seville area (registration \nnumber RAM-VIH-2015-02). Participants were given written \ninformation about the study and its objectives, and those who \nagreed to take part provided their written informed consent.\nRESULTS\nThe sample consisted of 223 patients with a median age \nof 53.0 years (IQR: 52.0-57.0), 86.5% males, were enrolled \ninto the study. Baseline characteristics of patients are shown \nin table 1. ART regimens consisted of two nucleoside reverse \ntranscriptase inhibitors (NRTI) plus a non-nucleoside reverse \ntranscriptase inhibitor (NNRTI) in 37.2% of patients; two NRTIs \nplus a boosted protease inhibitor in 18.8%; two NRTIs plus an \nintegrase strand transfer inhibitor (INSTI) in 12.6%, and other \ncombinations in 31.4% of patients (20% monotherapy and \n40% dual antiretroviral therapy). A majority (52%) of patients \nstarted antiretroviral therapy before 2002, 14.8% had been on \nthree or more ART regimens and 25.3% had been on STR. \nMedian number of concomitant drugs prescribed \nper patient were 3.0 (1.0-5.0). The median was the most \nfrequently prescribed therapeutic drug classes were as follows: \npsychotropic drugs (35.9%), lipid lowering drugs (29.1%), \ncardiovascular agents (29.1%), drugs used for treatment for \ngastroesophageal reflux disease (26.9%), and blood glucose-\nlowering drugs (11.7%).\nThe median of comorbidities per patient was 3.0 (IQR: 2.0-\n4.0). Viral liver diseases were diagnosed in 67.3% of patients, \ncardiovascular diseases or high blood pressure in 25.0%, and \ncentral nervous system diseases in 20.5% of patients. Of the \n126 patients who were calculated the multimorbidity pattern, \n73.8% were cardiometabolic, 12.7% were mixed, 11.6% were \ndepressive-psychogeriatric and 1.6% mechanical-thyroidal.Adherence to concomitant medication was measured \nusing the Morisky-Green questionnaire [21] and electronic \npharmacy dispensing records. A PLWH was considered \nadherent to concomitant medication if according to electronic \npharmacy dispensing records adherence was >90% and the \nMorisky-Green questionnaire scored 4. \nTo calculate the dispensing record, use the Medication \nPossession Ratio (MPR), as it measures the percentage of time \na patient has access to medication. The formulae to calculate \nMPR is: MPR Number of days ARV prescribed or dispensed/\nnumber of days in the interval. The follow-up time to the \nchronic medication adherence was 24 weeks.\nThe independent variable was polypharmacy, defined \nas treatment with six or more drugs (including antiretroviral \ntherapy). Major polypharmacy (more than 11 drugs) and excessive \npolypharmacy (more than 21 drugs) were also considered [13].\nPolypharmacy pattern was analyzed according to the \nCalder\u00f3n Larra\u00f1aga et al study [22], with a non-random \nassociation in drug prescription resulting in polypharmacy \npatterns. Three patterns were applied based on age of \nparticipants: cardiovascular, depression-anxiety, and chronic \nobstructive pulmonary (COPD) disease patterns, with a \ndifferent prevalence between men and women. A patient \nwas classified into a pattern when at least three drugs of \nthe treatment were in the same pattern. To calculate the \ncorresponding polypharmacy patterns of each patient, drugs \nwere classified according to the Anatomical Therapeutic \nChemical Classification System (ATC) using only the first three \nlevels of the classification. \nMultimorbidity patterns was analyzed according to \nthe Prados-Torres et al study. Chronic diseases resulted in \nthree multimorbidity patterns: cardiometabolic, depressive-\npsychogeriatric, and mechanical-thyroidal [23]. Patients were \nclassified into a type if they had two diseases included in a \npattern. ART drugs were obtained from a pharmacy-dispensing \noutpatient program (Dominion-Farmatools\u00a9). Non-ART drugs \nprescribed were provided by an electronic health prescription \nprogram of the Andalusian Public Health System. The \nremaining endpoints were obtained from laboratory tests, \nmicrobiology reports, and from the review of the medical \nhistory of each patient. \nFinally, the pharmacotherapy complexity value was \ncalculated through the MRCI [18]. This validated tool includes \n65 items divided into three subgroups: dose forms, dosing \nfrequencies, and additional instructions relevant to drug \nadministration. The calculated value was obtained through \nthe web tool of Colorado University available at http://\nwww.ucdenver.edu/academics/colleges/pharmacy/Research/\nresearchareas/Pages/MRCTool.aspx ) [24].\nStatistical analyses. Quantitative variables were given as \nmean and standard deviation or as median and interquartile \nrange (IQR) in case of a skewed distribution. Qualitative \nvariables were given as percentages (%). Determination of a cutoff value for medication regimen complexity index to predict polypharmacy in HIV+ \nolder patientR. Morillo-Verdugo, et al.\nRev Esp Quimioter 2019;32(5): 458-464461efficiently the presence of polypharmacy in older HIV-infected \npatients.\nAccording to data published by others author [5, 10\u201312], \nour study demonstrates that a half of HIV+ elderly patients \ncurrently have polypharmacy. It is particularly important \nthe number of patients who have higher polypharmacy, in \nour study 9.4%. Regarding the concept of polypharmacy, \navailable literature points to different definitions. Although \nfive medications have been generally a well-accepted criterion, \naccording to most recent recommendations, we suggest six \nmedications [13]. \nMcNicholl et al. suggested that in patients 50 years \nand older, targeting individuals with 11 or more chronic \nmedications would have the highest yield and greatest impact \n[26]. Sutton et al. in a retrospective HIV+ cohort studied a \ndifferent concept, the pill burden. It was associated with poor \nlevel of adherence and risk of hospitalization but not included \na proposal to analyse higher-risk patient based on this concept \n[27].\nGiven the increase in the number of patients older than \n50 years expected in the coming years, as well as the increase \nin the number of patients with polypharmacy,  our study \nindicates polypharmacy should be defined by the number and \ncomplexity of prescribed medication.  \nAdditionally, the main contributing factor for a higher \nMRCI was concomitant medication.  These results  are in line \nwith data published by Metz et al. [28]. This issue confirms the \nvalidity of the proposed cutoff.\nDesigning ART regimens that do not interact with other \nchronic medications or exacerbate comorbidities can be As regards the main variables, 56.1% of patients had \npolypharmacy, higher polypharmacy in 9.4% of cases and \nno patient had excessive polypharmacy. Of the 70 patients \nwho were calculated the polypharmacy pattern, 60.0% were \ncardiovascular, 27.1% were depression-anxiety, 7.1 were \nmixed and 5.8 % were COPD.\nPresence of polypharmacy was associated to higher PC \nvalues. Patients with high PC indices had a 50 times higher \nchance (p = 0.0001) of polypharmacy than those with low PC \nvalues. The PC index significantly correlated with the three \nindex rating sections.\nThe ROC curve was constructed, and this demonstrated \nthat a value of medication complexity index of 11.25 point \nwas the best cutoff for predict polypharmacy in older HIV-\ninfected patients (area under curve = 0.931; sensitivity of 77.6 \n% and specificity of 91.8%) (figure 1). \nDISCUSSION\nWe propose a redefinition of the concept of polypharmacy, \nincluding not only the quantitative aspect of the number of \nprescribed drugs but, the medication regimen complexity. A \ncut-off value of 11.25 for MRCI is proposed to determine if a \npatient reaches the criterion of polypharmacy.\nThe cutoff established showed high AUC and specificity  \nand moderate sensitivity which helps identifying more Characteristics (n=223 patients)\nDemographic Parameters\nGender (male); n (%) 153 (86.5)\nAge (years); (median + IQR) 53.0 (52.0-57.0)\nHIV risk factor; n (%)IDU 121 (54.3)\nSexual 68 (30.5)\nUnknown 34 (15.2)\nClinic Parameters\nUndetectable Plasmatic Viral Load (<50 cop/mL); n (%) 184 (84.4)\nCD4 Levels; n (%)<200 cells/\u00b5L 22 (10)\n\u2265200 cells/\u00b5L 198 (90)\nAdherence\nAntiretroviral treatment; n (%) 186 (83.6)\nConcomitant drugs; n (%) 84 (37.9)Table 1  Baseline demographic, clinic, \nrelated to lifestyle and adherence \ncharacteristics of the patients.\nIQR: interquartile range; IDU: injection drug users.Figure 1  Receiver operating characteristic curves for \npolypharmacy in relation to the Medication \nRegimen Complexity Index value .\nDetermination of a cutoff value for medication regimen complexity index to predict polypharmacy in HIV+ \nolder patientR. Morillo-Verdugo, et al.\nRev Esp Quimioter 2019;32(5): 458-464462and specificity, as most clinical measures do. Despite a long \nlist of possible dose formulations, frequencies, and directions, \nsome options are missed, such as once monthly and also miss -\ning details, such as how to code 2 once-daily medications that \ncannot be taken simultaneously. There exist other possibilities \nto analyse the PC as the antiretroviral regimen complexity In -\ndex (ARCI), which had many more such details. As the average \ncomplexity score is not significantly different from the MRCI \nfor ART regimens we prefer to choose MRCI for being more \nstudied in the literature, in the recent years [33\u201335].\nAlthough a finding of multiple medication uses or \npolypharmacy, defined by a certain cutoff number may be a \nuseful indication for a medication review in older adults, it may \nnot be clinically useful when being associated with adverse \noutcomes. Instead, exposure to specific pharmacological drug \nclasses, total medication exposure, drug-drug interactions, \nand medication adherence are important factors that may \nbe used to be considered when evaluating individual\u2019s risk for \ndeveloping adverse outcomes.\nGiven the characteristics of our population and the \npattern of polypharmacy and multimorbidity, coinciding with \nother published cohorts, our cutoff point offers strength, since \nit is based on the type of medication commonly used in this \ntype of patient [5, 8, 10, 11, 15, 36].\nOur study was not performed to use number of \nmedications to claim that polypharmacy causes different \nadverse outcomes nor clinical impairment, but simply to \ndetermine an optimal discriminating number of medications \nfor polypharmacy. Other important issues as geriatric \nsyndromes, functional outcomes, and mortality in HIV+ older \npopulation must be studied, including an analysis using frailty, \ndisability and mortality variables respectively.\nIt is known that multi-morbidity contributes to further \nvulnerability and complexity in clinical management in the \ncontemporary ART age. The interest in methods to identify \nindividuals at risk of multi-morbidity is strongest. The concept \nof frailty must be included routinely in HIV+ older patient \nbecause may be useful in discriminating whether it is the \nmorbidities themselves or the toxicity of prescribed treatments \nthat contributes more to adverse outcomes [26]. \nGiven the changing face of the HIV epidemic, providers \nwill be increasingly challenged to effectively manage older, \nHIV-infected patients with multi-morbidity, polypharmacy \nand high-level of PC. It is important to increase our knowledge \nof polypharmacy among the increasing older HIV-infected \npopulation in order to be able to develop prevention strategies \nfor the problems inherent in old age and multiple treatments. \nAccording with the literature polypharmacy in HIV+ older \npatient will increase in the coming years [12]. This fact and the \nprogressive physiological deterioration of patients will make it \nincreasingly common and necessary to use not only the classic \nassessment of actual or potential drug interactions but also \nother terminology about the use of drugs employed in other \ntypes of chronic patients, such as potentially inappropriate \nmedication, cholinergic risk or deprescribing [10\u201312, 26, 35].challenging, especially in heavily pretreated patients whose \nART options are limited. A recent retrospective study found \nan association between polypharmacy, and a lower likelihood \nof using singled-tablet-regimen (STR) [15]. Currently available \nSTR\u00b4s may be limited in this aging population by complex \ndrug\u0096drug and drug\u0096disease interactions, and the desire to \nmake treatment regimens more flexible but other strategies \nas Less-Drug-Regimen (LDR), including mono or bi-therapies, \nare becoming more frequent in this type of patients.  Manzano \net al. [29] demonstrated that the complexity of ART is being \nreduced mainly by new treatment strategies and the increasing \nappearance of pharmaceutical coformulations.\nIn addition, our results indicate that using MRCI \nscores adds information, particularly for concomitant  drug \nprescribed, extending beyond a simple pill count or pill burden \nconcept.  More efforts should optimize to simplify concomitant \nmedication\nIn this context, according to international guidelines,  \nit will be possible that HIV specialty pharmacists may assist \nprescribers in reducing polypharmacy and identifying \ninappropriate prescribing, using Beers or STOPP-START tools \n[30].\nA systematic review in non-HIV-infected patients has \nshowed that although there was heterogeneity regarding the \ndegree  of association between complexity and adherence, \nmost studies concluded that an increased regimen complexity \nreduces medication adherence [19]. In our study, the overall \nadherence calculated was high for ART, but particularly low \nfor concomitant medication. T-+his suggests a prioritization of \npatients\u2019 medication intake, derived from the patients\u2019 beliefs \nand perceptions regarding medications [31]. These results \nsuggested that, in older HIV patients, it is recommended that \nall prescribed medication be checked at least every six months \nin individuals who have more than four medications, and at \nleast once a year for the rest [13]. According to guidelines, \nit is recommended to carry out a review of the prescribed \npharmacotherapy in a systematized way and through a \nsequential and structured methodology [13]. Additionally, is \nnecessary to go beyond the virologic suppression and ensure \nadequate control of comorbidities, among other things, \nimproving adherence. Corless et al. raises the prospect that \naid providers by guiding their motivational interview to \nthose questions most closely associated with adherence, \nparticularly knowing factors about self-efficacy, depression, \nstressful life events, and stigma. It is necessary that HIV+ \nknows pharmacotherapy objectives, not only ART, to be more \nimplicated with this medication [32].\nA common limitation of other published studies is that \nthey only include data on medications of official medical pre -\nscriptions; they do not include private health system treat -\nments or alternative medicines. However, this is not seen as a \nvery significant limitation in our study; given the universal cov -\nerage of the public health system in Spain, with a small number \nof patients using alternative medications. However, the MRCI \nis an imperfect tool and faces tradeoffs between sensitivity Determination of a cutoff value for medication regimen complexity index to predict polypharmacy in HIV+ \nolder patientR. Morillo-Verdugo, et al.\nRev Esp Quimioter 2019;32(5): 458-4644636.  Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, \net al. Prevalence of comedications and effect of potential \ndrug-drug interactions in the Swiss HIV Cohort Study. \nAntivir Ther. 2010;15:413\u201323. doi:10.3851/IMP1540.\n7.  Negredo E, Back D, Blanco J-R, Blanco J, Erlandson \nKM, Garolera M, et al. Aging in HIV-Infected Subjects: \nA New Scenario and a New View. Biomed Res Int. \n2017;2017:5897298. doi:10.1155/2017/5897298.\n8.  Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, \nSeibel MJ, et al. Polypharmacy cutoff and outcomes: five \nor more medicines were used to identify community-\ndwelling older men at risk of different adverse outcomes. \nJ Clin Epidemiol. 2012;65:989\u201395. doi:10.1016/j.\njclinepi.2012.02.018.\n9.  Marcum ZA, Pugh MJ V., Amuan ME, Aspinall SL, \nHandler SM, Ruby CM, et al. Prevalence of Potentially \nPreventable Unplanned Hospitalizations Caused by \nTherapeutic Failures and Adverse Drug Withdrawal \nEvents Among Older Veterans. Journals Gerontol Ser \nA Biol Sci Med Sci. 2012;67:867\u201374. doi:10.1093/\ngerona/gls001.\n10.  Moore HN, Mao L, Oramasionwu CU. Factors associated \nwith polypharmacy and the prescription of multiple \nmedications among persons living with HIV (PLWH) \ncompared to non-PLWH. AIDS Care. 2015;27:1443\u20138. do\ni:10.1080/09540121.2015.1109583.\n11.  Gimeno-Gracia M, Crusells-Canales MJ, Armesto-\nGomez FJ, Compaired-Turlan V, Rabanaque-Hernandez \nMJ. Polypharmacy in older adults with human \nimmunodeficiency virus infection compared with the \ngeneral population. Clin Interv Aging. 2016;Volume \n11:1149\u201357. doi:10.2147/CIA.S108072.\n12.  Smith JM, Flexner C. The challenge of polypharmacy in an \naging population and implications for future antiretroviral \ntherapy development. AIDS. 2017;31 Suppl 2:S173\u201384. \ndoi:10.1097/QAD.0000000000001401.\n13.  Grupo de expertos de la Secretar\u00eda del Plan Nacional \nsobre el SIDA (SPNS), Sociedad Espa\u00f1ola de Geriatr\u00eda y \nGerontolog\u00eda (SEGG). Documento de consenso sobre edad \navanzada e infecci\u00f3n por el virus de la inmunodeficiencia \nhumana. 2015; Noviembre.\n14.  Cantudo-Cuenca MR, Jim\u00e9nez-Gal\u00e1n R, Almeida-Gonz\u00e1lez \nC V., Morillo-Verdugo R. Concurrent Use of Comedications \nReduces Adherence to Antiretroviral Therapy Among HIV-\nInfected Patients. J Manag Care Pharm. 2014;20:844\u201350. \ndoi:10.18553/jmcp.2014.20.8.844.\n15.  Guaraldi G, Menozzi M, Zona S, Calcagno A, Silva AR, \nSantoro A, et al. Impact of polypharmacy on antiretroviral \nprescription in people living with HIV. J Antimicrob \nChemother. 2017;72:511\u20134. doi:10.1093/jac/dkw437.\n16.  Martin S, Wolters PL, Calabrese SK, Toledo-Tamula MA, \nWood L V, Roby G, et al. The Antiretroviral Regimen \nComplexity Index. A novel method of quantifying regimen Future researches efforts will focus on include risk \nassessment, such as that offered by the MRCI Index in our \nstudy, to inform the prioritization of medications according \nto their risks and benefits for each patient. In addition, efforts \nto promote public health and multidisciplinary initiatives, \nbehavioral changes, and prevention aimed at reducing \npolypharmacy and MRCI should be investigated.\nAdditional studies are needed to establish its power and \nfor revealing possible opportunities for clinical intervention to \nreduce MRCI as a risk factor for nonadherence and its conse -\nquence in the use of health resources, including hospitaliza -\ntions, are proposed.\nIn conclusion, the concept of polypharmacy should \ninclude not only the number of prescribed drugs but also the \ncomplexity of them. The findings of this study provide evidence \nand clarification of the best cutoff value for the MRCI that \nshould be used to identify HIV+ older patient at possible risk \nof polypharmacy .\nFUNDING\nNone to declare.\nCONFLICTS OF INTEREST\nThe authors declare that they have no conflicts of interest\nREFERENCES\n1.  Tseng A, Szadkowski L, Walmsley S, Salit I, Raboud J. \nAssociation of Age With Polypharmacy and Risk of Drug \nInteractions With Antiretroviral Medications in HIV-\nPositive Patients. Ann Pharmacother. 2013;47:1429\u201339. \ndoi:10.1177/1060028013504075.\n2.  High KP, Brennan-Ing M, Clifford DB, Cohen MH, \nCurrier J, Deeks SG, et al. HIV and Aging. JAIDS J Acquir \nImmune Defic Syndr. 2012;60:S1\u201318. doi:10.1097/\nQAI.0b013e31825a3668.\n3.  van Sighem AI, Gras LAJ, Reiss P, Brinkman K, de \nWolf F, ATHENA national observational cohort study. \nLife expectancy of recently diagnosed asymptomatic \nHIV-infected patients approaches that of uninfected \nindividuals. AIDS. 2010;24:1527\u201335. doi:10.1097/\nQAD.0b013e32833a3946.\n4.  Edelman EJ, Gordon KS, Glover J, McNicholl IR, Fiellin \nDA, Justice AC. The next therapeutic challenge in \nHIV: polypharmacy. Drugs Aging. 2013;30:613\u201328. \ndoi:10.1007/s40266-013-0093-9.\n5.  Gimeno-Gracia M, Crusells-Canales MJ, Javier Armesto-\nG\u00f3mez F, Rabanaque-Hern\u00e1ndez MJ. Prevalence of \nconcomitant medications in older HIV+ patients and \ncomparison with general population. HIV Clin Trials. \n2015;16:117\u201324. doi:10.1179/1528433614Z.0000000012.Determination of a cutoff value for medication regimen complexity index to predict polypharmacy in HIV+ \nolder patientR. Morillo-Verdugo, et al.\nRev Esp Quimioter 2019;32(5): 458-46446428.  Metz KR, Fish DN, Hosokawa PW, Hirsch JD, Libby \nAM. Patient-Level Medication Regimen Complexity in \nPatients With HIV. Ann Pharmacother. 2014;48:1129\u201337. \ndoi:10.1177/1060028014539642.\n29.  Manzano-Garc\u00eda M, Robustillo-Cort\u00e9s A, Almeida-\nGonz\u00e1lez C V, Morillo-Verdugo R. [Evolution of the \nComplexity Index of the antiretroviral therapy in HIV+ \npatients in a real life clinical practice]. Rev Esp Quimioter. \n2017;30:429\u201335. PMID: 29115368. \n30.  Schafer JJ, Gill TK, Sherman EM, McNicholl IR. ASHP \nGuidelines on Pharmacist Involvement in HIV Care. Am \nJ Health Syst Pharm. 2016;73:468\u201394. doi:10.2146/\najhp150623.\n31.  Haro M\u00e1rquez C, Cantudo Cuenca MR, Almeida Gonz\u00e1lez \nCV, Morillo Verdugo R. [Patients\u2019adherence-related beliefs \nabout medicines prescribed for long-term conditions in \nHIV patients]. Farm Hosp. 2015;39:23\u20138. doi:10.7399/\nfh.2015.39.1.8127.\n32.  Corless IB, Hoyt AJ, Tyer-Viola L, Sefcik E, Kemppainen \nJ, Holzemer WL, et al. 90-90-90-Plus: Maintaining \nAdherence to Antiretroviral Therapies. AIDS Patient Care \nSTDS. 2017;31:227\u201336. doi:10.1089/apc.2017.0009.\n33.  Hirsch JD, Metz KR, Hosokawa PW, Libby AM. Validation \nof a patient-level medication regimen complexity index \nas a possible tool to identify patients for medication \ntherapy management intervention. Pharmacotherapy. \n2014;34:826\u201335. doi:10.1002/phar.1452.\n34.  Wimmer BC, Cross AJ, Jokanovic N, Wiese MD, George \nJ, Johnell K, et al. Clinical Outcomes Associated with \nMedication Regimen Complexity in Older People: A \nSystematic Review. J Am Geriatr Soc. 2017;65:747\u201353. \ndoi:10.1111/jgs.14682.\n35.  Nozza S, Malagoli A, Maia L, Calcagno A, Foc\u00e0 E, De Socio \nG, et al. Antiretroviral therapy in geriatric HIV patients: \nthe GEPPO cohort study. J Antimicrob Chemother. 2017. \ndoi:10.1093/jac/dkx169.\n36.  Guaraldi G, Brothers TD, Zona S, Stentarelli C, Carli F, \nMalagoli A, et al. A frailty index predicts survival and \nincident multimorbidity independent of markers of HIV \ndisease severity. AIDS. 2015;29:1633\u201341. doi:10.1097/\nQAD.0000000000000753.complexity. J Acquir Immune Defic Syndr. 2007;45:535\u2013\n44. doi:10.1097/QAI.0b013e31811ed1f1.\n17.  George J, Phun Y-T, Bailey MJ, Kong DC, Stewart K. \nDevelopment and Validation of the Medication Regimen \nComplexity Index. Ann Pharmacother. 2004;38:1369\u201376. \ndoi:10.1345/aph.1D479.\n18.  Libby AM, Fish DN, Hosokawa PW, Linnebur SA, \nMetz KR, Nair K V, et al. Patient-level medication \nregimen complexity across populations with chronic \ndisease. Clin Ther. 2013;35:385-398.e1. doi:10.1016/j.\nclinthera.2013.02.019.\n19.  Pantuzza LL, Ceccato M das GB, Silveira MR, Junqueira \nLMR, Reis AMM. Association between medication \nregimen complexity and pharmacotherapy adherence: a \nsystematic review. Eur J Clin Pharmacol. 2017;73:1475\u2013\n89. doi:10.1007/s00228-017-2315-2.\n20.  Knobel H, Alonso J, Casado JL, Collazos J, Gonz\u00e1lez J, Ruiz \nI, et al. Validation of a simplified medication adherence \nquestionnaire in a large cohort of HIV-infected patients: \nthe GEEMA Study. AIDS. 2002;16:605\u201313. PMID: \n11873004.\n21.  Morisky DE, Green LW, Levine DM. Concurrent and \npredictive validity of a self-reported measure of \nmedication adherence. Med Care. 1986;24:67\u201374. PMID: \n3945130. \n22.  Calder\u00f3n-Larra\u00f1aga A, Gimeno-Feliu LA, Gonz\u00e1lez-Rubio \nF, Poblador-Plou B, Lairla-San Jos\u00e9 M, Abad-D\u00edez JM, \net al. Polypharmacy patterns: unravelling systematic \nassociations between prescribed medications. PLoS One. \n2013;8:e84967. doi:10.1371/journal.pone.0084967.\n23.  Prados-Torres A, Poblador-Plou B, Calder\u00f3n-Larra\u00f1aga A, \nGimeno-Feliu LA, Gonz\u00e1lez-Rubio F, Poncel-Falc\u00f3 A, et \nal. Multimorbidity Patterns in Primary Care: Interactions \namong Chronic Diseases Using Factor Analysis. PLoS One. \n2012;7:e32190. doi:10.1371/journal.pone.0032190.\n24.  Universidad de Colorado. Electronic Data Capture and \nCoding Tool for Medication Regimen Complexity. http://\nwww.ucdenver.edu/academics/colleges/pharmacy/\nResearch/researchareas/Pages/MRCTool.aspx.\n25.   Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF. \nYouden Index and optimal cut-point estimated from \nobservations affected by a lower limit of detection. Biom \nJ. 2008;50:419\u201330. doi:10.1002/bimj.200710415.\n26.  McNicholl IR, Gandhi M, Hare CB, Greene M, Pierluissi \nE. A Pharmacist-Led Program to Evaluate and Reduce \nPolypharmacy and Potentially Inappropriate Prescribing \nin Older HIV-Positive Patients. Pharmacotherapy. \n2017;37:1498\u2013506. doi:10.1002/phar.2043.\n27.  Scott Sutton S, Magagnoli J, Hardin JW. Impact of Pill \nBurden on Adherence, Risk of Hospitalization, and Viral \nSuppression in Patients with HIV Infection and AIDS \nReceiving Antiretroviral Therapy. Pharmacotherapy. \n2016;36:385\u2013401. doi:10.1002/phar.1728.Rev Esp Quimioter 2019;32(5): 465-468465\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Listeria monocytogenes . La CMI de ampicilina y ceftriaxona se \ndeterminaron mediante el m\u00e9todo de microdiluci\u00f3n en caldo. \nLa sinergia se evalu\u00f3 mediante un ensayo en damero y el m\u00e9to -\ndo de curvas de tiempo-muerte.\nResultados. Las seis cepas de L. monocytogenes  fueron \nsensibles a ampicilina (CMI 0,25-0,5 mg/L). Se demostr\u00f3 una \nsinergia bacteriost\u00e1tica mediante un \u00edndice FIC de 0,5 y una \nreducci\u00f3n de 2,5 log10 UFC para concentraciones CMI de ampi -\ncilina m\u00e1s 16 mg/L de ceftriaxona en las seis cepas estudiadas.\nConclusiones. La asociaci\u00f3n de ceftriaxona con ampicili -\nna aumenta la actividad in vitro de ampicilina y, por lo tanto, \npodr\u00eda ser una opci\u00f3n valiosa en el tratamiento de la infecci\u00f3n \ninvasiva por L. monocytogenes .\nPalabras clave: ceftriaxona, ampicilina, sinergia, Listeria, SNC.\nINTRODUCTION\nInvasive infection by Listeria monocytogenes  presents a \nhigh mortality [1], which could be attributed to that the disease \nusually affects patients who present malignancies or immuno -\nsuppressive comorbidities [2, 3], together with that the penicil -\nlins have no bactericidal activity against L. monocytogenes  [4, \n5]. Based on the above, the enhancement of the bactericidal ef -\nfect of ampicillin could play an important role in the success of \nthe antimicrobial treatment, mainly when the infection affects \nthe Central Nervous System (CNS), where ampicillin levels can \nbe very variable and could be close to peri-MIC values along the \ndose interval [6, 7].\nRecent studies have shown the effectiveness of ampicil -\nlin-ceftriaxone combination for the treatment of endocardi -\ntis due to Enterococcus faecalis  [8]. L. monocytogenes  and E. \nfaecalis  share some characteristics regarding their antibiotic \nsusceptibility, such as the activity of ampicillin is bacteriostatic, \nand they are both resistant to ceftriaxone. The previous anti -\nbiotic combination could be also effective against L. monocy -\ntogenes improving the bactericidal activity of ampicillin. ABSTRACT\nObjectives.  To evaluate if the in vitro  activity of ampicillin \nincreases when combined with ceftriaxone.\nMaterial and methods.  The activity of ampicillin and \nceftriaxone was evaluated against six Listeria monocytogenes  \ninvasive clinical isolates. Ampicillin and ceftriaxone MICs were \ndetermined by the broth microdilution method. Synergy was \nevaluated by checkerboard and time-kill curves methods.\nResults . All six L. monocytogenes  strains were susceptible \nto ampicillin (MICs 0.25-0.5 mg/L). A bacteriostatic synergy was \ndemonstrated by the FIC index of 0.5 and a 2.5 log10 CFU reduc -\ntion on the six strains studied for MIC ampicillin plus 16 mg/L \nceftriaxone concentrations.\nConclusions.  The association of ceftriaxone with ampicil -\nlin increases the in vitro  activity of ampicillin, and therefore \ncould be a valuable option in the treatment of invasive infec -\ntion by L. monocytogenes .\nKeywords: ceftriaxone, ampicillin, synergy, Listeria, CNS.\nEstudio in vitro  de la sinergia de ampicilina con \nceftriaxona frente a Listeria monocytogenes\nRESUMEN\nObjetivo. Evaluar si la actividad in vitro  de ampicilina au -\nmenta cuando se combina con ceftriaxona.\nMaterial y m\u00e9todos. La actividad de la ampicilina y la \nceftriaxona se evalu\u00f3 frente a seis aislados cl\u00ednicos invasivos de In vitro  study of synergy of ampicillin with \nceftriaxone against Listeria monocytogenes\nClinical Unit of Infectious Diseases, Microbiology and Preventive Medicine. Institute of Biomedicine of Seville (IBiS), Uni -\nversity Hospital Virgen del Roc\u00edo/CSIC/University of Seville, Seville, SpainJos\u00e9 Antonio Lepe\n\u00c1ngel Rodr\u00edguez-Villodres\nGuillermo Mart\u00edn-Guti\u00e9rrez\nRafael Luque\nJavier Aznar\nCorrespondence:\nJos\u00e9 A. Lepe\nHospital Universitario Virgen del Roc\u00edo. Avda. Manuel Siurot s/n. 41013 Seville. Spain.\nPhone: +34-955013203\nE-mail: jalepe@cica.esBrief report\nArticle history\nReceived: 3 February 2019; Revision Requested: 28 May 2019; Revision Received: 1 June 2019; Accepted: 12 June 2019In vitro  study of synergy of ampicillin with ceftriaxone against Listeria monocytogenes J. A. Lepe , et al.\nRev Esp Quimioter 2019;32(5): 465-468466CAMHB-LHB according to CLSI methodology [12]. The assays \nwere performed in duplicate on all 6 strains in the presence of \nampicillin and ceftriaxone concentrations, alone and in combi -\nnation, previously identified as synergistic by the checkerboard \nassay. Bacterial counts were determined in duplicate at 3, 6 and \n24 hours of incubation. Synergy was defined as a 2-log10 de-\ncrease in the colony count at 24h with the combination com -\npared to that of the most active single agent [13].\nKilling-curves were modeled and studied by GraphPad -\nPrism 5.0 software (\u00a9 2014 GraphPad Software. Inc), using \nmean (+/- S.D.) values.\nRESULTS\nAll six L. monocytogenes strains were susceptible to am -\npicillin with MICs values ranging from 0.25-0.5 mg/L and the \nceftriaxone MIC value was 64 mg/L in all three strains tested \n(table 1). \nA bacteriostatic synergy effect of ampicillin association \nwith ceftriaxone was demonstrated by checkerboard and \ntime-killing curves methods.\n-Checkerboard assay: a bacteriostatic synergy was ob -\nserved with FIC index values of 0.49, was observed when the \nMIC concentrations of ampicillin are combined with a concen -\ntration of 16 mg/L of ceftriaxone. For lower ceftriaxone con -\ncentrations, the effect was additive (4-8 mg/L) or indifferent \n(\u22642 mg/L) (table 1). \n-Time-kill assay: a bacteriostatic synergy was observed at \nMIC concentrations of ampicillin plus 16 mg/L concentration \nof ceftriaxone, demonstrating that the association produces a The main objective of this study is to explore the possibility \nthat ampicillin in combination with ceftriaxone could increase \nits bactericidal activity, which could bring advantages in the \ntreatment of invasive diseases, mainly at the CNS level.\nMATERIAL AND METHODS \nBacterial isolates.  The activity of ampicillin and ceftriax -\none was evaluated against six L. monocytogenes  invasive clin -\nical isolates belonging to different PFGE types and serotypes: \n2 isolates 1/2a (LMP62 y LMP52), 2 isolates 1/2b (LMP22 y \nLMP42), and 2 isolates 4b (LMP43 y LMP36), which were isolat -\ned from CSF samples. \nAntimicrobial susceptibility testing . MICs of ampicillin \nand ceftriaxone were determined by the broth microdilution \nmethod in cation-adjusted Mueller Hinton broth with 5% lysed \nhorse blood (CAMHB-LHB) based on The Clinical & Laboratory \nStandards Institute (CLSI) criteria [9].\nSynergy studies.  Static synergy was evaluated by the \ncheckerboard assay in CAMHB-LHB in accordance to the \nAmerican Society for Microbiology recommendations [10]. The \nassays were performed in duplicate on all 6 strains, twofold \nserial dilutions of ampicillin (0,015-8 mg/L) and ceftriaxone \n(0,25-128 mg/L) were individually tested and in all possible \ncombinations of drug concentrations. Checkerboard synergy \nand non-synergy were defined by the fractional inhibitory con -\ncentration index (FICI): FICI \u22640.5 defined as synergy and FICI \n>0.5 as non-synergy (>0.5 to \u22641: additive and >1 to \u22644: indif -\nference) [11].\nThe dynamic synergy was studied by time-killing curves in \nMicrodilution Method Checkerboard Assay\nMIC (mg/L) MIC (mg/L) FIC index\nStrains AMP AMP+CAX CAX CAX+AMP Value Interpretation\n1/2a LMP220.25 0.06 64 16 0.49 Synergism\n0.25 0.125 64 8 0.62 Additive\n1/2a LMP420.5 0.125 64 16 0.49 Synergism\n0.5 0.25 64 8 0,62 Additive\n1/2b LMP530.25 0.06 64 16 0.49 Synergism\n0.25 0.125 64 8 0.62 Additive\n1/2b LMP620.25 0.06 64 16 0.49 Synergism\n0.25 0.125 64 8 0.62 Additive\n4b LMP380.5 0.125 64 16 0.49 Synergism\n0.5 0.25 64 8 0.62 Additive\n4b LMP430.5 0.125 64 16 0.49 Synergism\n0.5 0.25 64 8 0.62 AdditiveTable 1  Antibiotic susceptibility of L. monocytogenes  strains to \nampicillin (AMP) and ceftriaxone (CAX) by the microdilution \nand checkerboard methods.In vitro  study of synergy of ampicillin with ceftriaxone against Listeria monocytogenes J. A. Lepe , et al.\nRev Esp Quimioter 2019;32(5): 465-468467while aminoglycosides although they show an effective and \nrapid extracellular destruction, are not active intracellularly \n[19].\nCeftriaxone levels of 16 mg/L can be achieved in CSF. Even \nthough ceftriaxone penetrates poorly into CSF with uninflamed \nmeninges, clinical experience clearly shows that the drug dif -\nfuses well into the CSF of patients with bacterial meningitis, \nafter a single 100 mg/kg dose, at two hours after dosing, mean \nCSF concentrations were 20 mg/L [20]. In another study, in pa -\ntients with meningitis, the levels ranged from 0.85 to 18.29 \nmg/L for 4 g/day ceftriaxone dose [21]. Also, the French guide -\nline for meningitis treatment, unlike the American and Europe -\nan guidelines, recommends the prescription of a high concen -\ntrations of ceftriaxone (100 mg/kg/day) without limitation of \nthe dose [22]. Although these studies show a certain inter-in -\ndividual variability, many patients could benefit from this win -\ndow of high concentration of ceftriaxone, which could suppose \na not expected therapeutic advantage in many patients.\nThe combination is safe from the clinical point of view, \nsince the ceftriaxone plus ampicillin (and vancomycin) associa -\ntion is the recommended empirical treatment of meningitis in \npeople older than 50 years. [23]. In addition, empirical therapy \nwith cephalosporins does not affect the clinical outcome of \npatients with Listeria  meningitis when ampicillin was subse -\nquently added to treatment [24].\nIn conclusion, our results demonstrate that the association \nof ceftriaxone with ampicillin increases the activity of ampicil -\nlin, and therefore could be a valuable option in the treatment \nof invasive infection by L. monocytogenes , especially when \nthe CNS is compromised. Animal models and clinical studies \nshould have to evaluate whether ceftriaxone associated with \nampicillin offers a real and successful alternative of listeriosis \ntreatment.log10 CFU reduction of 2.5 for the six strains studied taken as a \nwhole; from 6.5 (95% CI: 6.2-6.8) at ampicillin MIC concentra -\ntion alone to 4 (95% CI: 3.7-4.3) when combined with ceftriax -\none 16 mg/L (figure 1).\nDISCUSSION\nThe results obtained from this in vitro study demonstrated \na synergistic effect among ampicillin and 16 mg/L of ceftriax -\none against L. monocytogenes . This effect could be related to a \ncomplementary inhibition of penicillin-binding proteins (PBP) \nby ceftriaxone, that would enhance the ampicillin killing. In \ngeneral, cephalosporins are a good inhibitor of PBP1, PBP2 and \nPBP4 in L. monocytogenes  [14] and the optimal killing by be -\nta-lactams is achieved only when several of the different PBPs \nare blocked [6]. A partial synergistic effect has been previously \nreported using ceftriaxone concentrations of 1-4 mg/L, lower \nthan those of this study of 16 mg/L, which could explain their \nlack of more conclusive results in these studies [15, 16].\nTo define the clinical relevance of these in vitro  results can \nbe difficult. However, from this study derive a series of consid -\nerations that could support its use in clinical practice.\nThis synergistic effect significantly improves the activity \nof ampicillin, very desirable aspect in the treatment of septic \npatients with underlying disease.\nThis combination may have pharmacokinetics advantages \nover the recommended ampicillin plus gentamicin association \nin invasive listeriosis [17], since gentamicin does not pene -\ntrate the CNS to achieve therapeutically useful concentrations. \nBased on the above, this combination does not provide a defi -\nnite clinical advantage over an aminopenicillin alone [18]. In \naddition, ceftriaxone is one of the cephalosporins with better \nintracellular penetration within phagocytic cells (30 to 40%), Figure 1  Log10 reduction (mean and SD) of bacterial growth of L. monocytogenes  \nobtained by time-killing curves with: 1xMIC concentration of ampicillin \n(AMP), 16 mg/L of ceftriaxone (CAX), and the combination of both \nantibiotics (AMP+CAX) against six strains studied taken as a whole.\nIn vitro  study of synergy of ampicillin with ceftriaxone against Listeria monocytogenes J. A. Lepe , et al.\nRev Esp Quimioter 2019;32(5): 465-46846814. Vicente MF, Perez-D\u00edaz JC, Baquero F Angel de Pedro M, Berenguer \nJ. Penicillin-binding protein 3 of Listeria monocytogenes  as the pri -\nmary lethal target for beta-lactams. Antimicrob Agents Chemother \n1990; 34:539-42. doi: 10.1128/aac.34.4.539\n15. Hoogkamp-Korstanje JA. Activity of cefotaxime and ceftriaxone \nalone and in combination with penicillin, ampicillin and piperacillin \nagainst neonatal meningitis pathogens. J Antimicrob Chemother \n1985; 16:327-34. doi: 10.1093/jac/16.3.327\n16. Kumaraswamy M, Do C, Sakoulas G, Tseng GW, King H. Listeria \nmonocytogenes  endocarditis: case report, review of the literature, \nand laboratory evaluation of potential novel antibiotic synergies. \nInt J Antimicrob Agents 2018; 51:468-78. doi: 10.1016/j.ijantimi -\ncag.2017.12.032.\n17. Hof H. An update on the medical management of lister -\niosis. Expert Opin Pharmacother. 2004; 5:1727-35. doi: \n10.1517/14656566.5.8.1727\n18. Hof H. Chemotherapy of Listeria  infections. GMS Infect Dis. 2013; \n1:1\u201310. doi: 10.3205/id000006\n19. Kuhn H, Angehrn P, Havas L. Autoradiographic evidence for pen -\netration of 3H-ceftriaxone (Rocephin) into cells of spleen, liv -\ner and kidney of mice. Chemotherapy. 1986;32:102-12. doi: \n10.1159/000238398\n20. Scheld WM, Rocha H, Sande MA, Bryan JP. Rationale for clinical \ntrials evaluating ceftriaxone in the therapy of bacterial meningitis. \nAm J Med. 1984;77(4C):42-9. PMID: 6093518\n21. Navas D, Deslandes G, Dailly E, Caillon A, Chiffoleau G, Potel V et \nal. Prescription of high dose of ceftriaxone for treatment of men -\ningitis: is therapeutic drug monitoring useful? A cohort study. In: \nAbstracts of the European Congress of Clinical Microbiology and \nInfectious Diseases, London, United Kingdom. Abstract P1614, p. \n441. Clin Microbiol Infect 2012;18: 114-715.\n22. Soci\u00e9t\u00e9 de pathologie infectieuse de langue fran\u00e7aise (SPILF). Prac -\ntice guidelines for acute bacterial meningitidis (except newborn \nand nosocomial meningitis). Med Mal Infect 2009; 39:356-67. \nPMID: 19645087\n23. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld \nWM et al. Practice guidelines for the management of bacterial \nmeningitis. Clin Infect Dis. 2004;39:1267-84. doi: 10.1086/425368\n24. Cherubin CE, Appleman MD, Heseltine PN, Khayr W, Stratton CW. \nEpidemiological spectrum and current treatment of listeriosis. Rev \nInfect Dis 1991; 13:1108-14. doi: 10.1093/clinids/13.6.1108FUNDING\nNone to declare.\nCONFLICTS OF INTEREST\nThe authors declare that they have no conflicts of interest\nREFERENCES\n1. Charlier C, Perrodeau \u00c9, Leclercq A, Cazenave B, Pilmis B, Henry \nB et al. Clinical features and prognostic factors of listeriosis: the \nMONALISA national prospective cohort study. Lancet Infect Dis. \n2017;17:510-519. doi: 10.1016/S1473-3099(16)30521-7.\n2. Ramsakal A, Nadaminti H, Field T, Vincent AL, Greene J, Dass VL et \nal. Listeria  infections in cancer patients. Infect Med 2004; 21:345-9.\n3. Allerberger F, Wagner M. Listeriosis: a resurgent foodborne infec -\ntion. Clin Microbiol Infect 2010; 16:16\u201323. doi: 10.1111/j.1469-\n0691.2009.03109.x.\n4. Hof H. Therapeutic activities of antibiotics in listeriosis. Infection \n1991;19 (suppl. 4): S229-33.\n5. Marget W, Seeliger HPR. Listeria monocytogenes : therapeutic pos -\nsibilities and problems. Infection 1988; 16 (suppl. 2): 175-7.\n6. Hof H, Nichterlein T, Kretschmar M. Management of listeriosis. Clin \nMicrobiol Rev 1997; 10:345\u201357. PMID: 9105758\n7. Chanteux H, Mingeot-Leclercq MP, Sonveaux E, Van Bambeke F, \nTulkens PM. Intracellular accumulation and activity of ampicillin \nused as free drug and as its phthalimidomethyl or pivaloylox -\nymethyl ester (pivampicillin) against Listeria monocytogenes  in \nJ774 macrophages. J Antimicrob Chemother 2003; 5:610-5. doi: \n10.1093/jac/dkg431\n8. Gavalda J, Torres C, Tenorio C, L\u00f3pez P, Zaragoza M, Capdevila JA \net al. Efficacy of ampicillin plus ceftriaxone in treatment of exper -\nimental endocarditis due to Enterococcus faecalis  strains highly \nresistant to aminoglycosides. Antimicrob Agents Chemother 1999; \n43:639-46. PMID: 10049280\n9. Clinical and Laboratory Standards Institute. Methods for Antimi -\ncrobial Dilution and Disk Susceptibility Testing of Infrequently Iso -\nlated or Fastidious Bacteria-Third Edition: Approved Standard M45. \nCLSI, Wayne, PA, USA, 2016.\n10. Garcia L. Synergism Testing: Broth Microdilution Checkerboard and \nBroth Macrodilution Methods. In: Leber AL, ed. Clinical Microbiolo -\ngy Procedures Handbook. Washington: ASM Press, 2010;140-62.\n11. Odds FC. Synergy, antagonism, and what the chequerboard puts \nbetween them. J Antimicrob Chemother 2003; 52:1. doi: 10.1093/\njac/dkg301\n12. Clinical and Laboratory Standards Institute. Methods for Determin -\ning Bactericidal Activity of Antimicrobial Agents. Approved Stand -\nard M26-A. CLSI, Wayne, PA, USA, 1999.\n13. Eliopoulos GM, Moellering RC. Antimicrobial combinations. In: Lo -\nrian V. ed. Antibiotics in Laboratory Medicine. Baltimore: The Wil -\nliams & Wilkins Co, 1996;330-96.Rev Esp Quimioter 2019;32(5): 469-472469\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).de abscesos, que incluy\u00f3 la siembra en medios de cultivo selec -\ntivos y no selectivos, en atm\u00f3sfera de CO2 y anaerobiosis. \nPara el estudio de los procesos cl\u00ednicos publicados, relacio -\nnados con esta bacteria, se localizaron los art\u00edculos generados \nen la base de datos MEDLINE en una b\u00fasqueda abierta, hasta \ndiciembre de 2018, con las palabras clave \u201c Gardnerella vagina -\nlis\u201d. As\u00ed se obtuvieron 1.620 publicaciones. Posteriormente, se \nseleccionaron, tras su revisi\u00f3n manual, los estudios publicados \nen los que se se\u00f1al\u00f3 la acci\u00f3n pat\u00f3gena por esta bacteria en \ncasos de infecci\u00f3n profunda en hombres. Esto condujo a la se -\nlecci\u00f3n de 10 trabajos cient\u00edficos. \nEl caso cl\u00ednico correspondi\u00f3 a un var\u00f3n de 67 a\u00f1os, con \nantecedentes personales de trastorno bipolar controlado y \nresecci\u00f3n transuretral, por un tumor urotelial vesical T1, de \nalto grado, hace a\u00f1os, sin revisiones posteriores por Urolog\u00eda. \nAcude al servicio de Urgencias porque sufri\u00f3 4 d\u00edas antes un \ntraumatismo en fosa renal izquierda que posteriormente co -\nmenz\u00f3 con dolor en esa localizaci\u00f3n, hematuria macrosc\u00f3pi -\nca intermitente, malestar general con escalofr\u00edos y deterioro \nprogresivo. En la exploraci\u00f3n, el paciente present\u00f3 un estado \ngeneral deteriorado, con tendencia a la hipotensi\u00f3n y taqui -\ncardia, sin fiebre, oliguria, y con una pu\u00f1o-percusi\u00f3n renal iz -\nquierda positiva. Anal\u00edticamente destacaban una creatinina de \n2,53 mg/dL, prote\u00edna C reactiva de 215 mg/L, hemoglobina de \n10,4 g/dL y 25.740 leucocitos/\u03bcL. Se le realiz\u00f3 un TAC sin con -\ntraste, que mostraba uretero-hidronefrosis izquierda de grado \n4, que podr\u00eda estar en relaci\u00f3n con una estenosis de la uni\u00f3n \nur\u00e9tero-vesical izquierda, con contenido ecog\u00e9nico, dentro del \nmencionado sistema excretor, que podr\u00eda corresponder con \nrestos hem\u00e1ticos o material purulento. Dado el estado del pa -\nciente, se inici\u00f3 tratamiento con imipenem y se ingres\u00f3 a cargo \ndel servicio de Urolog\u00eda para realizar una punci\u00f3n percut\u00e1nea \ny colocaci\u00f3n de nefrostom\u00eda izquierda, que se realiz\u00f3 sin in -\ncidencias. En la punci\u00f3n se obtuvo material purulento que se \nmand\u00f3 a cultivar. Tras 48 horas de incubaci\u00f3n en CO2 crecie -\nron colonias abundantes y \u00fanicas en el medio de agar sangre \n(Becton-Dickinson, Barcelona, Espa\u00f1a) que se identificaron co -Sr. Editor:  Gardnerella vaginalis  es un bacilo gramvaria -\nble, anaerobio facultativo e inm\u00f3vil, que carece de endosporas \ny c\u00e1psula. Su reservorio principal lo constituyen los genitales \nfemeninos, pudiendo encontrarse en enfermos y portadores \nsanos. Es un microorganismo que se asocia cl\u00ednicamente a la \nvaginosis bacteriana (VB) [1, 2], pero tambi\u00e9n se ha encontrado \nen exudados de heridas en cirug\u00edas p\u00e9lvicas, exudados endo -\ncervicales en mujeres con rotura prematura de membranas, \ncorioamnionitis, fiebre posparto y bacteriemia en neonatos [2, \n3]. Sin embargo, a pesar de su frecuente relaci\u00f3n con los geni -\ntales femeninos y su patolog\u00eda, se han encontrado otras posi -\nbles infecciones por G. vaginalis . As\u00ed, se han descrito casos de \ninfecciones del tracto urinario, balanitis, uretritis y hasta pros -\ntatitis cr\u00f3nica en el hombre [3], y otras infecciones extrageni -\ntales, tanto en mujeres como en hombres [4, 5]. La descripci\u00f3n \nde nuevas infecciones se ve facilitada por la introducci\u00f3n de \nla espectrometr\u00eda de masas, MALDI-TOF, en los laboratorios de \nMicrobiolog\u00eda Cl\u00ednica, ya que permite identificar con facilidad \neste microorganismo. El tratamiento de las infecciones por G. \nvaginalis  no est\u00e1 bien establecido, sobre todo fuera del tracto \ngenial femenino. Se ha demostrado la actividad de metroni -\ndazol, siendo el tratamiento de elecci\u00f3n, y teniendo como al -\nternativas clindamicina, amoxicilina-clavul\u00e1nico, vancomicina \no ampicilina [6].  Dada la rareza de las infecciones profundas \nen el var\u00f3n describimos la participaci\u00f3n de G. vaginalis  como \nagente productor de infecci\u00f3n renal en el hombre y se revisa la \npatolog\u00eda infecciosa descrita hasta el momento. \nPresentamos un caso cl\u00ednico de infecci\u00f3n profunda, rela -\ncionado con el aislamiento en nuestro Laboratorio de Micro -\nbiolog\u00eda del Hospital Virgen de las Nieves de Granada, median -\nte el procedimiento normalizado de trabajo para las muestras Infecciones profundas por Gardnerella vaginalis  en \nel var\u00f3n. Revisi\u00f3n de la literatura y a prop\u00f3sito de \nun caso\n1Departamento de Microbiolog\u00eda, Facultad de Medicina, Universidad de Granada- Instituto de Investigaci\u00f3n Biosanitaria \nde Granada. Granada. \n2Servicio de Urolog\u00eda, Hospital Universitario Virgen de las Nieves- Instituto de Investigaci\u00f3n Biosanitaria de Granada. \nGranada.\n3Servicio de Microbiolog\u00eda, Hospital Universitario Virgen de las Nieves- Instituto de Investigaci\u00f3n Biosanitaria de Grana -\nda. Granada.M\u00aa Lara Ruiz-G\u00f3mez1\nDavid Alejandro Mart\u00edn-\nWay2\nMaria Dolores P\u00e9rez-\nRam\u00edrez3\nJos\u00e9 Guti\u00e9rrez-Fern\u00e1ndez1,3\nCorrespondencia:\nJos\u00e9 Guti\u00e9rrez-Fern\u00e1ndez. \nServicio de Microbiolog\u00eda. Hospital Universitario Virgen de las Nieves.\nAvenida de las Fuerzas Armadas, 2. E-18012 Granada, Espa\u00f1a. \nE-mail: josegf@ugr.esCarta al Director\nArticle history\nReceived: 19 March 2019; Revision Requested: 19 April 2019; Revision Received: 7 July 2019; Accepted: 17 July 2019Infecciones profundas por Gardnerella vaginalis  en el var\u00f3n. Revisi\u00f3n de la literatura y a prop\u00f3sito de un caso M\u00aa L. Ruiz-G\u00f3mez, et al.\nRev Esp Quimioter 2019;32(5): 469-472470to de Candida kefyr  y el antifungigrama, realizado mediante \nE-test, mostr\u00f3 los siguientes valores de CMI: anfotericina B \n(0,25 mg/L), caspofungina (0,25 mg/L), fluconazol (1 mg/L), mi -\ncafungina (0,12 mg/L), voriconazol (0,12 mg/L), siendo inter -\npretados como sensibles anfotericina B y fluconazol. Entonces \nse a\u00f1adi\u00f3 al tratamiento fluconazol. A las 48 horas del inicio \ndel tratamiento antif\u00fangico el paciente estaba afebril y evo -\nlucion\u00f3 posteriormente de forma favorable. Se realiz\u00f3 un TAC \nde control, que inform\u00f3 que persist\u00eda la uretero-hidronefrosis \nizquierda grado 4, con el par\u00e9nquima renal muy atrofiado, y \ncon el cat\u00e9ter de nefrostom\u00eda bien colocado. Se realiz\u00f3 una cis -\ntoscopia que descart\u00f3 una recidiva tumoral vesical. Finalmen -\nte, dada la escasa funcionalidad del ri\u00f1\u00f3n izquierdo, se decidi\u00f3 \nrealizar una nefrectom\u00eda simple izquierda. El paciente no sufri\u00f3 \nninguna otra complicaci\u00f3n relacionada con su patolog\u00eda infec -\nciosa, y evolucion\u00f3 de forma favorable siendo dado de alta diez \nd\u00edas tras la cirug\u00eda.\nLa mayor\u00eda de las infecciones urinarias son provocadas, en \nambos sexos, por microorganismos gramnegativos ( Escherichia \ncoli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomona rrectamente mediante MALDI-TOF (Bruker Biotyper, Billerica, \nMA, USA), con un score 2,103, como G. vaginalis . Se estudi\u00f3 su \nsensibilidad mediante el m\u00e9todo de E-test (Biomerieux\u00ae, Ma -\ndrid, Espa\u00f1a) y para la interpretaci\u00f3n se siguieron los puntos \nde corte establecidos por CLSI para anaerobios. Nuestro aislado \nmostr\u00f3 los siguientes valores de CMI que fueron interpreta -\ndos como sensible: amoxicilina-\u00e1cido clavul\u00e1nico (0,125 mg/L), \nclindamicina (0,19 mg/L), metronidazol (8 mg/L) y vancomicina \n(0,38 mg/L). Ante este resultado se a\u00f1adi\u00f3 clindamicina al tra -\ntamiento, administr\u00e1ndose de forma intravenosa cada 8 horas \na dosis de 600 mg.\nDurante los primeros d\u00edas, tras la colocaci\u00f3n de la nefros -\ntom\u00eda, el paciente present\u00f3 mejor\u00eda de su estado general, se \nmantuvo afebril, recuper\u00f3 un ritmo de diuresis normal y pre -\nsent\u00f3 estabilidad hemodin\u00e1mica. Se cambi\u00f3 la antibioterapia \na amoxicilina con \u00e1cido clavul\u00e1nico, 1000/200 mg por v\u00eda in -\ntravenosa cada 8 horas. Sin embargo, accidentalmente, pierde \nel cat\u00e9ter y aparece febr\u00edcula en los d\u00edas posteriores. Se realiz\u00f3 \nnueva punci\u00f3n renal y colocaci\u00f3n de nefrostom\u00eda, con nue -\nva salida de material purulento. El cultivo mostr\u00f3 crecimien -PACIENTE N\u00ba  \n(CITA/A\u00d1O)EDAD FACTORES PREDISPONENTES MANIFESTACIONES CL\u00cdNICAS MUESTRA CL\u00cdNICA TRATAMIENTO M\u00c9TODO DIAGN\u00d3STICO \nMICROBIOL\u00d3GICO\n1 ([12]/1981) 37 Trasplante renal Absceso perinefr\u00edtico en \nri\u00f1\u00f3n trasplantadoHemocultivo y urocultivo.\nBiopsia de abscesoAmpicilina No consta\n2 ([13]/1989) 41 Alcoholemia Absceso pulmonar Aspiraciones broncosc\u00f3picas Metronidazol. \nClindamicinaNo consta\n3 ([14]/1990) 65 Adenoma de pr\u00f3stata Bacteriemia Urocultivo, hemocultivo Gentamicina\nAmoxicilinaNo consta\n4 ([15]/1997) 78 Alcoholemia, S\u00edndrome prost\u00e1tico, \ninfecci\u00f3n del tracto urinario inferior, \ncirug\u00eda de neoplasia pulmonarBacteriemia Urocultivo, \nHemocultivosCefonicid Vitek NHI\n5 ([9]/2005) 50 Fumador Absceso perinefr\u00edtico y \nempiema pleural derechoBiopsia de absceso y \nexudado de empiemaMetronidazol  \nAmoxicilinaAPI CORYNE\n6 ([4]/2008) 41 Ninguno Bacteriemia Hemocultivo y urocultivo Ciprofloxacino Secuenciaci\u00f3n ARNr 16S\n7 ([5]/2010) 39 Diabetes mellitus, hipertensi\u00f3n, \nalcoholemia y promiscuidadPielonefritis, endocarditis Hemocultivos Metronidazol Secuenciaci\u00f3n ARNr 16S\n8 ([16]/2013) 61 Diabetes mellitus, hipertensi\u00f3n, \nsobrepeso, cirug\u00eda digestiva tumoralBacteriemia Coprocultivo y hemocultivos Metronidazol MALDI-TOF \nRapid ID 32 Strep (BioM\u00e9rieux)\n9 ([17]/2015) 36 Ninguno Uretritis y Bacteriemia Urocultivos, hemocultivos Ciprofloxacino\nAzitromicina\nCeftriaxonaBacT/ALERT 3D System (BioM\u00e9rieux)\nMALDI-TOF\n10 ([18]/2018) 51 SIDA Bacteriemia Hemocultivos Trimetoprim- \nSulfametoxazol\nCeftriaxona\nMetronidazolMALDI-TOFTabla 1  Principales manifestaciones cl\u00ednicas en los pacientes varones con infecci\u00f3n profunda por Gardnerella vaginalis .Infecciones profundas por Gardnerella vaginalis  en el var\u00f3n. Revisi\u00f3n de la literatura y a prop\u00f3sito de un caso M\u00aa L. Ruiz-G\u00f3mez, et al.\nRev Esp Quimioter 2019;32(5): 469-472471Tambi\u00e9n queda patente la escasa experiencia en el manejo de \nla infecci\u00f3n profunda por G. vaginalis , lo que nos obligar\u00eda a \ndise\u00f1ar estudios patog\u00e9nicos sobre la infecci\u00f3n y la actividad \nde los antibi\u00f3ticos frente a este microorganismo.\nFINANCIACION\nLos autores declaran no haber recibido financiaci\u00f3n para \nla realizaci\u00f3n de este estudio.\nCONFLICTO DE INTERESES\nLos autores declaran no tener ning\u00fan conflicto de inte -\nreses.\nBIBLIOGRAFIA\n1. Carrillo-\u00c1vila J, Serrano-Garc\u00eda M, Fern\u00e1ndez-Parra J, Sorl\u00f3zano-\nPuerto A, Navarro-Mar\u00ed J, Stensvold C, et al. Prevalence and ge -\nnetic diversity of Trichomonas vaginalis  in the general popula -\ntion of Granada and co-infections with Gardnerella vaginalis  and \nCandida species. J Med Microbiol. 2017; 66: 1436-42. doi:10.1099/\njmm.0.000603.\n2. Sorl\u00f3zano-Puerto A, Esteban-Sanch\u00eds P, Heras-Ca\u00f1as V, Fern\u00e1ndez-\nParra J, Navarro-Mari JM, Guti\u00e9rrez-Fern\u00e1ndez J. Estudio prospecti -\nvo de la incidencia de pat\u00f3genos genitales oportunistas y estrictos \nque crecen en medios de cultivo artificiales, Rev Lab Clin. 2018; \n11:123-30. Doi: /10.1016/j.labcli.2017.11.009.\n3. Heras-Ca\u00f1as V, Guti\u00e9rrez-Soto B, Serrano-Garc\u00eda ML, V\u00e1zquez-\nAlonso F, Navarro-Mar\u00ed JM, Guti\u00e9rrez-Fern\u00e1ndez, J. Prostatitis cr\u00f3 -\nnica bacteriana. Estudio cl\u00ednico y microbiol\u00f3gico de 332 casos. Med \nClin. 2016; 147: 144-7. doi: /10.1016/j.medcli.2016.05.018.\n4. Lagac\u00e9-Wiens PR, Ng B, Reimer A, Burdz T, Wiebe D, Bernard K. \nGardnerella  vaginalis  bacteremia in a previously healthy man: case \nreport and characterization of the isolate. J Clin Microbiol. 2008; \n46: 804-6. doi: 10.1128/JCM.01545-07.\n5. Yoon HJ, Chun J, Kim JH, Kang SS, Na DJ. Gardnerella vaginalis  \nsepticaemia with pyelonephritis, infective endocarditis and septic \nemboli in the kidney and brain of an adult male. Int J STD AIDS. \n2010; 21:653-7. doi: 10.1258/ijsa.2010.009574.\n6. Mensa Pueyo J. Gu\u00eda de terap\u00e9utica antimicrobiana. 2018. 28th ed. \nAntares, p.382.\n7. S\u00e1nchez-Garc\u00eda JM, Sorl\u00f3zano-Puerto A, Navarro-Mar\u00ed JM, Gu -\nti\u00e9rrez Fern\u00e1ndez J. Evoluci\u00f3n de la resistencia a antibi\u00f3ticos de \nmicroorganismos causantes de infecciones del tracto urinario: \nun estudio de vigilancia epidemiol\u00f3gica de 4 a\u00f1os en pobla -\nci\u00f3n hospitalaria. Rev Clin Esp. 2019; 219:116-23. doi: 10.1016/j.\nrce.2018.07.005.\n8. Kline KA, Lewis AL. Gram-positive uropathogens, polymicrobial uri -\nnary tract infection, and the emerging microbiota of the urinary \ntract. Microbiol Spectr. 2016; 4(2). doi: 10.1128/microbiolspec.UTI-\n0012-2012.\n9. Calvert LD, Collins M, Bateman JR. Multiple abscesses caused by aeruginosa,  etc.) y en menor frecuencia por grampositivos \n(Enterococcus spp., Staphylococcus spp., etc.) [7]. En mujeres, \naunque no es frecuente, G. vaginalis  se considera un posible \nuropat\u00f3geno, y hay evidencia de la posible transmisi\u00f3n sexual \na varones [8]. Este hecho puede justificar un aumento de la \nprobabilidad de aislamientos de esta bacteria en cultivos de \norina en varones. Sin embargo, habitualmente, no se investi -\nga su presencia, ya que se ha descrito, cl\u00ednicamente, en raras \nocasiones como causa de infecciones urinarias, aunque puede \nexistir un infradiagn\u00f3stico de la misma. \nUn estudio [4] describi\u00f3 que un 7-11% de los varones \npresentan G. vaginalis  como parte de su flora urogenital y \nanorrectal, pudiendo, potencialmente provocar infecciones de \nestas zonas o ser el punto de origen. Aun as\u00ed, se han descrito \nmuy pocos casos de infecciones urinarias por esta bacteria en \nvarones, y habitualmente se han asociado a factores de riesgo. \nNo obstante, hay algunos casos publicados que describen in -\nfecciones m\u00e1s complejas (tabla 1). Entre los casos descritos de \ninfecci\u00f3n profunda por G. vaginalis  en el var\u00f3n adulto, encon -\ntramos endocarditis infecciosa, acompa\u00f1ada de embolia s\u00e9pti -\nca en ri\u00f1\u00f3n y cerebro [5]; uretritis [17], bacteriemia [4, 14-16, \n18] e, incluso, empiema asociado a absceso perinefr\u00edtico [9]. \nDichas infecciones que tienen lugar fuera del tracto urogeni -\ntal se relacionan, generalmente, con factores de riesgo, como \nel estado de inmunosupresi\u00f3n, anormalidades genitourinarias, \nalcoholismo [10] y relaciones sexuales no protegidas [11]. En \nnuestro conocimiento, se han descrito 10 casos previos de in -\nfecci\u00f3n profunda por G. vaginalis en el var\u00f3n adulto, por lo \nque estamos ante el d\u00e9cimo primer caso descrito. Actualmente \nestamos asistiendo a cambios epidemiol\u00f3gicos en la etiolog\u00eda \nde las infecciones, lo que obligar\u00e1 a una actuaci\u00f3n diagn\u00f3sti -\nca m\u00e1s completa, haciendo peticiones anal\u00edticas m\u00e1s amplias \ny adecuando los procedimientos disponibles a las necesidades \ncl\u00ednicas. \nLa pauta correcta de tratamiento para las infecciones \nprofundas por este microorganismo no est\u00e1 bien establecida. \nAunque G. vaginalis suele ser sensible a m\u00faltiples antibi\u00f3ticos \n(metronidazol, clindamicina, amoxicilina-clavul\u00e1nico, vanco -\nmicina), actualmente est\u00e1n aumentando las resistencias a me -\ntronidazol [6], y se desconoce exactamente la dosis y duraci\u00f3n \npara un tratamiento eficaz. Pensamos que la hidronefrosis de -\nbi\u00f3 ser clave en la facilidad para el desarrollo de la pionefrosis \ny en su agresividad cl\u00ednica en nuestro paciente.\nComo conclusi\u00f3n, se describe un nuevo caso de infecci\u00f3n \nprofunda por G. vaginalis , consistente en una pionefrosis de \nun paciente de 67 a\u00f1os, con hidronefrosis secundaria a una \nresecci\u00f3n transuretral, por un tumor urotelial vesical T1 de alto \ngrado. A pesar de su rareza, tras revisar los casos publicados, \ndestacamos la variedad de infecciones en las que ha estado \npresente esta bacteria, en muchos casos con factores de ries -\ngo asociados, por lo que se deber\u00eda tener en cuenta a la hora \nde su investigaci\u00f3n, expresa o no en el laboratorio, y su signi -\nficaci\u00f3n cl\u00ednica, ya que, actualmente, se puede simplificar su \nidentificaci\u00f3n mediante la t\u00e9cnica de MALDI-TOF. Adem\u00e1s, esta \ninfecci\u00f3n justifica una exhaustiva valoraci\u00f3n, en determinados \ncasos, de los posibles nuevos agentes microbianos en la orina. Infecciones profundas por Gardnerella vaginalis  en el var\u00f3n. Revisi\u00f3n de la literatura y a prop\u00f3sito de un caso M\u00aa L. Ruiz-G\u00f3mez, et al.\nRev Esp Quimioter 2019;32(5): 469-472472Gardnerella vaginalis  in an immunocompetent man. J Infect. 2005; \n51: E27-9. doi: 10.1016/j.jinf.2004.08.002.\n10. Catlin BW. Gardnerella vaginalis : characteristics, clinical considera -\ntions, and controversies. Clin Microbiol Rev. 1992; 5:213-37. PMID: \n1498765.\n11. Iser P, Read TH, Tabrizi S, Bradshaw C, Lee D, Horvarth L, et al. \nSymptoms of non-gonococcal urethritis in heterosexual men: a \ncase control study. Sex Transm Infect. 2005; 81:163-5. doi: 10.1136/\nsti.2004.010751.\n12. Finkelhor RS, Wolinsky E, Kim CH, Tchou P, Frengley JD. Gardnere -\nlla vaginalis  perinephric abscess in a transplanted kidney. N Engl J \nMed. 1981; 304:846. doi: 10.1056/NEJM198104023041418.\n13. Legrand JC, Alewaeters A, Leenaerts L, Gilbert P, Labbe M, Glup -\nczynski Y. Gardnerella vaginalis  bacteremia from pulmonary abs -\ncess in a male alcohol abuser. J Clin Microbiol. 1989; 27:1132-4. \nPMID: 2787333.\n14. Denoyel GA, Drouet EB, De Montclos HP, Schanen A, Michel S. \nGardnerel la vaginalis  bacteremia in a man with prostatic adenoma. \nJ Infect Dis 1990; 161: 367\u20138. PMID: 1688908.\n15. Bastida-Vil\u00e1 MT, L\u00f3pez-Onrubia P, Rovira-Lledos J, Martinez-Marti -\nnez JA, Exp\u00f3sito-Aguilera M. Garderella vaginalis  bacteremia in an \nadult male. Eur J Clin Microbiol Infect Dis 1997; 16: 400\u20131. PMID: \n9228486. \n16. Alidjinou EK, Bonnet I, Canis F, Dewulf G, Mazars E, Cattoen C. \nGardnerella vaginalis  bacteremia in a male patient. Med Mal Infect \n2013; 43: 434\u20135. doi: 10.1016/j.medmal.2013.07.007.\n17. Babics A, Roussellier P. Gardnerella vaginalis : An overlooked \npathogen in male patients? Med Mal Infect. 2015; 45: 423-4. Doi: \n10.1016/j.medmal.2015.09.007.\n18. Bhatia P, Temple J, Kantor M. Not your garden-variety bacteremia: \nGardnerella in an immunocompromised man. Clin Infect Dis. 2018; \n66: 1458-9. doi: 10.1093/cid/cix1054.Rev Esp Quimioter 2019;32(5): 473-474473\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).Mostraba signos de hipoperfusi\u00f3n en manos y pies. \nSe remitieron hemocultivos y muestras de tejidos al \nServicio de Microbiolog\u00eda. En la tinci\u00f3n de Gram se observaron \nleucocitos y cocos que tomaban mal la coloraci\u00f3n de Gram. \nA partir de las muestras de tejidos, se realiz\u00f3 inmunoensayo \ncromatogr\u00e1fico r\u00e1pido para la detecci\u00f3n cualitativa de \nant\u00edgenos de Estreptococo grupo A (Hangzhou AllTest Biotech \nCO., LTD, China) que fue positivo. Se a\u00f1adi\u00f3 al tratamiento \nclindamicina e inmunoglobulina IV. A las 24 horas, se aisl\u00f3 \nS. pyogenes a partir de las muestras  de tejido . La cepa se \ncaracteriz\u00f3 como serotipo M1, spe A, spe B, speC, speF, speG, \nspeJ, speZ. Los hemocultivos fueron negativos. \nPese a mejorar el cuadro sist\u00e9mico y retirar las drogas \nvasoactivas, present\u00f3 gangrena sim\u00e9trica perif\u00e9rica de manos y \npies precisando amputaci\u00f3n distal de las cuatro extremidades. \nSeis meses despu\u00e9s fue dada de alta del hospital, tras \ncierre completo de las heridas y en tratamiento rehabilitador. \nAl a\u00f1o del inicio de la patolog\u00eda, la paciente consigue buen \nacoplamiento a las pr\u00f3tesis biomec\u00e1nicas de manos y pies, \ndeambulando sin bastones.\nS. pyogenes es el agente etiol\u00f3gico m\u00e1s frecuente de \nFN tipo II, monomicrobiana, que puede afectar a pacientes \npreviamente sanos de cualquier edad sin necesidad de factores \nde riesgo; si bien, algunos autores establecen relaci\u00f3n con \ninyecciones intramusculares y traumatismo penetrantes [1]. El \ntraumatismo cerrado tambi\u00e9n podr\u00eda ser un factor de riesgo \npor una mayor expresi\u00f3n de vimentina, adhesina principal de \nS. pyogenes  a las c\u00e9lulas musculares lesionadas [2].  \nUna tercera parte de casos se asocian a s\u00edndrome de shock \nt\u00f3xico [1]. La mayor\u00eda de las cepas pertenecen a los serotipos \nM1 y M3, con capacidad de alterar la funci\u00f3n fagoc\u00edtica y la \nproducci\u00f3n de exotoxinas pirog\u00e9nicas (principalmente la SpeA) \nque pueden actuar como superant\u00edgenos [3]. El serotipo M1 es \nel m\u00e1s frecuente en la enfermedad invasiva en todo el mundo \n[4, 5]. \nEn el 50% de casos se desconoce la puerta de entrada. En Sr. Editor:  La fascitis necrotizante (FN) es una infecci\u00f3n \ngrave, r\u00e1pidamente progresiva y de dif\u00edcil diagn\u00f3stico en \nestadios tempranos. Afecta a la fascia muscular y al tejido \ncelular subcut\u00e1neo, produce trombosis de la microcirculaci\u00f3n \nsubcut\u00e1nea, necrosis y se asocia a elevada mortalidad. \nPresentamos un caso de FN y shock t\u00f3xico por \nStreptococcus pyogenes.\nMujer de 47 a\u00f1os de edad con antecedentes de \nhipertensi\u00f3n que acudi\u00f3 al Servicio de Urgencias por n\u00e1useas, \nv\u00f3mitos, sensaci\u00f3n dist\u00e9rmica, dolor intenso y tumefacci\u00f3n \ndel gl\u00fateo y muslo izquierdo desde que 24 horas antes \nle fuera administrada una inyecci\u00f3n intramuscular de \nmetilprednisolona por faringoamigdalitis. Presentaba eritema \n(3,5 x 3 cm) en regi\u00f3n gl\u00fatea izquierda, sin fluctuaci\u00f3n ni \ntumefacci\u00f3n, ni datos de repercusi\u00f3n sist\u00e9mica. Se recomend\u00f3 \nhielo local y continuar tratamiento iniciado el d\u00eda anterior \ncon amoxicilina-clavul\u00e1nico. Doce horas m\u00e1s tarde acudi\u00f3 \nde nuevo a Urgencias por aumento del dolor. Se objetiv\u00f3 TA: \n73/40 mm Hg, FC: 110 lpm, T\u00aa: 35,5\u00baC. Se realiz\u00f3 TC observando \naumento de tama\u00f1o de la zona gl\u00fatea con p\u00e9rdida de las \ninterfases y desflecamiento del contorno. Se inici\u00f3 tratamiento \ncon ertapenem y fluidoterapia, mejorando el cuadro \nhemodin\u00e1mico. Seis horas despu\u00e9s comenz\u00f3 de nuevo con \nhipotensi\u00f3n, taquicardia, hiperlactacidemia e hipoglucemia, \ncon progresi\u00f3n de la afectaci\u00f3n cut\u00e1nea en muslo. Se \nmodific\u00f3 tratamiento a meropenem y daptomicina. Se \nrealizaron fasciotom\u00eda y necrosectom\u00eda extensas, ingresando \nen el Servicio de Medicina Intensiva, donde present\u00f3 shock \nrefractario a volumen, precisando altas dosis de noradrenalina, \nsignos de coagulaci\u00f3n intravascular diseminada y fallo renal \ncon necesidad de hemofiltraci\u00f3n venovenosa continua. Fascitis necrotizante y s\u00edndrome del shock t\u00f3xico \npor Streptococcus  pyogenes  tras inyecci\u00f3n \nintramuscular\n1Servicio de Microbiolog\u00eda. Hospital Cl\u00ednico Universitario Lozano Blesa (Zaragoza)\n2Servicio de Medicina Intensiva. Hospital Cl\u00ednico Universitario Lozano Blesa (Zaragoza)\n3Servicio de Cirug\u00eda General. Hospital Cl\u00ednico Universitario Lozano Blesa (Zaragoza) Claudia Mendoza1\nSoledad Salvo1\nPilar Luque2\nHector Condado1\nMar\u00eda Azucena Gonzalo3\nSonia Algarate1\nCorrespondencia:\nClaudia Mendoza L\u00f3pez\nServicio de Microbiolog\u00eda. Hospital Cl\u00ednico Universitario Lozano Blesa\nAvenida San Juan Bosco 15. 50009. Zaragoza. Espa\u00f1a\nE-mail: cmendoza@salud.aragon.esCarta al Director\nArticle history\nReceived: 21 March 2019; Revision Requested: 14 May 2019; Revision Received: 5 June 2019; Accepted: 17 July 2019Fascitis necrotizante y s\u00edndrome del shock t\u00f3xico por Streptococcus  pyogenes  tras inyecci\u00f3n intramuscular C. Mendoza, et al.\nRev Esp Quimioter 2019;32(5): 473-4744742.  Bryant AE, Bayer CR, Huntington JD, Stevens DL. Group A strepto -\ncoccal myonecrosis: increased vimentin expression after skeletal-\nmuscle injury mediates the binding of Streptococcus pyogenes . J \nInfect Dis. 2006; 193(12):1685-92. DOI: 10.1086/504261\n3. Baxter F, McChesney J. Severe group A streptococcal infec -\ntion and streptococcal toxic shock syndrome. Can J Anaesth. \n2000;47(11):112940. DOI: 10.1007/BF03027968\n4.  Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. Global emm \ntype distribution of group A streptococci: systematic review \nand implications for vaccine development. Lancet Infect Dis. \n2009;9(10):611\u20136. DOI: 10.1016/S1473-3099(09)70178-1\n5.  Smit PW, Lindholm L, Lyytik\u00e4inen O, Jalava J, P\u00e4t\u00e4ri-Sampo A, \nVuopio J. Epidemiology and emm types of invasive group A \nstreptococcal infections in Finland, 2008\u20132013. Eur J Clin Microbiol \nInfect Dis. 2015;34(10):2131\u20136. DOI: 10.1007/s10096-015-2462-2\n6.  Wong C-H, Khin L-W, Heng K-S, Tan K-C, Low C-O. The LRINEC \n(Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool \nfor distinguishing necrotizing fasciitis from other soft tissue \ninfections. Crit Care Med. 2004;32(7):1535\u201341. DOI: 10.1097/01.\nCCM.0000129486.35458.7D\n7.  Gazzano V, Berger A, Benito Y, Freydiere A-M, Tristan A, Boisset S, \net al. Reassessment of the Role of Rapid Antigen Detection Tests \nin Diagnosis of Invasive Group A Streptococcal Infections. J Clin \nMicrobiol. 2016;54(4):994\u20139. DOI:10.1128/JCM.02516-15\n8.  Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, \nGorbach SL, et al. Executive Summary: Practice Guidelines for the \nDiagnosis and Management of Skin and Soft Tissue Infections: \n2014 Update by the Infectious Diseases Society of America. Clin \nInfect Dis. 2014;59(2):147\u201359. DOI: 10.1093/cid/ciu444\n9. Andreoni F, Z\u00fcrcher C, Tarnutzer A, Schilcher K, Neff A, Keller N, et \nal. Clindamycin Affects Group A Streptococcus  Virulence Factors \nand Improves Clinical Outcome. J Infect Dis. 2017; 215(2):269-277. \nDOI: 10.1093/infdis/jiw229\n10. Rac H, Bojikian KD, Lucar J, Barber KE. Successful Treatment of \nNecrotizing Fasciitis and Streptococcal Toxic Shock Syndrome with \nthe Addition of Linezolid. Case Rep Infect Dis. 2017;5720708. DOI: \n10.1155/2017/5720708nuestra paciente pudo producirse diseminaci\u00f3n hemat\u00f3gena \ndesde orofaringe hasta el microtraumatismo producido por \nla inyecci\u00f3n IM, pero en ausencia de cultivo far\u00edngeo, al igual \nque reconocen otros autores [1], no se pudo documentar \nfaringoamigdalitis. \nLa FN es una emergencia quir\u00fargica, requiere un \ndiagn\u00f3stico r\u00e1pido, manejo quir\u00fargico inmediato, tratamiento \nantibi\u00f3tico y soporte hemodin\u00e1mico.  Las pruebas de imagen \nse realizar\u00e1n siempre que no supongan una demora en el \ntratamiento del paciente. Un retraso en el diagn\u00f3stico est\u00e1 \nasociado a un aumento de la morbimortalidad [3]. \u00c9ste se \nbasa en la sospecha cl\u00ednica, cultivos, marcadores de sepsis y \nescala de \u201cLaboratory Risk Indicator for Necrotizing Fasciitis\u201d \n(LRINEC) [6]. Esta escala es una herramienta especialmente \n\u00fatil, una puntuaci\u00f3n mayor de 8 indica necesidad de cirug\u00eda \nurgente con desbridamiento de los tejidos, pero en el caso de \npuntuaci\u00f3n entre 6 y 8 no se puede excluir FN, y se necesitar\u00edan \notras pruebas como RMI, biopsia o finger test.\nAlgunos autores ante la sospecha de infecci\u00f3n invasiva \npor S. pyogenes han utilizado test r\u00e1pidos dise\u00f1ados para el \ndiagn\u00f3stico de faringoamigdalitis, su uso puede ser relevante \nante infecciones graves ayudando a una terapia dirigida [7]. \nS. pyogenes es sensible a los antibi\u00f3ticos \u03b2-lact\u00e1micos, \npor lo que se mantienen como tratamiento de primera l\u00ednea. La \nSociedad Americana de Enfermedades Infecciosas recomienda \nel uso de clindamicina junto a penicilina en el tratamiento de \nla FN [8]. Clindamicina act\u00faa inhibiendo la s\u00edntesis proteica y \nsu papel es esencial ya que inhibe la producci\u00f3n de factores \nde virulencia como la prote\u00edna M o el superant\u00edgeno, efecto \nque en animales de experimentaci\u00f3n se ha demostrado \nincluso en cepas resistentes a clindamicina [9]. Asimismo, \nlinezolid ha demostrado actividad in vitro frente a  S. pyogenes, \ninhibiendo la s\u00edntesis proteica, adem\u00e1s de otras endotoxinas \nestreptoc\u00f3cicas como la prote\u00edna M, estreptolisina O, Dnasa, \nSpe B y prote\u00edna F [10]. El uso IV de inmunoglobulina est\u00e1 \nrecomendado en caso de shock t\u00f3xico.\nConcluimos que el diagn\u00f3stico r\u00e1pido, el manejo \nquir\u00fargico inmediato y el tratamiento antibi\u00f3tico adecuado \nson esenciales para reducir la mortalidad en estos pacientes.\nFINANCIACI\u00d3N \nLos autores declaran no haber recibido financiaci\u00f3n para la \nrealizaci\u00f3n de este estudio. \nCONFLICTO DE INTERESES \nLos autores declaran no tener ning\u00fan conflicto de \nintereses.\nBIBLIOGRAF\u00cdA\n1.  Stevens DL, Bryant AE. Necrotizing Soft-Tissue Infections. N Engl J \nMed. 2017;377(23):2253\u201365. DOI: 10.1056/NEJMc1800049Rev Esp Quimioter 2019;32(5): 475-476475\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).was discharged and prescribed doxycycline 100mg/12h \nand levofloxacin 500mg/24h, by mouth for six months. At \nthe end of this period the control samples were negative. \nPossibly, the origin of the infection was the colonization \nof the skin by M. smegmatis , introduced during the sur -\ngical intervention, without confirmation. Microbiological Sir,\nMycobacterium smegmatis  is a rapid growth myco -\nbacteria (RGM) classified as group IV Runyon, scotochro -\nmogen mycobacterias. It has been found in soil and water \nand has been considered for many years to be a non-path -\nogenic environmental microorganism. \nThere are 3 RGM related to human pathology: Myco -\nbacterium  fortuitum , Mycobacterium  chelonae/abscessus  \nand Mycobacterium  smegmatis (M. smegmatis  sensu stric -\nto, wolinskyi  and goodie [1]), the latter rarely causing in -\nfection; associated with bronchopulmonary illnesses, skin \nand soft tissue infections [2], surgery and injections, as \nwell as infection of prosthetic material [1-5]. Sporadic cas -\nes of bacteremia have been observed [5]. \nWe present a case of surgical infection of a wound by \nM. smegmatis . In a 66 year old woman with a history of \nvertebral fixation due to kyphosis in 2011. In 2018 correc -\ntive surgery was carried out with extraction of previous \nmaterial and installation of new screws (figure 1). The pa -\ntient returned to Emergency 14 days after surgery due to \nhyperthermia of unknown cause, and was discharged after \nhaving been given paracetamol. Ten days later she was ad -\nmitted to Emergency with dehiscence of surgical wound \nwith purulent exudate. After cleaning and taking samples \nof wound exudate for microbiological culture, the patient \nwas treated with clindamycin 600 mg/8h and intravenous \nlinezolid 600 mg/24h. Seven days after taking the sam -\nple, the microbiological report indicated the growth of M. \nsmegmatis , confirmed by the second sample from the sur -\ngical exudate, resulting in changing the treatment to in -\ntravenous linezolid 600mg/12h. A month later the patient Infection of prosthetic material due to \nMycobacterium smegmatis\nConsorci Hospital General Universitari de Valencia, SPAIN Manuel Belda Alvarez\nMercedes Chanza Avi\u00f1o\nMiguel Sanfeliu Giner\nMaria del Remedio Guna \nSerrano\nConcepci\u00f3n Gimeno \nCardona\nCorrespondence:\nManuel Belda \u00c1lvarez\nConsorci Hospital General Universitari de Valencia, SPAIN \nE-mail: Manuelbelda89@gmail.comLetter to the Editor\nArticle history\nReceived: 27 March 2019; Revision Requested: 25 April 2019; Revision Received: 12 June 2019; Accepted: 8 July 2019\nFigure 1 Lateral chest radiograph\nInfection of prosthetic material due to Mycobacterium smegmatis M. Belda Alvarez, et al.\nRev Esp Quimioter 2019;32(5): 475-476476various authors have coincided in that it should be a com -\nbined and long-term treatment directed by sensitivity \nstudies for 6-12 months [5, 6], including the elimination of \ndead or infected tissue from the wound and the re-open -\ning and extraction of the prosthetic material [1]. \nFUNDING\nNone to declare\nCONFLICTS OF INTEREST\nThe authors declare that they have no conflicts of interest\nREFERENCES\n1. Zaid Saffo, DO, Anthony Ognjan, DO, FACP. Mycobacterium smeg -\nmatis  infection of a prosthetic total knee arthroplasty. IDCases \n2016; 5: 80\u201382. DOI:10.1016/j.idcr.2016.07.007\n2. Zhe Xu, Di Lu, Xia Zhang,a Haijing Li, Shufang Meng, Yue-Song \nPan, Alan S. Boyd, Lin Ma, Yi-Wei Tang. Mycobacterium smegmatis  \nin Skin Biopsy Specimens from Patients with Suppurative Gran -\nulomatous Inflammation. J Clin Microbiol 2013; 51:1028\u20131030. \nDOI:10.1128/JCM.0342112\n3. Albert J. Eid, Elie F. Berbari, Irene G. Sia, Nancy L. Wengenack, \nDouglas R. Osmon, and Raymund R. Razonable. Prosthetic Joint \nInfection Due to Rapidly Growing Mycobacteria: Report of 8 Cas -\nes and Review of the Literature. Clin Infect Dis 2007; 45:687\u201394. \nDOI:10.1086/520982\n4. Manyoung Kim, Chul-Won Ha, Jae Won Jang , Yong-Beom Park . \nRapidly growing non-tuberculous mycobacteria infection of pros -\nthetic knee joints: A report of two cases. Knee 2017;24:869-875. \nDOI:10.1016/j.knee.2017.04.015\n5. Frank Allen Zimba. Mycobacterium smegmatis  Infection of a Lum -\nbar Spine Instrumented Fusion. Am J Infect Dis 2011;7: 24-27. \nDOI:10.3844/ajidsp.2011.24.27\n6. Mary A. De Groote, and Gwen Huitt. Infections Due to Rapid -\nly Growing Mycobacteria. Clin Infect Dis 2006; 42:1756\u201363. \nDOI:10.1086/504381Processing: The samples were cultivated in aerobic/an -\naerobic media (blood agar, chocolate agar, MacConkey, \nBrain Heart Infussion and Thioglycolate). After 6 days of \nincubation some colonies appeared with yellow-orange \npigmentation in the blood agar and chocolate agar media \n(figure 2), with no growth in MacConkey which showed \nviolet crystal.\nIn the Ziehl-Neelsen stain acid-alcohol resistant bacilli \nwere observed. Identification was carried out using mass \nspectrometry (MALDI-TOF Bruker\u00ae) profiling as M. smeg -\nmatis,  confirmed by PCR-nesting and genome sequenc -\ning (amplification of DNA of the gene rRNA16s) with an \napproximation of 99%. The sensitivity study was carried \nout by microdilution, showing sensitivity to cotrimoxazol, \ndoxycycline, linezolid, amikacin, imipenem, ciprofloxacin, \nintermediate reaction to tobramycin and cefoxitin, and re -\nsistance to clarithromycin.\nInfections of prosthetic material occur in 1-5% of cas -\nes. Occasionally they are produced by RGM [1] and pre -\nvention is relatively complicated precisely due to relative \ninfrequency. It may be convenient to include the mycobac -\nteria culture in badly healing wounds. This poses a ther -\napeutic challenge due to limited experience [3] and lack \nof knowledge of the duration of the treatment; although Figure 2  Mycobacterium smegmatis  in chocolate \nagar\nRev Esp Quimioter 2019;32(5): 477-478477\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).The admission physical exam showed increased body \ntemperature (37.6\u00baC), tachycardia and mild neck stiffness. \nCSF drawn on admission contained 852 cells/\u03bcL (100% lym -\nphocytes), elevated protein (143 mg/dL), normal adenosine \ndeaminase level (5.1 U/L) and normal glucose level (55 mg/dL \nin CSF and 120 mg/dL in serum). The Gram\u00b4s stain was neg -\native. Intravenous antimicrobial therapy with acyclovir and \nceftriaxone, 750 mg/8h and 2g/12h respectively, were imme -\ndiately administered and the patient was placed under contact \nisolation. \nThe CSF analysis was conducted in the microbiology lab -\noratory as follows: Firstly, CSF was analysed for enterovirus -\nes (EV) detection by targeted testing platform Xpert EV PCR \n(Cepheid, Sunnyvale, CA, USA), yielding negative results. At this \npoint, a CSF aliquot was sent to a reference center (Hospital \nUniversitario Donostia) in which FilmArray ME assay was per -\nformed. A few hours after the patient\u00b4s admission, the FilmAr -\nray ME assay showed a positive result to HSV-2 being negative \nto bacterial targets. The patient\u00b4s measures of contact isolation \nand ceftriaxone administration were disrupted after learning \nthese results. Retrospectively, the patient admitted unprotect -\ned oral sex with his couple, but he did not remember any initial \ncutaneous or mucosal lesion. Screening for sexually transmit -\nted infections and urogenital HSV detection of the patient was \naccomplished (table 1). The patient was discharged without \nsymptoms after 14 days of intravenous acyclovir therapy.\nEV is the most frequent agent of viral meningitis, followed \nby varizela zoster virus and HSV-2 [5]. Nonetheless, the prev -\nalence of HSV-2 meningitis in Spain, is very low (1.2%), with \nfew cases reported in the literature [5\u20137]. Infection with HSV-2 \nis mucocutaneous and is acquired vertically as a neonate or \nas an adult principally through sexual activity [8]. Moreover, \nHSV-2 is a recognized cause of CNS infection, mainly menin -\ngitis and it is also related to benign recurrent meningitis [8]. \nCNS infection due to HSV-2, usually correspond to the reac -\ntivation of a latent virus in sensory ganglia, mostly in young \nfemales [8, 9]. As shown in previous reports, only 30% of the Sir,\nMeningitis and encephalitis are serious diseases with high \nmorbi-mortality, especially in bacterial meningitis. Rapid iden -\ntification of causative pathogens and prompt instauration of \nan appropriate antimicrobial therapy are crucial to reduce the \nmorbi-mortality, length hospital stay and healthcare costs as -\nsociated with these syndromes [1, 2]. Differential diagnostic \nbetween bacterial and aseptic meningitis is difficult; the former \nis a medical emergency that requires prompt recognition and \ntreatment, while the latter is a relatively common and often-be -\nnign infection mainly caused by viruses [3, 4]. Consequently, \ncerebrospinal fluid (CSF) indices and microbiological studies are \nrequired to identify the etiologic agent [1, 2]. The classic diag -\nnostic is based on a CSF Gram stain with culture and specific \nviruses PCR, which can delay the diagnostic [2]. Recently, U.S.A \nFood and Drug Administration (FDA) has approved the FilmArray \nMeningitis/Encephalitis (ME) panel (bioM\u00e9rieux, Marcy l\u2019Etoile, \nFrance) to detect central nervous system (CNS) infections. The \nFilmArray ME panel is a multiplex PCR that can identify the most \nfrequent causative agents of CNS infections in an one-step as -\nsay, which decreases the diagnostic time [1, 2].\nHerein, an uncommon case of aseptic meningitis due to \nherpes simplex virus type 2 (HSV-2) is presented as well as the \nusefulness of the FilmArray ME panel in prompt diagnostic, the \noptimization of antimicrobial therapy and the implementation \nof infection prevention measures.\nA 25-year old man was admitted in our department with \na 2-day history of general discomfort, fever, photophobia, \nnausea and acute headache. One week before admission, he \nwas treated with oral amoxicillin/clavulanic acid for five days, \nup until 72 hours before hospital admission. Usefulness of FilmArray Meningitis/Encephalitis \npanel in the management of an uncommon case of \nHerpes Simplex Virus type 2 meningitis\n1Servicio de Anestesiolog\u00eda y Reanimaci\u00f3n, Hospital El Bierzo\n2Servicio de Microbiolog\u00eda, Hospital de Zum\u00e1rraga\n3Unidad de Microbiolog\u00eda, Hospital El Bierzo\n4Departamento de Biolog\u00eda Funcional, \u00c1rea de Microbiolog\u00eda, Universidad de Oviedo\n5Instituto de Investigaci\u00f3n Sanitaria del Principado de AsturiasSarai Su\u00e1rez-Fern\u00e1ndez1\nAna Iturzaeta2\nCarlos Rodr\u00edguez-Lucas3,4,5\nCorrespondence:\nCarlos Rodr\u00edguez Lucas. \nUnidad de Microbiolog\u00eda, Hospital El Bierzo. M\u00e9dicos sin Fronteras 7, 24404-Ponferrada, \nSpain.\nPhone: +34 987455200\n E-mail: carlosrlucas87@gmail.comLetter to the Editor\nArticle history\nReceived: 11 April 2019; Revision Requested: 7 May 2019; Revision Received: 19 May 2019; Accepted: 28 May 2019Usefulness of FilmArray Meningitis/Encephalitis panel in the management of an uncommon case of Herpes \nSimplex Virus type 2 meningitisS. Su\u00e1rez-Fern\u00e1ndez, et al.\nRev Esp Quimioter 2019;32(5): 477-478478CONFLICTS OF INTEREST\nThe authors declare that they have no con -\nflicts of interest.\nREFERENCES\n1. Demogines A, Fouch S, Everhart K, Leber A, Barney \nT, Daly JA, et al. Multi-Center Clinical Evaluation of a Mul -\ntiplex Meningitis/Encephalitis PCR Panel for Simultaneous \nDetection of Bacteria, Yeast, and Viruses in Cerebrospi -\nnal Fluid Specimens. J Clin Microbiol 2015;54:2251\u201361. \ndoi:10.1128/JCM.00730-16.\n2. Hanson KE. The First Fully Automated Molecular \nDiagnostic Panel for Meningitis and Encephalitis: How \nWell Does It Perform, and When Should It Be Used? J Clin Microbi -\nol 2016;54:2222\u20134. doi:10.1128/JCM.01255-16.\n3. Bodilsen J, Storgaard M, Larsen L, Wiese L, Lebech A, Brandt C, et \nal. Infectious meningitis and encephalitis in adults in Denmark: \na prospective nationwide observational cohort study (DASGIB). \nClin Microbiol Infect 2018;24:1102.e1-1102.e5. doi:10.1016/j.\ncmi.2018.01.016.\n4. Jarrin I, Sellier P, Lopes A, Morgand M, Makovec T, Delcey V, et \nal. Etiologies and Management of Aseptic Meningitis in Patients \nAdmitted to an Internal Medicine Department. Med 2016;95:1\u20139. \ndoi:10.1097/MD.0000000000002372.\n5. Ory F De, Avell\u00f3n A, Echevarria J, S\u00e1nchez-Seco M, Trallero G, \nCabrerizo M, et al. Viral Infections of the Central Nervous Sys -\ntem in Spain: A Prospective Study. J Med Virol 2013;85:554\u201362. \ndoi:10.1002/jmv.\n6. Reina J, Leyes M, Taboada C. Lymphocytic meningitis caused \nby herpes simplex virus type 2. Rev Clin Esp 2016;216:290\u20131. \ndoi:10.1016/j.rce.2016.02.003.\n7. Flor\u00e9n-Zabala L, Chamizo-L\u00f3pez FJ, Eisman-Maraver A, P\u00e9rez-\nGonz\u00e1lez C, Ory-March\u00f3n F De, Trallero-Maso G, et al. Meningitis \nas\u00e9ptica en la poblaci\u00f3n adulta. Etiolog\u00eda y utilidad de las t\u00e9cnicas \nmoleculares en el manejo cl\u00ednico del paciente. Enferm Infecc Mi -\ncrobiol Clin 2012;30:361\u20136. doi:10.1016/j.eimc.2012.01.004.\n8. Miller S, Mateen FJ, Aksamit AJ. Herpes simplex virus 2 menin -\ngitis: a retrospective cohort study. J Nerovirol 2013;19:166\u201371. \ndoi:10.1007/s13365-013-0158-x.\n9. O\u2019Sullivan CE, Aksamit AJ, Harrington JR, Harmsen WS, Mitchell PS, \nPatel R. Clinical Spectrum and Laboratory Characteristics Associat -\ned With Detection of Herpes Simplex Virus DNA in Cerebrospinal \nFluid. Mayo Clin Proc 2003;78:1347\u201352. doi:10.4065/78.11.1347.\n10. Green DA, Pereira M, Miko B, Radmard S, Whittier S, Thakur K. Clin -\nical Significance of Human Herpesvirus 6 Positivity on the FilmAr -\nray Meningitis/Encephalitis Panel. Clin Infect Dis 2018;67:1125\u20138. \ndoi:10.1093/cid/ciy288.patients with HSV-2 meningitis had cutaneous or mucosal le -\nsion at the moment of CNS infection [4, 9]. Although stand -\nardized management for HSV-2 meningitis does not exist and \nit is often-benign infection, long-term neurological sequelae \nhad been reported in some cases, so prompt diagnostic and \nantiviral treatments are recommended [3].\nThe recent development of the FilmArray ME assay could \nhelp the etiologic diagnostic of meningitis, but unfortunate -\nly the high cost of this assay only allows its implementa -\ntion in reference hospitals. A rational use of this expensive \nassay could optimize the management of selected patients \nwith CNS infections. Recently Hanson et al., suggested that \ninmmunocompromised patients and those who had received \nantimicrobials before the diagnostic lumbar puncture could \nbe potential beneficiaries of this technology [2]. Although \nthis assay has some advantages with respect to classical \ntechniques for viruses CNS infections detection, like in house \nPCR or cultures, positive results must be interpreted along \nwith entire clinical picture of the patient (symptoms, labo -\nratory findings, cranial imaging\u2026) because other host-virus \nstate, like latency or asymptomatic viral reactivation, can al -\nso be detected [10].\nHerein, we present an algorithm to the management of \naseptic meningitis in a patient with predominance of lympho -\ncytes in CSF and also had antimicrobial therapy before the ad -\nmission. The implementation of new platforms, such as Xpert \nEV and FilmArray ME, under the aforementioned algorithm \nallows, in a relative short time, the identification of causative \npathogens of CNS infections to optimize the therapy, avoid -\ning unnecessary antimicrobial use and removing the necessity \nof contact isolation. The rational use of this new technology \ncan improve the management of CNS infections, and when \nthis assay is developed both under diagnostic algorithms and \nin selected patients, the FilmArray ME could be cost/effective, \nalthough further studies are necessary to assess this fact.\nFUNDING\nNone to declareSerologic findings HBV, HCV and HIV Negative\nSyphilis Negative\nHSV-2 IgG Positive\nHSV-2 IgM Negative\nHSV-1 IgG and IgM Negative\nPCR of HSV 1 and 2 in oral and urethral swabs NegativeTable 1  Screening of sexually transmitted infections.\nHSV: Herpes simplex virus; HBV: Hepatitis B virus; Hepatitis C virus; HIV: Human immunodeficien -\ncy virus.Rev Esp Quimioter 2019;32(5): 479-484479\n\u00a9The Author 2019. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 \nInternational (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).each species may be established, make it posible to differenti -\nate those who behave as harmless commensal bacteria from \nthose usually involved in infections. This precise identification \nwill gradually become easier with the implementation of se -\nquence-based molecular identification diagnostic methods or \nmass spectrophotometry (MALDI-TOF), fortunately increasing -\nly spreading in laboratories, which are relegating biochemical \nmethods, much less accurate, to identification second level.\nGiven the rarity of male genitourinary infections in which \nthe participation of C. glucuronolyticum  as an etiological agent \nhas been reported, in this study we review the cases of genito -\nurinary infectious pathology in which the involvement of this \nspecies has been proved so far and those publications in which \nthe bacteria is described as a participant in the pathogenesis \nof CBP.\nThe genus Corynebacterium  groups more than 60 species, \nmany of which were recently described. Most have been iso -\nlated from animals and humans, and many of them in samples \nfrom the urogenital tract [7]. Some are only commensal spe -\ncies and are part of the normal microbiota, while others be -\nhave like opportunistic pathogens, so it is necessary to make \nan identification of the isolate until reaching the species level \n[8]. They may be part of the normal microbiota of the skin or \nupper respiratory tract, digestive or genitourinary apparatus.\nA way to group corinebacteria, as it appears in a study \nled by Funke, et al. (1997), is based on its lipophilic or non-li -\npophilic character [8]. Lipophilic species, in turn, are classified \nas fermenters and non-sugar fermenters. The species  C. glu -\ncuronolyticum belongs to the group of fermenting lipophilic \nbacteria.\nIt was first described by Funke et al. in 1995 [9], isolating \nit from samples mostly belonging to males in which there was \nclinical suspicion of a genitourinary infectious process. During \nthe same year another independent research group, headed \nby Riegel, also isolated a new species belonging to the genus  \nCorynebacterium , from semen cultures from males with a his -Sir,\nCorinebacteria are often considered as part of the com -\nmensal microbiota that can be found in the genitourinary tract, \nhowever, there is growing evidence that their pathogenic role \nis being underestimated, even in immunocompetent individ -\nuals with no predisposing factors. The species on which this \nstudy is focused, Corynebacterium  glucuronolyticum , is occa -\nsionally involved in human infections, so it has an opportunis -\ntic pathogen role, presenting some specificity towards the male \ngenitourinary tract [1]. \nThus, different research groups have contributed by high -\nlighting its important role in non-gonococcal urethritis in male \n[1-3]; in chronic bacterial prostatitis (CBP) monomicrobial \npaucisymptomatic [4]; in the pathogenesis of persistent cys -\ntitis in males without predisposing factors [5] and its adverse \ninfluence on various laboratory parameters of semen, unknown \nuntil very recently [6], has also been investigated.\nThere are very few bibliographic references abous this spe -\ncies, hardly half a dozen relevant publications focusing on the \ngenitourinary tract. As Mestrovic et al. (2018) points out, one \nof the main reasons for this fact is that its presence in clinical \nsamples is not usually investigated, as its detection generally \nrequires employing methods that are not part of the basic di -\nagnostic protocols for genitourinary infections [1].\nThe pathogenic role of typical commensal microorgan -\nisms, such as corinebacteria, may come to play in the genito -\nurinary tract has not been fully clarified yet. For this reason, \nidentifying more accurately each species of corinebacteria is \nessential to move forward in this line of research. In this way, \nan increasingly precise determination of the pathogenicity of Male genitourinary infections by Corynebacterium \nglucuronolyticum . A review and clinical experience\n1Departamento de Microbiolog\u00eda, Facultad de Medicina, Universidad de Granada- Instituto de Investigaci\u00f3n Biosanitaria \nde Granada. Granada. \n2Departamento de Microbiolog\u00eda, Hospital Universitario Virgen de las Nieves- Instituto de Investigaci\u00f3n Biosanitaria de \nGranada. Granada.\n3Departamento de Medicina Interna, Hospital Universitario Virgen de las Nieves- Instituto de Investigaci\u00f3n Biosanitaria \nde Granada. Granada.Marta Ruiz-Pino1\nCarla Foronda-Garc\u00eda-\nHidalgo2\nPedro Alarc\u00f3n-Blanco3\nJos\u00e9 Guti\u00e9rrez-Fern\u00e1ndez1,2\nCorrespondence:\nJos\u00e9 Guti\u00e9rrez-Fern\u00e1ndez. \nServicio de Microbiolog\u00eda. Hospital Universitario Virgen de las Nieves.\nAvenida de las Fuerzas Armadas, 2. E-18012 Granada, Espa\u00f1a.  \nE-mail: josegf@ugr.esLetter to the Editor\nArticle history\nReceived: 28 May 2019;  Accepted: 8 July 2019Male genitourinary infections by Corynebacterium glucuronolyticum . A review and clinical experience M. Ruiz-Pino, et al.\nRev Esp Quimioter 2019;32(5): 479-484480Microscopic observation of colonies of C. glucuronolyti -\ncum after undergoing a Gram\u2019s stain yields similar results to \nthose of other species of corinebacteria. They are described \nas elongated grampositive bacilli, between 1 and 3 \u03bcm in \nlength [8], which can be grouped, either forming pairs, angular \nshapes, etc.; or even rather isolated [10].\nConcerning the results of biochemical tests, variability be -\ntween different strains is often found. Many of them are able \nto hydrolyze sculin, making of C. glucuronolyticum  one of the \nfew species causing human infections with this capacity. Some \nstrains have marked urease activity and others show little or \nnone urease activity. They all ferment glucose and sucrose, and \nnone of them mannitol. Fermentation of maltose, xylose and \nribose, as well as nitrate reduction is variable. As a result of \nglucose metabolization, they produce propionic acid. Other of \nthe metabolites they release are lactate and succinate. C. glu -\ncuronolyticum shows a powerful \u00df-glucuronidase and leucine \narilamidase activity. Its colonies are non-hemolytic in blood \nagar, but an intense CAMP effect does occur when they come \ninto contact with the \u00df-hemolisin produced by Staphylococ -\ncus aureus  [8, 10, 15].\nTo identify at the species level those strains of corinebac -\nteria that were detected in the laboratory methods such as API \nCoryne (BioMerieux, France), based on biochemical tests, used \nto be employed. However, due to the variability of results pro -\nvided by different strains of the same species, the results of \nthese techniques were not always reliable. Therefore, it is pref -\nerable to use methods based on mass spectrometry in order to \nget the most accurate identification at the species level. Thus, \ncurrently, C. glucuronolyticum  is correctly identified through tory of prostatitis and infertility, which he named Corynebac -\nterium seminale [10].\nInitially, it was considered that two different species had \nbeen described, but soon after it was discovered that both had \nan identical biochemical profile [11]. This seemed to indicate \nthat the two were, in fact, a single species. This was confirmed, \nin 1997, by Funke et al., by carrying out genetic tests of the \nalleged two species, which were eventually called C. glucu -\nronolyticum [8]. This thesis received the final confirmation two \nyears later, when Tanner et al. sequenced the 16S subunit of \nrRNA of the strains of the two alleged species, both being ge -\nnetically identical, with an homology of 97% [12]. Subsequent \ninvestigations by Devriese, et al. [13] confirmed that it was \ndefinitely the same species.\nCorinebacteria contain catalase and grow better in the \npresence of oxygen, so they can be considered aerobic or fac -\nultative anaerobic. They grow in conventional culture media \nused in the laboratory, albeit in a variable way depending on \nthe species. They multiply well at the standard incubation \ntemperature (37\u00baC) [14] and are not overly demanding spe -\ncies in terms of environmental conditions, although they do \ngrow faster in atmospheres with an enriched concentration of \nCO2 to 5%. One factor that needs to be taken into account is \nincubation time. After 24 hours, the colonies generated by  C. \nglucuronolyticum are not yet very evident, so it is advisable to \nwait until a minimum of 48 (figure 1). Regarding their pheno -\ntypical characteristics, the colonies are mucous and white-yel -\nlow. Its shape is convex and its diameter, small, about 1 mm in \nlength. In addition, they exhibit a characteristic smell that has \nbeen called \u201cEnglish caramel\u201d[10].\nFigure 1  Images of the growth of colonies of C. glucuronolyticum  in lamb blood agar medium \nat 24 h (left) and 48 h (right), in the presence of CO 2\nMale genitourinary infections by Corynebacterium glucuronolyticum . A review and clinical experience M. Ruiz-Pino, et al.\nRev Esp Quimioter 2019;32(5): 479-484481[17]. Although they may be asymptomatic, they usually pres -\nent with dysuria, tenesm, polaquiuria, nicturia, urinary reten -\ntion, perineal pain, discomfort during ejaculation, etc. [11]. The \nmost common clinical manifestations in patients with signifi -\ncant microbiological study are perineo-testicular pain, ejacu -\nlatory discomfort and hemospermia [17]. Typical urinary path -\nogens, such as gramnegative bacilli and some enterococci, are \nthe most common cause of bacterial prostatitis. The main eti -\nological agents described in our environment are Escherichia \ncoli and Enterococcus faecalis  [17, 18]. Generally, protocols \napplied in laboratories are aimed at detecting these etiological \nagents, making them ineffective in diagnosing other less com -\nmon agents, such as corinebacteria [11].\nTo reach the etiological diagnosis of CBP, both urine \nand semen culture are used in the microbiology laboratory. the MALDI-TOF technique with relative ease, providing usually \nscores above 2 [16].\nIn order to study the published clinical processes related \nto this bacteria, an open search of articles in MEDLINE data -\nbase, with the keywords \u201c Corynebacterium glucuronolyticum \u201d \nwas carried out in February 2019. This research made it posible \nto obtain a total of 15 publications. Subsequently, only pub -\nlished studies showing the pathogenic action of this bacterium \nat the genitourinary tract were selected by manual reviewing. \nThis led to the final selection of 7 scientific papers (table 1).\nIn general, CBPs are common infections in males, repre -\nsenting the main cause of prostatic disease in patients under \n50 years old and the third cause in patients over 50 years old \n(only overcome by prostate hyperplasia and prostate cancer) Patient number  \n(reference/publication year)Age/sex Predisposing factors Clinical \nmanifestationsClinical sample Treatment Microbiological \ndiagnostic method\n1 (13/ 2000) UNK /M UNK Infertility Semen UNK 16S rRNA sequencing\n2 (13/ 2000) UNK /M UNK Infertility Semen UNK 16S rRNA sequencing\n3 (13/ 2000) UNK /M UNK Infertility Semen UNK 16S rRNA sequencing\n4 (13/ 2000) UNK /M UNK Infertility Semen UNK 16S rRNA sequencing\n5 (13/ 2000) UNK /M UNK Infertility Semen UNK 16S rRNA sequencing\n6 (13/ 2000) UNK /M UNK Urethritis Urethral exudate UNK 16S rRNA sequencing\n7 (13/ 2000) UNK /M UNK Urethritis Urethral exudate UNK 16S rRNA sequencing\n8 (11/ 2002) 46 /M None Urethritis Semen Trimethoprim-\nsulfamethoxazole 3 weeks PORapID CB Plus system\n9 (2/ 2011) 18 /M Sexual intercourse with \nmultiple partnersUrethritis Urethral exudate Ciprofloxacin PO API Coryne\n10 (22/ 2014) 24 /M None Urethritis Urethral exudate and \nsemenDoxycycline 1 week PO API Coryne\n11 (3/ 2015) 37 /M None Urethritis Urethral exudate, semen \nand urineCiprofloxacin 10 days PO MALDI-TOF\n16S rRNA sequencing\n12 (11/ 2015) 57 /M None Cystitis Urine Vancomycin IV 16S rRNA sequencing\n13 (1/ 2018) 28/ M Chlamydia trachomatis  \nurethritis treated with \ndoxycycline (1 week, PO)Persistent urethritis Urethral exudate UNK API Coryne \nMALDI-TOF\n14 (1/ 2018) 36/ M Chlamydia trachomatis  \nurethritis treated with \ndoxycycline (1 week, PO)Persistent urethritis Urethral exudate UNK API Coryne\nMALDI-TOF\n15 (1/ 2018) 21/ M Chlamydia trachomatis  \nurethritis treated with \ndoxycycline (1 week, PO)Persistent urethritis Urethral exudate UNK API Coryne\nMALDI-TOF\n16 (OP/ 2019) 36/ M None Chronic prostatitis Semen Doxycycline + amoxicillin-\nclavulanic POMALDI-TOF\n17 (OP/ 2019) 52/ M None Chronic prostatitis Semen Levofloxacin 2 weeks PO MALDI-TOFTable 1  Review of reported cases of genitourinary infection caused by C. glucuronolyticum .\nUNK: unknown, OP: our patient.Male genitourinary infections by Corynebacterium glucuronolyticum . A review and clinical experience M. Ruiz-Pino, et al.\nRev Esp Quimioter 2019;32(5): 479-484482linezolid (0.064 mg/L), penicillin (0.094 mg/L) and tetracycline \n(0.0125 mg/L). In addition, the values of MIC were interpret -\ned as resistant following the criteria mentioned above against \nciprofloxacin ( \u02c332 mg/L), phosphomycin ( \u02c3256 mg/L) and gen -\ntamicin (8 mg/L).\nThe biochemical analysis and blood count that were re -\nquested yielded results within the normal range, without el -\nevation of the acute phase reactants. In terms of treatment, \nempirical therapy with ciprofloxacin was first dispensed at \ndoses of 750 mg every 12 hours. After verifying that the in -\nfecting strain was resistant to quinolones, the administration \nof trimethoprim/sulfamethoxazole was evaluated and the de -\npartment of Allergology studied the patient\u2019s hypersensitivity \nto sulfamides. No clinical contraindications were detected and \ncotrimoxazole was administered at doses of 160/800 mg every \n12 hours. A week later, treatment was discontinued because \na delayed phase reaction was suspected when a skin rush ap -\npeared. Finally, the treatment was changed to a combination \nof doxycycline (100 mg every 12 hours) and amoxicillin-clavu -\nlanic (875/125 mg every 8 hours), for 6 weeks. Within 3 days \nof starting treatment, febricula subsided and, in the following \nweeks, the rest of the clinical symptoms disappeared.\nThe second isolation of C. glucuronolyticum  was per -\nformed in a semen sample from a 52-year-old male, without \na medical history of high-interest, who requested a consulta -\ntion with a specialist of the department of Urology in February \n2018. During his visit, he referred symptomatology of a month \nof evolution consisting of discomfort at the area of the penis, \nitchy feeling in the urethra, both accompanied by intermittent \ndiscomfort in the perineum and during ejaculation. The patient \ndid not describe any febrile syndrome or voiding disfunction. \nThis second strain isolated showed the following MIC \nvalues, which were interpreted as susceptible according to \nthe criteria for corinebacteria in CLSI 2015: trimethoprim/\nsulfamethoxazole (0.19 mg/L), linezolid (0.094 mg/L), tetracy -\ncline (0.094 mg/L), ciprofloxacin (0.047 mg/L) and rifampicin \n(<0.016 mg/L). In addition, the MIC values were interpreted as \nresistant according to the criteria mentioned above against \nclindamycin ( \u02c3256 mg/L) and erythromycin ( \u02c3256 mg/L).\nPreviously, the patient had gone to the emergency room \nwhere he was prescribed phosphomycin and tamsulosin. De -\nspite some improvement with this treatment, no total remis -\nsion of the symptoms had occurred. The examination of the \npenis and testicles was normal, with no herniary points. The \nappearance of the urethral meate was also normal. His family \ndoctor, who referred him to the urologist, had requested blood \ncount, biochemistry and urine sediment, which were all nor -\nmal. PSA (<4) was within the normal range and the uroculture \nresult was also negative. Upon suspicion of CBP, the urologist \nrequested an abdominal and pelvic ultrasound, in which no \npathological findings were detected, and the measurement of \npost-mictional residue that was also normal. In addition, ure -\nthral exudate, post-ejaculated urine and semen cultures were \nrequested. The treatment was modified, adding Permixon (1 \ntab/12h for 1 month) and provisionally suspending tamsulosin. The classic method, designed by Meares and Stamey in 1968, \nwhich remains the Gold-standard despite its limitations, con -\nsists of the conduction of quantitative cultures of pre-ejacu -\nlation urine, semen and post-ejaculation urine [19]. Diagnosis \nof CBP requires a significant count of bacteria in semen and/\nor post-ejaculation urine, compared to the count obtained \nin pre-ejaculation urine, although, as suggested by the study \nconducted by Heras-Ca\u00f1as et al., the fractional culture for mi -\ncrobiological diagnosis of CBP could be simplified by growing \npre-semen urine and semen, without the need to culture sam -\nples of post-ejaculation urine. In this series of cases, 96.7% of \nCBP patients had positive semen cultures, while only 22.95% \nhad positive post-ejaculation urine cultures [17].\nHowever, interpreting the results obtained in segmented \ncultures is not always an easy task, since, as Nickel concludes, \nthe absence of growth of the microorganism in the culture \ndoes not exclude its participation in the pathological process \n[20]. This, based on the results provided by biopsies of CBP pa -\ntients, maintains the hypothesis that, through the influence of \nimmune defense and in response to antibiotics, the bacteria \ncan be cantoned in the ducts and prostate acinos forming tiny \ncolonies or biofilms surrounded by a layer of polymers, which \nprotect the bacteria and allow it to persist, even if antibiotics \nare used to eradicate it.\nDuring the month of June 2018, in the Microbiology Lab -\noratory of the Hospital Virgen de las Nieves in Granada, the \nspecies C. glucuronolyticum  was selectively isolated in counts \ngreater than 10,000 CFU/mL, in two samples of semen from \nmales who were being studied in suspicion of CBP by urolo -\ngists of the same hospital. \nThe established protocol for the study of CBP proposed by \nHeras-Ca\u00f1as et al., in 2016 [17] was followed. Culture mediums \nof 5% blood agar and chocolate agar revealed the presence of \ntiny whitish-yellow colonies convex and circular, with regular \nedges. Both media were incubated at 37\u00baC in a CO2-enriched \natmosphere. Bacterial growth could only be clearly detected \nafter 48 hours of incubation, remaining almost undetectable \nfor the first 24 hours. In the two cases described, a CFU num -\nber greater than 10,000/mL were obtained; reaching therefore \nclinically significant values in both cases. The correct identifi -\ncation of the bacteria was carried out through the MALDI-TOF \ntechnique.\nThe first strain isolated corresponded to a 36-year-old pa -\ntient whose medical history did not report anything relevant \nexcept for an alleged allergy to sulfamides. His main complaint \nwhen he visited the doctor was a feeling of perineal discom -\nfort that had been present during the previous two weeks; it \nirradiated to the groin area and was accompanied by a feeling \nof polaquiuria. In the last 5 days, febricula of up to 37.5\u00baC, of \nevening predominance, had appeared. The pre- and post-ejac -\nulation urocultures provided negative results, but C. glucu -\nronolyticum  could be isolated in semen samples. The isolated \nstrain showed the following MIC values, which were inter -\npreted as susceptible according to the criteria of CLSI 2015 for \ncorinebacteria: trimethoprim/sulfamethoxazole (0.75 mg/L), Male genitourinary infections by Corynebacterium glucuronolyticum . A review and clinical experience M. Ruiz-Pino, et al.\nRev Esp Quimioter 2019;32(5): 479-484483cated low-tract urinary tract infections, was tested in one of \nthe isolated strains in this laboratory, showing it resistance to \nthis antibiotic (MIC \u02c3256 mg/L). Conversely, the two isolated \nstrains of C. glucuronolyticum  turned out to be susceptible to \ntrimethoprim-sulfamethoxazole, obtaining MICs of 0.19 and \n0.75 mg/L. In addition, this antibiotic has an excellent penetra -\ntion capacity in prostatic tissue.\nIn general, C. glucuronolyticum  is susceptible to beta -\nlactamic antibiotics providing relatively low MIC values [11, \n22]. Penicillins are, within this group, the most useful antibi -\notics to provide outpatient treatment to patients with urinary \ntract infections caused by grampositive bacilli, but they lack \nclinical efficacy, due to the difficulty they find to penetrate \nthe prostate. Previous studies show that C. glucuronolyticum  is \nsusceptible to penicillin [1-3, 11, 22, 23], amoxicillin-clavulanic \n[22, 23] and piperacillin-tazobactam [23]. Penicillin was tested \nin one of the isolated strains in the laboratory and a MIC val -\nue of 0.094 mg/L was obtained, corresponding to the range of \nsusceptible.\nThe use of gentamicin, despite being restricted by its tox -\nicity and difficulty in entering the prostatic tissue, may be in -\ndicated in the treatment of other genital infections in male, \nsince C. glucuronolyticum  is usually susceptible to it [1, 11, 22, \n23]. However, genemicin-resistant strains [3] have been de -\ntected, as sustains one of the results obtained in our hospital \n(MIC 8 mg/L).\nTo date, no resistance to linezolid has been reported [3, \n22]. This is a useful antibiotic versus grampositive bacteria, \nrepresenting an effective alternative for the treatment of \nCBPs. The two isolated strains in this laboratory were suscepti -\nble to it (MIC 0.047-0.094 mg/L). Rifampicin was also very ac -\ntive against this species [1-3, 11, 22], as corroborates the MIC \nvalues obtained by this laboratory, which was \u02c20.016 mg/L in \nthe two strains.\nMore recently [24] we have reviewed the antibiotic sus -\nceptibility reported by all the strains of C. glucuronolyticum \nthat were isolated in the genitourinary samples that our center \nreceived during the years 2017 and 2018. In this research, a \nseries of 7 microbiologically significant isolates of  C. glucu -\nronolyticum , all from males (1 urine, semen 4 and 2 of urethral \nexudates) were reviewed retrospectively. Linezolid, rifampicin, \ntrimethoprim-sulfamethoxazole and vancomycin were active \nin all strains tested; but 83% of the strains were susceptible \nto tetracycline, 50% to penicillin, 43% to ciprofloxacin, 25% to \ngentamicin and erythromycin, and 20% to clindamycin.\nAlthough C. glucuronolyticum is not frequently isolated in \nclinical genitourinary samples, its potential pathogenicity has \nbeen demonstrated and, therefore, the necessary procedures \nto detect this species should be included in the diagnostic al -\ngorithm of these infections.\nTo identify some of the less common ethological agents \ncausing prostatitis, such as C. glucuronolyticum , some meth -\nods differing from the traditional growing in culture media \nneed to be employed. These methods are neccessary but they \nare not included in the standard protocols of the laboratories. After receiving the report from the Microbiology laboratory, \nwith culture of semen positive to  C. glucuronolyticum  levo -\nfloxacin (1 tab/24h for 6 weeks) was prescribed, with disap -\npearance of the clinical symptomatology of the patient.\nIn both cases, other etiological agents such as Chlamydia \ntrachomatis , Mycoplasma genitalium , Mycoplasma hominis , \nNeisseria gonorrhoeae , Trichomonas vaginalis , Ureaplasma \nparvum  and Ureaplasma urealyticum , which are common \ncauses of genitourinary infections were excluded by using mo -\nlecular PCR techniques (Becton Dickinson, Sparks, USA).\nThe study of antibiotic susceptibility is usually carried out \nby performing E-tests on isolates in lamb blood agar and in \nHTM in the case of trimethoprim-sulfamethoxazole. The plates \nare incubated according to the standard procedure, without \nthe need for CO2-enriched atmosphere, for a period of 24-48 \nhours; and the MICs are interpreted according to the updated \ncriteria of the CLSI or the EUCAST.\nQuinolones are one of the antibiotics that belong to the \nfirst line treatment in case of genitourinary tract infections. \nRecent studies support the success of ciprofloxacin, when it \nis indicated according to the antibiogram, in the treatment of \ngenitourinary infections caused by C. glucuronolyticum , reach -\ning its eradication and a total remission of symptoms [2, 3]. \nHowever, in recent years, there has been an increase in \nin-vitro resistances manifested by this species to different \nantibiotics, including ciprofloxacin [1, 6, 11, 22, 23]. Proof of \nthis is that one of the isolated strains in the laboratory gave a \nMIC interpretable as resistant to ciprofloxacin ( \u02c332 mg/L). The \nmechanism used by C. glucuronolyticum  to acquire such re -\nsistance could consist of a mutation in the gyrA gene. This can \nbe drawn from the fact that it has been confirmed that other \nspecies of corinebacteria have acquire resistance to ciprofloxa -\ncin by using a similar mechanism [14].\nTetracyclines are one of the groups of antibiotics most \ncommonly used in the treatment of non-gonococcal urethritis. \nHowever, there have been numerous cases in which isolates \nof the species C. glucuronolyticum have turned out to be re -\nsistant to tetracyclines [1, 3, 11, 22]. Despite this fact, the two \nisolated strains in the laboratory of this hospital gave MIC val -\nues corresponding to the susceptible category (0.094 \u2013 0.125 \nmg/L). In addition, doxycycline (at 100 mg doses for 7 days) \nhas proven to be effective in treating urethritis caused by C. \nglucuronolyticum  [23].\nAzithromycin is used, associated with ceftriaxone, in the \nempirical treatment of urethritis. But, resistance to both azith -\nromycin and erythromycin [2, 3, 11] is common. This is usually \ndue to the presence of the methylase ermX  gene, which is as -\nsociated with the macrolide-resistant phenotype \u2013 lincosamide \n\u2013 streptogramine B (MLSb). The expression of erythromycin \nresistance seems to be linked to clindamycin resistance [22]. \nThe isolate in which erythromycin was tested in this laboratory \nproved to be resistant, with a MIC of \u02c3256 mg/L. It was also \nresistant to clindamycin, obtaining MIC \u02c3256 mg/L.\nPhosphomycin, indicated in the treatment of uncompli -Male genitourinary infections by Corynebacterium glucuronolyticum . A review and clinical experience M. Ruiz-Pino, et al.\nRev Esp Quimioter 2019;32(5): 479-484484This fact suggests that there might be an unacceptable num -\nber of false negatives. Lack of awareness means that many \ncases of chronic prostatitis fall directly into the category of \nnon-infectious by providing the culture of samples with a \nfalsely negative result.\nFUNDING\nNone to declare\nCONFLICTS OF INTEREST\nThe authors declare that they have no conflicts of interest.\nREFERENCES\n1. Mestrovic T. A microbial game of whack-a-mole: clinical case se -\nries of urethral uncloaking phenomenon caused by Corynebacteri -\num glucuronolyticum  in men treated for Chlamydia trachomatis  \nurethritis. Infection. 2018; 47; 1:121-4.  doi: 10.1007/s15010-018-\n1211-8.\n2. Gal\u00e1n S\u00e1nchez F, Aznar Mar\u00edn P, Mar\u00edn Casanova P, Garc\u00eda Martos \nP, Rodr\u00edguez Iglesias M. Urethritis due to Corynebacterium glucu -\nronolyticum . J Infect Chemother 2011; 17:720\u20131. doi: 10.1007/\ns10156-011-0237-y.\n3. Gherardi G, di Bonaventura G, Pompilio A, Savini V. Corynebacte -\nrium glucuronolyticum causing genitourinary tract infection: Case \nreport and review of the literature. IDCases. 2015; 2:56-8. doi: \n10.1016/j.idcr.2015.03.001.\n4. Novo-Veleiro I, Hern\u00e1ndez-Cabrera M, Ca\u00f1as-Hern\u00e1ndez F, Pi -\nsos-\u00c1lamo E, Franc\u00e9s-Urmeneta A, Delgado-Yag\u00fce M, et al. Pau -\ncisymptomatic infectious prostatitis as a cause of fever without an \napparent origin. A series of 19 patients. Eur J Clin Microbiol Infect \nDis. 2013; 32:263-8. doi: 10.1007/s10096-012-1738-z.\n5. Curry CR, Saluja K, Das S, Thakral B, Dangle P, Keeler TC, et al. En -\ncrusted Cystitis Secondary to Corynebacterium glucuronolyticum  \nin a 57-Year-Old Man Without Predisposing Factors. Lab Med. \n2015; 46:136-9. doi: 10.1309/LMXQP557EINXBXIF.  \n6. Me\u0161trovi\u0107 T, Bedeni\u0107 B, Wilson J, Ljubin-Sternak S, Sviben M, Neu -\nberg M, et al. The impact of Corynebacterium glucuronolyticum  on \nsemen parameters: a prospective pre-post-treatment study. An -\ndrology. 2018; 6:223-9. doi: 10.1111/andr.12453.\n7. Khamis A, Raoult D, La Scola B. Comparison between rpoB and 16S \nrRNA gene sequencing for molecular identification of 168 clini -\ncal isolates of Corynebacterium . J Clin Microbiol. 2005; 43:1934-6. \nPMID: 15815024.\n8. Funke G, von Graevenitz A, Clarridge JE 3rd, Bernard KA. Clinical \nmicrobiology of coryneform bacteria. Clin Microbiol Rev. 1997; \n10:125-59. PMID: 8993861.  \n9. Funke G, Bernard KA, Bucher C, Pfyffer GE, Collins MD. Corynebac -\nterium glucuronolyticum  sp. nov. isolated from male patients with \ngenitourinary infections. Med Microbiol Lett. 1995; 4:204-15. \n10. Riegel P, Ruimy R, de Briel D, Pr\u00e9vost G, Jehl F, Bimet F, et al. \nCorynebacterium seminale  sp. nov., a new species associated \nwith genital infections in male patients. J Clin Microbiol. 1995; \n33:2244-9. PMID: 7494009. 11. Netzel TH, Rand KH. Prostatitis associated with Corynebacterium \nglucuronolyticum . Clin Microbiol Newslett. 2002; 24:94\u20135. doi: \n10.1016/S0196-4399(02)80023-X.\n12. Tanner MA, Shoskes D, Shahed A, Pace NR. Prevalence of \ncorynebacterial 16S rRNA sequences in patients with bacterial \nand \u201cnonbacterial\u201d prostatitis. J Clin Microbiol. 1999; 37:1863-70. \nPMID: 10325338. \n13. Devriese LA, Riegel P, Hommez J, Vaneechoutte M, de Baere T, \nHaesebrouck F. Identification of Corynebacterium glucuronolyti -\ncum strains from the urogenital tract of humans and pigs. J Clin \nMicrobiol. 2000; 38:4657-9. PMID: 11101617.  \n14. Bernard K. The genus Corynebacterium  and other medically rele -\nvant coryneform-like bacteria. J Clin Microbiol. 2012; 50:3152-8. \nPMID: 22837327.\n15. Riegel P, Ruimy R, Christen R, Monteil H. Species identities and an -\ntimicrobial susceptibilities of corynebacteria isolated from various \nclinical sources. Eur J Clin Microbiol Infect Dis. 1996; 15:657-62. \nPMID: 8894575. \n16. Alatoom AA, Cazanave CJ, Cunningham SA, Ihde SM, Patel R. \nIdentification of non-diphtheriae Corynebacterium  by use of \nmatrix-assisted laser desorption ionization-time of flight mass \nspectrometry. J Clin Microbiol. 2012; 50:160-3. doi: 10.1128/\nJCM.05889-11.\n17. Heras-Ca\u00f1as V, Guti\u00e9rrez-Soto B, Serrano-Garc\u00eda ML, \nV\u00e1zquez-Alonso F, Navarro-Mar\u00ed JM, Guti\u00e9rrez-Fern\u00e1ndez J. \nProstatitis cr\u00f3nica bacteriana. Estudio cl\u00ednico y microbiol\u00f3gico \nde 332 casos. Med Clin. 2016; 147:144-7. doi: 10.1016/j.medc -\nli.2016.05.018.\n18. Sorl\u00f3zano-Puerto A, Esteban-Sanch\u00eds P, Heras-Ca\u00f1as V, Fern\u00e1n -\ndez-Parra J, Navarro-Mari JM, Guti\u00e9rrez-Fern\u00e1ndez J. Estudio pro -\nspectivo de la incidencia de pat\u00f3genos genitales oportunistas y \nestrictos que crecen en medios de cultivo artificiales. Rev Lab Cl\u00edn. \n2018; 11: 123-30. doi: 10.1016/j.labcli.2017.11.009.\n19. Meares EM, Stamey TA. Bacteriologic localization patterns in \nbacterial prostatitis and urethritis. Invest Urol. 1968; 5:492-518. \nPMID: 4870505. \n20. Nickel JC. Prostatitis: myths and realities. Urology. 1998; 51:362-6. \nPMID: 9510337. \n21. Krieger JN, Riley DE, Roberts MC, Berger RE. Prokaryotic DNA se -\nquences in patients with chronic idiopathic prostatitis. J Clin Mi -\ncrobiol. 1996; 34:3120-8. PMID: 8940458. \n22. Funke G, P\u00fcnter V, von Graevenitz A. Antimicrobial susceptibility \npatterns of some recently established coryneform bacteria. Anti -\nmicrob Agents Chemother. 1996; 40:2874-8. PMID: 9124857.  \n23. Mestrovic T, Bedenic B, Ljubin-Sternak S, Sviben M, Profozic Z. \nCiprofloxacin resistant Corynebacterium glucuronolyticum  as a \ncause of male urethritis syndrome. JMM Case Rep. 2014; 2:7. DOI \n10.1099/jmmcr.0.000208.\n24. Casanovas-Moreno-Torres I, Borrego-Jim\u00e9nez J, Calatrava-Hern\u00e1n -\ndez E, Foronda- Garcia-Hidalgo C, Jim\u00e9menz-Guerra G, et al. Estu -\ndio de la sensibilidad antibi\u00f3tica de Corynebacterium glucurono -\nlyticum  y Aerococcus  spp. en muestras genitourinarias durante los \na\u00f1os 2017 y 2018. AMPAC. 2018;1:114-5.  http://ampac.sampac.es/\nsites/ampac.sampac.es/files/AMPAC_VOL1_NUM2_0.pdf", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}